<articles>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACG Case Rep J</journal-id><journal-id journal-id-type="iso-abbrev">ACG Case Rep J</journal-id><journal-id journal-id-type="publisher-id">crj</journal-id><journal-title-group><journal-title>ACG Case Reports Journal</journal-title></journal-title-group><issn pub-type="epub">2326-3253</issn><publisher><publisher-name>American College of Gastroenterology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358576</article-id><article-id pub-id-type="publisher-id">crj.2018.87</article-id><article-id pub-id-type="doi">10.14309/crj.2018.87</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Endoscopy</subject></subj-group></subj-group></article-categories><title-group><article-title>Endoscopic versus Surgical Intervention for Jejunal Bezoar Formation</article-title><alt-title alt-title-type="left-running-head">Berg et al</alt-title><alt-title alt-title-type="right-running-head">Jejunal Bezoar </alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Berg</surname><given-names>Dana</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chakinala</surname><given-names>Raja Chandra</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Veillette</surname><given-names>Gregory</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schorr-Lesnick</surname><given-names>Beth</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1">
<label>1</label>Division of Gastroenterology and Hepatobiliary Diseases, New York Medical College, Westchester Medical Center, Valhalla, NY</aff><aff id="aff2">
<label>2</label>Department of Internal Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY</aff><aff id="aff3">
<label>3</label>Department of Surgery, New York Medical College, Westchester Medical Center, Valhalla, NY</aff></contrib-group><author-notes><corresp>Correspondence: Raja Chandra Chakinala, MD, Westchester Medical Center, 100 Woods Road, Valhalla, NY 10595 (<email>rajachandra@gmail.com</email>).</corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2018</year></pub-date><volume>5</volume><elocation-id>e87</elocation-id><history><date date-type="received"><day>8</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Berg et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="CG_CGCR180075.pdf"/><abstract><p>Bezoar-induced small bowel obstruction is a rare entity, but it should be highly suspected in those with prior abdominal or bariatric surgery. The cornerstone of treatment for intestinal bezoars has been surgical exploration to relieve the obstruction. We present a patient with obstructive jejunal phytobezoar formation that was relieved via an endoscopic approach rather than a surgical modality.</p></abstract></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Bezoars are aggregates of undigested foreign material that accumulate in the gastrointestinal (GI) tract, particularly in the stomach and the narrowest points of the small bowel. There are currently four classifications of bezoars: phytobezoars, composed of vegetables and fibers<xref rid="B1" ref-type="bibr">1</xref>; trichobezoars, resulting from ingestion of hair<xref rid="B2" ref-type="bibr">2</xref>; lactobezoars, composed of milk curd; and pharmacobezoars, an accumulation of drugs and medications.<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">-</xref><xref rid="B6" ref-type="bibr">6</xref> Reports of bezoars causing GI obstruction dates as far back as the late 18th century.<xref rid="B7" ref-type="bibr">7</xref> Depending on the size and location of a bezoar, some may remain undetected, while others present with symptoms such as abdominal pain, nausea, vomiting, GI bleeding, and ileus or small bowel obstruction.<xref rid="B8" ref-type="bibr">8</xref> While traditionally removed via a surgical approach<xref rid="B3" ref-type="bibr">3</xref><sup>,</sup><xref rid="B9" ref-type="bibr">9</xref>, there are a select few cases of obstructive intestinal bezoars successfully managed via endoscopic removal. Endoscopic treatment of bezoars causing intestinal obstruction is challenging and scarcely reported in the literature.<xref rid="B4" ref-type="bibr">4</xref><sup>,</sup><xref rid="B8" ref-type="bibr">8</xref></p></sec><sec><title>Case Report</title><p>A 60-year old diabetic woman with a past cholecystectomy (1993) complicated by a bile duct injury requiring a Roux-en-Y hepaticojejunostomy (1994) presented with 2 days of nausea, bilious emesis, and diffuse abdominal pain. Physical examination revealed mild diffuse abdominal tenderness and hypoactive bowel sounds. Computed tomography (CT) of the abdomen and pelvis revealed a large (9&#x02013;10 cm) mass suggestive of a bezoar at the level of the jejunojejunal anastomosis (J-JA) (<xref ref-type="fig" rid="F1">Figure 1</xref>). A push enteroscopy revealed circumferential solid feculent and vegetable material (12 cm in diameter) obstructing the jejunal lumen (<xref ref-type="fig" rid="F2">Figure 2</xref>). It was just proximal to the J-JA site, 90 cm from enteroscope entry. A biopsy forceps combined with aggressive water irrigation was used to dissolve the bezoar (<xref ref-type="fig" rid="F2">Figure 2</xref>). While the patient symptomatically improved, persistent bezoar formation on repeat imaging led to a second push enteroscopy two days later. The previously identified bezoar was significantly smaller in size and was further fragmented via biopsy forceps and a polypectomy snare (<xref ref-type="fig" rid="F3">Figure 3</xref>). The patient was instructed to drink a cola beverage and/or papaya juice, and she was discharged home with complete resolution of her symptoms. She remained symptom-free at 1-month follow-up.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Computed tomography image suggestive of a 9&#x02013;10 cm bezoar (white arrow) in the mid small bowel.</p></caption><graphic xlink:href="CG-CGCR180075F001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Endoscopy showing (A) the initial jejunal bezoar and (B) the bezoar after breaking it with biopsy forceps and water irrigation.</p></caption><graphic xlink:href="CG-CGCR180075F002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Interval decrease in the size of bezoar seen on repeat endoscopy. (A) Bezoar, (B) breaking of the bezoar with forceps and snare, and (C) normal jejunum after complete breakdown of the bezoar.</p></caption><graphic xlink:href="CG-CGCR180075F003"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Bezoar formation is a rare cause of intestinal obstruction.<xref rid="B8" ref-type="bibr">8</xref> When found, they are commonly associated with patients who have impaired gastric motility as a result of prior gastric surgery, such as Billroth I or II operations, or diabetic gastroparesis.<xref rid="B1" ref-type="bibr">1</xref><sup>,</sup><xref rid="B3" ref-type="bibr">3</xref><sup>,</sup><xref rid="B7" ref-type="bibr">7</xref><sup>,</sup><xref rid="B9" ref-type="bibr">9</xref> Bezoars similarly occur in cases of anastomotic strictures after gastric or bowel surgery.<xref rid="B2" ref-type="bibr">2</xref> For these reasons, the patient in this case, who was diabetic with a prior history of a hepaticojejunostomy, was particularly susceptible to bezoar formation as a cause of her small bowel obstruction. Nevertheless, only 4% of small bowel obstructions are due to bezoars in the GI tract<xref rid="B8" ref-type="bibr">8</xref>, and therefore clinicians must maintain a high level of suspicion in the appropriate patient population. Early diagnosis is crucial because obstructive bezoars can cause severe complications, including GI ulceration and pressure necrosis.<xref rid="B8" ref-type="bibr">8</xref></p><p>Radiological imaging remains paramount in aiding diagnosis. CT with contrast enhancement, which has a sensitivity of 90% and a specificity of 57% in recognizing bezoars, is now the gold standard in diagnosing bezoars as the cause of small bowel obstruction.<xref rid="B5" ref-type="bibr">5</xref> On CT, small bowel phytobezoars typically appear as a well-defined, ovoid, intraluminal mass containing mottled gas, with dilated intestinal loops proximally collapsing distally.<xref rid="B6" ref-type="bibr">6</xref><sup>,</sup><xref rid="B10" ref-type="bibr">10</xref> Abdominal CT is effective for excluding other causes of intestinal obstruction and to detect the presence of intra-abdominal free-fluid, the level of obstruction, and development of intestinal infarction.<xref rid="B11" ref-type="bibr">11</xref> These findings assist in directing conservative versus surgical or endoscopic treatment strategies.<xref rid="B5" ref-type="bibr">5</xref><sup>,</sup><xref rid="B11" ref-type="bibr">11</xref></p><p>Management of phytobezoars depends on their anatomic location. Gastric bezoars are typically managed endoscopically with mechanical fragmentation via biopsy forceps, polypectomy snares, lithotripsy, or argon plasma coagulation.<xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">-</xref><xref rid="B17" ref-type="bibr">17</xref> Surgical removal is considered when one or more of these methods have failed.<xref rid="B18" ref-type="bibr">18</xref> Intestinal bezoars, on the other hand, are conventionally treated via surgical intervention.<xref rid="B8" ref-type="bibr">8</xref><sup>,</sup><xref rid="B18" ref-type="bibr">18</xref><xref rid="B19" ref-type="bibr">-</xref><xref rid="B20" ref-type="bibr">20</xref> The optimal surgical management includes laparoscopy for small to moderate bezoars or exploratory laparotomy for larger bezoars with enterotomy and evacuation.<xref rid="B8" ref-type="bibr">8</xref> Endoscopic treatment of intestinal bezoars causing obstruction is challenging and has been reported rarely in the literature. This may be due to inaccessibility, technical difficulties, and risk of perforation.<xref rid="B4" ref-type="bibr">4</xref><sup>,</sup><xref rid="B8" ref-type="bibr">8</xref></p><p>For example, in a review of fifteen case reports of phytobeozar formation after Roux-en-Y gastric bypass (RYGB), all gastric pouch bezoars were treated endoscopically, whereas bezoars at the jejunojejunostomy or other small bowel locations were treated with surgical intervention.<xref rid="B18" ref-type="bibr">18</xref> There are only a few case reports documenting successful endoscopic removal of intestinal bezoars. One such case involved a terminal ileum bezoar treated with colonoscopic fragmentation,<xref rid="B21" ref-type="bibr">21</xref><sup>,</sup><xref rid="B22" ref-type="bibr">22</xref> and the other a proximal jejunal phytobezoar fragmented via antegrade double-balloon enteroscopy (DBE).<xref rid="B23" ref-type="bibr">23</xref></p><p>In combination with endoscopic or surgical management, anecdotal treatment for gastric bezoars includes oral or endoscopic injection of a cola beverage, which helps dissolve the bezoar due to its acidity.<xref rid="B24" ref-type="bibr">24</xref> Bezoar dissolution may also be achieved with papain, an enzyme extracted from the <italic>Carica papaya</italic> plant.<xref rid="B18" ref-type="bibr">18</xref> Upon resolution of symptoms (whether achieved endoscopically, surgically, or even via conservative measures such as cola dissolution), nutritional counseling to prevent further bezoar formation remains paramount. Emphasis should be placed on sufficient chewing and avoiding excessive intake of high-fiber food.<xref rid="B18" ref-type="bibr">18</xref></p><p>This case is unusual in that it is perhaps the first report of a patient with a prior hepaticojejunostomy presenting with a phytobezoar at the jejunojejunal anastomosis who was successfully treated endoscopically. Surgical intervention would likely have resulted in a higher complication rate, increased expense, a longer recovery period, and length of hospital stay. The successful outcome in this case suggests that endoscopic management is feasible as an initial treatment for small intestinal bezoars. The location in the small bowel and its accessibility are key aspects to consider when deciding on the optimal approach. If endoscopic attempts fail or are not possible, surgery should undoubtedly remain the treatment of choice. Therefore, the decision to consider initial endoscopic decompression/management must be made in collaboration with the surgical service to optimize patient care and ultimately patient outcomes.</p></sec><sec><title>Disclosures</title><p>Author contributions: D Berg wrote the manuscript. RC Chakinala provided the images and edited the manuscript. G Veillette and B Schorr-Lesnick edited the manuscript. D Berg is the article guarantor.</p><p>Financial disclosure: None to report.</p><p>Informed consent was obtained for this case report.</p><p>Previous presentation: The abstract of this case report was submitted at the 2018 ACG Annual Meeting; October 5-10, 2018; Philadelphia, Pennsylvania.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quercioli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dallegri</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ottonello</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Montecucco</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Borgonovo</surname><given-names>G</given-names></name></person-group>
<article-title>Intestinal radiation-induced stricture favours small bowel obstruction by phytobezoar: Report of a case</article-title>. <source>Gastroenterol Res Pract</source>. <year>2009</year>;<volume>2009</volume>:<fpage>482039</fpage>.<pub-id pub-id-type="pmid">19587825</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarhan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shyamali</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Fakulujo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>L</given-names></name></person-group>
<article-title>Jejunal bezoar causing obstruction after laparoscopic Roux-en-Y gastric bypass</article-title>. <source>JSLS</source>. <year>2010</year>;<volume>14</volume>:<fpage>592</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">21605530</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>S</given-names></name></person-group>
<article-title>Small bowel obstruction due to phytobezoar: CT diagnosis</article-title>. <source>Abdominal Imaging</source>. <year>1997</year>;<volume>22</volume>:<fpage>471</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">9233879</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Menezes Ettinger</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Silva Reis</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>de Souza</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Filho Ede</surname><given-names>M</given-names></name>, <name name-style="western"><surname>G&#x000e3;lvao do Amaral</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Ettinger</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Fahel</surname><given-names>E</given-names></name></person-group>
<article-title>Laparoscopic management of intestinal obstruction due to phytobezoar</article-title>. <source>JSLS</source>. <year>2007</year>;<volume>11</volume>:<fpage>168</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">17651584</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Occhionorelli</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zese</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Targa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cappellari</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Stano</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vasquez</surname><given-names>G</given-names></name></person-group>
<article-title>A rare case of a double phytobezoar causing gastric and jejunum obstruction in an adult man: A case report</article-title>. <source>J Med Case Rep</source>. <year>2016</year>;<volume>10</volume>(<issue>1</issue>):<fpage>350</fpage>.<pub-id pub-id-type="pmid">27978851</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gayer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Jonas</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Apter</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Bezoars in the stomach and small bowel: CT appearance</article-title>. <source>Clin Radiol</source>. <year>1999</year>;<volume>54</volume>:<fpage>228</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">10210341</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitiakoudis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tsaroucha</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mimidis</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Esophageal and small bowel obstruction by occupational bezoar: Report of a case</article-title>. <source>BMC Gastroenterol</source>. <year>2003</year>;<volume>3</volume>:<fpage>13</fpage>.<pub-id pub-id-type="pmid">12795814</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abou Azar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wehbe</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Jamali</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hallal</surname><given-names>A</given-names></name></person-group>
<article-title>Small bowel obstruction secondary to a Metamucil bezoar: Case report and review of the literature</article-title>. <source>Case Rep Surg</source>. <year>2017</year>;<volume>2017</volume>:<fpage>2702896</fpage>.<pub-id pub-id-type="pmid">29085697</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cifuentes Tebar</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Robles Campos</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Parrilla Paricio</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lujan Mompean</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Escamilla</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liron Ruiz</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pellicer Franco</surname><given-names>EM</given-names></name></person-group>
<article-title>Gastric surgery and bezoars</article-title>. <source>Dig Dis Sci</source>. <year>1992</year>;<volume>37</volume>:<fpage>1694</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">1425068</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zissin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Osadchy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gutman</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rathaus</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Shapiro-Feinberg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gayer</surname><given-names>G</given-names></name></person-group>
<article-title>CT findings in patients with small bowel obstruction due to phytobezoar</article-title>. <source>Emerg Radiol</source>. <year>2004</year>;<volume>10</volume>:<fpage>197</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">15290490</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dikicier</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Altintoprak</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ozkan</surname><given-names>OV</given-names></name>, <name name-style="western"><surname>Yagmurkaya</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Uzunoglu</surname><given-names>MY</given-names></name></person-group>
<article-title>Intestinal obstruction due to phytobezoars: An update</article-title>. <source>World J Clin Cases</source>. <year>2015</year>;<volume>3</volume>:<fpage>721</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">26301232</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sz&#x000e1;nt&#x000f3;</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kiss</surname><given-names>J</given-names></name></person-group>
<article-title>Oesophagus bezoar diagnosed and removed endoscopically</article-title>. <source>Endoscopy</source>. <year>1976</year>;<volume>8</volume>:<fpage>206</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">1026391</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLoughlin</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Love</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Adgey</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Gough</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Varma</surname><given-names>MP</given-names></name></person-group>
<article-title>Intact removal of phytobezoar using fibreoptic endoscope in patient with gastric atony</article-title>. <source>Br Med J</source>. <year>1979</year>;<volume>1</volume>:<fpage>1466</fpage>.<pub-id pub-id-type="pmid">466066</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubke</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Winkelmann</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Berges</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Mecklenbeck</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wienbeck</surname><given-names>M</given-names></name></person-group>
<article-title>Gastric phytobezoar: endoscopic removal using the gallstone lithotripter</article-title>. <source>Z Gastroenterol</source>. <year>1988</year>;<volume>26</volume>:<fpage>393</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">3218281</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ugenti</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Travaglio</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lagouvardou</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Caputi Iambrenghi</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Martines</surname><given-names>G</given-names></name></person-group>
<article-title>Successful endoscopic treatment of gastric phytobezoar: A case report</article-title>. <source>Int J Surg Case Rep</source>. <year>2017</year>;<volume>37</volume>:<fpage>45</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28633127</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blam</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Lichtenstein</surname><given-names>GR</given-names></name></person-group>
<article-title>A new endoscopic technique for the removal of gastric phytobezoars</article-title>. <source>Gastrointest Endosc</source>. <year>2000</year>;<volume>52</volume>:<fpage>404</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10968861</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwamuro</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Okada</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Matsueda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Inaba</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kusumoto</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Imagawa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>K</given-names></name></person-group>
<article-title>Review of the diagnosis and management of gastrointestinal bezoars</article-title>. <source>World J Gastrointest Endosc</source>. <year>2015</year>;<volume>7</volume>:<fpage>336</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">25901212</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Porat</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sherf Dagan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Goldenshluger</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yuval</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Elazary</surname><given-names>R</given-names></name></person-group>
<article-title>Gastrointestinal phytobezoar following bariatric surgery: Systematic review</article-title>. <source>Surg Obes Relat Dis</source>. <year>2016</year>;<volume>12</volume>:<fpage>1747</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">27989523</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parsi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rivera</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vargas</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Silberstein</surname><given-names>MW</given-names></name></person-group>
<article-title>Laparoscopic-assisted extirpation of a phytobezoar causing small bowel obstruction after Roux-en-Y laparoscopic gastric bypass</article-title>. <source>Am Surg</source>. <year>2013</year>;<volume>79</volume>:<fpage>E93</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">23336647</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasri</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Calin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gilchrist</surname><given-names>B</given-names></name></person-group>
<article-title>A rare cause of small bowel obstruction due to bezoar in a virgin abdomen</article-title>. <source>Int J Surg Case Rep</source>. <year>2016</year>;<volume>19</volume>:<fpage>144</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">26764889</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>XY</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>L</given-names></name></person-group>
<article-title>Successful endoscopic treatment of an intestinal diospyrobezoar migrated from the stomach</article-title>. <source>BMJ Case Rep</source>. <year>2014</year>;<volume>2014</volume>:<fpage>bcr2014204966</fpage>.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chae</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>SW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Endoscopic removal of a phytobezoar obstructing the distal small bowel</article-title>. <source>Gastrointest Endosc</source>. <year>2001</year>;<volume>54</volume>:<fpage>264</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">11474411</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>HC</given-names></name></person-group>
<article-title>Obstructing small bowel phytobezoar successfully treated with an endoscopic fragmentation using double-balloon enteroscopy</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2009</year>;<volume>7</volume>:<fpage>e51</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">19361574</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ohara</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Naitoh</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group>
<article-title>Persimmon bezoar successfully treated by oral intake of Coca-Cola: A case report</article-title>. <source>Cases J</source>. <year>2008</year>;<volume>1</volume>:<fpage>385</fpage>.<pub-id pub-id-type="pmid">19077219</pub-id></mixed-citation></ref></ref-list></back></article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACG Case Rep J</journal-id><journal-id journal-id-type="iso-abbrev">ACG Case Rep J</journal-id><journal-id journal-id-type="publisher-id">crj</journal-id><journal-title-group><journal-title>ACG Case Reports Journal</journal-title></journal-title-group><issn pub-type="epub">2326-3253</issn><publisher><publisher-name>American College of Gastroenterology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358577</article-id><article-id pub-id-type="publisher-id">crj.2018.94</article-id><article-id pub-id-type="doi">10.14309/crj.2018.94</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Pancreas</subject></subj-group></subj-group></article-categories><title-group><article-title>Chronic Pancreatitis with Spontaneously Disappearing Calcifications</article-title><alt-title alt-title-type="left-running-head">Friedberg et al</alt-title><alt-title alt-title-type="right-running-head">Spontaneously Disappearing Calcifications</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Friedberg</surname><given-names>Scott</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Slivka</surname><given-names>Adam</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Dasyam</surname><given-names>Anil</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Dhiraj</given-names></name><degrees>MD, MPH</degrees></contrib><aff id="aff1">University of Pittsburgh Medical Center, Pittsburgh, PA</aff></contrib-group><author-notes><corresp>Correspondence: Scott Friedberg, MD, UPMC Montefiore Hospital, N-715, 200 Lothrop St, Pittsburgh, PA 15213 (<email>friedbergsr@upmc.edu</email>).</corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2018</year></pub-date><volume>5</volume><elocation-id>e94</elocation-id><history><date date-type="received"><day>5</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Friedberg et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="CG_CGCR180085.pdf"/><abstract><p>Pancreatic calcifications, exocrine insufficiency, and endocrine insufficiency are hallmarks of chronic pancreatitis, and their prevalence increases with the duration of disease. We present a case of chronic pancreatitis in which a dramatic and spontaneous decrease in the burden of both parenchymal and intraductal calcifications was noted during longitudinal follow-up. We discuss the possible reasons for spontaneously vanishing calcifications, an entity rarely described in the literature.</p></abstract></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Pancreatic calcifications, diabetes, and exocrine insufficiency are considered to be hallmarks of chronic pancreatitis. The prevalence of calcifications generally increases over time, and they can be observed on imaging studies in 70&#x02013;90% of patients with chronic pancreatitis.<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref> Calcifications are often classified as either intraductal (ie, within the main pancreatic duct or branch ducts) or parenchymal (ie, within the pancreatic tissue, separated from ducts).<xref rid="B3" ref-type="bibr">3</xref></p><p>A decrease in the number of pancreatic calcifications can occur after a drainage procedure, such as the Puestow procedure (lateral pancreaticojejunostomy).<xref rid="B2" ref-type="bibr">2</xref> One would also expect a decrease or disappearance of pancreatic ductal stones after successful endotherapy with or without extracorporeal shockwave lithotripsy. However, a spontaneous decrease in pancreatic calcifications has only rarely been described.<xref rid="B4" ref-type="bibr">4</xref><sup>,</sup><xref rid="B5" ref-type="bibr">5</xref> More recently, although not spontaneous, the disappearance has been demonstrated to occur following intraductal citrate administration as well as after oral trimethadione administration.<xref rid="B6" ref-type="bibr">6</xref><sup>,</sup><xref rid="B7" ref-type="bibr">7</xref></p></sec><sec><title>Case Report</title><p>A Caucasian woman without a significant past medical history was initially diagnosed with acute pancreatitis at the age of 19 years. After a workup, including genetic testing, her pancreatitis was attributed to a combination of alcohol and smoking; she had been abusing alcohol since the age of 9 and had been smoking 1&#x02013;1.5 packs of cigarettes per day from the age of 15. She stopped drinking at age 23 but continued smoking. She first presented to our facility at the age of 27 years with epigastric pain, nausea, vomiting, and weight loss. She was found to have intraductal calculi and extensive coarse pancreatic parenchymal calcifications (<xref ref-type="fig" rid="F1">Figure 1</xref>). She also had endocrine insufficiency (A1c 7.4%).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Contrast-enhanced axial computed tomography (CT) imaging from 2004 (age 27) showing intraductal calculi (arrow head) and extensive coarse pancreatic parenchymal calcifications (arrows).</p></caption><graphic xlink:href="CG-CGCR180085F001"/></fig><p>A Frey procedure was planned, but by the time of surgery the pancreatic duct was found to have spontaneously decompressed to 2&#x02013;3 mm. Due to the presence of a dense adhesion between the stomach and the anterior surface of the pancreas, a pancreaticogastric fistula was suspected to be the reason for ductal decompression; however, a fistula was not visually confirmed during surgery. A fistulectomy and limited wedge posterior wall gastrectomy was performed, and pathology subsequently confirmed the presence of an intramural fistula. At that time, she also was found to have a splenic vein thrombosis and pseudocyst at the body&#x02013;tail junction, with the latter resolving spontaneously after a few months.</p><p>Between the ages of 27 and 31, the patient&#x02019;s abdominal pain was well controlled with various opioid regimens, as documented during routine follow-ups in the pain clinic. During a hospitalization at age 32 for worsening abdominal pain, remarkably, a computed tomography scan showed dramatically reduced pancreatic calcifications (<xref ref-type="fig" rid="F2">Figure 2</xref>), as well as chronic splenic vein thrombosis with perigastric collaterals, but no other local complications.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Contrast-enhanced axial CT imaging from 2008 (age 32) showing punctate intraductal calculi (arrow head) and few punctate pancreatic parenchymal calcifications (arrow).</p></caption><graphic xlink:href="CG-CGCR180085F002"/></fig><p>Between the ages of 31 and 40, despite decreasing smoking to one-half pack per day, the abdominal pain persisted with increasing opioid requirement, occasional exacerbations requiring hospitalizations, and worsening endocrine insufficiency (A1c peaking at 13.3%) and exocrine insufficiency (&#x0003c;50 &#x003bc;g elastase/g stool). At age 35, magnetic resonance cholangiopancreatography revealed a ductal stricture in the pancreatic neck (<xref ref-type="fig" rid="F3">Figure 3</xref>) with associated mild pancreatic duct dilation to 5.2 mm, and she underwent stricture dilation and placement of a dorsal duct stent (5 French &#x000d7; 5 cm external pigtail stent). This did not alleviate her pain, and the stent was removed 1 month later. At age 38, endoscopic retrograde cholangiopancreatography for a rising alkaline phosphatase revealed a stricture in the ventral pancreatic duct in the head and lower third of the main bile duct. A 10-mm &#x000d7; 4-cm covered metal stent (<xref ref-type="fig" rid="F4">Figure 4</xref>) was placed in the distal common bile duct, with successful resolution of the stricture documented at the time of stent removal 4 months later. Computed tomography at age 39 for continued pain showed continued interval improvement of the calcifications, including disappearance of intraductal calcifications (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Contrast-enhanced coronal MRCP imaging from 2012 (age 35) demonstrating an abrupt termination of the pancreatic neck, consistent with a pancreatic neck stricture (arrow), with associated mild pancreatic duct dilation (A marker).</p></caption><graphic xlink:href="CG-CGCR180085F003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Contrast-enhanced axial CT imaging from 2015 (age 38) demonstrating a 10-mm &#x000d7; 4-mm covered metal stent within distal common bile duct (arrow).</p></caption><graphic xlink:href="CG-CGCR180085F004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Contrast-enhanced axial CT imaging from 2016 (age 39) demonstrating scattered punctate pancreatic parenchymal calcifications (arrow) but no intraductal calculi.</p></caption><graphic xlink:href="CG-CGCR180085F005"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>The disappearance of calcifications classically occurs in association with ductal drainage procedures, such as the Puestow procedure, either due to active removal of stones or postoperative passage of stones through pancreaticojejunostomy. Studies have also shown associations with intraductal citrate administration as well as oral trimethadione administration.<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref> Spontaneous disappearances, as described in this case, are uncommon.</p><p>Although this patient did not undergo a surgical drainage procedure, it is possible that she underwent an &#x0201c;auto&#x0201d; ductal drainage via the suspected pancreaticogastric fistula; the fistula was seen at age 27 and the greatest decrease in calcifications occurred between the ages of 27 and 31. While endotherapy can also result in a reduction of pancreatic stones, it is important to note that endotherapy in this patient was only initiated after a dramatic decrease in calcifications had already occurred. An alternative possibility is that the stones dissolved via chemical dissolution. To our knowledge, the patient did not receive any pharmacologic agent capable of dissolving pancreatic stones; however, spontaneous dissolution of the calcium stones is theoretically possible in advanced chronic pancreatitis via decreased pH from reduced bicarbonate secretion.</p><p>It is also interesting that this case demonstrated a reduction of both parenchymal and intraductal calcifications, which has not been described in prior studies. It is worth noting, however, that prior studies of disappearing calcifications often did not use cross-sectional imaging. It is possible that the parenchymal calcifications were actually intraductal calcifications, located within the small ductal branches deep within the tissue.</p><p>This case illustrates the fact that pancreatic calcifications, while a hallmark of chronic pancreatitis, may fluctuate in number and size and may in fact disappear in some patients spontaneously, independent of or with little correlation with disease activity.</p></sec><sec><title>Disclosures</title><p>Author contributions: S. Friedberg wrote the article. A. Slivka, A. Dasyam, and D. Yadav edited the article. D. Yadav is the article guarantor.</p><p>Financial disclosure: None to report.</p><p>Informed consent was obtained for this case report.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machicado</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Chari</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Timmons</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yadav</surname><given-names>D</given-names></name></person-group>
<article-title>A population-based evaluation of the natural history of chronic pancreatitis</article-title>. <source>Pancreatology</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>39</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">29221631</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammann</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Muench</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Otto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Buehler</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Freiburghaus</surname><given-names>AU</given-names></name>, <name name-style="western"><surname>Siegenthaler</surname><given-names>W</given-names></name></person-group>
<article-title>Evolution and regression of pancreatic calcification in chronic pancreatitis: A prospective long-term study of 107 patients</article-title>. <source>Gastroenterology</source>. <year>1988</year>;<volume>95</volume>(<issue>4</issue>):<fpage>1018</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">3410215</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campisi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brancatelli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Vullierme</surname><given-names>M-P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis</article-title>. <source>Clin Radiol</source>. <year>2009</year>;<volume>64</volume>(<issue>9</issue>):<fpage>903</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">19664481</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucker</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>IB</given-names></name></person-group>
<article-title>Vanishing pancreatic calcification in chronic pancreatitis: A sign of pancreatic carcinoma</article-title>. <source>N Engl J Med</source>. <year>1963</year>;<volume>268</volume>(<issue>1</issue>):<fpage>31</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">13994682</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baltaxe</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Leslie</surname><given-names>EV</given-names></name></person-group>
<article-title>Vanishing pancreatic calcifications. A case report</article-title>. <source>Am J Roentgenol Radium Ther Nucl Med</source>. <year>1967</year>;<volume>99</volume>(<issue>3</issue>):<fpage>643</fpage>&#x02013;<lpage>44</lpage>.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#x000fc;itr&#x000f3;n</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gonz&#x000e1;lez-Loya</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Barinagarrementer&#x000ed;a</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sarol</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Adalid</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rodr&#x000ed;guez-Delgado</surname><given-names>J</given-names></name></person-group>
<article-title>Dissolution of pancreatic lithiasis by direct citrate application into the pancreatic duct in two patients with chronic idiopathic pancreatitis</article-title>. <source>Dig Dis</source>. <year>1997</year>;<volume>15</volume>(<issue>1-2</issue>):<fpage>120</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">9101134</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noda</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Okuyama</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Murayama</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Dissolution of pancreatic stones by oral trimethadione in patients with chronic calcific pancreatitis</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2018</year>;<volume>9</volume>(<issue>5</issue>):<fpage>478</fpage>&#x02013;<lpage>85</lpage>.</mixed-citation></ref></ref-list></back></article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACG Case Rep J</journal-id><journal-id journal-id-type="iso-abbrev">ACG Case Rep J</journal-id><journal-id journal-id-type="publisher-id">crj</journal-id><journal-title-group><journal-title>ACG Case Reports Journal</journal-title></journal-title-group><issn pub-type="epub">2326-3253</issn><publisher><publisher-name>American College of Gastroenterology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358578</article-id><article-id pub-id-type="publisher-id">crj.2018.88</article-id><article-id pub-id-type="doi">10.14309/crj.2018.88</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Pancreas</subject></subj-group></subj-group></article-categories><title-group><article-title>Bile Cast Nephropathy Caused by Obstructive Pancreatic Carcinoma and Failed ERCP</article-title><alt-title alt-title-type="left-running-head"/><alt-title alt-title-type="right-running-head">Bile Cast Nephropathy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van de Ven</surname><given-names>Steffi EM</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pavlov</surname><given-names>Kirill V.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Beutler</surname><given-names>Jaap J.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Scheffer</surname><given-names>Robbert CH</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1">
<label>1</label>Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, &#x02018;s-Hertogenbosch, The Netherlands</aff><aff id="aff2">
<label>2</label>Department of Nephrology, Jeroen Bosch Hospital, &#x02018;s-Hertogenbosch, The Netherlands</aff></contrib-group><author-notes><corresp>Correspondence: Robbert CH Scheffer, Jeroen Bosch Hospital, Department of Gastroenterology, Postbox 90153, 5200 ME, &#x02018;s-Hertogenbosch, The Netherlands (<email>b.scheffer@jbz.nl</email>).</corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2018</year></pub-date><volume>5</volume><elocation-id>e88</elocation-id><history><date date-type="received"><day>7</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; van de Ven et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="CG_CGCR180076.pdf"/><abstract><p>Bile cast nephropathy is an often overlooked condition of acute renal injury in the setting of high serum bilirubin. While the exact pathophysiology remains unknown, possible mechanisms of renal injury are tubular obstruction from bile casts, direct toxicity from bile acids, and decreased renal perfusion due to hemodynamic changes. We present a patient with hyperbilirubinemia as a result of common bile duct obstruction due to pancreatic adenocarcinoma who developed anuric acute renal injury. Urine analysis showed bile casts that were highly suggestive for bile cast nephropathy. The patient underwent hemodialysis and bile drainage with full restoration of renal function.</p></abstract></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Bile cast nephropathy is an often overlooked condition of nephrotoxicity associated with hyperbilirubinemia. Although the exact pathophysiological mechanism is unknown, direct toxicity of bile casts to the nephron and tubular obstruction are hypothesized mechanisms.<xref rid="B1" ref-type="bibr">1</xref> Because of the rarity of the disease, there are no universally applied treatment guidelines, and the prevalence is likely greater than previously recognized.<xref rid="B2" ref-type="bibr">2</xref></p></sec><sec><title>Case Report</title><p>A 64-year-old white man with a history of well-controlled diabetes mellitus presented with a 4-week history of progressive jaundice, dark-colored urine, and light-colored stools. He reported weight loss of 20 kg in the preceding 5 months. Family history was negative for liver or kidney disease. He reported no alcohol, tobacco, or drug use. On physical examination the patient was jaundiced and alert; no other abnormalities were reported. Abdominal ultrasound (US) revealed intra- and extrahepatic bile duct dilatation, with a common bile duct (CBD) of 16 mm and a hypoechoic lesion in the pancreas. Subsequent computed tomography confirmed these findings, revealing a mass of 34 mm in the pancreatic head suspect for pancreatic carcinoma. The patient was referred to our hospital for a pancreaticoduodenectomy.</p><p>Laboratory results at the time of presentation (day 1) showed total serum bilirubin 336 &#x000b5;mol/L, asparate aminotransferase 46 U/L, gamma-glutamyltransferase 140 U/L, alkaline phosphatase 446 U/L, sodium 138 mmol/L, potassium 3.7 mmol/L, creatinine 58 &#x000b5;mol/L, and creatinine clearance &#x0003e;60 mL/min. On day 4 after presentation, an endoscopic retrograde cholangiopancreatography (ERCP) visualized a distal stenosis of the CBD. Biopsy and brush of the CBD revealed adenocarcinoma. Due to tumor obstruction, cannulation of the CBD during ERCP was not successful. On day 5, the patient developed cholangitis. Antibiotic therapy with cefuroxime was started, and percutaneous transhepatic bile duct drainage was performed on day 7. The patient received tobramycin once after the drainage procedure for fever and chills. The total bilirubin level at that time was 407 &#x000b5;mol/L. Blood cultures were positive for <italic>Streptococcus pneumoniae</italic> and pseudomonas, so the patient was treated with piperacillin/tazobactam. On day 8, his creatinine level increased (<xref ref-type="fig" rid="F1">Figure 1</xref>). On the same day, a kidney US revealed no abnormalities. In the following days, renal function continued to deteriorate despite adequate fluid therapy. Blood pressure and diuresis were continuously adequate. Urine analysis revealed the presence of bile casts (<xref ref-type="fig" rid="F2">Figure 2</xref>), bile pigments, and a normal percentage of dysmorphic erythrocytes with absence of leukocyte and erythrocyte casts. Having excluded renal and post-renal obstruction, and given the presence of bile casts in the urine, the diagnosis of bile cast nephropathy was made; we refrained from kidney biopsy. The patient underwent hemodialysis on day 11 and on day 19. After a total of five hemodialysis sessions, dialysis was discontinued because renal function had improved and the bilirubin level was declining (<xref ref-type="fig" rid="F1">Figure 1</xref>). Pancreaticoduodenectomy was performed on day 28, and histopathology showed adenocarcinoma with clear margins. Renal function improved to normal within 3 months after hospital admission.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Creatinine and bilirubin levels over time.</p></caption><graphic xlink:href="CG-CGCR180076F001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Urine analysis with the presence of a bile cast (arrow).</p></caption><graphic xlink:href="CG-CGCR180076F002"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Bile cast nephropathy is an often overlooked condition in which hyperbilirubinemia leads to acute renal injury. While the exact pathophysiologic mechanism of renal injury remains unknown, several underlying factors may contribute.<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref> Deposition of bile casts in the nephron, leading to tubular obstruction, is one possible mechanism.<xref rid="B4" ref-type="bibr">4</xref> The bile acid&#x02013;binding capacity of albumin is estimated to be in the range of 20 mg/dL. If albumin exceeds this level, bilirubin can accumulate, leading to cast formation and tubular obstruction.<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4-6</xref> Direct oxidative damage of renal tubular epithelial cell membranes is another proposed mechanism of renal injury. This is caused by the stimulation of oxygen-free radical production by excess bile acids.<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B7" ref-type="bibr">7-10</xref> In addition, sulfated bile salts inhibit the Na-H, Na-K, and Na-C pumps in the proximal tubules and in the loop of Henle, resulting in impaired cellular pH regulation and tubular injury.<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B6" ref-type="bibr">6,9,11</xref> Finally, bile salts have negative chronotropic and ionotropic effects. Peripheral vascular resistance is altered due to endotoxemia, hypoalbuminemia, and other mechanisms, all of which contribute to decreased renal perfusion.<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B5" ref-type="bibr">5,6</xref></p><p>In our case, a pre-renal cause of acute kidney injury was unlikely because the patient was never hypotensive, and diuresis was adequate during his hospital stay. A post-renal cause of acute kidney injury was excluded because a kidney US revealed no hydronephrosis. The lack of proteinuria and no increased dysmorphic erythrocytes made glomerulonephritis less likely. Medications, including tobramycin, are known to cause tubulointerstitial nephritis. While this possibility cannot be completely ruled out, the patient had only one dose of tobramycin, and the urinary analysis lacked the characteristic leukocyte and erythrocyte casts. The improvement of renal function after the clearance of hyperbilirubinemia further supports the diagnosis of bile cast nephropathy. While kidney biopsy is the gold standard in the diagnosis of bile cast nephropathy, we refrained from this procedure because we were sufficiently confident of our diagnosis, and renal biopsy is associated with a small but clinically relevant risk of complications.</p><p>Currently, there are no accepted treatment guidelines for bile cast nephropathy, but reduction of bilirubin levels is essential. This can be achieved by relief of biliary obstruction, hemodialysis, or plasmapheresis.<xref rid="B2" ref-type="bibr">2</xref> It has been hypothesized that early reduction of bilirubin levels is most effective because extensive bile cast formation can delay recovery of renal function.<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B4" ref-type="bibr">4</xref> The may have been the case with our patient. While bilirubin had already started trending downward, creatinine levels were still high (<xref ref-type="fig" rid="F1">Figure 1</xref>). Furthermore, bile sequestrants, such as cholestyramine and ursodeoxycholic acid, are less effective.<xref rid="B6" ref-type="bibr">6</xref></p><p>Early recognition and treatment aimed at relieving the hyperbilirubinemia are key to preventing lasting kidney damage. Bile cast nephropathy is an under-reported diagnosis and should be considered in all patients with hyperbilirubinemia and kidney injury.</p></sec><sec><title>Disclosures</title><p>Author contributions: SEM van de Ven wrote and revised the manuscript. KV Pavlov, JJ Beutler, and RCH Scheffer revised the manuscript. RCH Scheffer is the article guarantor.</p><p>Financial disclosure: None to report.</p><p>Informed consent was obtained for this case report.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sequeira</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>X</given-names></name></person-group>
<article-title>Bile cast nephropathy: An often forgotten diagnosis</article-title>. <source>Hemodial Int</source>. <year>2015</year>;<volume>19</volume>:<fpage>132</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">24725377</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Walayat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kalva</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Palmer-Hill</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dhillon</surname><given-names>S</given-names></name></person-group>
<article-title>Bile cast nephropathy: A case report and review of the literature</article-title>. <source>World J Gastroenterol</source>. <year>2016</year>;<volume>22</volume>:<fpage>6328</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">27468221</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabatabaee</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Elahi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Savaj</surname><given-names>S</given-names></name></person-group>
<article-title>Bile cast nephropathy due to cholestatic jaundice after using stanozolol in 2 amateur bodybuilders</article-title>. <source>Iran J Kidney Dis</source>. <year>2015</year>;<volume>9</volume>:<fpage>331</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">26174462</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Slambrouck</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Salem</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Meehan</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>A</given-names></name></person-group>
<article-title>Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction</article-title>. <source>Kidney Int</source>. <year>2013</year>;<volume>84</volume>:<fpage>192</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23486516</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sitprija</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Kashemsant</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Sriratanaban</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arthachinta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Poshyachinda</surname><given-names>V</given-names></name></person-group>
<article-title>Renal function in obstructive jaundice in man: Cholangiocarcinoma model</article-title>. <source>Kidney Int</source>. <year>1990</year>;<volume>38</volume>:<fpage>948</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">2176256</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betjes</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Bajema</surname><given-names>I</given-names></name></person-group>
<article-title>The pathology of jaundice-related renal insufficiency: Cholemic nephrosis revisited</article-title>. <source>J Nephrol</source>. <year>2006</year>;<volume>19</volume>:<fpage>229</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">16736428</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group>
<article-title>Clearance of myoglobin by high cutoff continuous veno-venous hemodialysis in a patient with rhabdomyolysis: A case report</article-title>. <source>Hemodial Int</source>. <year>2015</year>;<volume>19</volume>:<fpage>135</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">24766332</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fickert</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Krones</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Pollheimer</surname><given-names>MJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice</article-title>. <source>Hepatology</source>. <year>2013</year>;<volume>58</volume>:<fpage>2056</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">23813550</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bairaktari</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Liamis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tsolas</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Elisaf</surname><given-names>M</given-names></name></person-group>
<article-title>Partially reversible renal tubular damage in patients with obstructive jaundice</article-title>. <source>Hepatology</source>. <year>2001</year>;<volume>33</volume>:<fpage>1365</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11391524</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokol</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Devereaux</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Khandwala</surname><given-names>R</given-names></name>, <name name-style="western"><surname>O&#x02019;Brien</surname><given-names>K</given-names></name></person-group>
<article-title>Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes</article-title>. <source>Hepatology</source>. <year>1993</year>;<volume>17</volume>:<fpage>869</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">8387948</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sellinger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haag</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Burckhardt</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gerok</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Knauf</surname><given-names>H</given-names></name></person-group>
<article-title>Sulfated bile acids inhibit Na(+)-H+ antiport in human kidney brush-border membrane vesicles</article-title>. <source>Am J Physiol</source>. <year>1990</year>;<volume>258</volume>:<fpage>F986</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">2158747</pub-id></mixed-citation></ref></ref-list></back></article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACG Case Rep J</journal-id><journal-id journal-id-type="iso-abbrev">ACG Case Rep J</journal-id><journal-id journal-id-type="publisher-id">crj</journal-id><journal-title-group><journal-title>ACG Case Reports Journal</journal-title></journal-title-group><issn pub-type="epub">2326-3253</issn><publisher><publisher-name>American College of Gastroenterology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358579</article-id><article-id pub-id-type="publisher-id">crj.2018.92</article-id><article-id pub-id-type="doi">10.14309/crj.2018.92</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Small Bowel</subject></subj-group></subj-group></article-categories><title-group><article-title>New Treatment Option for Autoimmune Enteropathy: A Rare Case of Intractable Diarrhea Treated with Vedolizumab</article-title><alt-title alt-title-type="left-running-head">Robbins et al</alt-title><alt-title alt-title-type="right-running-head">Autoimmune Enteropathy Treated with Vedolizumab</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Robbins</surname><given-names>Gordon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tracht</surname><given-names>Jessica</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Drew</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Iskandar</surname><given-names>Heba</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1">
<label>1</label>Department of Medicine, Emory University School of Medicine, Atlanta, GA</aff><aff id="aff2">
<label>2</label>Department of Pathology, Emory University School of Medicine, Atlanta, GA</aff><aff id="aff3">
<label>3</label>Department of Digestive Diseases, Emory University School of Medicine, Atlanta, GA</aff></contrib-group><author-notes><corresp>Correspondence: Gordon Robbins, MD, Department of Medicine, Faculty Office Building, Emory University at Grady, 49 Jesse Hill Jr Dr SE (Armstrong Street), Atlanta GA, 30303 (<email>gordon.robbins@emory.edu</email>).</corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2018</year></pub-date><volume>5</volume><elocation-id>e92</elocation-id><history><date date-type="received"><day>3</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Robbins et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="CG_CGCR180082.pdf"/><abstract><p>Autoimmune enteropathy is an uncommon cause of chronic diarrhea rarely seen in adults. The disease is secondary to an autoimmune process in the gut that leads to villous blunting and subsequent watery diarrhea, abdominal pain, and severe weight loss. The disease has only been described in 37 adults prior to our case, and variable treatment success has been documented with steroids, immunomodulators, and TNF-&#x003b1; inhibitors. This case is the first to show success in treating autoimmune enteropathy with vedolizumab and provides physicians with an additional therapeutic option when limited by a patient&#x02019;s comorbidities and side effects of other drugs.</p></abstract></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Rarely seen in adults, autoimmune enteropathy (AIE) is a condition characterized by chronic diarrhea and malabsorption caused by dysregulated antibody activity in the gut. Symptoms are not improved with dietary modification, and the diagnosis requires evidence of villous blunting on histology. Disease frequently becomes so severe that patients require total parenteral nutrition.<xref rid="B1" ref-type="bibr">1</xref></p><p>Because only 37 cases of adult AIE have been cited, there is little data regarding diagnosis and best practices for treatment and management. There are no formal guidelines for AIE treatment, and patients are typically treated with corticosteroids initially, such as prednisone or budesonide.<xref rid="B4" ref-type="bibr">4</xref> However, approximately two thirds of these patients are steroid-dependent or refractory and require additional immunomodulators for maintenance. Therapy with agents including azathioprine, 6-mercaptopurine (6-MP), cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus, and infliximab have all been used with variable responses both clinically and histologically.<xref rid="B1" ref-type="bibr">1</xref><sup>,</sup><xref rid="B2" ref-type="bibr">2</xref><sup>,</sup><xref rid="B5" ref-type="bibr">5</xref> To our knowledge, adult AIE has not been treated with vedolizumab.</p></sec><sec><title>Case Report</title><p>A 46-year-old woman with Hashimoto&#x02019;s thyroiditis, idiopathic cardiomyopathy, and a body mass index of 14 kg/m<sup>2</sup> presented to clinic with more than 20 years of watery diarrhea and a previous diagnosis of celiac disease with microscopic colitis. However, a strict gluten-free diet provided her no relief. Additionally, this patient lacked typical celiac disease susceptibility HLA genotypes. Stool studies were negative for infectious pathogens. Fecal leukocytes were absent, and a magnetic resonance image was also negative. Colonoscopy was significant for a loss of the normal vascular pattern throughout the colon (<xref ref-type="fig" rid="F1">Figure 1</xref>). Duodenal and colonic biopsies were negative for malignancy but did reveal villous blunting, chronic inflammation of the lamina propria, intraepithelial lymphocytes, and decreased goblet cells (<xref ref-type="fig" rid="F2">Figure 2</xref>). Her laboratory studies revealed a presence of anti-goblet cell antibodies. Therefore, our patient was diagnosed with AIE, now having clinical, histological, and serological support.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Endoscopic picture from colonoscopy in 2016 revealing diffusely edematous mucosa.</p></caption><graphic xlink:href="CG-CGCR180082F001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The patient&#x02019;s 2015 biopsy revealed (A) villous blunting, increased lamina propria lymphoplasmacytic infiltrate, increased epithelial lymphocytes in the duodenum, and absence of goblet cells; and (B) increased lamina propria lymphoplasmacytic infiltrate and an absence of goblet cells in the colon. Patchy neutrophilic cryptitis and a marked increase in intraepithelial crypt apoptosis are also seen.</p></caption><graphic xlink:href="CG-CGCR180082F002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Endoscopic picture taken from the patient's most recent colonoscopy depicting a less inflamed but still edematous mucosa.</p></caption><graphic xlink:href="CG-CGCR180082F003"/></fig><p>Previously the patient had only minimal improvement with budesonide and mesalamine, and each caused her significant lower extremity swelling. After her new diagnosis, she was initiated on high-dose prednisone, which was later tapered with the addition of 6-MP. Even on 6-MP 75 mg daily, our patient reported frequent diarrhea. She had poor tolerance of 6-MP, noting nausea and decreased appetite, and she ultimately developed leukopenia, requiring the daily dose to be reduced to 50 mg. At her next appointment, she was still having significant stool burden, reporting 10&#x02013;15 watery stools per day with significant pain and bloating. TNF-&#x003b1; inhibitors were contraindicated for our patient due to her cardiomyopathy, so she began treatment with vedolizumab infusions (300 mg every 8 weeks) while continuing 6-MP. After 2 infusions, her abdominal symptoms resolved, and her stool frequency significantly reduced to 5&#x02013;7 stools per day. Repeat colonoscopy revealed reduced inflammation and only mild congestion, although there was still histological evidence of villous blunting, increased intraepithelial lymphocytes, and decreased goblet cells (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="fig" rid="F4">Figure 4</xref>). Nevertheless, our patient now has a body mass index of 30 kg/m<sup>2</sup> with plans to taper 6-MP. Her albumin and total serum protein have improved from 2.7 g/dL and 5.8 g/dL to 4.2 g/dL and 6.8 g/dL, respectively. Iron and vitamin D deficiency have both resolved, and she has remained steroid-free without any dietary restrictions. At her last visit, she reported that her stools are more formed and occur with less urgency. Because we believe there is still opportunity for further improvement, particularly on a microscopic level, we are now increasing our patient&#x02019;s infusion frequency to every 4 weeks.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>(A) Recent biopsy of the duodenum showing findings similar to those of previous biopsies, though with some improvement in the degree of inflammation and the amount of lymphoplasmacytic lamina propria inflammation. Note the more intact villous architecture of the duodenum. (B) Recent biopsy of the colon showing findings similar to prior biopsies with improvement in the amount of lymphoplasmacytic lamina propria inflammation and neutrophilic cryptitis. Increased crypt epithelial apoptoses are still present. A paucity of goblet cells remains, but they are increased in number compared to previous biopsies.</p></caption><graphic xlink:href="CG-CGCR180082F004"/></fig></sec><sec><title>Discussion</title><p>AIE is often misdiagnosed, and patients who are plagued with weight loss, anorexia, and frequent watery bowel movements are often incorrectly treated. Consider AIE in patients with chronic diarrhea and malabsorption that do not improve with changes in diet and have characteristic findings on biopsy. More common disorders with similar presentations such as infection, inflammatory bowel disease (IBD), celiac disease, and microscopic colitis should be excluded as well.<xref rid="B4" ref-type="bibr">4</xref> Histologic changes are most common in the small intestine and typically include villous atrophy, cryptitis, and lamina propria expansion with lymphocytic infiltration.<xref rid="B3" ref-type="bibr">3</xref> Of the adult cases seen, approximately 80% of those diagnosed with AIE have a predisposition for autoimmune disease, and more than 90% are positive for anti-enterocyte or anti-goblet cell antibodies.<xref rid="B1" ref-type="bibr">1</xref><sup>,</sup><xref rid="B2" ref-type="bibr">2</xref> Anti-enterocyte or anti-goblet cell antibodies are supportive of the diagnosis but are intentionally excluded from diagnostic criteria because these antibodies have also been reported in patients with IBD and celiac disease and, rarely, even in these patients&#x02019; relatives. At this time, the positive predictive value of these antibodies and their significance are still unknown.<xref rid="B2" ref-type="bibr">2</xref><sup>,</sup><xref rid="B4" ref-type="bibr">4</xref></p><p>Only 37 cases of adult AIE have been reported in the literature. In our review, monoclonal antibodies, specifically TNF-&#x003b1; inhibitors, have been used in only 4 of these patients. However, to our knowledge, this is the first case involving the use of vedolizumab or any integrin-binding antibody. Vedolizumab is approved by the FDA for the treatment of both moderate-to-severe ulcerative colitis and Crohn&#x02019;s disease. TNF-&#x003b1; inhibitors can worsen cardiac conditions and cause exacerbations in those with reduced ventricular ejection fractions, like our patient. In this case, vedolizumab&#x02019;s use was extrapolated from its role in IBD therapy. By blocking lymphocyte trafficking in the intestine, vedolizumab controls inflammatory dysregulation that occurs in both IBD and AIE.<xref rid="B6" ref-type="bibr">6</xref> Successful treatment of AIE with vedolizumab is significant because AIE treatment requires ongoing immunosuppression, and steroid-sparing agents are preferred.<xref rid="B5" ref-type="bibr">5</xref> In addition, many patients, like ours, have poor or only modest response to steroid therapy. The previously mentioned list of immunosuppressive agents is not without their own side effects and specific contraindications. Further-more, vedolizumab is generally well-tolerated with gut specificity and remains a therapeutic option when TNF-&#x003b1; inhibitors are contraindicated, such as in our patient.</p><p>Ideally, increased awareness of adult AIE will allow for an increase in appropriate diagnoses of the disease. Thus, while formal treatment guidelines do not yet exist, sharing unique therapeutic successes is critical to best prepare our physicians for these difficult cases.</p></sec><sec><title>Disclosures</title><p>Author contributions: G. Robbins wrote the article and reviewed the literature. J. Tracht and D. Davis reviewed the histology and provided detailed description of the pathology appreciated at each stage. H. Iskandar edited the manuscript, provided the endoscopic images, and is the article guarantor.</p><p>Financial disclosure: None to report.</p><p>Informed consent was obtained for this case report.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gentile</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Pardi</surname><given-names>DS</given-names></name></person-group>
<article-title>Autoimmune enteropathy: A review and update of clinical management</article-title>. <source>Curr Gastroenterol Rep</source>. <year>2012</year>;<volume>14</volume>(<issue>5</issue>):<fpage>380</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">22810979</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Pardi</surname><given-names>DS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Adult autoimmune enteropathy: Mayo Clinic Rochester Experience</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2007</year>;<volume>5</volume>:<fpage>1282</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">17683994</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masia</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Peyton</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lauwers</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>I</given-names></name></person-group>
<article-title>Gastrointestinal biopsy findings of autoimmune enteropathy: A review of 25 cases</article-title>. <source>Am J Surg Pathol</source>. <year>2014</year>;<volume>38</volume>(<issue>10</issue>):<fpage>1319</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">25188868</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Siddiqui</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Chaitanya Arudra</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>de Las Casas</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Akpunonu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nawras</surname><given-names>A</given-names></name></person-group>
<article-title>Diffuse autoimmune enteropathy and colopathy in an adult patient successfully treated with adalimumab and a review of the literature</article-title>. <source>Am J Ther</source>. <year>2016</year>;<volume>23</volume>(<issue>3</issue>):<fpage>e963</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25379737</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daum</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sahin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Jansen</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Adult autoimmune enteropathy treated successfully with tacrolimus</article-title>. <source>Digestion</source>. <year>2003</year>;<volume>68</volume>(<issue>2-3</issue>):<fpage>86</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">14581765</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bye</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Jairath</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Travis</surname><given-names>SPL</given-names></name></person-group>
<article-title>Systematic review: The safety of vedolizumab for the treatment of inflammatory bowel disease</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2017</year>;<volume>46</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">28449273</pub-id></mixed-citation></ref></ref-list></back></article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACG Case Rep J</journal-id><journal-id journal-id-type="iso-abbrev">ACG Case Rep J</journal-id><journal-id journal-id-type="publisher-id">crj</journal-id><journal-title-group><journal-title>ACG Case Reports Journal</journal-title></journal-title-group><issn pub-type="epub">2326-3253</issn><publisher><publisher-name>American College of Gastroenterology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358580</article-id><article-id pub-id-type="publisher-id">crj.2018.89</article-id><article-id pub-id-type="doi">10.14309/crj.2018.89</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Liver</subject></subj-group></subj-group></article-categories><title-group><article-title>Bile Acid Synthesis Defect and Hyperinsulinism</article-title><alt-title alt-title-type="left-running-head">Rogers et al</alt-title><alt-title alt-title-type="right-running-head">Bile Acid Defect and Hyperinsulism</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rogers</surname><given-names>Michael</given-names></name><degrees>DO</degrees></contrib><contrib contrib-type="author"><name><surname>Sylvester</surname><given-names>Francisco</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Lichtman</surname><given-names>Steven</given-names></name><degrees>MD</degrees></contrib><aff id="aff1">Department of Pediatric Gastroenterology, University of North Carolina Children&#x02019;s Hospital, Chapel Hill, NC</aff></contrib-group><author-notes><corresp>Correspondence: Michael Rogers, MD, 260 MacNider Building, CB# 7220, Chapel Hill, NC 27599-7220 (<email>rogers09@med.unc.edu</email>).</corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2018</year></pub-date><volume>5</volume><elocation-id>e89</elocation-id><history><date date-type="received"><day>3</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>2</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Rogers et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="CG_CGCR180077.pdf"/><abstract><p>Congenital defects of bile acid synthesis are rare disorders that cause progressive liver dysfunction. Prolonged neonatal hyperinsulism (PNH) is a separate entity that leads to persistent hypoglycemia secondary to stress. We present a 4-month-old infant who presented with liver failure secondary to a bile acid synthesis defect. The patient&#x02019;s liver failure resolved with oral cholic acid therapy. This patient also developed PNH, which slowly resolved over time. This case illustrates a possible relationship between cholestatic liver failure and PNH. This relationship may help define specific stressors that increase the likelihood of developing PNH.</p></abstract></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>The primary bile acids, cholic acid and chenodeoxycholic acid, are derived from cholesterol in the liver via a series of intermediate steps catalyzed by specific enzymes.<xref rid="B1" ref-type="bibr">1</xref> Various enzyme deficiencies in this pathway lead to disruption in bile acid synthesis.<xref rid="B2" ref-type="bibr">2</xref> When bile acid synthesis is affected, the accumulation of hepatotoxic atypical bile acids and interruption of normal bile flow lead to liver injury and cholestasis.<xref rid="B3" ref-type="bibr">3</xref></p><p>Prolonged neonatal hyperinsulinism (PNH) is a rare form of transient hyperinsulinism (HI) that leads to a period of persistent hypoglycemia. PNH is typically confirmed by an insulin level greater than 3 mU/L, a glucagon challenge with a rise in glucose of at least 30 mg/dL, or requiring a glucose infusion rate (GIR) greater than 8 mg/kg/min to maintain euglycemia.<xref rid="B4" ref-type="bibr">4</xref> The etiology of PNH is unknown, but stress on a young infant is thought to trigger it.<xref rid="B5" ref-type="bibr">5</xref> PNH resolves over time, but resolution may take 6&#x02013;12 months.</p></sec><sec><title>Case Report</title><p>A previously healthy 4-month-old female infant presented to the emergency department with a 3-day history of worsening jaundice, lassitude, and poor feeding. Her physical exam was notable for scleral icterus without evidence of hepatosplenomegaly. Laboratory values are presented in <xref rid="T1" ref-type="table">Table 1</xref>. Her serum glucose was 51 mg/dL (normal 65&#x02013;150 mg/dL). She was started on intravenous (IV) 10% dextrose, and her hypoglycemia resolved. She was admitted for further evaluation and management of acute liver failure.</p><table-wrap id="T1" orientation="portrait" position="anchor"><label>Table 1.</label><caption><p>Laboratory test results.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Initial Presentation</th><th align="left" rowspan="1" colspan="1">1 Week on Cholic Acid</th><th align="left" rowspan="1" colspan="1">1 Month on Cholic Acid</th><th align="left" rowspan="1" colspan="1">Normal Range</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Total bilirubin, mg/dL</td><td rowspan="1" colspan="1">12.2</td><td rowspan="1" colspan="1">5.5</td><td rowspan="1" colspan="1">1.1</td><td rowspan="1" colspan="1">0&#x02013;1.2</td></tr><tr><td rowspan="1" colspan="1">Direct bilirubin, mg/dL</td><td rowspan="1" colspan="1">9.2</td><td rowspan="1" colspan="1">3.4</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">0&#x02013;0.4</td></tr><tr><td rowspan="1" colspan="1">Serum albumin, g/dL</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3.6</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">3.5&#x02013;5.0</td></tr><tr><td rowspan="1" colspan="1">Total protein, g/dL</td><td rowspan="1" colspan="1">5.6</td><td rowspan="1" colspan="1">5.8</td><td rowspan="1" colspan="1">6.5</td><td rowspan="1" colspan="1">6.6&#x02013;8.0</td></tr><tr><td rowspan="1" colspan="1">ALP, U/L</td><td rowspan="1" colspan="1">587</td><td rowspan="1" colspan="1">331</td><td rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1">145&#x02013;320</td></tr><tr><td rowspan="1" colspan="1">ALTP, U/L</td><td rowspan="1" colspan="1">1,514</td><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">12&#x02013;45</td></tr><tr><td rowspan="1" colspan="1">Prothrombin time, s</td><td rowspan="1" colspan="1">26.4</td><td rowspan="1" colspan="1">12.5</td><td rowspan="1" colspan="1">12.2</td><td rowspan="1" colspan="1">10.3&#x02013;13.3</td></tr><tr><td rowspan="1" colspan="1">INR</td><td rowspan="1" colspan="1">2.24</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">1.1</td><td rowspan="1" colspan="1">0.9&#x02013;1.2</td></tr><tr><td rowspan="1" colspan="1">GGT, U/L</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">11&#x02013;49</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ALP: alkaline phosphatase; ALT: alanine aminotransferase; INR: international normalized ratio; GGT: gamma-glutamyl transferase.</p></fn></table-wrap-foot></table-wrap><p>An ultrasound with Doppler flow revealed normal size and echogenicity of the liver, with normal patent flow of hepatic vasculature. A percutaneous liver biopsy revealed giant cell hepatitis and minute areas of confluent hepatocellular necrosis (<xref ref-type="fig" rid="F1">Figure 1</xref>). Serum total bile acids were undetectable. Serologies for CMV, EBV, enterovirus, and viral hepatitis A, B, and C were all negative.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(A) Liver biopsy revealing typical characteristics of a bile acid synthesis defect with giant cell hepatitis, marked canalicular cholestasis, and ductular reaction with fibroedematous expansion of portal areas. (B) Liver biopsy revealing typical characteristics of a bile acid synthesis defect with minute areas of confluent hepatocellular necrosis.</p></caption><graphic xlink:href="CG-CGCR180077F001"/></fig><p>Based on the suspicion of a bile acid synthetic defect, oral cholic acid (Cholbam<sup>TM</sup>) was started at 50 mg twice daily (10 mg/kg/dose). The urine bile acid profile obtained prior to starting cholic acid was consistent with a deficiency of the 3&#x003b2;-hydroxy-&#x003b4;5-c27-steroid oxidoreductase (HSD3B7) enzyme. Two pathogenic variants were subsequently detected in the <italic>HSD3B7</italic> gene: one copy of a c.45_46delAG and one copy of a c.453delC (p.Y151X). Parents denied consanguinity. The cholestasis and liver function improved with the use of cholic acid for 1 week (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>However, the patient continued to be persistently hypoglycemic. She was started on IV dextrose with a GIR of 8.7 mg/kg/min to maintain her serum glucose levels above 65 mg/dL. This was slowly weaned down over several weeks, but she was never able to be weaned down further than a GIR of 2.8 mg/kg/min. Complete metabolic evaluation including glycogen storage diseases and disorders of fatty acid oxidation was negative.</p><p>During a period of hypoglycemia, her plasma growth hormone was 9.46 ng/mL (0.01&#x02013;3.61 ng/mL), cortisol 3.3 &#x003bc;g/dL (1.7&#x02013;14.1 &#x003bc;g/dL), &#x003b2;-hydroxybutyrate 0.23 mmol/L (0.02&#x02013;0.27 mmol/L), insulin 2.5 mU/L (3&#x02013;25 mU/L), and C-peptide 0.5 ng/mL (1.1&#x02013;4.4 ng/mL). Urinalysis was negative for ketones during hypoglycemia. These tests were repeated during four episodes of hypoglycemia with similar results. In a glucagon challenge, serum glucose improved from 35 mg/dL to 55 mg/dL over 30 minutes. Given the presence of serum insulin during hypoglycemia with negative urine ketones, as well as a modest response to glucagon, a diagnosis of HI was made.</p><p>She was then started on oral diazoxide. However, she was unable to be weaned completely off of the IV dextrose after 1 week on diazoxide. She did not have any known genetic mutations associated with HI, including mutations in <italic>ABCC8</italic>, <italic>GCK</italic>, <italic>GLUD1</italic>, <italic>HADH</italic>, <italic>HNF1A</italic>, <italic>HNF4A</italic>, <italic>INSR</italic>, <italic>KCNJ11</italic>, <italic>KDM6A</italic>, <italic>KMT2D</italic>, <italic>PGM1</italic>, <italic>PMM2</italic>, and <italic>UPC2</italic>. Due to persistent hypoglycemia, she was transferred to the HI program at The Children&#x02019;s Hospital of Philadelphia for further evaluation. There she was slowly weaned off IV dextrose over the course of 1 week and remained normoglycemic solely on oral intake. She was discharged home and continues on cholic acid.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>We present a patient with a very unusual association of a defect in bile acid synthesis due to mutations in <italic>HSD3B7</italic> with PNH. To our knowledge, this association has not been reported previously. A bile acid synthesis defect was suspected in this patient based on serologic evidence of cholestatic liver failure (eg, elevated total and direct bilirubin, low albumin, and elevated international normalized ratio), normal gamma-glutamyl transferase, and undetectable serum total bile acids. The diagnosis was confirmed with mass spectrometric analysis of urine at the Cincinnati Children&#x02019;s Hospital and Medical Center, which revealed a pattern consistent with deficiency of the HSD3B7 enzyme. Subsequent genetic analysis revealed the underlying pathogenic mutations. HSD3B7 deficiency was treated with oral cholic acid (Cholbam<sup>TM</sup>), which may reduce the synthesis of abnormal bile acids and may promote bile acid&#x02013;dependent bile flow via an unknown mechanism.<xref rid="B6" ref-type="bibr">6</xref> Our patient had gradual resolution of liver dysfunction with cholic acid and is expected to have an excellent long-term prognosis. Liver transplant is not needed when there is prompt diagnosis with initiation of oral cholic acid to reverse the liver injury, as in this case.</p><p>PNH was suspected due to the presence of insulin during a period of hypoglycemia with absent ketones on urinalysis and no evidence of another metabolic disorder. In typical cases of hypoglycemia, ketones are present in the urine and the serum insulin level should be undetectable. Our patient required a GIR of more than 8 mg/kg/min early in the course, which met diagnostic criteria for PNH. The GIR was gradually decreased over a period of several weeks, which shows that the PNH was improving prior to further investigatory studies. This is why the insulin level, while inappropriately detectable, did not meet strict criteria for classic HI. C-peptide level corresponded well with the insulin level, which excluded exogenous insulin as a cause of patient&#x02019;s hypoglycemia. Negative genetic screening for HI along with the gradual resolution of the hypoglycemia without medication or surgery led to the diagnosis of PNH. Given this patient&#x02019;s underlying bile acid synthesis defect leading to early acute liver failure, it is plausible that this caused enough stress to the patient to cause PNH. The fact that the hypoglycemia gradually resolved after correction of the underlying liver disease further supports this theory.</p><p>This case highlights the possibility of persistent hypoglycemia due to PNH in the context of a bile acid synthesis defect that responds to cholic acid. Because the etiology of PNH is unknown, this possible relationship with cholestatic liver failure in a neonate may prove useful in determining more about the specific stressors that increase the likelihood of developing PNH. More understanding of the mechanism of PNH is required going forward.</p></sec><sec><title>Disclosures</title><p>Author contributions: All authors contributed equally to the manuscript. S Lichtman is the article guarantor.</p><p>Financial disclosure: None to report.</p><p>Informed consent was obtained for this case report.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bove</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Heubi</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Balistreri</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Setchell</surname><given-names>KD</given-names></name></person-group>
<article-title>Bile acid synthetic defects and liver disease: A comprehensive review</article-title>. <source>Pediatr Dev Pathol</source>. <year>2004</year>;<volume>7</volume>(<issue>4</issue>):<fpage>315</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">15383928</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heubi</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Setchell</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Bove</surname><given-names>KE</given-names></name></person-group>
<article-title>Inborn errors of bile acid metabolism</article-title>. <source>Semin Liver Dis</source>. <year>2007</year>;<volume>27</volume>(<issue>3</issue>):<fpage>282</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">17682975</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacquemin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Setchell</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>O&#x02019;Connell</surname><given-names>NC</given-names></name>, <etal>et al</etal></person-group>
<article-title>A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency</article-title>. <source>J Pediatr</source>. <year>1994</year>;<volume>125</volume>(<issue>3</issue>):<fpage>379</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">7915305</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoe</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Thornton</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Wanner</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Steinkrauss</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Simmons</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Stanley</surname><given-names>CA</given-names></name></person-group>
<article-title>Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism</article-title>. <source>J Pediatr</source>. <year>2006</year>;<volume>148</volume>(<issue>2</issue>):<fpage>207</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">16492430</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palladino</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Stanley</surname><given-names>CA</given-names></name></person-group>
<article-title>Hyperinsulinism in infancy and childhood: When an insulin level is not always enough</article-title>. <source>Clinical Chemistry</source>. <year>2008</year>;<volume>54</volume>(<issue>2</issue>):<fpage>256</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">18156285</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horslen</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Lawson</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Malone</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Clayton</surname><given-names>PT</given-names></name></person-group>
<article-title>3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency: Effect of chenodeoxycholic acid therapy on liver histology</article-title>. <source>J Inherit Metab Dis</source>. <year>1992</year>;<volume>15</volume>(<issue>1</issue>):<fpage>38</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">1583874</pub-id></mixed-citation></ref></ref-list></back></article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACG Case Rep J</journal-id><journal-id journal-id-type="iso-abbrev">ACG Case Rep J</journal-id><journal-id journal-id-type="publisher-id">crj</journal-id><journal-title-group><journal-title>ACG Case Reports Journal</journal-title></journal-title-group><issn pub-type="epub">2326-3253</issn><publisher><publisher-name>American College of Gastroenterology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358581</article-id><article-id pub-id-type="publisher-id">crj.2018.99</article-id><article-id pub-id-type="doi">10.14309/crj.2018.99</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Colon</subject></subj-group></subj-group></article-categories><title-group><article-title>Fusobacterium Septicemia with Liver and Lung Abscesses Due to Diverticulitis</article-title><alt-title alt-title-type="left-running-head">Sharma et al</alt-title><alt-title alt-title-type="right-running-head">Fusobacterium Septicemia Due to Diverticulitis</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sharma</surname><given-names>Akshay</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goyal</surname><given-names>Sachin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arsene</surname><given-names>Camelia</given-names></name><degrees>MD, PhD, MHS</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Krishnamoorthy</surname><given-names>Geetha</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ehrinpreis</surname><given-names>Murray</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1">
<label>1</label>Department of Internal Medicine, Sinai Grace Hospital, Detroit Medical Center/Wayne State University, Detroit, MI</aff><aff id="aff2">
<label>2</label>Department of Internal Medicine, Division of Gastroenterology, Detroit Medical Center/Wayne State University, Detroit, MI</aff></contrib-group><author-notes><corresp>Correspondence: Akshay Sharma, MD, 4201 Antoine St, Ste 2E, Detroit, MI 48201 (<email>g.akshaysharma@gmail.com</email>).</corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>19</day><month>12</month><year>2018</year></pub-date><volume>5</volume><elocation-id>e99</elocation-id><history><date date-type="received"><day>8</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Sharma et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="CG-CGCR180087.pdf"/><abstract><p>The <italic>Fusobacterium</italic> species is known for its association with septic thrombophlebitis of the internal jugular vein (Lemierre&#x02019;s syndrome). Lemierre&#x02019;s syndrome is associated with septic emboli to the liver and lungs, often causing multiple abscesses. We present a unique case of <italic>Fusobacterium</italic> septicemia in which the bacteria invaded the portal vein through the gastrointestinal mucosa due to diverticulitis and spread hematogenously to the liver and lungs, causing abscesses. It was treated successfully with 6 weeks of antibiotics. Physicians should be aware of this rare pathogen and suspect its presence in severe pharyngitis or culture-negative liver abscess.</p></abstract></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p><italic>Fusobacterium</italic> species is an obligate anaerobe residing in the oropharyngeal and gastrointestinal (GI) mucosa. Until recently, it was thought to be a rare cause of serious infections in humans.<xref rid="B1" ref-type="bibr">1</xref> It is known to cause Lemierre&#x02019;s syndrome, which is characterized by an oropharyngeal infection followed by septic thrombophlebitis of the internal jugular vein with embolization to different organs, including lungs and liver.<xref rid="B2" ref-type="bibr">2</xref> Although <italic>Fusobacterium</italic> infection originating in the GI tract is rare and seldom reported, it can invade the GI mucosa and cause bacteremia with fatal complications.<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">-</xref><xref rid="B5" ref-type="bibr">5</xref></p></sec><sec><title>Case Report</title><p>A 52-year-old man with a past medical history of hypertension and hidradenitis suppurativa presented with productive cough, chills, diarrhea, and decreased appetite for 1 week. Physical exam was significant for blood pressure 99/58 mm Hg, heart rate 100 beats/min, respiratory rate 20 breaths/min, and temperature 39.1<bold>&#x000b0;</bold>C. His head, neck, and throat examination was completely benign, with no lymphadenopathy, neck swelling/tenderness, tonsillar enlargement, or exudates. Abdominal examination revealed mild tenderness in the right upper quadrant without any peritoneal signs. Murphy&#x02019;s sign was negative. He had normal bowel sounds in all quadrants. Auscultation of the lungs revealed coarse crackles over the right lung base that did not disappear with deep breaths. Skin examination revealed purulent drainage from 2 tender, fluctuant masses 2&#x02013;3 cm in diameter in the left and right axillary regions. His laboratory tests revealed neutrophilic leukocytosis 17.2 &#x000d7; 10<sup>9</sup>/L with 12% bands. Lactic acid level was 3.5 mg/dL. Chest radiograph was normal. Blood cultures were obtained, and the patient was started on intravenous ceftriaxone, doxycycline, and metronidazole to address the possible right lower lobe pneumonia as well as the axillary abscesses. Incision and drainage of the abscesses was performed, but anaerobic culture and Gram stain were negative. Streptococcal pneumonia antigen, legionella urine antigen, mycoplasma antibody IgM, polymerase chain reaction for influenza A, B, and RSV, and DNA amplification for <italic>Clostridium difficile</italic> came back negative. Blood cultures were positive for <italic>Fusobacterium</italic> species on day 5 of admission. The patient was switched to ceftriaxone and clindamycin, but he continued to have persistent fever and tachycardia. Due to the persistent mild right upper quadrant abdominal pain, he underwent abdominal ultrasound, which showed a liver with heterogeneous texture suspicious for abscesses. Abdominal computed tomography (CT) demonstrated diverticulitis involving the distal descending and proximal sigmoid colon along with multiple liver abscesses and a lung abscess (<xref ref-type="fig" rid="F1">Figure 1</xref>). A CT-guided liver fine-needle aspiration core biopsy showed portal triaditis and findings consistent with liver abscess with a negative culture (<xref ref-type="fig" rid="F2">Figure 2</xref>). It showed no signs of malignancy. The patient was switched to ampicillin-sulbactam, which was continued for 6 weeks as he showed clinical improvement. Repeat CT of abdomen in 3 weeks showed that the abscesses were nearly resolved (<xref ref-type="fig" rid="F3">Figure 3</xref>). The patient underwent a follow-up colonoscopy, which was negative for polyps or malignancy.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Contrast-enhanced abdominal computed tomography (CT) showing multiple liver abscesses.</p></caption><graphic xlink:href="CG-CGCR180087F001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Hematoxylin and eosin stain of a cell block section of a liver abscess showing benign hepatocytes, associated numerous neutrophils, and degenerated hepatocytes (200&#x000d7;).</p></caption><graphic xlink:href="CG-CGCR180087F002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Contrast-enhanced abdominal CT after 3 weeks of treatment with ampicillin-sulbactam showing resolution of liver abscesses.</p></caption><graphic xlink:href="CG-CGCR180087F003"/></fig></sec><sec><title>Discussion</title><p>Fusobacteria are anaerobic, nonsporulating, Gram-negative bacilli that exhibit pleomorphism as well as irregular staining.<xref rid="B6" ref-type="bibr">6</xref>
<italic>F. nucleatum</italic> is the most common source of infection, while <italic>F. necrophorum</italic> is the most virulent species.<xref rid="B7" ref-type="bibr">7</xref> In one study, the incidence of such infections was estimated to be as low as 5.5 cases per million population per annum.<xref rid="B8" ref-type="bibr">8</xref> It has, however, recently been found to cause pharyngitis more commonly than streptococcus in young adults.<xref rid="B9" ref-type="bibr">9</xref> Its prevalence had declined considerably since the advent of antibiotics, but it has been on the rise again for the past 20 years.<xref rid="B10" ref-type="bibr">10</xref> One of the proposed explanations for this is the conservative use of antibiotics in the last 2 decades, during which time multiple cases of Lemierre&#x02019;s syndrome have been reported. This disease has several complications, such as osteomyelitis, meningitis, and acute respiratory distress syndrome.<xref rid="B11" ref-type="bibr">11</xref> Mortality was extremely high (90&#x02013;100%) in the preantibiotic era but has diminished with the advent of antibiotics.<xref rid="B11" ref-type="bibr">11</xref></p><p>Even though <italic>Fusobacterium</italic> most commonly causes bacteremia through the oropharynx and internal jugular vein, recent literature has shown that it can readily invade the GI mucosa as well and cause suppurative thrombophlebitis of the portal vein (pylephlebitis) in the setting of an inflammatory process in the gut.<xref rid="B3" ref-type="bibr">3</xref> Our case adds to this evidence and demonstrates how it can also cause septic emboli in the liver and lungs through the portal vein, similar to conventional Lemierre&#x02019;s syndrome, in which the site of infection is typically the oropharynx and involves the internal jugular vein. Antibiotics have improved survival from <italic>Fusobacterium</italic> infection. However, mortality is still quite high (10&#x02013;15%), as presented in other recent case reports.<xref rid="B3" ref-type="bibr">3</xref></p><p>Another case of <italic>Fusobacterium</italic> septicemia and liver abscess was recently reported in which the source was found to be colorectal cancer.<xref rid="B4" ref-type="bibr">4</xref> Recent literature has also shown an increased risk of colorectal cancer in patients with bacteremia from <italic>Fusobacterium nucleatum</italic>.<xref rid="B12" ref-type="bibr">12</xref>
<italic>Fusobacterium</italic> infection is difficult to diagnose because it is a fastidious organism that is difficult to culture and lacks pathognomonic symptoms. <italic>Fusobacterium</italic> may be resistant to penicillin, and there is widespread resistance to erythromycin and other macrolides.<xref rid="B11" ref-type="bibr">11</xref> It is treated with ampicillin-sulbactam, piperacillin tazobactam, metronidazole, or clindamycin.<sup>11</sup></p><p><italic>Fusobacterium</italic> can invade the GI mucosa due to an underlying pathology and cause sepsis with potentially fatal complications like liver and lung abscess. However, it can be successfully treated with early recognition and appropriate antibiotic treatment as illustrated by our case. <italic>Fusobacterium</italic> is a rare cause of liver abscess, and infection can occur by hematogenous seeding not only from the internal jugular vein secondary to tonsillar abscess, but also through the portal vein secondary to an underlying pathology of the gut. It is difficult to culture and therefore should be considered as an etiology in culture-negative liver abscess. <italic>Fusobacterium</italic> infection should be suspected in patients with severe exudative pharyngitis and culture-negative abscesses of the liver or lung. In cases of <italic>Fusobacterium</italic> septicemia in which the source of infection is unclear, a thorough investigation for an intra-abdominal pathology should be done, including a colonoscopy to rule out colorectal cancer as the cause of bacteremia.</p></sec><sec><title>Disclosures</title><p>Author contributions: All authors contributed equally to the writing and editing of the manuscript. G. Krishnamoorthy is the article guarantor.</p><p>Financial disclosure: None.</p><p>Informed consent was obtained for this case report.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huggan</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Murdoch</surname><given-names>DR</given-names></name></person-group>
<article-title>Fusobacterial infections: clinical spectrum and incidence of invasive disease</article-title>. <source>J Infection</source>. <year>2008</year>;<volume>57</volume>(<issue>4</issue>):<fpage>283</fpage>&#x02013;<lpage>89</lpage>.</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ianniello</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ferri</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Pinzani</surname><given-names>A</given-names></name></person-group>
<article-title>[Septic thrombophlebitis of the internal jugular vein due to Fusobacterium necrophorum (Lemierre's syndrome): Case report and review of literature]</article-title>. <source>Acta Otorhinolaryngol Ital</source>. <year>1998</year>;<volume>18</volume>(<issue>5</issue>):<fpage>332</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">10361747</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mellor</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Logan</surname><given-names>J</given-names></name></person-group>
<article-title>Lemierre's syndrome variant of the gut</article-title>. <source>BMJ Case Rep</source>. <year>2017</year>;<volume>20</volume>:<fpage>2017</fpage>.</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia Carretero</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lopez-Lomba</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vazquez-Gomez</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Rodriguez-Maya</surname><given-names>B</given-names></name></person-group>
<article-title>Bacteraemia and liver abscess due to Fusobacterium necrophorum</article-title>. <source>BMJ Case Rep</source>. <year>2017</year>;<volume>27</volume>:<fpage>2017</fpage>.</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Fukae</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kawai</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Case of Fusobacterium necrophorum sepsis (Lemierre's syndrome) with pulmonary septic emboli and liver abscess</article-title>. <source>Nihon Rinsho Meneki Gakkai Kaishi</source>. <year>2011</year>;<volume>34</volume>(<issue>5</issue>):<fpage>431</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">22041432</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langworth</surname><given-names>BF</given-names></name></person-group>
<article-title>Fusobacterium necrophorum: Its characteristics and role as an animal pathogen</article-title>. <source>Bacteriol Rev</source>. <year>1977</year>;<volume>41</volume>(<issue>2</issue>):<fpage>373</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">329831</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>WY</given-names></name>, <name name-style="western"><surname>Bellas</surname><given-names>J</given-names></name></person-group>
<article-title>Fusobacterium: Elusive cause of life-threatening septic thromboembolism</article-title>. <source>Can Fam Physician</source>. <year>2007</year>;<volume>53</volume>(<issue>9</issue>):<fpage>1451</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">17872873</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afra</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Laupland</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Leal</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lloyd</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gregson</surname><given-names>D</given-names></name></person-group>
<article-title>Incidence, risk factors, and outcomes of fusobacterium species bacteremia</article-title>. <source>BMC Infect Dis</source>. <year>2013</year>;<volume>13</volume>:<fpage>264</fpage>.<pub-id pub-id-type="pmid">23734900</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Centor</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Ratliff</surname><given-names>AE</given-names></name>, <etal>et al</etal></person-group>
<article-title>The clinical presentation of fusobacterium-positive and streptococcal-positive pharyngitis in a university health clinic: A cross-sectional study</article-title>. <source>Ann Internal Med</source>. <year>2015</year>;<volume>162</volume>(<issue>4</issue>):<fpage>241</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">25686164</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karkos</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Asrani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Karkos</surname><given-names>CD</given-names></name>, <etal>et al</etal></person-group>
<article-title>Lemierre's syndrome: A systematic review</article-title>. <source>Laryngoscope</source>. <year>2009</year>;<volume>119</volume>(<issue>8</issue>):<fpage>1552</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">19554637</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johannesen</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Bodtger</surname><given-names>U</given-names></name></person-group>
<article-title>Lemierre's syndrome: current perspectives on diagnosis and management</article-title>. <source>Infect Drug Resist</source>. <year>2016</year>;<volume>9</volume>:<fpage>221</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">27695351</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwong</surname><given-names>TNY</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Nakatsu</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer</article-title>. <source>Gastroenterology</source>. <year>2018</year>;<volume>155</volume>(<issue>2</issue>):<fpage>383</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">29729257</pub-id></mixed-citation></ref></ref-list></back></article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes Immun</journal-id><journal-id journal-id-type="iso-abbrev">Genes Immun</journal-id><journal-title-group><journal-title>Genes and Immunity</journal-title></journal-title-group><issn pub-type="ppub">1466-4879</issn><issn pub-type="epub">1476-5470</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358585</article-id><article-id pub-id-type="pmid">29362510</article-id><article-id pub-id-type="publisher-id">10</article-id><article-id pub-id-type="doi">10.1038/s41435-017-0010-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Choriodecidual leukocytes display a unique gene expression signature in spontaneous labor at term</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arenas-Hernandez</surname><given-names>Marcia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gomez-Lopez</surname><given-names>Nardhy</given-names></name><address><phone>+(313) 577-8904</phone><email>nardhy.gomez-lopez@wayne.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Garcia-Flores</surname><given-names>Valeria</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rangel-Escare&#x000f1;o</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Alvarez-Salas</surname><given-names>Luis M.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Martinez-Acu&#x000f1;a</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Vazquez-Perez</surname><given-names>Joel A.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2405-9045</contrib-id><name><surname>Vega-Sanchez</surname><given-names>Rodrigo</given-names></name><address><phone>+52 (55) 55209900</phone><email>r.vega@inper.mx</email><email>vegarodrig@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1773 5302</institution-id><institution-id institution-id-type="GRID">grid.419218.7</institution-id><institution>Departamento de Nutrici&#x000f3;n y Bioprogramaci&#x000f3;n, </institution><institution>Instituto Nacional de Perinatolog&#x000ed;a Isidro Espinosa de los Reyes, </institution></institution-wrap>Mexico City, MEX Mexico </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2165 8782</institution-id><institution-id institution-id-type="GRID">grid.418275.d</institution-id><institution>Departamento de Biomedicina Molecular, Centro de Investigaci&#x000f3;n y de Estudios Avanzados, </institution><institution>Instituto Polit&#x000e9;cnico Nacional, </institution></institution-wrap>Mexico City, MEX Mexico </aff><aff id="Aff3"><label>3</label>Department of Obstetrics and Gynecology &#x00026; Immunology and Microbiology, Wayne State University School of Medicine, Perinatal Research Initiative in Support of the Perinatology Research Branch, Detroit, MI USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2165 8782</institution-id><institution-id institution-id-type="GRID">grid.418275.d</institution-id><institution>Departamento de Gen&#x000e9;tica y Biolog&#x000ed;a Molecular, </institution><institution>Centro de Investigaci&#x000f3;n y de Estudios Avanzados, </institution></institution-wrap>Instituto Polit&#x000e9;cnico Nacional, Mexico City, MEX Mexico </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0627 7633</institution-id><institution-id institution-id-type="GRID">grid.452651.1</institution-id><institution>Departamento de Gen&#x000f3;mica Computacional, </institution><institution>Instituto Nacional de Medicina Gen&#x000f3;mica, </institution></institution-wrap>Mexico City, MEX Mexico </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8515 3604</institution-id><institution-id institution-id-type="GRID">grid.419179.3</institution-id><institution>Departamento de Micolog&#x000ed;a y Virolog&#x000ed;a, </institution><institution>Instituto Nacional de Enfermedades Respiratorias, </institution></institution-wrap>Mexico City, MEX Mexico </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2019</year></pub-date><volume>20</volume><issue>1</issue><fpage>56</fpage><lpage>68</lpage><history><date date-type="received"><day>1</day><month>9</month><year>2017</year></date><date date-type="rev-recd"><day>1</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. If you remix, transform, or build upon this article or a part thereof, you must distribute your contributions under the same license as the original. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Prior to and during the process of human labor, maternal circulating leukocytes infiltrate the maternal-fetal interface (choriodecidua) and become activated resembling choriodecidual leukocytes. Since, there is no evidence comparing maternal circulating and choriodecidual leukocytes, herein, we characterized their transcriptome and explored the biological processes enriched in choriodecidual leukocytes. From women undergoing spontaneous term labor we isolated circulating and choriodecidual leukocytes, performed microarray analysis (<italic>n</italic>&#x02009;=&#x02009;5) and qRT-PCR validation (<italic>n</italic>&#x02009;=&#x02009;9) and interaction network analysis with up-regulated genes. We found 270 genes up-regulated and only 17 genes down-regulated in choriodecidual leukocytes compared to maternal circulating leukocytes. The most up-regulated genes were <italic>CCL18, GPNMB, SEPP1, FN1, RNASE1, SPP1, C1QC</italic>, and <italic>PLTP</italic>. The biological processes enriched in choriodecidual leukocytes were cell migration and regulation of immune response, chemotaxis, and humoral immune responses. Our results show striking differences between the transcriptome of choriodecidual and maternal circulating leukocytes. Choriodecidual leukocytes are enriched in immune mediators implicated in the spontaneous process of labor at term.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Labor is recognized as a physiological process of sterile inflammation [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>], characterized by the infiltration of immune cells into the cervix [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>], myometrium [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], and maternal-fetal interface [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. This interface includes two areas of contact between the mother and the fetus: the decidua parietalis, which lines the uterine cavity not covered by the placenta and is juxtaposed to the chorion laeve; and the decidua basalis, which lays on the basal plate of the placenta and is invaded by the interstitial trophoblast [<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17"> 17</xref>]. Decidua parietalis is composed of stroma-type cells, glandular cells, and leukocytes [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], and the portion that is attainable is attached to the chorioamniotic membranes; therefore, this anatomical site is known as the choriodecidua [<xref ref-type="bibr" rid="CR16">16</xref>]. Since the choriodecidua represents the major site of fetal antigenic exposure to the maternal immune system, our studies have focused on understanding the mechanisms whereby maternal leukocytes are recruited into the maternal-fetal interface and their role in the processes of term and preterm labor [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par3">The current hypothesis is that the chorioamniotic membranes exhibit chemotactic processes driven by specific chemokines in order to recruit maternal circulating leukocytes into the choriodecidua [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. In addition, the responsiveness of peripheral leukocytes to be attracted to chemotactic stimuli derived from the chorioamniotic membranes seems to be a key feature in this process [<xref ref-type="bibr" rid="CR26">26</xref>]. Consistent with such a hypothesis, previous studies have demonstrated that peripheral leukocytes displayed increased chemotactic activity and cytokine production during the process of labor [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], resembling an inflammatory phenotype similar to that observed in pathological conditions [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Collectively, these data suggest that the chorioamniotic membranes, and most likely the decidual stromal cells, recruit maternal circulating leukocytes into the choriodecidua prior to and during the process of labor. Following recruitment, the choriodecidual leukocytes expressed cell adhesion molecules (CAMs) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>] and labor mediators including cytokines/chemokines [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref><xref ref-type="bibr" rid="CR34">, 34</xref>] and matrix metalloproteinases (MMPs) [<xref ref-type="bibr" rid="CR35">35</xref>]. All of which elicit cell-mediated immune responses that participate in the process of labor [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par4">All of the above suggests that the maternal circulating leukocytes are activated prior to and during the process of labor and that their activation status may be similar to that expressed by the choriodecidual leukocytes. However, a direct comparison between the choriodecidual leukocytes and maternal circulating leukocytes during the process of labor at term has not been made. The aims of this study were: (1) to characterize the transcriptome of the choriodecidual leukocytes and maternal circulating leukocytes from the same woman undergoing spontaneous labor at term, and (2) to explore the biological processes enriched in these choriodecidual leukocytes.</p></sec><sec id="Sec2" sec-type="results"><title>Results and discussion</title><p id="Par5">To our knowledge, this is the first study comparing the transcriptomic signatures of the choriodecidual leukocytes and maternal circulating leukocytes during the process of labor at term. Our first finding was that the transcriptome of the choriodecidual leukocytes was different from the transcriptome of the maternal circulating leukocytes. The heat map in Fig. <xref rid="Fig1" ref-type="fig">1</xref> shows a mirrored image between the transcriptomic changes of choriodecidual leukocytes and maternal circulating leukocytes; in other words, up-regulated genes in the choriodecidua were down-regulated in the maternal circulation and vice versa. Similarly, the volcano plot (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) shows the differentially expressed genes between choriodecidual and maternal circulating leukocytes.<fig id="Fig1"><label>Fig. 1</label><caption><p>Heat map representation of the differentially expressed genes in the choriodecidual leukocytes or maternal circulating leukocytes from women who underwent spontaneous labor at term. Heat map displays the unsupervised hierarchical clustering of the 775 genes demonstrating the transcriptomic changes of choriodecidual leukocytes and maternal circulating leukocytes. The negative <italic>z</italic>-score indicates the down-regulated genes (shown in green), and the positive <italic>z</italic>-score indicates the up-regulated genes (shown in red). The labels on the top of the heat map indicate individual women samples (<italic>n</italic>&#x02009;=&#x02009;5 each)</p></caption><graphic xlink:href="41435_2017_10_Fig1_HTML" id="d29e511"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Volcano plot displaying the differentially expressed genes between choriodecidual leukocytes and maternal circulating leukocytes from women who underwent spontaneous labor at term. B-statistic values are plotted against the log fold change (base 2). A B-statistic of zero corresponds to a 50&#x02013;50 chance that the gene is differentially expressed (gray line). A B-statistic of &#x02265;3 indicates a 95.3% chance that the gene is differentially expressed (black line). On the <italic>x</italic>-axis, values outside the red lines represent log fold changes of &#x02265;0.3 between choriodecidual leukocytes and maternal circulating leukocytes. Red dots represent the up-regulated genes and green dots represent the down-regulated genes</p></caption><graphic xlink:href="41435_2017_10_Fig2_HTML" id="d29e523"/></fig></p><p id="Par6">These results demonstrate that there are drastic differences between the transcriptome of the choriodecidual leukocytes compared to the maternal circulating leukocytes during the process of labor at term. Although there is no doubt that the maternal circulating leukocytes are activated prior to and during the process of labor [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>], the findings, herein, support the concept that the maternal-fetal interface (decidua basalis and choriodecidua or decidua parietalis) is an enriched microenvironment that includes specific leukocyte subsets during the process of labor [<xref ref-type="bibr" rid="CR22">22</xref><xref ref-type="bibr" rid="CR33">, 33</xref>].</p><p id="Par7">We found that choriodecidual leukocytes overexpressed several genes associated with cell migration and regulation of immune response. A total of 270 genes were up-regulated while only 17 genes were down-regulated in the choriodecidual leukocytes compared to the maternal circulating leukocytes. The top 100 up-regulated genes are displayed in Table <xref rid="Tab1" ref-type="table">1</xref>. The most up-regulated genes (fold change &#x0003e;32) in choriodecidual leukocytes, demonstrated by qRT-PCR (Table <xref rid="Tab2" ref-type="table">2</xref>) were the following: (1) C-C motif chemokine ligand 18 (<italic>CCL18</italic>), (2) glycoprotein nmb (<italic>GPNMB</italic>), (3) selenoprotein P (<italic>SEPP1</italic>), (4) fibronectin 1 (<italic>FN1</italic>), (5) ribonuclease A family member 1, pancreatic (<italic>RNASE1</italic>), (6) secreted phosphoprotein 1 (<italic>SPP1</italic>), (7) complement C1q C chain (<italic>C1QC</italic>), and (8) phospholipid transfer protein (<italic>PLTP</italic>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>List of the top 100 differentially up-regulated genes between choriodecidual leukocytes and maternal circulating leukocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Name</th><th>Symbol</th><th>Log fold change (base 2)</th><th>Fold change</th><th><italic>B</italic>-statistic</th><th>Adjusted <italic>P-</italic> value</th></tr></thead><tbody><tr><td>C-C motif chemokine ligand 18</td><td>
<italic>CCL18</italic>
</td><td>6.98</td><td>126.50</td><td>17.77</td><td>3.7E&#x02212;09</td></tr><tr><td>Glycoprotein nmb</td><td>
<italic>GPNMB</italic>
</td><td>6.47</td><td>88.89</td><td>16.91</td><td>9.4E&#x02212;09</td></tr><tr><td>Selenoprotein P</td><td>
<italic>SEPP1</italic>
</td><td>6.40</td><td>84.51</td><td>15.36</td><td>8.3E&#x02212;08</td></tr><tr><td>Fibronectin 1</td><td>
<italic>FN1</italic>
</td><td>6.17</td><td>71.80</td><td>17.17</td><td>9.3E&#x02212;09</td></tr><tr><td>Ribonuclease A family member 1, pancreatic</td><td>
<italic>RNASE1</italic>
</td><td>5.98</td><td>63.22</td><td>18.02</td><td>3.7E&#x02212;09</td></tr><tr><td>Secreted phosphoprotein 1</td><td>
<italic>SPP1</italic>
</td><td>5.69</td><td>51.59</td><td>8.94</td><td>2.9E&#x02212;05</td></tr><tr><td>Complement C1q C chain</td><td>
<italic>C1QC</italic>
</td><td>5.39</td><td>41.93</td><td>13.49</td><td>7.2E&#x02212;07</td></tr><tr><td>Phospholipid transfer protein</td><td>
<italic>PLTP</italic>
</td><td>5.12</td><td>34.70</td><td>12.08</td><td>2.6E&#x02212;06</td></tr><tr><td>C-C motif chemokine ligand 2</td><td>
<italic>CCL2</italic>
</td><td>4.87</td><td>29.27</td><td>9.37</td><td>2.3E&#x02212;05</td></tr><tr><td>Cathepsin L</td><td>
<italic>CTSL</italic>
</td><td>4.81</td><td>28.10</td><td>15.40</td><td>8.3E&#x02212;08</td></tr><tr><td>Formyl peptide receptor 3</td><td>
<italic>FPR3</italic>
</td><td>4.81</td><td>28.05</td><td>16.94</td><td>9.4E&#x02212;09</td></tr><tr><td>Legumain</td><td>
<italic>LGMN</italic>
</td><td>4.78</td><td>27.54</td><td>13.01</td><td>1.1E&#x02212;06</td></tr><tr><td>Complement C1q B chain</td><td>
<italic>C1QB</italic>
</td><td>4.76</td><td>27.18</td><td>14.10</td><td>3.5E&#x02212;07</td></tr><tr><td>Mannose receptor C-type 1</td><td>
<italic>MRC1</italic>
</td><td>4.60</td><td>24.33</td><td>12.12</td><td>2.6E&#x02212;06</td></tr><tr><td>Peripheral myelin protein 22</td><td>
<italic>PMP22</italic>
</td><td>4.52</td><td>22.94</td><td>16.47</td><td>1.8E&#x02212;08</td></tr><tr><td>Metallothionein 1G</td><td>
<italic>MT1G</italic>
</td><td>4.30</td><td>19.71</td><td>12.52</td><td>1.9E&#x02212;06</td></tr><tr><td>Solute carrier organic anion transporter family member 2B1</td><td>
<italic>SLCO2B1</italic>
</td><td>4.28</td><td>19.47</td><td>10.18</td><td>1.3E&#x02212;05</td></tr><tr><td>Epithelial membrane protein</td><td>
<italic>EMP1</italic>
</td><td>4.24</td><td>18.94</td><td>9.03</td><td>2.8E&#x02212;05</td></tr><tr><td>Metallothionein 1&#x000d7;</td><td>
<italic>MT1X</italic>
</td><td>4.23</td><td>18.75</td><td>10.96</td><td>7.3E&#x02212;06</td></tr><tr><td>V-set and immunoglobulin domain containing 4</td><td>
<italic>VSIG4</italic>
</td><td>4.01</td><td>16.07</td><td>14.08</td><td>3.5E&#x02212;07</td></tr><tr><td>T-cell immunoglobulin and mucin domain containing 4</td><td>
<italic>TIMD4</italic>
</td><td>3.99</td><td>15.89</td><td>5.82</td><td>3.2E&#x02212;04</td></tr><tr><td>Regulator of G-protein signaling 1</td><td>
<italic>RGS1</italic>
</td><td>3.90</td><td>14.95</td><td>11.10</td><td>6.6E&#x02212;06</td></tr><tr><td>Metallothionein 1E</td><td>
<italic>MT1E</italic>
</td><td>3.88</td><td>14.75</td><td>14.56</td><td>2.4E&#x02212;07</td></tr><tr><td>C-&#x000d7;-C motif chemokine ligand 10</td><td>
<italic>CXCL10</italic>
</td><td>3.79</td><td>13.83</td><td>8.37</td><td>4.6E&#x02212;05</td></tr><tr><td>Membrane spanning 4-domains A4A</td><td>
<italic>MS4A4A</italic>
</td><td>3.64</td><td>12.48</td><td>10.27</td><td>1.2E&#x02212;05</td></tr><tr><td>Oxidized low density lipoprotein receptor 1</td><td>
<italic>OLR1</italic>
</td><td>3.63</td><td>12.35</td><td>4.39</td><td>8.2E&#x02212;04</td></tr><tr><td>Folate receptor beta</td><td>
<italic>FOLR2</italic>
</td><td>3.62</td><td>12.30</td><td>8.74</td><td>3.4E&#x02212;05</td></tr><tr><td>Interferon alpha inducible protein 27</td><td>
<italic>IFI27</italic>
</td><td>3.59</td><td>12.00</td><td>7.18</td><td>1.1E&#x02212;04</td></tr><tr><td>Complement C1q A chain</td><td>
<italic>C1QA</italic>
</td><td>3.58</td><td>11.95</td><td>13.32</td><td>8.3E&#x02212;07</td></tr><tr><td>Apolipoprotein C1</td><td>
<italic>APOC1</italic>
</td><td>3.57</td><td>11.85</td><td>11.67</td><td>3.6E&#x02212;06</td></tr><tr><td>Macrophage scavenger receptor 1</td><td>
<italic>MSR1</italic>
</td><td>3.55</td><td>11.73</td><td>8.94</td><td>2.9E&#x02212;05</td></tr><tr><td>Interleukin 6</td><td>
<italic>IL6</italic>
</td><td>3.52</td><td>11.49</td><td>6.41</td><td>2.1E&#x02212;04</td></tr><tr><td>Complement C2</td><td>
<italic>C2</italic>
</td><td>3.50</td><td>11.34</td><td>9.80</td><td>1.8E&#x02212;05</td></tr><tr><td>CD80 molecule</td><td>
<italic>CD80</italic>
</td><td>3.42</td><td>10.70</td><td>6.03</td><td>2.7E&#x02212;04</td></tr><tr><td>Ectonucleotide pyrophosphatase/phosphodiesterase 2</td><td>
<italic>ENPP2</italic>
</td><td>3.41</td><td>10.65</td><td>9.23</td><td>2.5E&#x02212;05</td></tr><tr><td>Matrix metallopeptidase 19</td><td>
<italic>MMP19</italic>
</td><td>3.27</td><td>9.64</td><td>8.86</td><td>3.1E&#x02212;05</td></tr><tr><td>C-C motif chemokine ligand 13</td><td>
<italic>CCL13</italic>
</td><td>3.22</td><td>9.34</td><td>7.70</td><td>7.7E&#x02212;05</td></tr><tr><td>Metallothionein 1M</td><td>
<italic>MT1M</italic>
</td><td>3.22</td><td>9.34</td><td>3.50</td><td>1.6E&#x02212;03</td></tr><tr><td>Nuclear protein 1, transcriptional regulator</td><td>
<italic>NUPR1</italic>
</td><td>3.22</td><td>9.33</td><td>14.32</td><td>3.0E&#x02212;07</td></tr><tr><td>ADAM like decysin 1</td><td>
<italic>ADAMDEC1</italic>
</td><td>3.20</td><td>9.18</td><td>10.16</td><td>1.3E&#x02212;05</td></tr><tr><td>C-C motif chemokine ligand 4</td><td>
<italic>CCL4</italic>
</td><td>3.19</td><td>9.14</td><td>5.40</td><td>4.3E&#x02212;04</td></tr><tr><td>Neuropilin 2</td><td>
<italic>NRP2</italic>
</td><td>3.08</td><td>8.48</td><td>11.79</td><td>3.4E&#x02212;06</td></tr><tr><td>SLAM family member 8</td><td>
<italic>SLAMF8</italic>
</td><td>3.03</td><td>8.17</td><td>9.57</td><td>2.2E&#x02212;05</td></tr><tr><td>Plasminogen activator, urokinase</td><td>
<italic>PLAU</italic>
</td><td>3.02</td><td>8.12</td><td>6.60</td><td>1.8E&#x02212;04</td></tr><tr><td>Chromosome 15 open reading frame 48</td><td>
<italic>C15orf48</italic>
</td><td>2.96</td><td>7.77</td><td>3.00</td><td>2.2E&#x02212;03</td></tr><tr><td>Malic enzyme 1</td><td>
<italic>ME1</italic>
</td><td>2.92</td><td>7.57</td><td>10.33</td><td>1.2E&#x02212;05</td></tr><tr><td>Activating transcription factor 3</td><td>
<italic>ATF3</italic>
</td><td>2.92</td><td>7.56</td><td>7.58</td><td>8.4E&#x02212;05</td></tr><tr><td>DAB2, clathrin adapter protein</td><td>
<italic>DAB2</italic>
</td><td>2.88</td><td>7.36</td><td>5.58</td><td>3.6E&#x02212;04</td></tr><tr><td>C-C motif chemokine ligand 8</td><td>
<italic>CCL8</italic>
</td><td>2.86</td><td>7.26</td><td>4.46</td><td>8.0E&#x02212;04</td></tr><tr><td>Formin like 2</td><td>
<italic>FMNL2</italic>
</td><td>2.85</td><td>7.20</td><td>9.51</td><td>2.2E&#x02212;05</td></tr><tr><td>CD163 molecule</td><td>
<italic>CD163</italic>
</td><td>2.82</td><td>7.07</td><td>5.21</td><td>4.7E&#x02212;04</td></tr><tr><td>Ral guanine nucleotide dissociation stimulator like 1</td><td>
<italic>RGL1</italic>
</td><td>2.81</td><td>7.03</td><td>7.98</td><td>6.2E&#x02212;05</td></tr><tr><td>Sprouty related EVH1 domain containing 1</td><td>
<italic>SPRED1</italic>
</td><td>2.81</td><td>7.01</td><td>9.34</td><td>2.3E&#x02212;05</td></tr><tr><td>Neuropilin 2</td><td>
<italic>NRP2</italic>
</td><td>2.79</td><td>6.92</td><td>8.70</td><td>3.5E&#x02212;05</td></tr><tr><td>Lipoma HMGIC fusion partner-like 2</td><td>
<italic>LHFPL2</italic>
</td><td>2.77</td><td>6.81</td><td>10.74</td><td>8.3E&#x02212;06</td></tr><tr><td>Metallothionein 1A</td><td>
<italic>MT1A</italic>
</td><td>2.76</td><td>6.78</td><td>7.54</td><td>8.5E&#x02212;05</td></tr><tr><td>C-X-C motif chemokine ligand 2</td><td>
<italic>CXCL2</italic>
</td><td>2.74</td><td>6.69</td><td>4.31</td><td>8.7E&#x02212;04</td></tr><tr><td>Stearoyl-CoA desaturase</td><td>
<italic>SCD</italic>
</td><td>2.74</td><td>6.69</td><td>6.05</td><td>2.7E&#x02212;04</td></tr><tr><td>Solute carrier family 7 member 8</td><td>
<italic>SLC7A8</italic>
</td><td>2.74</td><td>6.66</td><td>4.81</td><td>6.3E&#x02212;04</td></tr><tr><td>Phospholipase A2 group VII</td><td>
<italic>PLA2G7</italic>
</td><td>2.73</td><td>6.61</td><td>10.36</td><td>1.2E&#x02212;05</td></tr><tr><td>Transcobalamin 2</td><td>
<italic>TCN2</italic>
</td><td>2.72</td><td>6.61</td><td>9.15</td><td>2.5E&#x02212;05</td></tr><tr><td>Chloride intracellular channel 2</td><td>
<italic>CLIC2</italic>
</td><td>2.72</td><td>6.61</td><td>10.27</td><td>1.2E&#x02212;05</td></tr><tr><td>Lamin A/C</td><td>
<italic>LMNA</italic>
</td><td>2.72</td><td>6.60</td><td>6.10</td><td>2.6E&#x02212;04</td></tr><tr><td>C-C motif chemokine ligand 3</td><td>
<italic>CCL3</italic>
</td><td>2.72</td><td>6.57</td><td>6.40</td><td>2.1E&#x02212;04</td></tr><tr><td>MER proto-oncogene, tyrosine kinase</td><td>
<italic>MERTK</italic>
</td><td>2.71</td><td>6.55</td><td>9.53</td><td>2.2E&#x02212;05</td></tr><tr><td>Olfactomedin like 2B</td><td>
<italic>OLFML2B</italic>
</td><td>2.71</td><td>6.54</td><td>8.05</td><td>5.9E&#x02212;05</td></tr><tr><td>G protein-coupled receptor 34</td><td>
<italic>GPR34</italic>
</td><td>2.71</td><td>6.53</td><td>5.27</td><td>4.5E&#x02212;04</td></tr><tr><td>RasGEF domain family member 1B</td><td>
<italic>RASGEF1B</italic>
</td><td>2.68</td><td>6.42</td><td>3.26</td><td>1.8E&#x02212;03</td></tr><tr><td>GDNF family receptor alpha 2</td><td>
<italic>GFRA2</italic>
</td><td>2.68</td><td>6.41</td><td>7.58</td><td>8.4E&#x02212;05</td></tr><tr><td>Serpin family E member 1</td><td>
<italic>SERPINE1</italic>
</td><td>2.67</td><td>6.38</td><td>9.12</td><td>2.5E&#x02212;05</td></tr><tr><td>Serpin family F member 1</td><td>
<italic>SERPINF1</italic>
</td><td>2.66</td><td>6.31</td><td>6.47</td><td>2.0E&#x02212;04</td></tr><tr><td>Epiregulin</td><td>
<italic>EREG</italic>
</td><td>2.65</td><td>6.26</td><td>4.56</td><td>7.6E&#x02212;04</td></tr><tr><td>Interferon gamma</td><td>
<italic>IFNG</italic>
</td><td>2.64</td><td>6.24</td><td>4.20</td><td>9.5E&#x02212;04</td></tr><tr><td>Nuclear receptor subfamily 4 group A member 1</td><td>
<italic>NR4A1</italic>
</td><td>2.61</td><td>6.10</td><td>6.34</td><td>2.1E&#x02212;04</td></tr><tr><td>Amphiregulin</td><td>
<italic>AREG</italic>
</td><td>2.58</td><td>5.97</td><td>3.28</td><td>1.8E&#x02212;03</td></tr><tr><td>Hematopoietic prostaglandin D synthase</td><td>
<italic>HPGDS</italic>
</td><td>2.58</td><td>5.97</td><td>8.38</td><td>4.6E&#x02212;05</td></tr><tr><td>Metallothionein 1H</td><td>
<italic>MT1H</italic>
</td><td>2.56</td><td>5.89</td><td>4.94</td><td>5.9E&#x02212;04</td></tr><tr><td>Pleckstrin homology like domain family A member 1</td><td>
<italic>PHLDA1</italic>
</td><td>2.56</td><td>5.88</td><td>5.73</td><td>3.2E&#x02212;04</td></tr><tr><td>Fatty acid binding protein 3</td><td>
<italic>FABP3</italic>
</td><td>2.53</td><td>5.79</td><td>5.72</td><td>3.2E&#x02212;04</td></tr><tr><td>Heat shock protein family B</td><td>
<italic>HSPB1</italic>
</td><td>2.53</td><td>5.78</td><td>4.72</td><td>6.7E&#x02212;04</td></tr><tr><td>Acid phosphatase 5, tartrate resistant</td><td>
<italic>ACP5</italic>
</td><td>2.51</td><td>5.71</td><td>9.43</td><td>2.2E&#x02212;05</td></tr><tr><td>CD69 molecule</td><td>
<italic>CD69</italic>
</td><td>2.51</td><td>5.70</td><td>6.94</td><td>1.4E&#x02212;04</td></tr><tr><td>Sialic acid binding Ig like lectin 1</td><td>
<italic>SIGLEC1</italic>
</td><td>2.49</td><td>5.61</td><td>5.75</td><td>3.2E&#x02212;04</td></tr><tr><td>Solute carrier family 30 member 1</td><td>
<italic>SLC30A1</italic>
</td><td>2.47</td><td>5.56</td><td>3.16</td><td>2.0E&#x02212;03</td></tr><tr><td>X-C motif chemokine ligand 2</td><td>
<italic>XCL2</italic>
</td><td>2.46</td><td>5.51</td><td>4.44</td><td>8.0E&#x02212;04</td></tr><tr><td>Metallothionein 1F</td><td>
<italic>MT1F</italic>
</td><td>2.45</td><td>5.46</td><td>5.86</td><td>3.1E&#x02212;04</td></tr><tr><td>Chemerin chemokine-like receptor 1</td><td>
<italic>CMKLR1</italic>
</td><td>2.44</td><td>5.44</td><td>4.85</td><td>6.1E&#x02212;04</td></tr><tr><td>Metallothionein 1 pseudogene 3</td><td>
<italic>MT1P3</italic>
</td><td>2.41</td><td>5.31</td><td>9.93</td><td>1.6E&#x02212;05</td></tr><tr><td>Acid phosphatase 2, lysosoma</td><td>
<italic>ACP2</italic>
</td><td>2.39</td><td>5.23</td><td>10.11</td><td>1.4E&#x02212;05</td></tr><tr><td>Leukocyte immunoglobulin like receptor B4</td><td>
<italic>LILRB4</italic>
</td><td>2.38</td><td>5.20</td><td>11.77</td><td>3.4E&#x02212;06</td></tr><tr><td>Transferrin receptor</td><td>
<italic>TFRC</italic>
</td><td>2.37</td><td>5.19</td><td>6.66</td><td>1.7E&#x02212;04</td></tr><tr><td>Tetraspanin 15</td><td>
<italic>TSPAN15</italic>
</td><td>2.35</td><td>5.11</td><td>9.35</td><td>2.3E&#x02212;05</td></tr><tr><td>Peroxisome proliferator activated receptor gamma</td><td>
<italic>PPARG</italic>
</td><td>2.35</td><td>5.09</td><td>9.68</td><td>2.0E&#x02212;05</td></tr><tr><td>Solute carrier family 1 member 3</td><td>
<italic>SLC1A3</italic>
</td><td>2.35</td><td>5.09</td><td>3.83</td><td>1.2E&#x02212;03</td></tr><tr><td>Colony stimulating factor 1</td><td>
<italic>CSF1</italic>
</td><td>2.34</td><td>5.07</td><td>5.83</td><td>3.1E&#x02212;04</td></tr><tr><td>Serpin family G member 1</td><td>
<italic>SERPING1</italic>
</td><td>2.31</td><td>4.96</td><td>6.65</td><td>1.8E&#x02212;04</td></tr><tr><td>Dual specificity phosphatase 10</td><td>
<italic>DUSP10</italic>
</td><td>2.31</td><td>4.94</td><td>5.70</td><td>3.3E&#x02212;04</td></tr><tr><td>Solute carrier family 41 member 2</td><td>
<italic>SLC41A2</italic>
</td><td>2.30</td><td>4.92</td><td>7.41</td><td>9.5E&#x02212;05</td></tr><tr><td>MAM domain containing 2</td><td>
<italic>MAMDC2</italic>
</td><td>2.30</td><td>4.91</td><td>5.24</td><td>4.6E&#x02212;04</td></tr><tr><td>Nuclear receptor subfamily 4 group A member 3</td><td>
<italic>NR4A3</italic>
</td><td>2.27</td><td>4.82</td><td>5.36</td><td>4.4E&#x02212;04</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>qRT-PCR validation in selected genes differentially expressed in the choriodecidual leukocytes and maternal circulating leukocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene name</th><th>Gene symbol</th><th colspan="3">qRT-PCR (<italic>n</italic>&#x02009;=&#x02009;9)</th></tr><tr><th/><th/><th>Higher median expression in</th><th>Fold change (median)<sup>a</sup></th><th><italic>P</italic>-value<sup>b</sup></th></tr></thead><tbody><tr><td>C-C motif chemokine ligand 18</td><td>
<italic>CCL18</italic>
</td><td>Choriodecidual leukocytes</td><td>5691.58</td><td>&#x0003c;0.001</td></tr><tr><td>Glycoprotein nmb</td><td>
<italic>GPNMB</italic>
</td><td>Choriodecidual leukocytes</td><td>477.82</td><td>&#x0003c;0.001</td></tr><tr><td>Selenoprotein P</td><td>
<italic>SEPP1</italic>
</td><td>Choriodecidual leukocytes</td><td>1507.69</td><td>&#x0003c;0.001</td></tr><tr><td>Fibronectin 1</td><td>
<italic>FN1</italic>
</td><td>Choriodecidual leukocytes</td><td>1198.83</td><td>&#x0003c;0.001</td></tr><tr><td>Ribonuclease A family member 1, pancreatic</td><td>
<italic>RNASE1</italic>
</td><td>Choriodecidual leukocytes</td><td>952.14</td><td>&#x0003c;0.001</td></tr><tr><td>Secreted phosphoprotein 1</td><td>
<italic>SPP1</italic>
</td><td>Choriodecidual leukocytes</td><td>157.86</td><td>&#x0003c;0.001</td></tr><tr><td>Complement C1q C chain</td><td>
<italic>C1QC</italic>
</td><td>Choriodecidual leukocytes</td><td>439.91</td><td>&#x0003c;0.001</td></tr><tr><td>Phospholipid transfer protein</td><td>
<italic>PLTP</italic>
</td><td>Choriodecidual leukocytes</td><td>466.74</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Genes with a differential expression of logFCh&#x02009;&#x0003e;&#x02009;5 and <italic>B</italic>&#x02009;&#x0003e;&#x02009;3</p><p><sup>a</sup>Fold change calculated with the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method</p><p><sup>b</sup>Statistical differences were analyzed using Mann-Whitney <italic>U</italic> tests</p></table-wrap-foot></table-wrap></p><p id="Par8">These results coincide with previous studies demonstrating that choriodecidual leukocytes express CAMs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], cytokines [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], chemokines [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], and their receptors [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], enzymes [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], antimicrobial peptides [<xref ref-type="bibr" rid="CR46">46</xref>], markers of activation [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>], and even hormone receptors [<xref ref-type="bibr" rid="CR50">50</xref>] before and during the process of labor. Together, these findings demonstrate that the choriodecidual leukocytes are a rich source of inflammatory mediators that can participate in the pro-inflammatory milieu that accompanies the process of labor.</p><p id="Par9">The current study also demonstrated that the choriodecidual leukocytes from women who underwent spontaneous labor at term overexpressed genes implicated in the process of chemotaxis, including CCL2, CCL3, CCL4, and CXCL10. This finding is in line with previous studies demonstrating that the chorioamniotic membranes (including the decidua) exhibit leukocyte chemotaxis through the expression of these chemokines during the process of labor [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. These results suggest that besides being a source of pro-inflammatory mediators, the choriodecidual leukocytes can actively participate in the process of leukocyte recruitment during the process of labor. In other words, this data suggests that leukocytes infiltrating the choriodecidua trigger a positive feedback mechanism whereby more leukocytes are recruited into the maternal-fetal interface.</p><p id="Par10">To gain a deeper understanding of the biological processes up-regulated in the choriodecidual leukocytes from women who underwent spontaneous labor at term, analysis of functional protein association networks was performed with the eight most up-regulated genes (<xref rid="MOESM1" ref-type="media">Supplementary Figure 2</xref>). Such analysis demonstrated that these genes do not have significant interactions. This means that the interactions between these genes/proteins are unknown or that they do not have a meaningful biological interaction. Since we did not find interactions among the eight most up-regulated genes, gene ontology was performed in all of the up-regulated genes in the choriodecidual leukocytes. Figure <xref rid="Fig3" ref-type="fig">3</xref> shows that the following biological processes were enriched in the choriodecidual leukocytes from women who underwent spontaneous labor at term: (Group 1) cell migration and regulation of immune response, (Group 2) chemotaxis, and (Group 3) humoral immune response.<fig id="Fig3"><label>Fig. 3</label><caption><p>STRING-based analysis representing up-regulated genes in the choriodecidual leukocytes from women who underwent spontaneous labor at term. The interaction networks show significantly up-regulated transcripts (fold change &#x0003e;2 and adjusted <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) from microarray data. For functional enrichment analysis, the up-regulated genes were divided into three categories based on their fold change: Group 1: fold change &#x0003e;2 and &#x0003c;5, Group 2: fold change &#x0003e;5 and &#x0003c;10, and Group 3: fold change &#x0003e;10</p></caption><graphic xlink:href="41435_2017_10_Fig3_HTML" id="d29e3136"/></fig></p><p id="Par11">The most up-regulated of these biological processes was the humoral immune response pathway, including T-cell and B-cell responses. Previously, we demonstrated that the chorioamniotic membranes can recruit T cells, which are implicated in the physiological [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>] and pathological [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR55">55</xref>] processes of labor. Indeed, in vivo activation of T cells through the CD3 complex induces premature labor and delivery [<xref ref-type="bibr" rid="CR56">56</xref>]. B cells can also be recruited by the chorioamniotic membranes [<xref ref-type="bibr" rid="CR14">14</xref>] and constitute a portion of the choriodecidual leukocytes [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. The role of B cells during pregnancy and its complications have been widely studied by Jensen and collaborators [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR69">68</xref>]. Taken together, these data provide further evidence that the adaptive limb of immunity is involved in the process of labor.</p><p id="Par12">Choriodecidual leukocytes up-regulated the expression of genes involved in the complement activation pathway. Such a pathway has been implicated in susceptibility to viral infections [<xref ref-type="bibr" rid="CR70">69</xref>] and the pathological process of preterm labor [<xref ref-type="bibr" rid="CR71">70</xref>&#x02013;<xref ref-type="bibr" rid="CR75">74</xref>], but not in the physiological process of labor at term. Therefore, this finding requires further investigation.</p><p id="Par13">The fact that choriodecidual leukocytes express transcripts implicated in the humoral immune response pathway is in line with previous reports indicating that visfatin, a pre-B-cell colony enhancing factor, is expressed in the decidua [<xref ref-type="bibr" rid="CR76">75</xref>] and amniotic fluid [<xref ref-type="bibr" rid="CR77">76</xref>] during the physiologic and infection-related pathologic processes of labor. Together, these data suggest that the humoral immune response pathway is implicated in the mechanisms of labor amplification and the host defense response against intra-amniotic infection.</p><p id="Par14">Interestingly, the choriodecidual leukocytes overexpressed the peroxisome proliferator-activated receptor gamma (PPAR&#x003b3;) during the process of labor. PPAR&#x003b3; is expressed in the choriodecidual tissues [<xref ref-type="bibr" rid="CR78">77</xref>], including decidual macrophages [<xref ref-type="bibr" rid="CR79">78</xref>], where it was suggested to participate in the process of labor [<xref ref-type="bibr" rid="CR80">79</xref>]. Recently, we reported that PPAR&#x003b3; activation (via rosiglitazone) attenuates the pro-inflammatory response at the maternal-fetal interface induced by a microbial product [<xref ref-type="bibr" rid="CR79">78</xref>] or activation of invariant natural killer T cells [<xref ref-type="bibr" rid="CR55">55</xref>]. Altogether, these data suggest that the choriodecidual leukocytes express PPAR&#x003b3; in order to dampen the pro-inflammatory microenvironment that accompanies the process of labor.</p><p id="Par15">A limitation of the current study is that the isolated choriodecidual leukocytes had a moderate purity (&#x0003e;70%), which suggest that the gene expression reported, herein, may also include the transcripts expressed by decidual and stromal choriodecidual cells. Yet, most of the mediators reported herein are involved in immune responses.</p><p id="Par16">In conclusion, this study demonstrated that there are transcriptomic differences between the choriodecidual leukocytes and maternal circulating leukocytes during the process of labor at term. The biological processes enriched in the choriodecidual leukocytes during the process of labor are: (1) cell migration and regulation of immune response, (2) chemotaxis, and (3) humoral immune response, which includes T-cell and B-cell responses. Collectively, these data show that there are striking differences between the transcriptome of the choriodecidual leukocytes and the transcriptome of maternal circulating leukocytes. The interaction network analysis revealed that the choriodecidual leukocytes are enriched in immune mediators implicated in the spontaneous process of labor at term.</p></sec><sec id="Sec3" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec4"><title>Human samples and clinical definitions</title><p id="Par17">This study was approved by the Internal Review Board of the Instituto Nacional de Perinatolog&#x000ed;a in Mexico City (Register number 212250-02191). Maternal peripheral blood samples were collected within 30&#x02009;min before delivery and the chorioamniotic membranes immediately after delivery from the same woman. Participants included healthy women who underwent spontaneous labor at term (&#x0003e;37 weeks of gestation, calculated from the date of the last menstrual period) resulting in delivery. Labor was defined by the presence of regular uterine contractions and cervical changes (&#x0003e;2&#x02009;cm). Five participants were included in the first phase of the study (microarrays) and nine participants were included in the second phase of the study (qRT-PCR). The demographic characteristics of the study population are shown in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Demographic characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Microarrays (<italic>n</italic>&#x02009;=&#x02009;5)</th><th>qRT-PCR (<italic>n</italic>&#x02009;=&#x02009;9)</th><th>Microarrays vs. qRT-PCR (<italic>P</italic>-value)<sup>b</sup></th></tr><tr><th/><th>Maternal circulating leukocytes</th><th>Choriodecidual leukocytes</th><th><italic>P-</italic>value<sup>a</sup></th><th/><th/></tr></thead><tbody><tr><td>Maternal age</td><td>32 (20&#x02013;39)</td><td>31 (16&#x02013;33)</td><td>0.310</td><td>26 (18&#x02013;32)</td><td>0.315</td></tr><tr><td>Gestational age (weeks)</td><td>39.4 (37.2&#x02013;41.3)</td><td>39.4 (37.2&#x02013;41.3)</td><td>0.690</td><td>39.0 (37.2&#x02013;41.3)</td><td>0.968</td></tr><tr><td>Number of pregnancies</td><td>2.5 (1&#x02013;4)</td><td>2.5 (1&#x02013;4)</td><td>0.686</td><td>2 (1&#x02013;4)</td><td>0.442</td></tr><tr><td>Number of live births</td><td>2.0 (1&#x02013;4)</td><td>2.0 (1&#x02013;4)</td><td>0.686</td><td>1.5 (1&#x02013;3)</td><td>0.645</td></tr><tr><td>Newborn&#x02019;s sex</td><td>Male&#x02009;=&#x02009;2 Female&#x02009;=&#x02009;3</td><td>Male&#x02009;=&#x02009;3 Female&#x02009;=&#x02009;2</td><td>0.527</td><td>Male&#x02009;=&#x02009;5 Female&#x02009;=&#x02009;4</td><td>0.809</td></tr></tbody></table><table-wrap-foot><p>Values are presented as medians (range). Differences were assessed using Mann-Whitney <italic>U</italic> test for all variables, except for Newborn&#x02019;s sex where <italic>Chi</italic>-square test was used</p><p><sup>a</sup>Differences between maternal circulating leukocytes and choriodecidual leukocytes samples used in microarrays</p><p><sup>b</sup>Differences between microarray samples and qRT-PCR samples</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Isolation of maternal leukocytes</title><p id="Par18">Maternal circulating leukocytes were isolated using a density gradient (Polymorphprep; Axis-Shield, Oslo, Norway), according to the manufacturer&#x02019;s instructions. Mononuclear and polymorphonuclear leukocytes were collected and washed with 1&#x000d7; phosphate buffered saline (PBS). Red blood cells were lysed by incubating the leukocyte suspensions with erythrocyte lysis buffer (150&#x02009;mM ammonium chloride, 10&#x02009;mM potassium bicarbonate, 0.1&#x02009;mM EDTA) for 15&#x02009;min at room temperature. Leukocyte suspensions were then washed with 1&#x000d7; PBS and the resulting cell pellet was resuspended in RNA<italic>later</italic> solution (Ambion, Life Technologies, Carlsbad, CA, USA) and stored at &#x02212;80&#x02009;&#x000b0;C. The entire process of isolation was performed using ice-cold buffers in order to minimize RNA degradation.</p></sec><sec id="Sec6"><title>Isolation of choriodecidual leukocytes</title><p id="Par19">Following collection of the chorioamniotic membranes, the amnion was separated from the chorion manually. Next, the entire chorion was cut into fragments (approximately 3&#x02009;&#x000d7;&#x02009;3&#x02009;cm), which were placed into a flask containing 50&#x02013;100&#x02009;mL of a digestion solution [Dubelcco&#x02019;s Modified Eagle Medium containing 0.1% of trypsin]. The flask was then incubated at 37&#x02009;&#x000b0;C for 5&#x02013;10&#x02009;min with low agitation. The volume of the digestion solution and the time of incubation depended on the size of the chorion. After incubation, the tissue suspension was filtered using sterile gauze and the flow-through was collected. The resulting cell suspension was washed with 1&#x000d7; PBS and red blood cells were lysed using the erythrocyte lysis buffer, as previously described. Choriodecidual leukocytes were then isolated from other choriodecidual cells present in the cell suspension by magnetic cell sorting. Briefly, cell suspensions were incubated with a CD45 microbead-conjugated antibody and leukocytes (CD45+ cells) were isolated, according to the manufacturer&#x02019;s instructions (Miltenyi Biotec, Auburn, CA, USA). Purified choriodecidual leukocytes were stored at &#x02212;80&#x02009;&#x000b0;C in RNA<italic>later</italic> solution. The purity of choriodecidual leukocytes was &#x0003e;70% of CD45+ cells (<xref rid="MOESM1" ref-type="media">Supplementary Figure 1</xref>). The entire process of isolation was performed using ice-cold buffers to minimize RNA degradation.</p></sec><sec id="Sec7"><title>RNA isolation</title><p id="Par20">The TRIzol<sup>&#x000ae;</sup> reagent (Invitrogen, Life Technologies Corporation, Grand Island, NY, USA) was used to extract the total RNA from RNA<italic>later</italic> solution-stored leukocytes, following the manufacturer&#x02019;s instructions. RNA purity and concentration were assessed with the 6000 NanoDrop<sup>&#x000ae;</sup> spectrophotometer, and RNA integrity was evaluated with the Bioanalyzer 2100 (Agilent Technologies, Wilmington, DE, USA). RNA integrity numbers (RIN) were &#x0003e;7.</p></sec><sec id="Sec8"><title>cDNA synthesis</title><p id="Par21">For microarray experiments, 200&#x02009;ng of total RNA was amplified with the Ambion WT Expression kit, following the manufacturer&#x02019;s instructions (Ambion, Life Technologies, Carlsbad, CA, USA). Newly synthesized complementary (c)DNA was fragmented and labeled with the GeneChip<sup>&#x000ae;</sup> WT Terminal Labeling kit (Affymetrix, Santa Clara, CA, USA), according to the manufacturer&#x02019;s instructions.</p><p id="Par22">For qRT-PCR experiments, 500&#x02009;ng of total RNA was used to generate cDNA using the Transcriptor First Strand cDNA Synthesis kit (Roche Applied Science, Mannheim, Germany) and random hexamers as primers. cDNA synthesis was carried out in a Mastercycler Gradient Thermalcycler (Eppendorf, Hamburg, Germany). Next, cDNA was stored at &#x02013;20&#x02009;&#x000b0;C until use.</p></sec><sec id="Sec9"><title>Microarray analysis</title><p id="Par23">Five sets of matched samples from choriodecidual leukocytes and maternal circulating leukocytes were utilized for microarray analysis (Table <xref rid="Tab3" ref-type="table">3</xref>). The GeneChip<sup>&#x000ae;</sup> Human Gene 1.0 ST array (Affymetrix Inc., Santa Clara, CA, USA) was used to measure the gene expression levels in each specimen, following manufacturer&#x02019;s instructions. This array included 28,869 well-annotated genes with 764,885 probes.</p></sec><sec id="Sec10"><title>Real-time quantitative polymerase chain reaction</title><p id="Par24">To validate the gene expression results from the microarray, eight up-regulated genes in choriodecidual leukocytes compared to maternal circulating leukocytes and two reference genes (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>) were selected for qRT-PCR analysis. Validation was performed using a set of nine matched samples (choriodecidual leukocytes and maternal circulating leukocytes from nine different women). The expression analysis was performed by using the 48.48 Dynamic Array integrated fluidics chips (BioMark Fluidigm Corporation, San Francisco, CA, USA), following the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec11"><title>Statistical analyses</title><p id="Par25">Raw microarray data were background-corrected using the Robust multi-array average (RMA) method [<xref ref-type="bibr" rid="CR81">80</xref>], and normalized using the Quantile Normalization method [<xref ref-type="bibr" rid="CR82">81</xref>]. Differential expression was determined using statistical linear models with arbitrary coefficients; contrasts of interest were analyzed using the bioconductor library limma [<xref ref-type="bibr" rid="CR83">82</xref>, <xref ref-type="bibr" rid="CR84">83</xref>]. Correction for multiple hypotheses was applied using a false discovery rate (FDR). Genes were selected based on a log fold change &#x02265;0.3 and a B-statistic &#x02265;3.</p><p id="Par26">Differential expression between experimental qRT-PCR data was determined with the 2<sup>&#x02013;&#x00394;&#x00394;Ct</sup> method [<xref ref-type="bibr" rid="CR85">84</xref>]. The qRT-PCR data were non-normally distributed according to the Shapiro-Wilk test. The Mann-Whitney <italic>U</italic> test was used for comparisons between groups. A <italic>P</italic>-value &#x02264;&#x02009;0.05 was considered statistically significant. The statistical analysis was performed using the SPSS version 20 software (IBM Corporation, North Castle, NY, USA).</p></sec><sec id="Sec12"><title>Interaction network analysis</title><p id="Par27">The functional network analysis for up-regulated genes in the tested conditions (fold change &#x0003e;2, adjusted <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) was constructed using protein&#x02013;protein associations using the STRING (Search Tool for the Retrieval of Interacting Genes) v.10.0 software [<xref ref-type="bibr" rid="CR86">85</xref>]. The network was built using high-quality associations (interaction score &#x02265;0.700). Genes were grouped based on their fold change expression into three different groups: Group 1: fold change &#x0003e;2 and &#x0003c;5, Group 2: fold change &#x0003e;5 and &#x0003c;10, and Group 3: fold change &#x0003e;10. These groups were analyzed separately using the STRING v.10.0 software. Gene ontology annotation was added to the graph based on the functional enrichment analysis results for the analyzed genes.</p></sec><sec id="Sec13" sec-type="data-availability"><title>Data availability</title><p id="Par28">All of the data are available in the tables and figures of the manuscript. Microarray data is available upon request at r.vega@inper.mx / vegarodrig@gmail.com</p></sec></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec14"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41435_2017_10_MOESM1_ESM.pdf"><caption><p>Supplementary figures</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41435_2017_10_MOESM2_ESM.docx"><caption><p>Supplementary Table 1</p></caption></media></supplementary-material>
</p></sec></sec></body><back><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1038/s41435-017-0010-z) contains supplementary material, which is available to authorized users.</p></sec><ack><title>Acknowledgements</title><p>We gratefully acknowledge Jorge Beltran Montoya, Rolando Maida Claros, Raul Mojica-Espinosa, Juan Pablo Aragon, and Karla MacDonald-Ramos for their contributions to the execution of this study.</p><sec id="FPar1"><title>Author contributions</title><p id="Par29">MAH, NGL, and RVS participated in the experimental design of the study; MAH and JAVP performed the experimental work; VGF, CRE, LMAS, and NMA performed the statistical analyses, and MAH, NGL, VGF, and RVS analyzed and interpreted the data and wrote the manuscript. All authors read and approved the final version of the manuscript.</p></sec></ack><notes notes-type="funding-information"><sec id="FPar2"><title>Funding</title><p id="Par30">This study was funded by grant SALUD-2010-01-141144 from CONACYT and project 212250-02191 (RVS). NGL is supported by the Wayne State University Perinatal Initiative in Maternal, Perinatal, and Child Health. MAH was supported by a MSc scholarship and currently holds a doctoral scholarship both from CONACyT.</p></sec></notes><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar3"><title>Conflict of interest</title><p>The authors declare that they have no competing interest.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Espinoza</surname><given-names>J</given-names></name><name><surname>Goncalves</surname><given-names>LF</given-names></name><name><surname>Kusanovic</surname><given-names>JP</given-names></name><name><surname>Friel</surname><given-names>LA</given-names></name><name><surname>Nien</surname><given-names>JK</given-names></name></person-group><article-title>Inflammation in preterm and term labour and delivery</article-title><source>Semin Fetal Neonatal Med</source><year>2006</year><volume>11</volume><fpage>317</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.siny.2006.05.001</pub-id><?supplied-pmid 16839830?><pub-id pub-id-type="pmid">16839830</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>R</given-names></name><name><surname>Tromp</surname><given-names>G</given-names></name><name><surname>Kuivaniemi</surname><given-names>H</given-names></name><name><surname>Chaiworapongsa</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Mazor</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature</article-title><source>Am J Obs Gynecol</source><year>2006</year><volume>195</volume><fpage>394</fpage><pub-id pub-id-type="doi">10.1016/j.ajog.2005.08.057</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>JE</given-names></name><name><surname>Bollapragada</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Nelson</surname><given-names>SM</given-names></name></person-group><article-title>Inflammatory pathways in the mechanism of parturition</article-title><source>BMC Pregnancy Childbirth</source><year>2007</year><volume>7</volume><fpage>S7</fpage><pub-id pub-id-type="doi">10.1186/1471-2393-7-S1-S7</pub-id><?supplied-pmid 17570167?><pub-id pub-id-type="pmid">17570167</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Romero R, Xu Y, Plazyo O, Chaemsaithong P, Chaiworapongsa T, Unkel R, et al. A role for the inflammasome in spontaneous labor at term. Am J Reprod Immunol. 2016. 10.1111/aji.12440.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisti</surname><given-names>G</given-names></name><name><surname>Kanninen</surname><given-names>TT</given-names></name><name><surname>Witkin</surname><given-names>SS</given-names></name></person-group><article-title>Maternal immunity and pregnancy outcome: focus on preconception and autophagy</article-title><source>Genes Immun</source><year>2016</year><volume>17</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/gene.2015.57</pub-id><?supplied-pmid 26656449?><pub-id pub-id-type="pmid">26656449</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Liggins</surname><given-names>G</given-names></name></person-group><source>Cervical ripening as an inflammatory reaction</source><year>1981</year><publisher-loc>Edinburgh</publisher-loc><publisher-name>Churchill Livingstone</publisher-name></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackler</surname><given-names>AM</given-names></name><name><surname>Iezza</surname><given-names>G</given-names></name><name><surname>Akin</surname><given-names>MR</given-names></name><name><surname>McMillan</surname><given-names>P</given-names></name><name><surname>Yellon</surname><given-names>SM</given-names></name></person-group><article-title>Macrophage trafficking in the uterus and cervix precedes parturition in the mouse</article-title><source>Biol Reprod</source><year>1999</year><volume>61</volume><fpage>879</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1095/biolreprod61.4.879</pub-id><?supplied-pmid 10491619?><pub-id pub-id-type="pmid">10491619</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>I</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Ledingham</surname><given-names>MA</given-names></name><name><surname>Thomson</surname><given-names>AJ</given-names></name><name><surname>Jordan</surname><given-names>F</given-names></name><name><surname>Greer</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, decidua, cervix and myometrium before and during labour at term</article-title><source>Mol Hum Reprod</source><year>2003</year><volume>9</volume><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1093/molehr/gag001</pub-id><?supplied-pmid 12529419?><pub-id pub-id-type="pmid">12529419</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>KJ</given-names></name><name><surname>Clyde</surname><given-names>LA</given-names></name><name><surname>Weldon</surname><given-names>AJ</given-names></name><name><surname>Milford</surname><given-names>TA</given-names></name><name><surname>Yellon</surname><given-names>SM</given-names></name></person-group><article-title>Residency and activation of myeloid cells during remodeling of the prepartum murine cervix</article-title><source>Biol Reprod</source><year>2012</year><volume>87</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1095/biolreprod.112.101840</pub-id><?supplied-pmid 22914314?><pub-id pub-id-type="pmid">22914314</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>AJ</given-names></name><name><surname>Telfer</surname><given-names>JF</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>CJ</given-names></name><name><surname>Cameron</surname><given-names>IT</given-names></name><etal/></person-group><article-title>Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process</article-title><source>Hum Reprod</source><year>1999</year><volume>14</volume><fpage>229</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1093/humrep/15.1.229</pub-id><?supplied-pmid 10374126?><pub-id pub-id-type="pmid">10374126</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shynlova</surname><given-names>O</given-names></name><name><surname>Nedd-Roderique</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Dorogin</surname><given-names>A</given-names></name><name><surname>Lye</surname><given-names>SJ</given-names></name></person-group><article-title>Myometrial immune cells contribute to term parturition, preterm labour and post-partum involution in mice</article-title><source>J Cell Mol Med</source><year>2013</year><volume>17</volume><fpage>90</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2012.01650.x</pub-id><?supplied-pmid 23205502?><pub-id pub-id-type="pmid">23205502</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shynlova</surname><given-names>O</given-names></name><name><surname>Tsui</surname><given-names>P</given-names></name><name><surname>Dorogin</surname><given-names>A</given-names></name><name><surname>Lye</surname><given-names>SJ</given-names></name></person-group><article-title>Monocyte chemoattractant protein-1 (CCL-2) integrates mechanical and endocrine signals that mediate term and preterm labor</article-title><source>J Immunol</source><year>2008</year><volume>181</volume><fpage>1470</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.2.1470</pub-id><?supplied-pmid 18606702?><pub-id pub-id-type="pmid">18606702</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>I</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Jordan</surname><given-names>F</given-names></name><name><surname>Greer</surname><given-names>IA</given-names></name><name><surname>Norman</surname><given-names>JE</given-names></name></person-group><article-title>Leukocyte density and proinflammatory mediator expression in regional human fetal membranes and decidua before and during labor at term</article-title><source>J Soc Gynecol Investig</source><year>2006</year><volume>13</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.jsgi.2005.12.002</pub-id><?supplied-pmid 16443501?><pub-id pub-id-type="pmid">16443501</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Estrada-Gutierrez</surname><given-names>G</given-names></name><name><surname>Jimenez-Zamudio</surname><given-names>L</given-names></name><name><surname>Vega-Sanchez</surname><given-names>R</given-names></name><name><surname>Vadillo-Ortega</surname><given-names>F</given-names></name></person-group><article-title>Fetal membranes exhibit selective leukocyte chemotaxic activity during human labor</article-title><source>J Reprod Immunol</source><year>2009</year><volume>80</volume><fpage>122</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2009.01.002</pub-id><?supplied-pmid 19406481?><pub-id pub-id-type="pmid">19406481</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Gomez-Lopez N, Vadillo-Perez L, Hernandez-Carbajal A, Godines-Enriquez M, Olson DM, Vadillo-Ortega F. Specific inflammatory microenvironments in the zones of the fetal membranes at term delivery. Am J Obs Gynecol. 2011;205:235.e15&#x02013;235.e24.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Vega-Sanchez</surname><given-names>R</given-names></name><name><surname>Castillo-Castrejon</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Cubeiro-Arreola</surname><given-names>K</given-names></name><name><surname>Vadillo-Ortega</surname><given-names>F</given-names></name></person-group><article-title>Evidence for a role for the adaptive immune response in human term parturition</article-title><source>Am J Reprod Immunol</source><year>2013</year><volume>69</volume><fpage>212</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/aji.12074</pub-id><?supplied-pmid 23347265?><pub-id pub-id-type="pmid">23347265</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sindram-Trujillo</surname><given-names>A</given-names></name><name><surname>Scherjon</surname><given-names>S</given-names></name><name><surname>Kanhai</surname><given-names>H</given-names></name><name><surname>Roelen</surname><given-names>D</given-names></name><name><surname>Claas</surname><given-names>F</given-names></name></person-group><article-title>Increased T-cell activation in Decidua Parietalis compared to Decidua Basalis in uncomplicated human term pregnancy</article-title><source>Am J Reprod Immunol</source><year>2003</year><volume>49</volume><fpage>261</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0897.2003.00041.x</pub-id><?supplied-pmid 12854730?><pub-id pub-id-type="pmid">12854730</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessin</surname><given-names>DL</given-names></name><name><surname>Hunt</surname><given-names>JS</given-names></name><name><surname>King</surname><given-names>CR</given-names></name><name><surname>Wood</surname><given-names>GW</given-names></name></person-group><article-title>Antigen expression by cells near the maternal-fetal interface</article-title><source>Am J Reprod Immunol Microbiol</source><year>1988</year><volume>16</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0897.1988.tb00169.x</pub-id><?supplied-pmid 3369615?><pub-id pub-id-type="pmid">3369615</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vince</surname><given-names>GS</given-names></name><name><surname>Starkey</surname><given-names>PM</given-names></name><name><surname>Jackson</surname><given-names>MC</given-names></name><name><surname>Sargent</surname><given-names>IL</given-names></name><name><surname>Redman</surname><given-names>CW</given-names></name></person-group><article-title>Flow cytometric characterisation of cell populations in human pregnancy decidua and isolation of decidual macrophages</article-title><source>J Immunol Methods</source><year>1990</year><volume>132</volume><fpage>181</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(90)90028-T</pub-id><?supplied-pmid 2145368?><pub-id pub-id-type="pmid">2145368</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>ML</given-names></name><name><surname>Santos</surname><given-names>JL</given-names></name><name><surname>Ruiz</surname><given-names>C</given-names></name><name><surname>Montes</surname><given-names>MJ</given-names></name><name><surname>Aleman</surname><given-names>P</given-names></name><name><surname>Garcia-Tortosa</surname><given-names>C</given-names></name><etal/></person-group><article-title>Comparison of the proportions of leukocytes in early and term human decidua</article-title><source>Am J Reprod Immunol</source><year>1993</year><volume>29</volume><fpage>135</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0897.1993.tb00578.x</pub-id><?supplied-pmid 7690570?><pub-id pub-id-type="pmid">7690570</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castrechini</surname><given-names>NM</given-names></name><name><surname>Murthi</surname><given-names>P</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Kusuma</surname><given-names>GD</given-names></name><name><surname>Wilton</surname><given-names>L</given-names></name><name><surname>Abumaree</surname><given-names>M</given-names></name><etal/></person-group><article-title>Decidua parietalis-derived mesenchymal stromal cells reside in a vascular niche within the choriodecidua</article-title><source>Reprod Sci</source><year>2012</year><volume>19</volume><fpage>1302</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1177/1933719112450334</pub-id><?supplied-pmid 22886285?><pub-id pub-id-type="pmid">22886285</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>StLouis</surname><given-names>D</given-names></name><name><surname>Lehr</surname><given-names>MA</given-names></name><name><surname>Sanchez-Rodriguez</surname><given-names>EN</given-names></name><name><surname>Arenas-Hernandez</surname><given-names>M</given-names></name></person-group><article-title>Immune cells in term and preterm labor</article-title><source>Cell Mol Immunol</source><year>2014</year><volume>11</volume><fpage>571</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/cmi.2014.46</pub-id><?supplied-pmid 24954221?><pub-id pub-id-type="pmid">24954221</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Vadillo-Perez</surname><given-names>L</given-names></name><name><surname>Nessim</surname><given-names>S</given-names></name><name><surname>Olson</surname><given-names>DM</given-names></name><name><surname>Vadillo-Ortega</surname><given-names>F</given-names></name></person-group><article-title>Choriodecidua and amnion exhibit selective leukocyte chemotaxis during term human labor</article-title><source>Am J Obs Gynecol</source><year>2011</year><volume>204</volume><fpage>364</fpage><pub-id pub-id-type="doi">10.1016/j.ajog.2010.11.010</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Hernandez-Santiago</surname><given-names>S</given-names></name><name><surname>Lobb</surname><given-names>AP</given-names></name><name><surname>Olson</surname><given-names>DM</given-names></name><name><surname>Vadillo-Ortega</surname><given-names>F</given-names></name></person-group><article-title>Normal and premature rupture of fetal membranes at term delivery differ in regional chemotactic activity and related chemokine/cytokine production</article-title><source>Reprod Sci</source><year>2013</year><volume>20</volume><fpage>276</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1177/1933719112452473</pub-id><?supplied-pmid 22836164?><pub-id pub-id-type="pmid">22836164</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Tong</surname><given-names>WC</given-names></name><name><surname>Arenas-Hernandez</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Hajar</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Chemotactic activity of gestational tissues through late pregnancy, term labor, and RU486-induced preterm labor in Guinea pigs</article-title><source>Am J Reprod Immunol</source><year>2015</year><volume>73</volume><fpage>341</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/aji.12333</pub-id><?supplied-pmid 25329235?><pub-id pub-id-type="pmid">25329235</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Zaeem</surname><given-names>Z</given-names></name><name><surname>Metz</surname><given-names>GA</given-names></name><name><surname>Olson</surname><given-names>DM</given-names></name></person-group><article-title>Maternal circulating leukocytes display early chemotactic responsiveness during late gestation</article-title><source>BMC Pregnancy Childbirth</source><year>2013</year><volume>13</volume><fpage>S8</fpage><pub-id pub-id-type="doi">10.1186/1471-2393-13-S1-S8</pub-id><?supplied-pmid 23445935?><pub-id pub-id-type="pmid">23445935</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>F</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Harnett</surname><given-names>MM</given-names></name><name><surname>Norman</surname><given-names>JE</given-names></name></person-group><article-title>Leukocytes are primed in peripheral blood for activation during term and preterm labour</article-title><source>Mol Hum Reprod</source><year>2009</year><volume>15</volume><fpage>713</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1093/molehr/gap054</pub-id><?supplied-pmid 19628509?><pub-id pub-id-type="pmid">19628509</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vega-Sanchez</surname><given-names>R</given-names></name><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Flores-Pliego</surname><given-names>A</given-names></name><name><surname>Clemente-Galvan</surname><given-names>S</given-names></name><name><surname>Estrada-Gutierrez</surname><given-names>G</given-names></name><name><surname>Zentella-Dehesa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Placental blood leukocytes are functional and phenotypically different than peripheral leukocytes during human labor</article-title><source>J Reprod Immunol</source><year>2010</year><volume>84</volume><fpage>100</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2009.08.002</pub-id><?supplied-pmid 19748682?><pub-id pub-id-type="pmid">19748682</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galicia</surname><given-names>JC</given-names></name><name><surname>Henson</surname><given-names>BR</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Khan</surname><given-names>AA</given-names></name></person-group><article-title>Gene expression profile of pulpitis</article-title><source>Genes Immun</source><year>2016</year><volume>17</volume><fpage>239</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/gene.2016.14</pub-id><?supplied-pmid 27052691?><pub-id pub-id-type="pmid">27052691</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussman</surname><given-names>JP</given-names></name><name><surname>Beecham</surname><given-names>AH</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>McCauley</surname><given-names>JL</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name><etal/></person-group><article-title>GWAS analysis implicates NF-kappaB-mediated induction of inflammatory T cells in multiple sclerosis</article-title><source>Genes Immun</source><year>2016</year><volume>17</volume><fpage>305</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/gene.2016.23</pub-id><?supplied-pmid 27278126?><pub-id pub-id-type="pmid">27278126</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>N</given-names></name><name><surname>Fernekorn</surname><given-names>U</given-names></name><name><surname>Hallmann</surname><given-names>R</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group><article-title>Alterations in the expression of homing-associated molecules at the maternal/fetal interface during the course of pregnancy</article-title><source>Biol Reprod</source><year>2002</year><volume>66</volume><fpage>333</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1095/biolreprod66.2.333</pub-id><?supplied-pmid 11804946?><pub-id pub-id-type="pmid">11804946</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>I</given-names></name><name><surname>Crawford</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>F</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Norman</surname><given-names>J</given-names></name><name><surname>Thomson</surname><given-names>A</given-names></name></person-group><article-title>Expression and localization of cell adhesion molecules in human fetal membranes during parturition</article-title><source>J Reprod Immunol</source><year>2004</year><volume>63</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2004.04.003</pub-id><?supplied-pmid 15284000?><pub-id pub-id-type="pmid">15284000</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Guilbert</surname><given-names>LJ</given-names></name><name><surname>Olson</surname><given-names>DM</given-names></name></person-group><article-title>Invasion of the leukocytes into the fetal-maternal interface during pregnancy</article-title><source>J Leukoc Biol</source><year>2010</year><volume>88</volume><fpage>625</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1189/jlb.1209796</pub-id><?supplied-pmid 20519637?><pub-id pub-id-type="pmid">20519637</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>SA</given-names></name><name><surname>Tower</surname><given-names>CL</given-names></name><name><surname>Jones</surname><given-names>RL</given-names></name></person-group><article-title>Identification of chemokines associated with the recruitment of decidual leukocytes in human labour: potential novel targets for preterm labour</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e56946</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0056946</pub-id><?supplied-pmid 23451115?><pub-id pub-id-type="pmid">23451115</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo-Castrejon</surname><given-names>M</given-names></name><name><surname>Meraz-Cruz</surname><given-names>N</given-names></name><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Flores-Pliego</surname><given-names>A</given-names></name><name><surname>Beltran-Montoya</surname><given-names>J</given-names></name><name><surname>Viveros-Alcaraz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Choriodecidual cells from term human pregnancies show distinctive functional properties related to the induction of labor</article-title><source>Am J Reprod Immunol</source><year>2014</year><volume>71</volume><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/aji.12179</pub-id><?supplied-pmid 24286217?><pub-id pub-id-type="pmid">24286217</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vadillo-Ortega</surname><given-names>F</given-names></name><name><surname>Gonzalez-Avila</surname><given-names>G</given-names></name><name><surname>Furth</surname><given-names>EE</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Muschel</surname><given-names>RJ</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><etal/></person-group><article-title>92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor</article-title><source>Am J Pathol</source><year>1995</year><volume>146</volume><fpage>148</fpage><lpage>56</lpage><?supplied-pmid 7856724?><pub-id pub-id-type="pmid">7856724</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>MD</given-names></name><name><surname>Romero</surname><given-names>RJ</given-names></name><name><surname>Edwin</surname><given-names>SS</given-names></name><name><surname>Trautman</surname><given-names>MS</given-names></name></person-group><article-title>Prostaglandins and parturition</article-title><source>Reprod Fertil Dev</source><year>1995</year><volume>7</volume><fpage>623</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1071/RD9950623</pub-id><?supplied-pmid 8606975?><pub-id pub-id-type="pmid">8606975</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltier</surname><given-names>MR</given-names></name></person-group><article-title>Immunology of term and preterm labor</article-title><source>Reprod Biol Endocrinol</source><year>2003</year><volume>1</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/1477-7827-1-122</pub-id><?supplied-pmid 14651749?><pub-id pub-id-type="pmid">14651749</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Repnik</surname><given-names>U</given-names></name><name><surname>Tilburgs</surname><given-names>T</given-names></name><name><surname>Roelen</surname><given-names>DL</given-names></name><name><surname>van der Mast</surname><given-names>BJ</given-names></name><name><surname>Kanhai</surname><given-names>HHH</given-names></name><name><surname>Scherjon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Comparison of Macrophage phenotype between Decidua Basalis and Decidua Parietalis by flow cytometry</article-title><source>Placenta</source><year>2008</year><volume>29</volume><fpage>405</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.placenta.2008.02.004</pub-id><?supplied-pmid 18353434?><pub-id pub-id-type="pmid">18353434</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilburgs</surname><given-names>T</given-names></name><name><surname>Scherjon</surname><given-names>SA</given-names></name><name><surname>Roelen</surname><given-names>DL</given-names></name><name><surname>Claas</surname><given-names>FHJ</given-names></name></person-group><article-title>Decidual CD8+ CD28- T cells express CD103 but not perforin</article-title><source>Hum Immunol</source><year>2009</year><volume>70</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2008.12.006</pub-id><?supplied-pmid 19150377?><pub-id pub-id-type="pmid">19150377</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Thomson</surname><given-names>AJ</given-names></name><name><surname>Ledingham</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>F</given-names></name><name><surname>Greer</surname><given-names>IA</given-names></name><name><surname>Norman</surname><given-names>JE</given-names></name></person-group><article-title>Immunolocalization of proinflammatory cytokines in myometrium, cervix, and fetal membranes during human parturition at term</article-title><source>Biol Reprod</source><year>2002</year><volume>66</volume><fpage>445</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1095/biolreprod66.2.445</pub-id><?supplied-pmid 11804961?><pub-id pub-id-type="pmid">11804961</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>C</given-names></name><name><surname>Hummerdal</surname><given-names>P</given-names></name><name><surname>Matthiesen</surname><given-names>L</given-names></name><name><surname>Berg</surname><given-names>G</given-names></name><name><surname>Ekerfelt</surname><given-names>C</given-names></name><name><surname>Ernerudh</surname><given-names>J</given-names></name></person-group><article-title>Cytokine secretion in decidual mononuclear cells from term human pregnancy with or without labour: ELISPOT detection of IFN-gamma, IL-4, IL-10, TGF-beta and TNF-alpha</article-title><source>J Reprod Immunol</source><year>2006</year><volume>71</volume><fpage>41</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2005.12.009</pub-id><?supplied-pmid 16730071?><pub-id pub-id-type="pmid">16730071</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilburgs</surname><given-names>T</given-names></name><name><surname>Schonkeren</surname><given-names>D</given-names></name><name><surname>Eikmans</surname><given-names>M</given-names></name><name><surname>Nagtzaam</surname><given-names>NM</given-names></name><name><surname>Datema</surname><given-names>G</given-names></name><name><surname>Swings</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Human Decidual tissue contains differentiated CD8+ effector-memory T cells with unique properties</article-title><source>J Immunol</source><year>2010</year><volume>185</volume><fpage>4470</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903597</pub-id><?supplied-pmid 20817873?><pub-id pub-id-type="pmid">20817873</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>BH</given-names></name><name><surname>Greer</surname><given-names>IA</given-names></name><name><surname>Liston</surname><given-names>WA</given-names></name><name><surname>Haddad</surname><given-names>NG</given-names></name><name><surname>Johnston</surname><given-names>TA</given-names></name></person-group><article-title>Immunocytochemical localization of neutrophil elastase in term placenta decidua and myometrium in pregnancy-induced hypertension</article-title><source>Br J Obs Gynaecol</source><year>1991</year><volume>98</volume><fpage>929</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.1991.tb13516.x</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Gomez-Lopez N, Romero R, Xu Y, Plazyo O, Unkel R, Than NG, et al. A Role for the inflammasome in spontaneous labor at term with acute histologic chorioamnionitis. Reprod Sci. 2016;24:934&#x02013;953. 1933719116675058.</mixed-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Barker</surname><given-names>G</given-names></name><name><surname>Lappas</surname><given-names>M</given-names></name></person-group><article-title>Human cathelicidin antimicrobial protein 18 (hCAP18/LL-37) is increased in foetal membranes and myometrium after spontaneous labour and delivery</article-title><source>J Reprod Immunol</source><year>2015</year><volume>107</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2014.10.002</pub-id><?supplied-pmid 25435436?><pub-id pub-id-type="pmid">25435436</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sindram-Trujillo</surname><given-names>AP</given-names></name><name><surname>Scherjon</surname><given-names>SA</given-names></name><name><surname>Miert</surname><given-names>PP</given-names></name><name><surname>van</surname><given-names>H</given-names></name><name><surname>Kanhai</surname><given-names>HHH</given-names></name><name><surname>Roelen</surname><given-names>DL</given-names></name><name><surname>Claas</surname><given-names>FHJ</given-names></name></person-group><article-title>Comparison of decidual leukocytes following spontaneous vaginal delivery and elective cesarean section in uncomplicated human term pregnancy</article-title><source>J Reprod Immunol</source><year>2004</year><volume>62</volume><fpage>125</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2003.11.007</pub-id><?supplied-pmid 15288188?><pub-id pub-id-type="pmid">15288188</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilburgs</surname><given-names>T</given-names></name><name><surname>Roelen</surname><given-names>DL</given-names></name><name><surname>van der Mast</surname><given-names>BJ</given-names></name><name><surname>van Schip</surname><given-names>JJ</given-names></name><name><surname>Kleijburg</surname><given-names>C</given-names></name><name><surname>de Groot-Swings</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Differential distribution of CD4(+)CD25(bright) and CD8(+)CD28(-) T-cells in decidua and maternal blood during human pregnancy</article-title><source>Placenta</source><year>2006</year><volume>27</volume><fpage>S47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.placenta.2005.11.008</pub-id><?supplied-pmid 16442616?><pub-id pub-id-type="pmid">16442616</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilburgs</surname><given-names>T</given-names></name><name><surname>van der Mast</surname><given-names>BJ</given-names></name><name><surname>Nagtzaam</surname><given-names>NMA</given-names></name><name><surname>Roelen</surname><given-names>DL</given-names></name><name><surname>Scherjon</surname><given-names>SA</given-names></name><name><surname>Claas</surname><given-names>FHJ</given-names></name></person-group><article-title>Expression of NK cell receptors on decidual T cells in human pregnancy</article-title><source>J Reprod Immunol</source><year>2009</year><volume>80</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2009.02.004</pub-id><?supplied-pmid 19394706?><pub-id pub-id-type="pmid">19394706</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>JS</given-names></name><name><surname>Yamamoto</surname><given-names>SY</given-names></name><name><surname>Bryant-Greenwood</surname><given-names>GD</given-names></name></person-group><article-title>Relaxin modulates proinflammatory cytokine secretion from human decidual macrophages</article-title><source>Biol Reprod</source><year>2011</year><volume>85</volume><fpage>788</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1095/biolreprod.110.089201</pub-id><?supplied-pmid 21734258?><pub-id pub-id-type="pmid">21734258</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacques</surname><given-names>SM</given-names></name><name><surname>Qureshi</surname><given-names>F</given-names></name></person-group><article-title>Chronic chorioamnionitis: a clinicopathologic and immunohistochemical study</article-title><source>Hum Pathol</source><year>1998</year><volume>29</volume><fpage>1457</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(98)90016-8</pub-id><?supplied-pmid 9865833?><pub-id pub-id-type="pmid">9865833</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CJ</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Chaemsaithong</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name></person-group><article-title>Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance</article-title><source>Am J Obs Gynecol</source><year>2015</year><volume>213</volume><fpage>S53</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2015.08.041</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>CJ</given-names></name><name><surname>Tarca</surname><given-names>AL</given-names></name><name><surname>Chhauy</surname><given-names>S</given-names></name><name><surname>LaJeunesse</surname><given-names>C</given-names></name><etal/></person-group><article-title>Villitis of unknown etiology is associated with a distinct pattern of chemokine upregulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease</article-title><source>J Immunol</source><year>2009</year><volume>182</volume><fpage>3919</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803834</pub-id><?supplied-pmid 19265171?><pub-id pub-id-type="pmid">19265171</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>MR</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Friel</surname><given-names>L</given-names></name><name><surname>Espinoza</surname><given-names>J</given-names></name><etal/></person-group><article-title>Involvement of Hofbauer cells and maternal T cells in villitis of unknown aetiology</article-title><source>Histopathology</source><year>2008</year><volume>52</volume><fpage>457</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2008.02964.x</pub-id><?supplied-pmid 18315598?><pub-id pub-id-type="pmid">18315598</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St Louis</surname><given-names>D</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Plazyo</surname><given-names>O</given-names></name><name><surname>Arenas-Hernandez</surname><given-names>M</given-names></name><name><surname>Panaitescu</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Invariant NKT cell activation induces late preterm birth that is attenuated by rosiglitazone</article-title><source>J Immunol</source><year>2016</year><volume>196</volume><fpage>1044</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501962</pub-id><pub-id pub-id-type="pmid">26740111</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Lopez</surname><given-names>N</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Arenas-Hernandez</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>H</given-names></name><name><surname>Panaitescu</surname><given-names>B</given-names></name><name><surname>Vadillo-Ortega</surname><given-names>F</given-names></name><etal/></person-group><article-title>In vivo T-cell activation by a monoclonal alphaCD3epsilon antibody induces preterm labor and birth</article-title><source>Am J Reprod Immunol</source><year>2016</year><volume>76</volume><fpage>386</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/aji.12562</pub-id><?supplied-pmid 27658719?><pub-id pub-id-type="pmid">27658719</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Xu Y, Plazyo O, Romero R, Hassan SS, Gomez-Lopez N. Isolation of leukocytes from the human maternal&#x02013;fetal interface. J Vis Exp. 2015;99:e52863.</mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Arenas-Hernandez M, Sanchez-Rodriguez EN, Mial TN, Robertson S, Gomez-Lopez N. Isolation of leukocytes from the murine tissues at the maternal-fetal interface. J Vis Exp. 2015;99:e52866.</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>F</given-names></name><name><surname>Wallukat</surname><given-names>G</given-names></name><name><surname>Herse</surname><given-names>F</given-names></name><name><surname>Budner</surname><given-names>O</given-names></name><name><surname>El-Mousleh</surname><given-names>T</given-names></name><name><surname>Costa</surname><given-names>SD</given-names></name><etal/></person-group><article-title>CD19+ CD5+ cells as indicators of preeclampsia</article-title><source>Hypertension</source><year>2012</year><volume>59</volume><fpage>861</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.111.188276</pub-id><?supplied-pmid 22353610?><pub-id pub-id-type="pmid">22353610</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bommer</surname><given-names>I</given-names></name><name><surname>Muzzio</surname><given-names>DO</given-names></name><name><surname>Zygmunt</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name></person-group><article-title>Progesterone and estradiol exert an inhibitory effect on the production of anti-inflammatory cytokine IL-10 by activated MZ B cells</article-title><source>J Reprod Immunol</source><year>2016</year><volume>116</volume><fpage>113</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2016.05.008</pub-id><?supplied-pmid 27317920?><pub-id pub-id-type="pmid">27317920</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzzio</surname><given-names>DO</given-names></name><name><surname>Soldati</surname><given-names>R</given-names></name><name><surname>Ehrhardt</surname><given-names>J</given-names></name><name><surname>Utpatel</surname><given-names>K</given-names></name><name><surname>Evert</surname><given-names>M</given-names></name><name><surname>Zenclussen</surname><given-names>AC</given-names></name><etal/></person-group><article-title>B cell development undergoes profound modifications and adaptations during pregnancy in mice</article-title><source>Biol Reprod</source><year>2014</year><volume>91</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.1095/biolreprod.114.122366</pub-id><?supplied-pmid 25210132?><pub-id pub-id-type="pmid">25210132</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzzio</surname><given-names>D</given-names></name><name><surname>Zenclussen</surname><given-names>AC</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name></person-group><article-title>The role of B cells in pregnancy: the good and the bad</article-title><source>Am J Reprod Immunol</source><year>2013</year><volume>69</volume><fpage>408</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/aji.12079</pub-id><?supplied-pmid 23351028?><pub-id pub-id-type="pmid">23351028</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzzio</surname><given-names>DO</given-names></name><name><surname>Soldati</surname><given-names>R</given-names></name><name><surname>Rolle</surname><given-names>L</given-names></name><name><surname>Zygmunt</surname><given-names>M</given-names></name><name><surname>Zenclussen</surname><given-names>AC</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name></person-group><article-title>B-1a B cells regulate T cell differentiation associated with pregnancy disturbances</article-title><source>Front Immunol</source><year>2014</year><volume>5</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00006</pub-id><?supplied-pmid 24478775?><pub-id pub-id-type="pmid">24478775</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzzio</surname><given-names>D</given-names></name><name><surname>Zygmunt</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name></person-group><article-title>The role of pregnancy-associated hormones in the development and function of regulatory B cells</article-title><source>Front Endocrinol</source><year>2014</year><volume>5</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.3389/fendo.2014.00039</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>F</given-names></name><name><surname>Muzzio</surname><given-names>D</given-names></name><name><surname>Soldati</surname><given-names>R</given-names></name><name><surname>Fest</surname><given-names>S</given-names></name><name><surname>Zenclussen</surname><given-names>AC</given-names></name></person-group><article-title>Regulatory B10 cells restore pregnancy tolerance in a mouse model</article-title><source>Biol Reprod</source><year>2013</year><volume>89</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1095/biolreprod.113.110791</pub-id><?supplied-pmid 23986569?><pub-id pub-id-type="pmid">23986569</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolle</surname><given-names>L</given-names></name><name><surname>Memarzadeh Tehran</surname><given-names>M</given-names></name><name><surname>Morell-Garcia</surname><given-names>A</given-names></name><name><surname>Raeva</surname><given-names>Y</given-names></name><name><surname>Schumacher</surname><given-names>A</given-names></name><name><surname>Hartig</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cutting edge: IL-10-producing regulatory B cells in early human pregnancy</article-title><source>Am J Reprod Immunol</source><year>2013</year><volume>70</volume><fpage>448</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/aji.12157</pub-id><?supplied-pmid 24118333?><pub-id pub-id-type="pmid">24118333</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfson</surname><given-names>ML</given-names></name><name><surname>Muzzio</surname><given-names>DO</given-names></name><name><surname>Ehrhardt</surname><given-names>J</given-names></name><name><surname>Franchi</surname><given-names>AM</given-names></name><name><surname>Zygmunt</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name></person-group><article-title>Expression analysis of cannabinoid receptors 1 and 2 in B cells during pregnancy and their role on cytokine production</article-title><source>J Reprod Immunol</source><year>2016</year><volume>116</volume><fpage>23</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2016.05.001</pub-id><?supplied-pmid 27163857?><pub-id pub-id-type="pmid">27163857</pub-id></element-citation></ref><ref id="CR69"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzzio</surname><given-names>DO</given-names></name><name><surname>Ziegler</surname><given-names>KB</given-names></name><name><surname>Ehrhardt</surname><given-names>J</given-names></name><name><surname>Zygmunt</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name></person-group><article-title>Marginal zone B cells emerge as a critical component of pregnancy well-being</article-title><source>Reproduction</source><year>2016</year><volume>151</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1530/REP-15-0274</pub-id><?supplied-pmid 26493101?><pub-id pub-id-type="pmid">26493101</pub-id></element-citation></ref><ref id="CR70"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>Real</surname><given-names>LM</given-names></name><name><surname>Rivero-Juarez</surname><given-names>A</given-names></name><name><surname>Pineda</surname><given-names>JA</given-names></name><name><surname>Camacho</surname><given-names>A</given-names></name><name><surname>Macias</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection</article-title><source>Genes Immun</source><year>2015</year><volume>16</volume><fpage>134</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/gene.2014.71</pub-id><?supplied-pmid 25569262?><pub-id pub-id-type="pmid">25569262</pub-id></element-citation></ref><ref id="CR71"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>E</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Richani</surname><given-names>K</given-names></name><name><surname>Espinoza</surname><given-names>J</given-names></name><name><surname>Nien</surname><given-names>JK</given-names></name><name><surname>Chaiworapongsa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Anaphylatoxins in preterm and term labor</article-title><source>J Perinat Med</source><year>2005</year><volume>33</volume><fpage>306</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1515/JPM.2005.051</pub-id><?supplied-pmid 16207115?><pub-id pub-id-type="pmid">16207115</pub-id></element-citation></ref><ref id="CR72"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaisbuch</surname><given-names>E</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Erez</surname><given-names>O</given-names></name><name><surname>Mazaki-Tovi</surname><given-names>S</given-names></name><name><surname>Kusanovic</surname><given-names>JP</given-names></name><name><surname>Soto</surname><given-names>E</given-names></name><etal/></person-group><article-title>Fragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammation</article-title><source>J Matern Fetal Neonatal Med</source><year>2009</year><volume>22</volume><fpage>905</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1080/14767050902994663</pub-id><?supplied-pmid 19603351?><pub-id pub-id-type="pmid">19603351</pub-id></element-citation></ref><ref id="CR73"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>E</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Richani</surname><given-names>K</given-names></name><name><surname>Yoon</surname><given-names>BH</given-names></name><name><surname>Chaiworapongsa</surname><given-names>T</given-names></name><name><surname>Vaisbuch</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection</article-title><source>J Matern Fetal Neonatal Med</source><year>2009</year><volume>22</volume><fpage>983</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.3109/14767050902994747</pub-id><?supplied-pmid 19900036?><pub-id pub-id-type="pmid">19900036</pub-id></element-citation></ref><ref id="CR74"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaisbuch</surname><given-names>E</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Erez</surname><given-names>O</given-names></name><name><surname>Mazaki-Tovi</surname><given-names>S</given-names></name><name><surname>Kusanovic</surname><given-names>JP</given-names></name><name><surname>Soto</surname><given-names>E</given-names></name><etal/></person-group><article-title>Activation of the alternative pathway of complement is a feature of pre-term parturition but not of spontaneous labor at term</article-title><source>Am J Reprod Immunol</source><year>2010</year><volume>63</volume><fpage>318</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0897.2009.00800.x</pub-id><?supplied-pmid 20163401?><pub-id pub-id-type="pmid">20163401</pub-id></element-citation></ref><ref id="CR75"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Girardi</surname><given-names>G</given-names></name></person-group><article-title>Cervical remodeling/ripening at term and preterm delivery: the same mechanism initiated by different mediators and different effector cells</article-title><source>PLoS ONE.</source><year>2011</year><volume>6</volume><fpage>e26877</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0026877</pub-id><?supplied-pmid 22073213?><pub-id pub-id-type="pmid">22073213</pub-id></element-citation></ref><ref id="CR76"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ognjanovic</surname><given-names>S</given-names></name><name><surname>Bryant-Greenwood</surname><given-names>GD</given-names></name></person-group><article-title>Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes</article-title><source>Am J Obstet Gynecol</source><year>2002</year><volume>187</volume><fpage>1051</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1067/mob.2002.126295</pub-id><?supplied-pmid 12389004?><pub-id pub-id-type="pmid">12389004</pub-id></element-citation></ref><ref id="CR77"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazaki-Tovi</surname><given-names>S</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Kusanovic</surname><given-names>JP</given-names></name><name><surname>Erez</surname><given-names>O</given-names></name><name><surname>Gotsch</surname><given-names>F</given-names></name><name><surname>Mittal</surname><given-names>P</given-names></name><etal/></person-group><article-title>Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition</article-title><source>J Perinat Med</source><year>2008</year><volume>36</volume><fpage>485</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1515/JPM.2008.084</pub-id><?supplied-pmid 18598235?><pub-id pub-id-type="pmid">18598235</pub-id></element-citation></ref><ref id="CR78"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marvin</surname><given-names>KW</given-names></name><name><surname>Eykholt</surname><given-names>RL</given-names></name><name><surname>Keelan</surname><given-names>JA</given-names></name><name><surname>Sato</surname><given-names>TA</given-names></name><name><surname>Mitchell</surname><given-names>MD</given-names></name></person-group><article-title>The 15-deoxy-delta(12,14)-prostaglandin J(2)receptor, peroxisome proliferator activated receptor-gamma (PPARgamma) is expressed in human gestational tissues and is functionally active in JEG3 choriocarcinoma cells</article-title><source>Placenta</source><year>2000</year><volume>21</volume><fpage>436</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1053/plac.1999.0485</pub-id><?supplied-pmid 10833383?><pub-id pub-id-type="pmid">10833383</pub-id></element-citation></ref><ref id="CR79"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Kadam</surname><given-names>L</given-names></name><name><surname>Mial</surname><given-names>TN</given-names></name><name><surname>Plazyo</surname><given-names>O</given-names></name><etal/></person-group><article-title>An M1-like macrophage polarization in decidual tissue during spontaneous preterm labor that is attenuated by rosiglitazone treatment</article-title><source>J Immunol</source><year>2016</year><volume>196</volume><fpage>2476</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1502055</pub-id><?supplied-pmid 26889045?><pub-id pub-id-type="pmid">26889045</pub-id></element-citation></ref><ref id="CR80"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>EB</given-names></name><name><surname>Eykholt</surname><given-names>R</given-names></name><name><surname>Helliwell</surname><given-names>RJ</given-names></name><name><surname>Gilmour</surname><given-names>RS</given-names></name><name><surname>Mitchell</surname><given-names>MD</given-names></name><name><surname>Marvin</surname><given-names>KW</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor isoform expression changes in human gestational tissues with labor at term</article-title><source>Mol Pharmacol</source><year>2003</year><volume>64</volume><fpage>1586</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1124/mol.64.6.1586</pub-id><?supplied-pmid 14645690?><pub-id pub-id-type="pmid">14645690</pub-id></element-citation></ref><ref id="CR81"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Beazer-Barclay</surname><given-names>YD</given-names></name><name><surname>Antonellis</surname><given-names>KJ</given-names></name><name><surname>Scherf</surname><given-names>U</given-names></name><etal/></person-group><article-title>Exploration, normalization, and summaries of high density oligonucleotide array probe level data</article-title><source>Biostatistics</source><year>2003</year><volume>4</volume><fpage>249</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/4.2.249</pub-id><?supplied-pmid 12925520?><pub-id pub-id-type="pmid">12925520</pub-id></element-citation></ref><ref id="CR82"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Astrand</surname><given-names>M</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>A comparison of normalization methods for high density oligonucleotide array data based on variance and bias</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><fpage>185</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/19.2.185</pub-id><?supplied-pmid 12538238?><pub-id pub-id-type="pmid">12538238</pub-id></element-citation></ref><ref id="CR83"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>Linear models and empirical Bayes methods for assessing differential expression in microarray experiments</article-title><source>Stat Appl Genet Mol Biol</source><year>2004</year><volume>3</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2202/1544-6115.1027</pub-id></element-citation></ref><ref id="CR84"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucl Acids Res</source><year>2015</year><volume>43</volume><fpage>e47</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><?supplied-pmid 25605792?><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="CR85"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><year>2001</year><volume>25</volume><fpage>402</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="CR86"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Forslund</surname><given-names>K</given-names></name><name><surname>Heller</surname><given-names>D</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><etal/></person-group><article-title>STRING v10: protein-protein interaction networks, integrated over the tree of life</article-title><source>Nucl Acids Res</source><year>2015</year><volume>43</volume><fpage>D447</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1003</pub-id><?supplied-pmid 25352553?><pub-id pub-id-type="pmid">25352553</pub-id></element-citation></ref></ref-list></back></article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Spinal Cord</journal-id><journal-id journal-id-type="iso-abbrev">Spinal Cord</journal-id><journal-title-group><journal-title>Spinal Cord</journal-title></journal-title-group><issn pub-type="ppub">1362-4393</issn><issn pub-type="epub">1476-5624</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358587</article-id><article-id pub-id-type="pmid">30089893</article-id><article-id pub-id-type="publisher-id">180</article-id><article-id pub-id-type="doi">10.1038/s41393-018-0180-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The protective effect of microRNA-21 in neurons after spinal cord injury</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ni</surname><given-names>Shuangfei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Zixiang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Ye</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hu</surname><given-names>Jianzhong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Lu</surname><given-names>Hongbin</given-names></name><address><email>hongbinlu@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution>Department of Sports Medicine, Research Center of Sports Medicine, Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, Hunan People&#x02019;s Republic of China </aff><aff id="Aff2"><label>2</label>Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, Hunan People&#x02019;s Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution>Department of Spine Surgery, Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, Hunan People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2019</year></pub-date><volume>57</volume><issue>2</issue><fpage>141</fpage><lpage>149</lpage><history><date date-type="received"><day>19</day><month>12</month><year>2017</year></date><date date-type="rev-recd"><day>25</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>25</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Study design</title><p id="Par1">Experimental animal study.</p></sec><sec><title>Objectives</title><p id="Par2">To validate the anti-apoptosis effect of microRNA-21 in neurons after spinal cord injury (SCI) and explore the mechanism.</p></sec><sec><title>Setting</title><p id="Par3">Xiangya Hospital, Central South University, Changsha, Hunan, People&#x02019;s Republic of China.</p></sec><sec><title>Methods</title><p id="Par4">In situ hybridization was used to detect the expression of miR-21 in spinal cord neurons (<italic>n</italic>&#x02009;=&#x02009;24). In a rat contusion SCI model (<italic>n</italic>&#x02009;=&#x02009;48), we upregulated the miR-21 level around the injured area using miR-21 lentiviral vectors and evaluated the therapeutic effect with histology and behavioural scores. In neuronal cells, oxygen-glucose deprivation (OGD) was exerted to imitate SCI, and we explored the biomechanism using molecular biology and a dual-luciferase reporter assay.</p></sec><sec><title>Results</title><p id="Par5">miR-21 was expressed in spinal cord neurons and was found to improve neuronal survival and promote functional recovery in rat SCI models. The in vitro results in PC-12 cells revealed that the augmentation of endogenous miR-21 was able to reduce neuronal cell death after OGD. In addition, overexpression of miR-21 was able to reduce cellular apoptosis via decreasing PDCD4 protein levels, and caspase-3 activity was also influenced. Transfection of miR-21 into 293T cells was able to decrease luciferase activity in a reporter assay system, including the 3&#x02032; untranslated region of PDCD4.</p></sec><sec><title>Conclusions</title><p id="Par6">miR-21 may have a protective role in neuronal apoptosis after SCI. PDCD4 may be a functional target gene involved in the miR-21-mediated anti-apoptotic effect through an miR-21/PDCD4/caspase-3 pathway.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>81371956</award-id><award-id>81672174</award-id><principal-award-recipient><name><surname>Hu</surname><given-names>Jianzhong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; International Spinal Cord Society 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par7">To treat spinal cord injury (SCI) more effectively, many basic and clinical investigators focus on the underlying pathological mechanisms of SCI, which involve primary mechanical injury and secondary injury. During secondary injury, ischaemia/hypoxia and reperfusion are some of the key pathophysiological changes and lead to a series of apoptotic neuronal cell death. Neurons in the injured boundary zone may be rescued, and the survival of these neurons is crucial for functional rehabilitation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, the potential molecular mechanisms that determine neuronal apoptosis are still not entirely clear.</p><p id="Par8">miRNAs are endogenous non-coding RNAs (18&#x02013;22 nucleotides) that can negatively regulate gene expression at the post-transcriptional level [<xref ref-type="bibr" rid="CR3">3</xref>]. To date, several miRNAs have been detected in the mammalian brain and spinal cord, and they seem to play vital roles in some neurological functions [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In particular, miR-21 is a strong anti-apoptotic gene in solid tumours [<xref ref-type="bibr" rid="CR6">6</xref>] that regulates the expression of certain genes, such as PDCD4 and PTEN. Furthermore, it was reported that miR-21 is upregulated in some types of central nervous system injuries, such as stroke and traumatic brain injury [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Previously, we found using miRNA arrays that miR-21 was one of the most dysregulated miRNAs after SCI in a rat model, and knockdown of miR-21 by an antagomir was correlated with apoptosis and functional deficits [<xref ref-type="bibr" rid="CR9">9</xref>]. Nevertheless, the relevant biological roles of miR-21 in spinal cord neurons remain poorly understood and require further study.</p><p id="Par9">In the present study, we measured miR-21 expression in neurons from the rat contused spinal cord and PC-12 neuroblastoma cell lines, which underwent oxygen&#x02013;glucose deprivation (OGD). To investigate the biologic effect of miR-21 in SCI neurons, we artificially overexpressed miR-21 via lentiviral vectors. Furthermore, we explored the potential mechanisms by examining PDCD4, which was associated with ischaemia/hypoxia reperfusion-induced apoptosis [<xref ref-type="bibr" rid="CR10">10</xref>]. PDCD4 is thought to induce apoptosis by activating the caspase-3 pathway [<xref ref-type="bibr" rid="CR11">11</xref>]. Our results indicate that miR-21 is upregulated in neurons after SCI, and it appears to be able to reduce neuronal sensitivity to apoptosis by targeting PDCD4.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Lentiviral vector construction</title><p id="Par10">The lentiviral vectors were constructed by GeneChem (Shanghai, China) to artificially overexpress miR-21, and a green fluorescent protein (GFP) tag was encoded in the vector sequence. The sequence of mir-21(6648-1)-P1 was AGCTGTACAAGTAAGTGGCATTAAGCCCCGGCAAG, and the sequence of mir-21(6648-1)-P2 was GGGAGAGGGGCTTAGTGCAAGTCTCATGAGACATAAG. The pre-miR-21 hairpin structure and scramble control hairpin were inserted in the lentiviral expression vector GV254 (Ubi-EGFP-MCS-IRES-Puromycin), which was provided by GeneChem (Shanghai, China) using a Nhel site. Packaging of the GV254 miR-21 lentivirus particles was completed in a pseudoviral particle producer cell line (293 TN cells) by co-transfecting with the envelope plasmids Pmd2.G and pPAX using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The supernatant was harvested 48 and 72&#x02009;h after transfection. The viral particles were further concentrated, as described previously [<xref ref-type="bibr" rid="CR12">12</xref>]. An empty vector was used as a negative control.</p></sec><sec id="Sec4"><title>Animal model of SCI</title><p id="Par11">Adult male Sprague-Dawley (SD) rats weighing 180&#x02013;220&#x02009;g were anaesthetized by 10% chloral hydrate (3&#x02009;mg/kg). Moderate SCI models (<italic>n</italic>&#x02009;=&#x02009;64) were induced by a modified Allen&#x02019;s weight drop apparatus at the thoracic vertebra level 10. After the rats were anaesthetized, an incision was made on the dorsomedial line, and the spine was exposed clearly centred at the T10 vertebra. A laminectomy was carefully performed to reveal the spinal dura mater, approximately 3&#x02009;mm in length. Then, moderate contusion injury was induced by a modified Allen&#x02019;s weight drop apparatus (8&#x02009;g weight at a vertical height of 40&#x02009;mm, 8&#x02009;g&#x02009;&#x000d7;&#x02009;40&#x02009;mm). Successful signs of a rat SCI model were as follows: bleeding and oedema in the T10 spinal dura mater, retracted flapping of both hind limbs, spasmodic sway of the tail, and flaccid paralysis after palinesthesia. Uninjured animals (<italic>n</italic>&#x02009;=&#x02009;12) were subjected only to laminectomy. A total of eight uninjured and 16 SCI rats were allocated for in situ hybridization (ISH) and laser capture microdissection (LCM). The other 48 SCI rats were randomly divided into two groups: the LV-miR21 group (<italic>n</italic>&#x02009;=&#x02009;24) and the negative control (LV-NC) group (<italic>n</italic>&#x02009;=&#x02009;24). Each animal in the two groups received 5&#x02009;&#x003bc;l of the respective implant (LV/miR-21-shRNA suspension for the LV-miR21 group and NC-LV suspension for LV-NC group) at the rostral and caudal areas of the cord around the lesion (2.5&#x02009;&#x003bc;l at each point). Post-operative care of rats included analgesia (0.25% Bupivacaine, subcutaneous, 0.1&#x02009;ml) and daily manual bladder training until the reflexive control of bladder function was restored. At different time points, animals were euthanized with an overdose of 10% chloral hydrate (10&#x02009;mg/kg), and a 10-mm segment of spinal cord encompassing the injured site was harvested for subsequent testing.</p></sec><sec id="Sec5"><title>Basso, Beattie and Bresnahan (BBB) score</title><p id="Par12">Functional recovery was evaluated at 7 and 14 days postsurgery using the BBB open field locomotor test, as described previously [<xref ref-type="bibr" rid="CR13">13</xref>]. The behaviours of the trunk, tail and hindlimbs of the rats were assessed in an open field. The observers were blind to the treatment.</p></sec><sec id="Sec6"><title>Tissue preparation</title><p id="Par13">Spinal cord tissues were harvested through three methods. For total protein extraction, the spinal cord segments were directly separated after euthanasia and then immediately preserved in liquid nitrogen. For cryosectioning, rats were terminally anaesthetized and transcardially perfused with 37&#x02009;&#x000b0;C heparinized saline, followed by 4% paraformaldehyde (PFA). The spinal cord tissue around the injured site was removed carefully, post-fixed in 4% PFA overnight at 4&#x02009;&#x000b0;C, and dehydrated in 15 and 30% sucrose solution until sinking. Next, the tissue was embedded in an optimal cutting temperature (OCT) and frozen at &#x02212;20&#x02009;&#x000b0;C. The frozen tissue was transected and vertically sectioned in 10&#x02009;&#x000b5;m sections for ISH and LCM. For paraffin sectioning, the spinal cord tissue was embedded in paraffin after post-fixing overnight. Transverse sections (10&#x02009;&#x003bc;m) were taken for Nissl staining.</p></sec><sec id="Sec7"><title>ISH and immunofluorescence staining</title><p id="Par14">To verify whether miR-21 is expressed in spinal cord neurons, ISH was performed on transverse frozen sections using the 30% LNA-70% DNA3&#x02032;-DIG-labelled mercury probes (Exiqon, Vedbaedk, Denmark), according to the manufacturer&#x02019;s protocol. Hybridized miR-21 was visualized with Alkaline Phosphatase (AP). After ISH, sections were blocked in PBS containing 0.5% BSA and 0.05% Tween 20 for immunostaining. Incubation with a NeuN antibody (1:500; Abcam) was followed by incubation with a fluorescent secondary antibody. Finally, cells were stained with DAPI (1:7500, Sigma, USA) for 10&#x02009;min to visualize nuclei.</p></sec><sec id="Sec8"><title>LCM</title><p id="Par15">LCM was used to separate neurons from the spinal cord to detect miR-21 in only spinal cord neurons by Real Time-Polymerase Chain Reaction (RT-PCR). Transverse frozen sections (10&#x02009;&#x003bc;m) of spinal cord samples were mounted on LCM membrane slides and immunostained with an antibody against NeuN (1:250; Abcam), as previously reported [<xref ref-type="bibr" rid="CR14">14</xref>]. Approximately 1000 NeuN-positive cells from each animal were captured on a thermoplastic film using the laser microdissection system (Leica LMD 6 500/7000, Wetzlar, Germany). Cells were transferred to Eppendorf tubes containing 300&#x02009;&#x003bc;l lysis buffer and stored at &#x02212;80&#x02009;&#x000b0;C before RNA isolation.</p></sec><sec id="Sec9"><title>Nissl staining and cell counts</title><p id="Par16">The area of the spinal cord 3&#x02212;5&#x02009;mm rostral and caudal to the injury (adjacent area) was transversely sectioned (10&#x02009;&#x003bc;m) with adjacent sections 200&#x02009;&#x003bc;m apart from each other. Sections were stained with Nissl Solution (Beyotime), and six sections (three rostral and three caudal) were counted from each rat. In each section, 10 squares (area&#x02009;=&#x02009;0.01&#x02009;mm<sup>2</sup>) were selected at 400&#x000d7; magnification to count the neuron number, including four squares in the anterior horn, four squares in the posterior horn and two squares around the myelocoele. During the counting procedure, only neurons whose nuclei were cut and visible were counted. After calculating the area of the grey matter using IPP (Image-Pro Plus 5.0.2; Media Cybernetics Inc.), we counted the neuron number in the grey matter. The grey matter and white matter were separated by the positive results, which were higher in the grey matter. The number of positively stained cells in the entire grey matter area was counted and averaged per section in a blind manner.</p></sec><sec id="Sec10"><title>Cell culture and transfection</title><p id="Par17">PC-12 cells were purchased from the Cell Storage Center of Wuhan University (Wuhan, China). Native PC-12 cells were maintained in the Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) that was supplemented with 10% foetal bovine serum (FBS, Gibco), 5% horse serum (Gibco), 100&#x02009;U/ml penicillin and 100&#x02009;&#x003bc;g/ml streptomycin at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub>.</p><p id="Par18">For miRNA transfection, cells were seeded in a six-well plate at 4&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells per well, and the lentiviral vectors with 8&#x02009;&#x000b5;g/ml polybrene were added to the media (MOI&#x02009;=&#x02009;20), according to the protocol to infect PC-12 cells. After infection for 24&#x02009;h, the cells were selected using 3&#x02009;&#x000b5;g/ml puromycin for 3 days. The living cells after puromycin selection were used for subsequent experiments. For PDCD4 transfection, the PDCD4 cDNA was transfected into PC-12 cells by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec11"><title>OGD and reoxygenation</title><p id="Par19">For OGD, the stably transfected PC-12 cells were seeded into a six-well plate premixed with 50&#x02009;ng/ml nerve growth factor (NGF 2.5S, Invitrogen) at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells/well. After culturing at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub> for 72&#x02009;h, culture medium was replaced with glucose-free DMEM (Gibco), and cells were placed into an anaerobic chamber suffused with 94% N<sub>2</sub>/1% O<sub>2</sub>/5% CO<sub>2</sub> for 4&#x02009;h at 37&#x02009;&#x000b0;C. Subsequently, the cells were washed twice with RPMI 1640 and incubated for 24&#x02009;h in their normal culture medium for the subsequent measurements.</p></sec><sec id="Sec12"><title>Apoptosis assay</title><p id="Par20">The level of apoptosis was measured by flow cytometry (FACS) using an annexin V-PE apoptosis detection kit (Beyotime), and caspase-3 activity was measured with a caspase-3 colorimetric assay kit (Keygen). For FACS, approximately 105 cells were harvested and incubated in 195&#x02009;&#x003bc;l binding buffer containing 5&#x02009;&#x003bc;l Annexin V-PE at 25&#x02009;&#x000b0;C for 10&#x02013;20&#x02009;min, as recommended by the manufacturer. The detection of caspase-3 activity was performed following the manufacturer&#x02019;s instructions, and the relative luminescence intensity was presented as the fold-change compared with untreated controls.</p></sec><sec id="Sec13"><title>Real-time semi-quantitative RT-PCR</title><p id="Par21">Total RNA from cultured PC-12 cells and spinal cord neurons separated by LCM were extracted using TRIzol (Invitrogen), according to the manufacturer&#x02019;s instructions. cDNA was prepared from total RNA using the PrimeScript RT reagent kit (TaKaRa), and qRT-PCR was performed using the SYBR Premix Ex Taq (TaKaRa). The relative miR-21 levels were normalized using U6 as an internal control. Although U6 was thought to be affected by freeze&#x02013;thaw cycles [<xref ref-type="bibr" rid="CR15">15</xref>], it is a common reference and is still used in many studies. The analysis of gene expression was performed by the 2&#x02212;&#x00394;&#x00394;CT method.</p></sec><sec id="Sec14"><title>Western blotting</title><p id="Par22">The expression level of PDCD4, a target gene of miR-21, was determined by Western blot analysis. The freshly harvested spinal cord, including the injured spinal cord and the PC-12 cells harvested for Western blot analysis, were lysed, and the protein concentrations were determined using the BCA protein assay kit (Pierce). The protocol was performed as described previously [<xref ref-type="bibr" rid="CR9">9</xref>]. Primary antibodies used in this study included an anti-rabbit-PDCD4 antibody (1:1000, Cell Signaling Technology) and an anti-GAPDH antibody (1:1000, Cell Signaling Technology).</p></sec><sec id="Sec15"><title>Dual-luciferase reporter assay</title><p id="Par23">To further confirm the targeted relationship between miR-21 and PDCD4, a pMiR luciferase reporter assay with the PDCD4 3&#x02032; untranslated region (3&#x02032;UTR) (sequence: GGAGGGACCGAAGAGTAACCACCTATGTGTGGGGTGTTCTGATAAGCTACTTTCTAAGTG; mutant sequence: GGAGGGACCGAAGAGTAACCACCTATGTGTGGGGTGTGGATAATTTAGGCTTTCTAAGTG) was used for analysis (GeneChem Co. Ltd., Shanghai). Co-transfection of 293T cells with PDCD4-3&#x02032;UTR WT (3&#x02032;UTR WT)/PDCD4-3&#x02032;UTR Mutant (3&#x02032;UTR MU)/PDCD4-3&#x02032;UTR negative control (3&#x02032;UTR NC) and miR-21/miR-21 negative control (miR21-NC) in 24-well plates was completed using Lipofectamine 2000 (Invitrogen), according to the manufacturer&#x02019;s instructions. After 48&#x02009;h of transfection, firefly and Renilla luciferase activities were analyzed with the luciferase reporter assay (Promega), according to the manufacturer&#x02019;s protocol.</p><sec id="Sec17"><title>Statistics</title><p id="Par25">The data are all presented as the mean&#x02009;&#x000b1;&#x02009;SD and analyzed using SPSS 13.0 statistical software (SPSS Inc., Chicago, IL, USA). Differences between groups were analyzed by two-way ANOVA with Bonferroni&#x02019;s post hoc test or Student&#x02019;s <italic>t</italic>-test. A value of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered significant.</p></sec></sec></sec><sec id="Sec18" sec-type="results"><title>Results</title><sec id="Sec19"><title>miR-21 was upregulated in injured spinal cord neurons</title><p id="Par26">ISH was performed to investigate whether SCI affected miR-21 expression in neurons. In the uninjured spinal cord, miR-21 was detected at low levels, but abundant miR-21 signals were detected in cells bordering the lesion zone 7 days after SCI. At 14&#x02009;day after SCI, miR-21 expression could still be detected, but it was lower than expression on the seventh day (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. a1&#x02013;a3). Moreover, to determine whether neurons express miR-21 in vivo following SCI, we co-stained NeuN protein, a marker of neurons. The immunostaining indicated that many cells with positive miR-21 signals were also NeuN-positive, but not all (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. b1&#x02013;b3). These data showed that miR-21 is upregulated in neurons around the lesion area.<fig id="Fig1"><label>Fig. 1</label><caption><p>miR-21 was expressed in rat spinal cord neurons, and the expression was upregulated after SCI. <bold>a1</bold>&#x02013;<bold>a3</bold> The results of in situ hybridization showed that the expression of miR-21 increased after SCI in the injury boundary zone, especially on the seventh day after SCI (vertical sections). <bold>b1</bold>&#x02013;<bold>b3</bold> In situ hybridization and immunofluorescence revealed that miR-21 was co-localized with NeuN in some cells of the rat spinal cord on the seventh day after SCI (transections) (The region within the arc showed the rat spinal cord injury zone)</p></caption><graphic xlink:href="41393_2018_180_Fig1_HTML" id="d29e535"/></fig></p><p id="Par27">However, miR-21 is not upregulated in neurons specifically, and ISH is not appropriate to quantify the gene expression. Therefore, neurons were isolated from the injured boundary zone of the injured spinal cord after SCI using LCM for RT-PCR analysis. The results revealed that there was a remarkable upregulation of miR-21 in injured neurons compared to those isolated from the uninjured spinal cord. miR-21 expression increased 3.68&#x02009;&#x000b1;&#x02009;0.18-fold at 7 days post-injury (<italic>n</italic>&#x02009;=&#x02009;4; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test), and the average increase in expression was approximately 3.22&#x02009;&#x000b1;&#x02009;0.16 times higher at 14 days after SCI (<italic>n</italic>&#x02009;=&#x02009;4; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test), relative to the uninjured spinal cord. Therefore, these data suggested that miR-21 expression was significantly augmented in neurons after SCI.</p></sec><sec id="Sec20"><title>Positive role of miR-21 in neuronal survival in vivo</title><p id="Par28">In the present study, we investigated the effect of miR-21 on the neurons adjacent to the lesion site by Nissl staining at days 7 and 14 after SCI (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a, b</xref>). The number of surviving neurons per section in the LV-miR21 group was significantly greater than that of the LV-NC group at the seventh (<italic>n</italic>&#x02009;=&#x02009;4; 221&#x02009;&#x000b1;&#x02009;33 vs. 188&#x02009;&#x000b1;&#x02009;21, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test) and 14th day after injury (<italic>n</italic>&#x02009;=&#x02009;4; 286&#x02009;&#x000b1;&#x02009;18 vs. 220&#x02009;&#x000b1;&#x02009;34, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). In the LV-miR-21 group, there were a higher number of survival neurons at day 14 than at day 7, while there was no significant difference in the LV-NC group. However, even in the miR-21 group on the 14th day following SCI, the number of surviving neurons was only approximately 52.4% of the number in the uninjured group. Moreover, we performed the BBB locomotor scale to evaluate whether miR-21 could improve functional recovery after SCI. After SCI, all rats exhibited complete paralysis in both hindlimbs (BBB score&#x02009;=&#x02009;0), and hindlimb locomotor function showed a gradual improvement with time in both groups (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>). Compared to the scores of the LV-NC group, the BBB scores of the LV-miR21 animals were significantly higher at post-injury day 14 (<italic>n</italic>&#x02009;=&#x02009;12; 6.83&#x02009;&#x000b1;&#x02009;0.94 vs. 5.50&#x02009;&#x000b1;&#x02009;1.00, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), while there was no difference at day 7 (<italic>n</italic>&#x02009;=&#x02009;12; 1.67&#x02009;&#x000b1;&#x02009;0.49 vs. 1.50&#x02009;&#x000b1;&#x02009;0.52, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (Two-way ANOVA: factor miR-21: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;11.28<italic>, p</italic>&#x02009;=&#x02009;0.0016; factor time: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;421.15, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; interaction: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;6.82, <italic>p</italic>&#x02009;=&#x02009;0.0123).<fig id="Fig2"><label>Fig. 2</label><caption><p>LV-miR21 treatment was able to promote neuronal survival and functional recovery in the injured spinal cord. Neurons were visualized by Nissl staining in the boundary zone of the injured spinal cord in cross-sections, and the spinal cord function was evaluated by BBB scores (mean&#x02009;&#x000b1;&#x02009;SD). <bold>a</bold>&#x02013;<bold>c</bold> Representative images and quantitative analysis of surviving neurons by Nissl staining in different groups at different time points; <bold>b</bold> shows a higher magnification of the boxed area in <bold>a</bold>. <bold>d</bold> The BBBs scores showed functional recovery in different groups at different time points (<italic>n</italic>&#x02009;=&#x02009;4; *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, the difference was significant between the LV-miR21 and LV-NC groups; <sup>#</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, the difference was significant between the different time points)</p></caption><graphic xlink:href="41393_2018_180_Fig2_HTML" id="d29e657"/></fig></p></sec><sec id="Sec21"><title>miR-21 decreased apoptosis of neurons in vitro</title><p id="Par29">To observe the dynamics of miR-21 in vitro, we used a model of ischaemia and reperfusion in which PC-12 cells were successively subjected to OGD and reoxygenation. We found that miR-21 expression increased significantly after OGD/reoxygenation for 24&#x02009;h (2.48&#x02009;&#x000b1;&#x02009;0.15-fold compared to expression in normal cells; <italic>n</italic>&#x02009;=&#x02009;3; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test). We further evaluated the effect of miR-21 on the apoptosis of PC-12 cells using FACS analysis of annexin-V-stained cells. Overexpression of miR-21 decreased the percentage of annexin V-positive cells compared with the control group percentage (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Therefore, miR-21 was able to inhibit apoptosis in cultured PC-12 cells.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Cell apoptosis in response to the transfection of LV-miR21 and LV-NC determined by FACS analysis of annexin-V-stained cells and caspase-3 activity (mean&#x02009;&#x000b1;&#x02009;standard deviation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>LV-NC</th><th>LV-miR-21</th></tr></thead><tbody><tr><td>Annexin-positive cells (%)</td><td>35.27&#x02009;&#x000b1;&#x02009;1.20</td><td>22.37&#x02009;&#x000b1;&#x02009;1.79<sup>a</sup></td></tr><tr><td>Relative caspase-3 activity</td><td>1.00&#x02009;&#x000b1;&#x02009;0.16</td><td>0.66&#x02009;&#x000b1;&#x02009;0.06<sup>a</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, difference was significant between the LV-miR21 and LV-NC groups, <italic>n</italic>&#x02009;=&#x02009;3</p></table-wrap-foot></table-wrap></p><p id="Par30">Caspase-3 is known to play a vital role in apoptosis. To determine whether the anti-apoptotic effect of miR-21 occurred via the pathway of caspase-3, we measured the caspase-3 activity. The results showed that caspase-3 enzymatic activity was reduced in LV-miR21 cells compared with activity in LV-NC cells (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Therefore, caspase-3 might be involved in the anti-apoptotic process of miR-21 after OGD/reoxygenation.</p></sec><sec id="Sec22"><title>PDCD4 expression was attenuated by miR-21 as a potential target gene</title><p id="Par31">Previous reports showed that miR-21 targeted PDCD4 and decreased its expression in some cancer cells [<xref ref-type="bibr" rid="CR11">11</xref>]. However, the role of PDCD4 in neuronal apoptosis is currently unclear. In this study, PDCD4 was overexpressed by PDCD4 cDNA transfection in PC-12 cells (<italic>n</italic>&#x02009;=&#x02009;3; 1.00&#x02009;&#x000b1;&#x02009;0.03 vs. 2.24&#x02009;&#x000b1;&#x02009;0.06, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>), and the apoptosis rate of these cells increased after OGD (<italic>n</italic>&#x02009;=&#x02009;3; 28.95&#x02009;&#x000b1;&#x02009;2.50 vs. 39.43&#x02009;&#x000b1;&#x02009;1.76, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). In PC-12 cells, upregulated miR-21 could decrease the expression of PDCD4, although PDCD4 levels increased after OGD in both the LV-NC (<italic>n</italic>&#x02009;=&#x02009;3; 1.32&#x02009;&#x000b1;&#x02009;0.05 vs. 1.00&#x02009;&#x000b1;&#x02009;0.06, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and LV-miR21 (0.69&#x02009;&#x000b1;&#x02009;0.10 vs. 0.56&#x02009;&#x000b1;&#x02009;0.07, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>) (Two-way ANOVA: factor miR-21: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;223.95, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; factor time: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;39.73, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; interaction: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;6.66, <italic>p</italic>&#x02009;=&#x02009;0.024). In rat models, the expression of PDCD4 in the LV-miR21 group was also lower than in the LV-NC group at both the seventh day and 14th day after SCI (<italic>n</italic>&#x02009;=&#x02009;4; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d</xref>) (Two-way ANOVA: factor miR-21: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;311.03, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; factor time: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;0.56, <italic>p</italic>&#x02009;=&#x02009;0.467; interaction: <italic>F</italic>(df&#x02009;=&#x02009;1)&#x02009;=&#x02009;0.96, <italic>p</italic>&#x02009;=&#x02009;0.3476). These data show that PDCD4 is a target gene of miR-21 involved in the mediation of neuronal apoptosis.<fig id="Fig3"><label>Fig. 3</label><caption><p>PDCD4 is a direct target gene of miR-21 and is involved in the miR-21-mediated anti-apoptotic effect in PC-12 cells (mean&#x02009;&#x000b1;&#x02009;SD). <bold>a</bold> PDCD4 was overexpressed by adding PDCD4 cDNA to PC-12 cells. <bold>b</bold> Overexpression of PDCD4 resulted in a higher rate of apoptosis induced by OGD/reperfusion detected via FACS analysis. <bold>c</bold>&#x02013;<bold>d</bold> Modulation of PDCD4 expression by LV-miR21 in PC-12 cells (<italic>n</italic>&#x02009;=&#x02009;3) and in rats (<italic>n</italic>&#x02009;=&#x02009;4); the overexpression of miR-21 was able to decrease the expression of PDCD4 (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, the difference was significant between the LV-miR21 and LV-NC groups; #<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, the difference was significant between the different times in one group). <bold>e</bold> Validation of the binding sites of miR-21 in PDCD4 by a luciferase reporter assay. A fragment of the 3&#x02032;-UTR of PDCD4 mRNA with the putative miR-21 binding sequence cloned into a firefly luciferase reporter and transfected into 293T cells together with miR-21 and miR21-NC. Firefly luciferase activity was normalized to Renilla luciferase expression (<italic>n</italic>&#x02009;=&#x02009;3, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 compared with the miR21-NC group)</p></caption><graphic xlink:href="41393_2018_180_Fig3_HTML" id="d29e870"/></fig></p><p id="Par32">When we co-transfected 3&#x02032;-UTR-WT with miR-21 in 293T cells, the luciferase activity was only 72.8&#x02009;&#x000b1;&#x02009;1.4% compared to activity in cells co-transfected with miR21-NC (<italic>n</italic>&#x02009;=&#x02009;3; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>t</italic>-test), while there was no difference in activity in the group transfected with 3&#x02032;-UTR-MU (<italic>n</italic>&#x02009;=&#x02009;3; <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05, <italic>t</italic>-test, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3e</xref>). These data therefore indicate that miR-21 could bind to the PDCD4 transcript via complementarity to its sequence.</p></sec></sec><sec id="Sec23" sec-type="discussion"><title>Discussion</title><p id="Par33">The present study confirmed that miR-21 was able to protect neurons after SCI in vitro and in vivo. miR-21 was expressed in neurons of the spinal cord and was significantly upregulated after injury. Overexpression of miR-21 could decrease the apoptosis of neurons by inhibiting the PDCD4/caspase-3 pathway and improve the recovery of locomotor function.</p><p id="Par34">Recently, various studies have reported that many miRNAs are involved in the prognosis of SCI through various pathways, including apoptosis, regeneration, inflammation and demyelination [<xref ref-type="bibr" rid="CR16">16</xref>]. It is well known that apoptosis is considered to be a crucial mechanism of cell death in many neurological diseases and SCI [<xref ref-type="bibr" rid="CR17">17</xref>]. The apoptotic process is associated with numerous genes, and therapeutic strategies might be able to prevent programmed cell death [<xref ref-type="bibr" rid="CR18">18</xref>]. In particular, miR-21 has been shown to be an anti-apoptotic factor in many cancer cells [<xref ref-type="bibr" rid="CR19">19</xref>], and its expression is significantly upregulated in some CNS diseases [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Our previous study revealed that miR-21 was upregulated 3 days following rat SCI using miRNA microarray [<xref ref-type="bibr" rid="CR9">9</xref>], and in a study by Oneil [<xref ref-type="bibr" rid="CR21">21</xref>], miR-21 expression increased significantly at 5 weeks after SCI. However, these studies were both completed in animals and did not reveal whether miR-21 was upregulated in neurons after SCI. Our present study demonstrated that miR-21 was expressed in neurons and was upregulated after rat SCI, but the expression was not specific.</p><p id="Par35">Moreover, it has been shown that miR-21 has protective effects in the injury of different organs. In the injured region after myocardial infarction, miR-21 expression increased and played a protective role [<xref ref-type="bibr" rid="CR22">22</xref>]. In addition, miR-21 was able to attenuate the apoptosis of cardiac cells induced by H<sub>2</sub>O<sub>2</sub> [<xref ref-type="bibr" rid="CR23">23</xref>], and it was involved in ischaemic preconditioning-mediated cardiac protection [<xref ref-type="bibr" rid="CR24">24</xref>]. Moreover, miR-21 expression was also upregulated after traumatic brain injury [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. After stroke, the overexpression of miR-21 protected neurons from ischaemia by targeting Fasl [<xref ref-type="bibr" rid="CR26">26</xref>]. In a rat SCI model, when miR-21 was downregulated by antagomir-21, apoptosis increased, and the expression of Fasl and PTEN increased [<xref ref-type="bibr" rid="CR9">9</xref>]. In the present study, we found that overexpression of miR-21 decreased neuronal apoptosis and downregulated the expression of PDCD4.</p><p id="Par36">PDCD4 is a pro-apoptotic gene and is able to regulate various aspects of many human diseases as a direct miR-21 target. In cancer, PDCD4 universally acts as a potential target for anticancer therapies [<xref ref-type="bibr" rid="CR27">27</xref>]. In diabetes mellitus, PDCD4 is able to induce the apoptosis of pancreatic &#x003b2;-cells, and this process is controlled by miR-21 [<xref ref-type="bibr" rid="CR28">28</xref>]. In heart ischaemia/reperfusion injury, PDCD4 is involved in cardiovascular biology by regulating the apoptosis of cardiac cells and vascular smooth muscle cells [<xref ref-type="bibr" rid="CR24">24</xref>]. Caspases are the final effectors in the apoptotic pathway, and caspase-3 is a major mediator of apoptosis following injury [<xref ref-type="bibr" rid="CR29">29</xref>]. PDCD4 is thought to at least partly drive apoptosis via the activation of the caspase-3 pathway [<xref ref-type="bibr" rid="CR30">30</xref>]. Liu [<xref ref-type="bibr" rid="CR31">31</xref>] showed that exercise leads to elevated levels of miR-21, which are correlated with changes in PDCD4 expression after SCI. Our experimental data showed that the miR-21/PDCD4/caspase-3 pathway participates in neuronal apoptosis in vitro and following SCI in vivo.</p><p id="Par37">However, there were still some limitations in this study. The ischaemia/reperfusion injury model was established in PC-12 cells, not in primary cultured neurons. When treated with NGF, the PC-12 cells stop dividing and terminally differentiate into neuron-like cells. This makes PC-12 cells useful as a model to study the function and pathophysiology of neurons [<xref ref-type="bibr" rid="CR32">32</xref>], and such a model has been used in SCI research [<xref ref-type="bibr" rid="CR33">33</xref>]. We therefore thought its use was appropriate for this study. In addition, the mechanism of SCI is complex, and miR-21 was not the unique protective element during secondary SCI. Similarly, PDCD4 is not unique as a target gene of miR-21; there are other genes as well.</p><p id="Par38">In summary, in rat SCI models and in the ischaemia/reperfusion injury of PC-12 cells, miR-21 had a protective effect by reducing neuronal apoptosis via the miR-21/PDCD4/caspase-3 pathway. Identifying the roles of miR-21 in neuronal protection might make it a novel therapeutic target for secondary SCI.</p></sec></body><back><ack><sec id="FPar1"><title>Funding</title><p id="Par39">This work was supported by the National Natural Science Foundation of China (No. 81371956, No. 81171698 and No. 81672174).</p></sec></ack><notes notes-type="author-contribution"><title>Author contribution</title><p>TZ was responsible for drafting and revising the article and conducting the research. SN contributed to conducting the research. ZL and YL contributed to data extraction and analysis. JH and HL were responsible for conceiving and designing the research and playing an important role in interpreting the results.</p></notes><notes notes-type="COI-statement"><sec id="FPar2"><title>Conflict of interest</title><p>The authors declare that they have no conflict of interest.</p></sec><sec id="FPar202"><title>Statement of ethics</title><p>We certify that all applicable institutional and governmental regulations concerning the ethical use of animals were followed during the course of this research.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardone</surname><given-names>R</given-names></name><name><surname>Pikija</surname><given-names>S</given-names></name><name><surname>Mutzenbach</surname><given-names>JS</given-names></name><name><surname>Seidl</surname><given-names>M</given-names></name><name><surname>Leis</surname><given-names>S</given-names></name><name><surname>Trinka</surname><given-names>E</given-names></name><etal/></person-group><article-title>Current and emerging treatment options for spinal cord ischemia</article-title><source>Drug Discov Today</source><year>2016</year><volume>21</volume><fpage>1632</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2016.06.015</pub-id><pub-id pub-id-type="pmid">27326910</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Melatonin inhibits neural cell apoptosis and promotes locomotor recovery via activation of the Wnt/beta-catenin signaling pathway after spinal cord injury</article-title><source>Neurochem Res</source><year>2017</year><volume>42</volume><fpage>2336</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/s11064-017-2251-7</pub-id><pub-id pub-id-type="pmid">28417262</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosik</surname><given-names>KS</given-names></name></person-group><article-title>The neuronal microRNA system</article-title><source>Nat Rev Neurosci</source><year>2006</year><volume>7</volume><fpage>911</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/nrn2037</pub-id><pub-id pub-id-type="pmid">17115073</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhalala</surname><given-names>OG</given-names></name><name><surname>Srikanth</surname><given-names>M</given-names></name><name><surname>Kessler</surname><given-names>JA</given-names></name></person-group><article-title>The emerging roles of microRNAs in CNS injuries</article-title><source>Nat Rev Neurol</source><year>2013</year><volume>9</volume><fpage>328</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2013.67</pub-id><pub-id pub-id-type="pmid">23588363</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>D</given-names></name><etal/></person-group><article-title>Potential role of microRNA: identification and functional analysis of microRNA in corticospinal tract after unilateral lesions of the medullary pyramid</article-title><source>Neurosci Lett</source><year>2014</year><volume>564</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.12.050</pub-id><pub-id pub-id-type="pmid">24513234</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>LP</given-names></name><name><surname>He</surname><given-names>CY</given-names></name><name><surname>Zhu</surname><given-names>ZT</given-names></name></person-group><article-title>Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>23675</fpage><lpage>89</lpage><?supplied-pmid 28423589?><pub-id pub-id-type="pmid">28423589</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>LY</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>WS</given-names></name></person-group><article-title>miR-21 represses FasL in microglia and protects against microglia-mediated neuronal cell death following hypoxia/ischemia</article-title><source>Glia</source><year>2012</year><volume>60</volume><fpage>1888</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1002/glia.22404</pub-id><pub-id pub-id-type="pmid">22907769</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><etal/></person-group><article-title>MiR-21 alleviates secondary blood-brain barrier damage after traumatic brain injury in rats</article-title><source>Brain Res</source><year>2015</year><volume>1603</volume><fpage>150</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2015.01.009</pub-id><pub-id pub-id-type="pmid">25598202</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>JZ</given-names></name><name><surname>Huang</surname><given-names>JH</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>HB</given-names></name></person-group><article-title>Anti-apoptotic effect of microRNA-21 after contusion spinal cord injury in rats</article-title><source>J Neurotrauma</source><year>2013</year><volume>30</volume><fpage>1349</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1089/neu.2012.2748</pub-id><pub-id pub-id-type="pmid">23647386</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ischemic postconditioning-regulated miR-499 protects the rat heart against ischemia/reperfusion injury by inhibiting apoptosis through PDCD4</article-title><source>Cell Physiol Biochem</source><year>2016</year><volume>39</volume><fpage>2364</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1159/000452506</pub-id><pub-id pub-id-type="pmid">27832626</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>K</given-names></name><name><surname>Dempsie</surname><given-names>Y</given-names></name><name><surname>Caruso</surname><given-names>P</given-names></name><name><surname>Wallace</surname><given-names>E</given-names></name><name><surname>McDonald</surname><given-names>RA</given-names></name><name><surname>Stevens</surname><given-names>H</given-names></name><etal/></person-group><article-title>Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis</article-title><source>Hypertension</source><year>2014</year><volume>64</volume><fpage>185</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.113.03037</pub-id><pub-id pub-id-type="pmid">24732886</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutner</surname><given-names>RH</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Reiser</surname><given-names>J</given-names></name></person-group><article-title>Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.22</pub-id><pub-id pub-id-type="pmid">19300443</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>DM</given-names></name><name><surname>Beattie</surname><given-names>MS</given-names></name><name><surname>Bresnahan</surname><given-names>JC</given-names></name></person-group><article-title>A sensitive and reliable locomotor rating scale for open field testing in rats</article-title><source>J Neurotrauma</source><year>1995</year><volume>12</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1089/neu.1995.12.1</pub-id><pub-id pub-id-type="pmid">7783230</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Chopp</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>RL</given-names></name><name><surname>Hozeska-Solgot</surname><given-names>A</given-names></name><name><surname>Gregg</surname><given-names>SC</given-names></name><name><surname>Buller</surname><given-names>B</given-names></name><etal/></person-group><article-title>Angiopoietin 2 mediates the differentiation and migration of neural progenitor cells in the subventricular zone after stroke</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>22680</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.006551</pub-id><pub-id pub-id-type="pmid">19553662</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>M</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><etal/></person-group><article-title>U6 is not a suitable endogenous control for the quantification of circulating microRNAs</article-title><source>Biochem Biophys Res Commun</source><year>2014</year><volume>454</volume><fpage>210</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.10.064</pub-id><pub-id pub-id-type="pmid">25450382</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identifying the role of microRNAs in spinal cord injury</article-title><source>Neurol Sci</source><year>2014</year><volume>35</volume><fpage>1663</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s10072-014-1940-0</pub-id><pub-id pub-id-type="pmid">25231644</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgens</surname><given-names>RB</given-names></name><name><surname>Liu-Snyder</surname><given-names>P</given-names></name></person-group><article-title>Understanding secondary injury</article-title><source>Q Rev Biol</source><year>2012</year><volume>87</volume><fpage>89</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1086/665457</pub-id><pub-id pub-id-type="pmid">22696939</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>PK</given-names></name><name><surname>Malaspina</surname><given-names>A</given-names></name></person-group><article-title>Spinal cord trauma and the molecular point of no return</article-title><source>Mol Neurodegener</source><year>2012</year><volume>7</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-7-6</pub-id><pub-id pub-id-type="pmid">22315999</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godwin</surname><given-names>JG</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Stephan</surname><given-names>K</given-names></name><name><surname>Jurisch</surname><given-names>A</given-names></name><name><surname>Tullius</surname><given-names>SG</given-names></name><name><surname>Iacomini</surname><given-names>J</given-names></name></person-group><article-title>Identification of a microRNA signature of renal ischemia reperfusion injury</article-title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>107</volume><fpage>14339</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912701107</pub-id><pub-id pub-id-type="pmid">20651252</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>EB</given-names></name><name><surname>Hochfelder</surname><given-names>CG</given-names></name><name><surname>Lamberty</surname><given-names>BG</given-names></name><name><surname>Meays</surname><given-names>BM</given-names></name><name><surname>Morsey</surname><given-names>BM</given-names></name><name><surname>Kelso</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Traumatic brain injury increases levels of miR-21 in extracellular vesicles: implications for neuroinflammation</article-title><source>FEBS Open Bio</source><year>2016</year><volume>6</volume><fpage>835</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.12092</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhalala</surname><given-names>OG</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Sahni</surname><given-names>V</given-names></name><name><surname>McGuire</surname><given-names>TL</given-names></name><name><surname>Gruner</surname><given-names>K</given-names></name><name><surname>Tourtellotte</surname><given-names>WG</given-names></name><etal/></person-group><article-title>microRNA-21 regulates astrocytic response following spinal cord injury</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>17935</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3860-12.2012</pub-id><pub-id pub-id-type="pmid">23238710</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Long</surname><given-names>C</given-names></name><etal/></person-group><article-title>Expression of microRNA-1 and microRNA-21 in different protocols of ischemic conditioning in an isolated rat heart model</article-title><source>Cardiology</source><year>2012</year><volume>122</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1159/000338149</pub-id><pub-id pub-id-type="pmid">22699357</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4</article-title><source>J Mol Cell Cardiol</source><year>2009</year><volume>47</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2009.01.008</pub-id><pub-id pub-id-type="pmid">19336275</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4</article-title><source>Cardiovasc Res</source><year>2010</year><volume>87</volume><fpage>431</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq082</pub-id><pub-id pub-id-type="pmid">20219857</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury</article-title><source>Brain Res</source><year>2009</year><volume>1284</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2009.05.074</pub-id><pub-id pub-id-type="pmid">19501075</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buller</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>RL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Hozeska-Solgot</surname><given-names>A</given-names></name><etal/></person-group><article-title>MicroRNA-21 protects neurons from ischemic death</article-title><source>FEBS J</source><year>2010</year><volume>277</volume><fpage>4299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07818.x</pub-id><pub-id pub-id-type="pmid">20840605</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Tang</surname><given-names>HM</given-names></name><name><surname>To</surname><given-names>SS</given-names></name></person-group><article-title>Targeting strategies on miRNA-21 and PDCD4 for glioblastoma</article-title><source>Arch Biochem Biophys</source><year>2015</year><volume>580</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2015.07.001</pub-id><pub-id pub-id-type="pmid">26142886</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Kameswaran</surname><given-names>V</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Matschinsky</surname><given-names>F</given-names></name><etal/></person-group><article-title>The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>12030</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.1101450108</pub-id><pub-id pub-id-type="pmid">21730150</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannan</surname><given-names>JL</given-names></name><name><surname>Matsui</surname><given-names>H</given-names></name><name><surname>Sopko</surname><given-names>NA</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Weyne</surname><given-names>E</given-names></name><name><surname>Albersen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Caspase-3 dependent nitrergic neuronal apoptosis following cavernous nerve injury is mediated via RhoA and ROCK activation in major pelvic ganglion</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>29416</fpage><pub-id pub-id-type="doi">10.1038/srep29416</pub-id><pub-id pub-id-type="pmid">27388816</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>K</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Nakashima</surname><given-names>W</given-names></name><name><surname>Ura</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>SI</given-names></name></person-group><article-title>Loss of programmed cell death 4 induces apoptosis by promoting the translation of procaspase-3 mRNA</article-title><source>Cell Death Differ</source><year>2012</year><volume>19</volume><fpage>573</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/cdd.2011.126</pub-id><pub-id pub-id-type="pmid">21959934</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Keeler</surname><given-names>BE</given-names></name><name><surname>Zhukareva</surname><given-names>V</given-names></name><name><surname>Houle</surname><given-names>JD</given-names></name></person-group><article-title>Cycling exercise affects the expression of apoptosis-associated microRNAs after spinal cord injury in rats</article-title><source>Exp Neurol</source><year>2010</year><volume>226</volume><fpage>200</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2010.08.032</pub-id><pub-id pub-id-type="pmid">20816819</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Bogaart</surname><given-names>G</given-names></name><name><surname>Meyenberg</surname><given-names>K</given-names></name><name><surname>Risselada</surname><given-names>HJ</given-names></name><name><surname>Amin</surname><given-names>H</given-names></name><name><surname>Willig</surname><given-names>KI</given-names></name><name><surname>Hubrich</surname><given-names>BE</given-names></name><etal/></person-group><article-title>Membrane protein sequestering by ionic protein-lipid interactions</article-title><source>Nature</source><year>2011</year><volume>479</volume><fpage>552</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/nature10545</pub-id><pub-id pub-id-type="pmid">22020284</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name></person-group><article-title>Dimercaprol is an acrolein scavenger that mitigates acrolein-mediated PC-12 cells toxicity and reduces acrolein in rat following spinal cord injury</article-title><source>J Neurochem</source><year>2017</year><volume>141</volume><fpage>708</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/jnc.14025</pub-id><pub-id pub-id-type="pmid">28301040</pub-id></element-citation></ref></ref-list></back></article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.5.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art550.dtd?><?SourceDTD.Version 5.5.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_MOLMET757 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEfigs1 jpg ?><?FILEfigs2 jpg ?><?FILEfigs3 jpg ?><?FILEfigs4 jpg ?><?FILEfigs5 jpg ?><?FILEmmc1 docx ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Mol Metab</journal-id><journal-title-group><journal-title>Molecular Metabolism</journal-title></journal-title-group><issn pub-type="epub">2212-8778</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358588</article-id><article-id pub-id-type="publisher-id">S2212-8778(18)31027-5</article-id><article-id pub-id-type="doi">10.1016/j.molmet.2018.12.005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Natural helix 9 mutants of PPAR&#x003b3; differently affect its transcriptional activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Broekema</surname><given-names>Marjoleine F.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Massink</surname><given-names>Maarten P.G.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Donato</surname><given-names>Cinzia</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>de Ligt</surname><given-names>Joep</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Schaarschmidt</surname><given-names>Joerg</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Borgman</surname><given-names>Anouska</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Schooneman</surname><given-names>Marieke G.</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Melchers</surname><given-names>Diana</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Gerding</surname><given-names>Martin N.</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Houtman</surname><given-names>Ren&#x000e9;</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Bonvin</surname><given-names>Alexandre M.J.J.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Majithia</surname><given-names>Amit R.</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Monajemi</surname><given-names>Houshang</given-names></name><xref rid="aff9" ref-type="aff">9</xref><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>van Haaften</surname><given-names>Gijs W.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Soeters</surname><given-names>Maarten R.</given-names></name><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Kalkhoven</surname><given-names>Eric</given-names></name><email>e.kalkhoven@umcutrecht.nl</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands</aff><aff id="aff2"><label>2</label>Department of Molecular Cancer Research, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands</aff><aff id="aff3"><label>3</label>Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands</aff><aff id="aff4"><label>4</label>Bijvoet Center for Biomolecular Research, Faculty of Science, Utrecht University, Utrecht, the Netherlands</aff><aff id="aff5"><label>5</label>Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands</aff><aff id="aff6"><label>6</label>PamGene International B. V., 's-Hertogenbosch, the Netherlands</aff><aff id="aff7"><label>7</label>Deventer Hospital, Deventer, the Netherlands</aff><aff id="aff8"><label>8</label>Division of Endocrinology, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA</aff><aff id="aff9"><label>9</label>Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Amsterdam, the Netherlands</aff><aff id="aff10"><label>10</label>Rijnstate Hospital, Arnhem, the Netherlands</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Center for Molecular Medicine, Department of Molecular Cancer Research, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. <email>e.kalkhoven@umcutrecht.nl</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>16</day><month>12</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>2</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2018</year></pub-date><volume>20</volume><fpage>115</fpage><lpage>127</lpage><history><date date-type="received"><day>22</day><month>10</month><year>2018</year></date><date date-type="rev-recd"><day>5</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Authors</copyright-statement><copyright-year>2018</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Objective</title><p>The nuclear receptor PPAR&#x003b3; is the master regulator of adipocyte differentiation, distribution, and function. In addition, PPAR&#x003b3; induces terminal differentiation of several epithelial cell lineages, including colon epithelia. Loss-of-function mutations in <italic>PPARG</italic> result in familial partial lipodystrophy subtype 3 (FPDL3), a rare condition characterized by aberrant adipose tissue distribution and severe metabolic complications, including diabetes. Mutations in <italic>PPARG</italic> have also been reported in sporadic colorectal cancers, but the significance of these mutations is unclear. Studying these natural <italic>PPARG</italic> mutations provides valuable insights into structure-function relationships in the PPAR&#x003b3; protein. We functionally characterized a novel FPLD3-associated PPAR&#x003b3; L451P mutation in helix 9 of the ligand binding domain (LBD). Interestingly, substitution of the adjacent amino acid K450 was previously reported in a human colon carcinoma cell line.</p></sec><sec><title>Methods</title><p>We performed a detailed side-by-side functional comparison of these two PPAR&#x003b3; mutants.</p></sec><sec><title>Results</title><p>PPAR&#x003b3; L451P shows multiple intermolecular defects, including impaired cofactor binding and reduced RXR&#x003b1; heterodimerisation and subsequent DNA binding, but not in DBD-LBD interdomain communication. The K450Q mutant displays none of these functional defects. Other colon cancer-associated PPAR&#x003b3; mutants displayed diverse phenotypes, ranging from complete loss of activity to wildtype activity.</p></sec><sec><title>Conclusions</title><p>Amino acid changes in helix 9 can differently affect LBD integrity and function. In addition, FPLD3-associated PPAR&#x003b3; mutations consistently cause intra- and/or intermolecular defects; colon cancer-associated PPAR&#x003b3; mutations on the other hand may play a role in colon cancer onset and progression, but this is not due to their effects on the most well-studied functional characteristics of PPAR&#x003b3;.</p></sec></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Mutations in <italic>PPARG</italic>, encoding for the nuclear receptor PPAR&#x003b3;, underly lipodystrophy.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">A novel lipodystrophy-associated PPAR&#x003b3; mutant, L451P, displays impaired activity.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Mutation of the adjacent K450, detected in colon cancer, has no effect.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0030">Other colon cancer-associated PPAR&#x003b3; mutants display diverse phenotypes.</p></list-item><list-item id="u0035"><label>&#x02022;</label><p id="p0035">Lipodystrophy but not cancer-associated PPAR&#x003b3; mutants consistently display defects.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Lipodystrophy</kwd><kwd>FPLD3</kwd><kwd>PPARG</kwd><kwd>Nuclear receptor</kwd><kwd>Adipose tissue</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0040">Unraveling the complex genetics and molecular and cellular mechanisms in adipose tissue physiology improves the understanding of adipose tissue dysfunction and its related metabolic complications. Adipose tissue dysfunction is a hallmark of pathologic conditions including obesity, type 2 diabetes mellitus (T2DM), and lipodystrophies. The nuclear receptor peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;), encoded by the <italic>PPARG</italic> gene, is the master regulator of adipocyte differentiation, maintenance, and function <xref rid="bib1" ref-type="bibr">[1]</xref>. Differential promoter usage and alternative splicing generates two major protein isoforms, PPAR&#x003b3;1 and PPAR&#x003b3;2 <xref rid="bib2" ref-type="bibr">[2]</xref>. PPAR&#x003b3;1 is highly expressed in colon epithelial cells, adipocytes, and monocytes/macrophages. PPAR&#x003b3;2 contains an additional 28 amino acids at the N-terminus and is predominantly expressed in adipose tissue <xref rid="bib1" ref-type="bibr">[1]</xref>. Both PPAR&#x003b3; isoforms are essential in adipogenesis <xref rid="bib3" ref-type="bibr">[3]</xref>.</p><p id="p0045">PPAR&#x003b3; forms an obligatory heterodimer with RXR&#x003b1; <xref rid="bib4" ref-type="bibr">[4]</xref>. The PPAR&#x003b3;/RXR&#x003b1; heterodimer regulates the transcription of PPAR&#x003b3; responsive genes by binding to PPAR-response elements (PPRE) in the promoter and/or enhancer regions. The PPAR&#x003b3; cistrome is gene- and cell type-specific <xref rid="bib5" ref-type="bibr">[5]</xref>. In the absence of a ligand, PPAR&#x003b3;/RXR&#x003b1; heterodimers are able to bind to PPREs. Transcription is actively repressed via interactions with corepressors like NCoR and SMRT, which recruit histone deacetylases. Upon ligand binding, the PPAR&#x003b3; ligand binding domain (LBD) undergoes a conformational change that causes the release of the corepressors and binding of coactivators like SRC-1 and CBP, initiating transcription of PPAR&#x003b3; target genes. PPAR&#x003b3; can be activated by various endogenous ligands including polyunsaturated fatty acids and eicosanoids <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>. PPAR&#x003b3; is the cognate receptor for thiazolidinediones, a class of anti-hyperglycemic agents, including rosiglitazone and pioglitazone <xref rid="bib8" ref-type="bibr">[8]</xref>. Despite their beneficial effects in glycemic control, the clinical use of thiazolidinediones is restricted due to their side effects <xref rid="bib9" ref-type="bibr">[9]</xref>.</p><p id="p0050">Loss-of-function mutations in the <italic>PPARG</italic> gene cause familial partial lipodystrophy subtype 3 (FPLD3), a rare clinical condition characterized by progressive and gradual change of subcutaneous adipose tissue distribution during peripubertal phase <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>. FPLD3 patients have a marked muscular appearance due to a paucity of subcutaneous adipose tissue in the extremities and gluteal region with co-existent lipohypertrophy in face, neck, and trunk. Patients manifest with T2DM, hepatic steatosis, recurrent episodes of pancreatitis, eruptive xanthomata, and pronounced acanthosis nigricans.</p><p id="p0055">The co-segregation of lipodystrophy with mutations in <italic>PPARG</italic> underscores the importance of PPAR&#x003b3; for adipocyte biology. In addition, PPAR&#x003b3; also induces the terminal differentiation in several other cell lineages, including colon, breast, prostate, and lung epithelial cells <xref rid="bib1" ref-type="bibr">[1]</xref>. Somatic <italic>PPARG</italic> mutations have been reported in sporadic colorectal carcinomas, but functional characterization is limited and complete side-by-side comparison of their activity in a given experimental setting is currently lacking <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>. In addition, high expression levels of <italic>PPARG</italic>, but no <italic>PPARG</italic> mutations, have been reported in certain cancer cell lines, including breast cancer <xref rid="bib18" ref-type="bibr">[18]</xref> and prostate cancer <xref rid="bib19" ref-type="bibr">[19]</xref>. Hemizygous deletions of <italic>PPARG</italic> have also been described in prostate cancers <xref rid="bib19" ref-type="bibr">[19]</xref>. Therefore, the importance of PPAR&#x003b3; in tumor initiation and progression is not exactly known. However, PPAR&#x003b3; ligands can inhibit tumor growth <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, and TZDs synergistically enhance carboplantin-mediated tumor growth inhibition in a PPAR&#x003b3;-dependent fashion in various types of cancer <xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref>. This synergistic effect is partly explained by a PPAR&#x003b3;-mediated downregulation of methallothioneins <xref rid="bib20" ref-type="bibr">[20]</xref> or increased DNA damage and subsequent p53-mediated apoptosis <xref rid="bib22" ref-type="bibr">[22]</xref>.</p><p id="p0060">Here we report the identification and functional characterization of a novel natural PPAR&#x003b3; L451P mutant in a family affected by FPLD3. Interestingly, substitution of the adjacent amino acid K450 was previously described in a human colon carcinoma cell line refractory to PPAR&#x003b3;-ligand induced growth inhibition <xref rid="bib17" ref-type="bibr">[17]</xref>. Here we show that, in contrast to the tumor-associated K450Q mutant, the FPLD3-associated L451P mutant significantly impairs the transcriptional activity of PPAR&#x003b3; due to a range of molecular defects. Our findings support the view that FPLD3-associated mutations consistently cause intra- and/or intermolecular defects, while the effect of colon cancer-associated PPAR&#x003b3; mutations varies considerably, suggesting subtler or context-dependent effects.</p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec2.1"><label>2.1</label><title>Case presentation</title><p id="p0065">Written informed consent for study participation and publication was obtained from the patient. The index patient was referred because of a suspicion of lipodystrophy (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A&#x02013;F, detailed patient description is available in the Supplemental Data). We subjected the index patient to whole exome sequencing to identify the gene responsible for the lipodystrophic phenotype. Considering the family medical history, we performed a pedigree analysis. The patient's mother was originally diagnosed with T2DM, hypertension, and hypertriglyceridemia. Furthermore, she was suffering from ischemic heart disease. The patient's sister and aunt were both initially diagnosed with T2DM and hypertriglyceridemia. The index patient's brother, who was seemingly unaffected albeit slightly overweight, appeared to have a mild T2DM and clear hypertriglyceridemia (Supplemental Data). We sequenced the candidate variant in several family members.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p><bold>The identification of PPAR&#x003b3; L451P.</bold> A-F. Clinical characteristics of the index patient. Phenotypically, she has a marked muscular habitus with trunk-sparing lipodystrophy (A, with written patient consent). In neck and axilla region patient developed acanthosis nigricans and multiple acrochordons (skin tags, B and C). Transaxial T1-weigthed MRI scans at levels of the abdomen (D) thighs (E), and calfs (F). Please note an excess of subcutaneous adipose tissue in the abdomen with a decreased amount of subcutaneous adipose tissue in the patient's lower extremities. G. Family pedigree of the index patient. Each family member is numbered for identification. The proband is indicated by the arrow. Squares and circles indicate males and females, respectively. Phenotypes are elaborated by color segments showing the presence of specific features (depicted in the figure legend). Grey symbols denote individuals that were not available for DNA analysis. Deceased individuals are indicated by a diagonal line through the symbol. No consanguinity is observed in this family pedigree. H. DNA sequence analysis showing the heterozygous L451P mutation. The chromatogram shows both alleles from the patient (lower panel) in comparison with corresponding genomic DNA from a non-affected individual (upper panel). For tracing, the nucleotide and amino acid sequence are shown. The position of the mutation in the patient is indicated by the arrow. The PPAR&#x003b3; nomenclature refers to PPAR&#x003b3;2. I. Peripheral adipose tissue expandability risk score analysis in the PPAR&#x003b3; L451P index patient to determine the contribution of genetic background to the FPLD3-phenotype. Genotypes for 53 previously described loci were extracted from the UKHLS GWAS dataset (EGA accession EGAD00010000890) to reconstruct a background distribution of a healthy female population. The index patient harbors 53 risk alleles (red vertical line). J. Crystal structure of an intact PPAR&#x003b3;&#x02013;RXR&#x003b1; complex (PPAR&#x003b3; in green; RXR&#x003b1; in blue) bound to DNA (left panel) showing leucine 451&#x000a0;at the end of helix 9. The square box indicates the magnified region shown in the right panels. L451 (upper) is highlighted in yellow, K450 is highlighted in pink (bottom), both residues generated in the stick format. Protein Database entry 3DZY. The figures were generated by open source software PyMOL 099rc6 (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org" id="interref0010">www.pymol.org</ext-link>).</p></caption><alt-text id="alttext0035">Figure&#x000a0;1</alt-text><graphic xlink:href="gr1"/></fig></p></sec><sec id="sec2.2"><label>2.2</label><title>Materials</title><p id="p0070">Rosiglitazone maleate was from Alexis. WY14643 was from Enzo Life Sciences. 15-deoxy-&#x00394;12,14-prostaglandin J2 (abbreviated as 15d-PGJ2), was from Cayman Chemicals. Synthetic RXR&#x003b1; agonist 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]nicotinic acid (abbreviated as LG100268) was purchased from Sigma&#x02013;Aldrich. Anti-PPAR&#x003b3; (sc-7196; RRID: AB_654710), anti-PPAR&#x003b1; (sc-9000; RRID: AB_2165737), anti-PPAR&#x003b1; (sc-1985; RRID: AB_2165740), anti-Gal4 DBD (sc-510; RRID: AB_627655), anti-RXR&#x003b1; (sc-553: RRID: AB_2184874), and anti-tubulin (Sigma Aldrich T9026: RRID: AB_477593) used for western blotting, were from Santa Cruz Biotechnology, Inc. Protein A Sepharose 4B Fast Flow beads were from Sigma&#x02013;Aldrich.</p></sec><sec id="sec2.3"><label>2.3</label><title>DNA sequence analysis</title><p id="p0075">Genomic DNA was extracted from peripheral-blood leukocytes in venous blood samples using QIAamp DNA Blood Mini Kit (Qiagen Hilden, Germany). Whole exome sequencing, mapping, and data analysis were performed as described previously <xref rid="bib23" ref-type="bibr">[23]</xref>. The mutation identified in the index patient, corresponds to c.1352T&#x000a0;&#x0003e;&#x000a0;C and p.L451P in reference sequences NM_015869 and NP_056953.2, respectively. The identified genetic variant was validated by Sanger sequencing. The variant p.L451P was absent in the variation databases NHLBI GO Exome Sequencing Project (ESP) <xref rid="bib24" ref-type="bibr">[24]</xref>, 1000 Genomes <xref rid="bib25" ref-type="bibr">[25]</xref>, and Single Nucleotide Polymorphism Database (dbSNP) <xref rid="bib26" ref-type="bibr">[26]</xref>, and The Genome Aggregation Database (gnomAD) <xref rid="bib27" ref-type="bibr">[27]</xref>. Amplification and Sanger sequencing of exon 6 and flanking regions were performed to genotype family members. Primers are available upon request.</p></sec><sec id="sec2.4"><label>2.4</label><title>Plasmids</title><p id="p0080">The luciferase reporter 3xPPRE-tk-Luc was kindly provided by Dr. R.M. Evans. pGL3-mFabp4-Tk-Luc (fatty acid binding protein 4; Fabp4) was a kind gift from Dr. S. Mandrup. pGL3-mCidec-Luc (cell-death-inducing DFFA-like effector c; Cidec) was a kind gift from Dr. P.F. Marrero Gonzales. The reporter construct 5xGal4-E1BTATA-pGL3 has been described previously <xref rid="bib28" ref-type="bibr">[28]</xref>. pCDNA3.1 vectors containing the complete coding region of hPPAR&#x003b3;2 wildtype (WT), a kind gift from Dr. V.K.K. Chatterjee <xref rid="bib29" ref-type="bibr">[29]</xref>, and Gal4DBD-hPPAR&#x003b3;-AF2 WT (amino acids 204-507) <xref rid="bib12" ref-type="bibr">[12]</xref> were used to generate R181D/R183D, K450Q, K450P, L451G, L451P, and E455K mutants using QuikChange mutagenesis kit (Stratagene). pCDNA3.1-hPPAR&#x003b3;1 was used for generating Q268P, R288H, S289C, V290M, K319X, K422Q, and L423P. S414P was generated in the pCDNA3.1 vector containing PPAR&#x003b1;. pGEX-PPAR&#x003b3; LBD WT was used to generate the K450Q and L451P mutants. Successful mutagenesis was verified by Sanger sequence analysis. pCDNA3.1 vectors containing RXR&#x003b1;, PPAR&#x003b3; L464R, and PPAR&#x003b3; L496A/E499A have been described previously <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>. pGEX constructs containing RXR&#x003b1;, SRC1 (AA 570-780), SMRT (AA 2302-2352), and PGC1&#x003b1; (AA 1-338) have been described previously <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref></p></sec><sec id="sec2.5"><label>2.5</label><title>Cell culture and reporter assays</title><p id="p0085">For luciferase-based reporter assays the human osteosarcoma cell line U2OS and the human embryonic kidney cell line HEK293T were maintained in DMEM 4.5&#x000a0;g/L <sc>d</sc>-glucose supplemented with 10% fetal calf serum (Invitrogen), and 100&#x000a0;&#x003bc;g penicillin/ml and 100&#x000a0;&#x003bc;g streptomycin/ml (Invitrogen). Cells were transfected using the calcium phosphate precipitation method as described previously <xref rid="bib12" ref-type="bibr">[12]</xref>. The results are averages of at least three independent experiments assayed in duplicate&#x000a0;&#x000b1;&#x000a0;SEM. Student's t-tests were used. A statistically significant difference was defined as a <italic>p</italic> value of <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec><sec id="sec2.6"><label>2.6</label><title>Western blot analysis</title><p id="p0090">The protein expression of the transfected U2OS and HEK293T cells was determined by western blot analysis as described <xref rid="bib12" ref-type="bibr">[12]</xref>. Anti-PPAR&#x003b3;, anti-PPAR&#x003b1;, anti-Gal4 DBD, anti-RXR&#x003b1;, and anti-Tubulin were used for detection of the proteins. Enhanced chemiluminescence (Amersham Biosciences) was used for visualization.</p></sec><sec id="sec2.7"><label>2.7</label><title>NR-coregulator interaction analyses</title><p id="p0095">The NR-Coregulator interaction profiling was performed as described previously <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>. GST-pull down assays were performed as described previously <xref rid="bib12" ref-type="bibr">[12]</xref>.</p></sec><sec id="sec2.8"><label>2.8</label><title>EMSA</title><p id="p0100">EMSAs were performed as described <xref rid="bib12" ref-type="bibr">[12]</xref>. Double-stranded DNA oligomers containing a consensus PPRE and natural PPREs derived from <italic>Fabp4</italic> (ARE6) and <italic>Cidec</italic> promoters were labeled with [&#x003b3;-32P] deoxy-ATP using T4 polynucleotide kinase (Biolabs). For binding and competition analysis the following DNA oligomers were used: consensus PPRE sense probe 5&#x02032; CCGGGGACCAGGACAAAGGTCACGAAGCT 3&#x02032; (underlined characters indicate the DR1 element), mutant consensus PPRE sense probe 5&#x02032; CCGGGGACCAGCACAAAGCACACCGAAGCT 3&#x02032;; mouse <italic>Fabp4</italic> sense probe 5&#x02032; CTCTCTGGGTGAAATGTGCATTTCT 3&#x02032;, and mouse <italic>Cidec</italic> sense probe 5&#x02032; CTGTGCCCTCTTGCCTAGTGC 3&#x02032;.</p></sec><sec id="sec2.9"><label>2.9</label><title>Association of genetic variants with FPLD3 phenotype in index patient</title><p id="p0105">PCR was performed in the index patient to genotype the lead SNPs in 53 genomic regions that were previously identified to impair peripheral adipose tissue storage <xref rid="bib34" ref-type="bibr">[34]</xref>. Primer sequences are available upon request. Upon download of the full dataset SNPs were extracted based on rsID from the imputed dataset (EGAS00001001232_UKHLS.UK10K+1&#x000a0;KG-imputed.phwe_1e-4.info_0.4.filtered). These SNPs were further processed using plink (v. 1.9b3) to extract compound genotypes and dosage. A custom R script (code and data attached in supplement) was used to further process these data and calculate the number of risk alleles in the population and calculate a Z-score.</p></sec><sec id="sec2.10"><label>2.10</label><title>Molecular modeling PPAR&#x003b3;- RXR&#x003b1; nuclear receptor complex</title><p id="p0110">Molecular Modeling of loop 9/10 of PPAR&#x003b3; with and without the L451P mutation was performed using Rosetta 3.8 <xref rid="bib35" ref-type="bibr">[35]</xref>. Briefly, modeling was based on the structure of the PPAR&#x003b3;&#x02013;RXR&#x003b1; Nuclear Receptor Complex (PDB ID <ext-link ext-link-type="uri" xlink:href="pdb:3DZY" id="intref0010">3DZY</ext-link>) <xref rid="bib36" ref-type="bibr">[36]</xref>. A set of 3000 models was built for the WT and L451P variant respectively, using the kinematic loop modeling protocol <xref rid="bib37" ref-type="bibr">[37]</xref> followed by a relaxation of the structures. The structures were clustered using Calibur <xref rid="bib38" ref-type="bibr">[38]</xref>. All models were evaluated based on energy and cluster size. Visualization and image generation was done using the PyMOL Molecular Graphics System Version 1.8 (2015) provided by SBGrid <xref rid="bib39" ref-type="bibr">[39]</xref>.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Identification of the novel PPAR&#x003b3; L451P mutant in a family affected by FPLD3</title><p id="p0115">Whole exome sequencing (WES) of the index patient revealed a heterozygous missense mutation in exon 6 (genomic position: chromosome 3:12475478, corresponding to c.1352T&#x000a0;&#x0003e;&#x000a0;C in reference sequences NM_015869 and NP_056953.2, respectively) in the gene <italic>PPARG</italic>, which causes the substitution of a leucine residue located at position 451 into a proline (p.L451P). This genetic variant was absent in the variation databases; the Genome Aggregation Database <xref rid="bib27" ref-type="bibr">[27]</xref> contains the rare variant p.L451V, but whether this variant has any clinical implications, is unknown as information regarding phenotype are not available.</p><p id="p0120">The clinical characteristics of the index patient closely resemble previously described cases of FPLD3, including lipodystrophy in the upper- and lower extremities with preserved truncal adipose tissue (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A, D&#x02013;F), and acanthosis nigricans (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B,C). Paternal and maternal family history showed T2DM and hypertriglyceridemia (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>G). This prompted us to analyze the pedigree of the index patient (III-2). The mutation was identified in her mother (II-4), sister (III-4), and an aunt (II-2). All had a clear lipodystrophic phenotype and a medical history comprising T2DM, hypertriglyceridemia, and/or cardiovascular disease. The <italic>PPARG</italic> mutation was also identified in the index patient's brother (III-1). The redistribution of adipose tissue was less obvious in the brother, he was diagnosed with T2DM during the study.</p><p id="p0125">A recent population-level genetic study identified 53 genomic regions in which single nucleotide polymorphisms (SNPs) are associated with insulin resistance <xref rid="bib34" ref-type="bibr">[34]</xref>. An increased number of these risk alleles is associated with an impaired ability to store adipose tissue in peripheral compartments <xref rid="bib34" ref-type="bibr">[34]</xref>. While rare variants in <italic>PPARG</italic> certainly contribute to lipodystrophy, this study suggests that SNPs in regulatory regions may contribute too. Our index patient harbors 53 risk alleles (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>I; <xref rid="appsec1" ref-type="sec">Supplemental Table&#x000a0;1</xref>). To determine whether our patient is at an increased risk for a lipodystrophic phenotype based on her genetic background, we constructed a genetic background distribution in a healthy female population (UKHLS GWAS dataset (EGA accession EGAD00010000890); n&#x000a0;=&#x000a0;5,296 female). Compared to this population distribution the index patient is not at increased risk (z-score&#x000a0;=&#x000a0;&#x02212;1.28). Taken together, the lipodystrophic phenotype in our index patient is most likely due to the novel <italic>PPARG</italic> L451P mutation.</p></sec><sec id="sec3.2"><label>3.2</label><title>The FPLD-associated mutant L451P, but not the colon cancer-associated mutant K450Q, displays impaired transcriptional activity</title><p id="p0130">The mutation identified by WES alters a leucine residue located at position 451&#x000a0;at the C-terminus of helix 9 into a proline (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>J). While L451P is the first FPLD3-associated PPAR&#x003b3;2 mutant in helix 9 of the LBD, a previous study in human colon cancer cells lines reported a K422Q mutant in PPAR&#x003b3;1, which corresponds to K450Q in the PPAR&#x003b3;2 protein (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>J) <xref rid="bib17" ref-type="bibr">[17]</xref>. As the amino acid sequence of PPAR&#x003b3;2 helix 9, including K450 and L451, is highly conserved among species (<xref rid="appsec1" ref-type="sec">Supplemental Figure&#x000a0;1</xref>), we compared the ability of the natural L451P and K450Q mutants and some artificial mutants to activate PPAR&#x003b3;-mediated transcription in reporter assays. These experiments were conducted in the human osteosarcoma cell line U2OS, which express negligible levels of endogenous PPAR&#x003b3; but display robust activation upon PPAR&#x003b3; overexpression and induction <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib40" ref-type="bibr">[40]</xref>. The transcriptional activity of the L451P mutant on a reporter construct containing three copies of a consensus PPRE (3xPPRE) was significantly impaired under both basal and induced conditions compared to the WT protein in U2OS cells (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A) and in HEK293T cells (data not shown). Increasing L451P protein concentrations led to a proportional increase in transcriptional activity, but the mutant never reached WT levels (<xref rid="appsec1" ref-type="sec">Supplemental Figure&#x000a0;2</xref>). Additional mutants were analyzed to characterize the functional defect better. Mutation of L451 into a glycine residue (L451G), which may also potentially disrupt helix 9, showed no clear effect (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A). The K450Q mutant activated transcription similar to the PPAR&#x003b3;2 WT protein (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A and data not shown). Substitution of lysine 450 into a proline (K450P) however impaired transcriptional activity similar to the L451P mutation (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A, left panel). Similar results were obtained with 15d-PGJ2, a potential natural PPAR&#x003b3; ligand (<xref rid="appsec1" ref-type="sec">Supplemental Figure&#x000a0;3</xref>). Increasing ligand concentrations did not compensate for the transcriptional defect observed (data not shown). The analogous mutation in the PPAR&#x003b3;1 isoform (L423P) displayed a similar defect (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A, right panel). In agreement with our findings for PPAR&#x003b3;2, the K-to-Q mutation (K422Q, corresponding to K450Q in PPAR&#x003b3;2) did not impair transcriptional activity. Next, the PPAR&#x003b3; L451P mutant was tested on reporter constructs that harbor the promoter regions of the well-characterized PPAR&#x003b3; target genes <italic>Cidec</italic> and <italic>Fabp4</italic>. The PPAR&#x003b3;2 L451P mutant also shows impaired transcriptional activity on these natural PPRE-containing promoters (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p><bold>The FPLD-associated L451P mutant, but not the colon cancer-associated mutant K450Q, displays impaired transcriptional activity.</bold> A-D. U2OS cells were transiently cotransfected with expression vectors encoding PPAR&#x003b3;2 WT or mutants (A, left panel and C), PPAR&#x003b3;1 WT or mutants (A, right panel) or PPAR&#x003b1; WT or S414P mutant (C). The activation of 3&#x000d7; peroxisome proliferator response element (PPRE)-Tk-Luc reporter (A and C), <italic>Cidec</italic>- (B), or <italic>Fabp4</italic>-Luc reporter (B), in the absence or presence of 1&#x000a0;&#x003bc;M rosiglitazone (PPAR&#x003b3;) or 100&#x000a0;&#x003bc;M Wy14643, is expressed as fold induction over that with empty vector (EV). D. U2OS cells were transfected with equal amounts of plasmids harboring PPAR&#x003b3;2 WT, L451P, and L496A/E499A in absence and presence of 1&#x000a0;&#x003bc;M rosiglitazone. Results are averages of at least three independent experiments assayed in duplicate&#x000a0;&#x000b1;&#x000a0;SEM. *P&#x000a0;&#x0003c;&#x000a0;0.05; **P&#x000a0;&#x0003c;&#x000a0;0.01 cells transfected with mutant <italic>vs</italic>. WT. Expression levels of the different proteins were confirmed by western blot analysis using a PPAR&#x003b3; or PPAR&#x003b1; specific antibody. The arrow indicates PPAR&#x003b3; and the asterisk indicates an unknown non-specific band. WT, wildtype.</p></caption><alt-text id="alttext0040">Figure&#x000a0;2</alt-text><graphic xlink:href="gr2"/></fig></p><p id="p0135">The amino acid sequence and structure of PPAR&#x003b3;2 helix 9 is highly conserved among species (<xref rid="appsec1" ref-type="sec">Supplemental Figure&#x000a0;1</xref>). The human PPAR&#x003b3;, PPAR&#x003b1;, and PPAR&#x003b4; proteins share a high degree of homology in the sequence and structure of their LBDs, but K450 and L451 positions in PPAR&#x003b3; are not conserved between the 3 PPAR isotypes (<xref rid="appsec1" ref-type="sec">Supplemental Figure&#x000a0;1</xref>). Substitution of serine 414 into a proline in PPAR&#x003b1;, which corresponds to L451P in PPAR&#x003b3;, however, clearly inhibited the transcriptional activity of this protein (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). The amino acid corresponding to K450 in PPAR&#x003b3;2 is a glutamine residue in both PPAR&#x003b1; and PPAR&#x003b4;, suggesting that either a lysine or a glutamine residue is structurally tolerated at this position. This view is supported by the lack of phenotype observed with the PPAR&#x003b3;2 K450Q mutant (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A).</p><p id="p0140">Previous studies show that FPLD3-associated PPAR&#x003b3;2 mutants exert their pathogenic effects by either haploinsufficiency or dominant negative activity towards the PPAR&#x003b3;2 wildtype protein on the level of DNA binding or cofactor binding <xref rid="bib10" ref-type="bibr">[10]</xref>. Reporter assays using cells transfected with both PPAR&#x003b3; wildtype and L451P showed no decrease in transcriptional activity when compared with cells transfected with PPAR&#x003b3; wildtype alone, indicating that the L451P mutant exhibits no dominant-negative activity in this assay (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>D). In contrast, the artificial L496A/E499A mutant displayed a strong dominant negative activity, as shown earlier <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>.</p><p id="p0145">Taken together, these finding show that disruption of helix 9 by proline residues (PPAR&#x003b3;2: L451P, K450P; PPAR&#x003b3;1: L432P; PPAR&#x003b1;: S414P) negatively affects PPAR function, while the natural K450Q mutation in helix 9 has no clear effect.</p></sec><sec id="sec3.3"><label>3.3</label><title>The L451P substitution shows that PPAR&#x003b3; activity does not crucially depend on PPAR&#x003b3; DBD-LBD interdomain communication</title><p id="p0150">Next, we wished to identify the molecular defects of the L451P mutant (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). A recent structural and functional study on the multi-domain RAR&#x003b2;-RXR&#x003b1; heterodimer revealed that physical interactions between the RAR&#x003b2; DBD and LBD are implicated in allosteric signal transmission between the domains <xref rid="bib41" ref-type="bibr">[41]</xref>. Apart from important differences in quaternary structure between the RAR&#x003b2;-RXR&#x003b1; and PPAR&#x003b3;&#x02013;RXR&#x003b1; heterodimers <xref rid="bib41" ref-type="bibr">[41]</xref>, an intramolecular interaction interface - though smaller than in RAR&#x003b2; - is also present between the PPAR&#x003b3; LBD, involving the loop between helix 9 and 10, and PPAR&#x003b3; DBD <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib41" ref-type="bibr">[41]</xref> (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A&#x02013;C). We investigated whether the L451P substitution would interfere with the DBD-LBD interface by functionally assessing the importance of this interface for the transcriptional activity of PPAR&#x003b3;. Remodeling experiments on the quaternary PPAR&#x003b3;&#x02013;RXR&#x003b1; heterodimer structure revealed physical interactions between a glutamic acid residue at position 455 in the loop connecting helix 9 and 10 with arginine and histidine residues at position 181 and 183 of the PPAR&#x003b3; DBD, respectively (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A&#x02013;C). Introducing mutations at the PPAR&#x003b3;2 LBD-DBD interface did not compromise the transcriptional activity of PPAR&#x003b3;2 (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D). Our data suggest that in contrast to the larger and well-formed RAR&#x003b2; LBD-DBD interface <xref rid="bib41" ref-type="bibr">[41]</xref>, transcriptional activity of PPAR&#x003b3; does not crucially depend on the transmission of allosteric signals between the DBD-LBD intramolecular interface. Therefore, the impact of L451P on this intramolecular interdomain communication is probably limited.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p><bold>The L451P substitution shows that PPAR&#x003b3; activity does not crucially depend on PPAR&#x003b3; DBD-LBD interdomain communication.</bold> A. The crystal structure of an intact PPAR&#x003b3;&#x02013;RXR&#x003b1; complex (PPAR&#x003b3; in green; RXR&#x003b1; in blue) bound to DNA shows that a single patch consisting of helix 9 and 10 of the PPAR&#x003b3; LBD is involved in the formation of PPAR&#x003b3; LBD-PPAR&#x003b3; DBD interactions. Amino acid residue 451 is highlighted in yellow generated in the stick format. The square box indicates the magnified region shown in B (PPAR&#x003b3; WT) and C (PPAR&#x003b3; L451P). B. Remodeling experiments on the crystal structures show interactions between E455 (LBD) and R181 (DBD) and H183 (DBD) in the WT situation. C. Remodeling experiments showing the disruption of the end of helix 9 by L451P and the altered configuration of amino acids at the PPAR&#x003b3; DBD-LBD interaction interface. Protein Database entry 3DZY. The figures were generated by PyMOL Molecular Graphics System Version 1.8 (2015) provided by SBGrid <xref rid="bib39" ref-type="bibr">[39]</xref>. D. U2OS cells were transiently cotransfected with expression vectors encoding PPAR&#x003b3; WT or PPAR&#x003b3; mutants respectively, and 3&#x000d7; peroxisome proliferator response element (PPRE)-Tk-Luc reporter. Activation of the luciferase reporter, in the absence or presence of 1&#x000a0;&#x003bc;M rosiglitazone, is expressed as fold induction over that with empty vector (EV). Results are averages of three independent experiments assayed in duplicate&#x000a0;&#x000b1;&#x000a0;SEM. *P&#x000a0;&#x0003c;&#x000a0;0.05 cells transfected with mutant <italic>vs</italic>. WT. Expression levels of the different proteins were confirmed by western blot analysis using a PPAR&#x003b3; or PPAR&#x003b1; specific antibody. The arrow indicates PPAR&#x003b3; and the asterisk indicates an unknown non-specific band. WT, wildtype.</p></caption><alt-text id="alttext0045">Figure&#x000a0;3</alt-text><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec3.4"><label>3.4</label><title>L451P causes a general ligand-mediated cofactor binding defect</title><p id="p0155">The position of L451P in the LBD suggests that it can potentially disrupt intermolecular interactions, such as ligand-mediated cofactor interactions and/or RXR&#x003b1; heterodimerisation. To address these options, we first performed reporter assays in which PPAR&#x003b3; driven transcription relies on ligand-mediated cofactor recruitment, but is independent of heterodimerisation with RXR&#x003b1; <xref rid="bib12" ref-type="bibr">[12]</xref>. For this, the mutations described above were introduced into a chimeric Gal4DBD-PPAR&#x003b3; LBD receptor and expressed together with a Gal4 reporter gene in U2OS cells. Both the wild type Gal4-PPAR&#x003b3; LBD receptor and the dimerization defective L464R mutant <xref rid="bib12" ref-type="bibr">[12]</xref> clearly activated transcription, but the L451P mutant displayed reduced activity (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). The activity of the K450Q protein was comparable to the WT version, similar to our findings with the full-length protein (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). Even high concentrations of thiazolidinediones, including rosiglitazone and pioglitazone, or the tyrosine-based agonist GW1929 were unable to restore the transcriptional activity to WT levels (data not shown).<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p><bold>PPAR&#x003b3; L451P mutant displays general ligand-mediated cofactor binding defects.</bold> A. U2OS cells were transiently transfected with chimeric Gal4 DBD-hPPAR&#x003b3; LBD wildtype and mutant fusion proteins and 5xGal4-E1BTATA-Luciferase. Cells were treated with or without 1&#x000a0;&#x003bc;M rosiglitazone. Shown results are average of three independent experiments assayed in duplicate&#x000a0;&#x000b1;&#x000a0;SEM. **P&#x000a0;&#x0003c;&#x000a0;0.01 cells transfected with mutant <italic>vs</italic>. WT. DBD, DNA binding domain; LBD, ligand binding domain. Comparable amounts of Gal4 DBD-hPPAR&#x003b3; LBD proteins were detected by western blot analysis using an antibody against Gal4 DBD. B. Pamgene&#x000ae; chips containing 154 different cofactor derived peptides (containing either LxxLL or LxxxIxxxL motifs) were incubated with recombinant GST-PPAR&#x003b3;-LBD or GST-PPAR&#x003b3; L451P-LBD and anti-GST-alexa, in the absence or presence of rosiglitazone. After 102 pump cycles a CCD camera recorded fluorescence (100&#x000a0;ms). Experiment was performed in triplo. Four representative images are shown. C. GST fusion proteins as indicated in the figure coupled to glutathione-Sepharose beads were incubated with [<sup>35</sup>S] methionine-labeled PPAR&#x003b3; (wildtype or mutant) in absence and presence of rosiglitazone (indicated by&#x000a0;+&#x000a0;R, 10&#x000a0;&#x003bc;M) to determine the effect of L451P on interactions with coregulators. GST alone was used as a negative control. 10% of the total lysate of the [<sup>35</sup>S] methionine-labeled PPAR&#x003b3; proteins used for the pull down assay was applied as control (input). Levels of GST-proteins have been confirmed by Coomassie staining.</p></caption><alt-text id="alttext0050">Figure&#x000a0;4</alt-text><graphic xlink:href="gr4"/></fig></p><p id="p0160">To further analyze the interaction of the L451P mutant with transcriptional cofactors, we performed MARCoNI assays, a peptide-based microarray containing 154 NR binding motifs present in different coactivators and corepressors <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>. The NR-coregulator interaction profiles showed an overall impairment of binding, both in the absence and in the presence of rosiglitazone (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B and <xref rid="appsec1" ref-type="sec">Supplementary Figure&#x000a0;3</xref>). In contrast, the K450Q mutant protein displayed binding profiles similar to the WT protein (data not shown). Independent GST pulldown experiments confirmed that PPAR&#x003b3; L451P, but not K450Q, interacts less efficiently in absence and presence of ligand with coactivators PGC1&#x003b1; and SRC1 and corepressor SMRT (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C). Together, these results indicate that mutation of L451 into proline, but not K450 into glutamine, causes a general ligand-mediated cofactor binding defect.</p></sec><sec id="sec3.5"><label>3.5</label><title>The L451P substitution disrupts PPAR&#x003b3;/RXR&#x003b1; heterodimerization and DNA binding</title><p id="p0165">As leucine 451 is located relatively close to the RXR&#x003b1; binding interface in the LBD <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref> (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>J), and RXR&#x003b1; heterodimerization is essential for subsequent DNA binding <xref rid="bib4" ref-type="bibr">[4]</xref>, we also examined the effect of the L451P substitution on these PPAR&#x003b3; functions. First, we performed <italic>in&#x000a0;vitro</italic> binding assays using GST-RXR&#x003b1; and [<sup>35</sup>S]-methionine labeled PPAR&#x003b3; (wildtype and mutants). A clear reduction in RXR&#x003b1; heterodimerization was observed when comparing the L451P mutant protein to the WT version (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). The K450Q mutation did not affect RXR&#x003b1; heterodimerization (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A), in agreement with previous data <xref rid="bib17" ref-type="bibr">[17]</xref>. Similar findings were made when using GST-PPAR&#x003b3;-LBD and [<sup>35</sup>S]-methionine labeled RXR&#x003b1; (data not shown). To confirm and extend these findings in a cellular setting, we performed mammalian two-hybrid reporter assays in which we tethered PPAR&#x003b3; LBD WT and mutant versions to the DNA and coexpressed RXR&#x003b1;, either in the absence or presence of a synthetic RXR&#x003b1; ligand (LG 100268). In this setting, reporter activity depends on the interaction between the transcriptionally silent Gal4-DBD&#x02013;hPPAR&#x003b3;-LBD protein and its ligand-activated RXR&#x003b1; binding partner (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). While the activity of Gal4-DBD&#x02013;hPPAR&#x003b3;-LBD WT and K450Q could be stimulated by RXR&#x003b1; and further enhanced by LG100268, the L451P protein showed only weak activity under these conditions. As a control, we used the dimerization-defective L464R mutant <xref rid="bib12" ref-type="bibr">[12]</xref>, which indeed failed to respond to the addition of RXR&#x003b1; protein (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). Therefore, we conclude that substitution of L451 into proline impairs heterodimerization with RXR&#x003b1;; the K450Q mutant displayed no obvious dimerization defect.<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p><bold>The L451P substitution disrupts PPAR&#x003b3;/RXR&#x003b1; heterodimerisation and DNA binding</bold>. A. GST PPAR&#x003b3; fusion proteins (WT or mutant) coupled to glutathione-Sepharose beads were incubated with [<sup>35</sup>S] methionine-labeled RXR&#x003b1; to determine the effect of L451P on heterodimerization with binding partner RXR&#x003b1;. GST alone was used as a negative control. 10% of the total lysate of the [<sup>35</sup>S] methionine-labeled RXR&#x003b1; proteins used for the pull down assay was applied as control (input). Levels of GST-proteins have been confirmed by Coomassie staining. B. HEK293T cells were transfected with chimeric Gal4 DBD-hPPAR&#x003b3; LBD wildtype and mutant fusion proteins and 5xGal4-E1BTATA-Luciferase, as indicated. For induction of gene expression cells were treated with 10&#x000a0;nM synthetic RXR&#x003b1; ligand (LG 100268). Shown results are average of three independent experiments assayed in duplicate. DBD, DNA binding domain; LBD, ligand binding domain. C. <italic>In&#x000a0;vitro</italic> translated RXR&#x003b1; and/or PPAR&#x003b3; (wildtype or mutant) proteins were incubated with [<sup>32</sup>P]-labeled DNA probes in the absence or presence of 10&#x000d7; unlabeled wildtype and mutant probes as indicated. The formed protein-DNA complexes were separated from unbound DNA on nondenaturating SDS-polyacrylamide gels and visualized by autoradiography of dried gels. Expression levels of the different proteins were confirmed by western blot analysis using a PPAR&#x003b3; specific antibody. WT, wildtype.</p></caption><alt-text id="alttext0055">Figure&#x000a0;5</alt-text><graphic xlink:href="gr5"/></fig></p><p id="p0170">To investigate the consequences of impaired RXR&#x003b1; interaction on binding of the PPAR&#x003b3;/RXR&#x003b1; heterodimer to DNA, we performed electrophoretic mobility shift assays (EMSA) using a consensus PPRE and PPREs derived from the <italic>Fabp4</italic> and <italic>Cidec</italic> genes. Binding of the L451P mutant protein was impaired on all 3 DNA elements, which was most pronounced when lower amounts of protein were tested (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C). As a control, we again used the dimerization-defective L464R mutant <xref rid="bib12" ref-type="bibr">[12]</xref>, which indeed failed to bind DNA (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C). Taken together, these data indicate that the FPLD-associated L451P mutation results in impaired transcriptional activity due to impaired cofactor binding and reduced DNA binding, while the adjacent K450Q mutant, which was found in a human colon cancer cell line <xref rid="bib17" ref-type="bibr">[17]</xref>, displays no clear functional defects.</p></sec><sec id="sec3.6"><label>3.6</label><title>Colon cancer-associated PPAR&#x003b3; mutants display variable phenotypes</title><p id="p0175">The FPLD3-associated PPAR&#x003b3; mutants reported so far, including the currently characterized PPAR&#x003b3;2 L451P, all show a consistent and profound impairment in PPAR&#x003b3; transcriptional activity due to different repertoires of inter- and intramolecular defects <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>. Our functional characterization of the colon cancer-associated PPAR&#x003b3;2 K450Q (corresponding to PPAR&#x003b3;1 K422Q) suggests that K450Q does not display major functional defects, at least under our experimental settings. To determine whether this is a general feature of colon carcinoma-associated PPAR&#x003b3;1 mutants, we performed a side-by-side analysis of other previously reported colon cancer-associated PPAR&#x003b3;1 mutants Q286P, R288H, and K319X <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>. Two additional mutants were included, S289C <xref rid="bib43" ref-type="bibr">[43]</xref> and V290M <xref rid="bib10" ref-type="bibr">[10]</xref>. PPAR&#x003b3;1 S289C is the first <italic>PPARG</italic> germline mutation that is associated with dyslipidemia and colonic polyp formation with progression to full-blown adenocarcinoma, without features of FPLD3 <xref rid="bib43" ref-type="bibr">[43]</xref>. PPAR&#x003b3;1 V290M is one of the first identified FPLD3-associated mutants <xref rid="bib10" ref-type="bibr">[10]</xref>. Whereas the activity of PPAR&#x003b3;1 mutants Q286P and K319X is negligible in presence of rosiglitazone and 15d-PGJ2, the transcriptional activity of PPAR&#x003b3;1 R288H, alike K422Q, is clearly not impaired when induced with rosiglitazone (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B). In line with a previous study <xref rid="bib16" ref-type="bibr">[16]</xref>, impaired transcriptional activity was observed when PPAR&#x003b3;1 R288H was treated 15d-PGJ2, a potential natural PPAR&#x003b3; ligand. Although PPAR&#x003b3;1 mutants S289C and V290M were both still able to initiate transcription, their activity was impaired (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B), in agreement with previous reports <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>. Interestingly, the transcriptional activity of PPAR&#x003b3;1 S289C reached wildtype levels upon induction with 15d-PGJ2. Collectively, these results indicate that the colon carcinoma-associated PPAR&#x003b3; mutants have diverse effects on transcriptional activity and suggest that colon carcinoma-associated <italic>PPARG</italic> mutations, in contrast to FPLD3-associated <italic>PPARG</italic> mutations, do not always lead to robust molecular defects. Accordingly, if the <italic>PPARG</italic> mutations are related to colon cancer onset and progression, this is not due to their effects on the most well-studied functional characteristics of PPAR&#x003b3;.<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p><bold>Colon cancer-associated PPAR&#x003b3; mutants display variable phenotypes</bold>. A. Crystal structure of an intact PPAR&#x003b3;&#x02013;RXR&#x003b1; complex (PPAR&#x003b3; in green; RXR&#x003b1; in blue) bound to DNA (left panel). The square box indicates the magnified region shown in the right panel. In pink, PPAR&#x003b3; Q286, R288, and S289 in helix 3 and K319. Substitution of these residues is associated with colon carcinoma. PPAR&#x003b3; V290, in helix 3, indicated in yellow has previously been described in FPLD3. Protein Database entry 3DZY. The figures were generated by open source software PyMOL 099rc6 (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org" id="interref0015">www.pymol.org</ext-link>). B. U2OS cells were transiently cotransfected with expression vectors encoding PPAR&#x003b3;1 WT or PPAR&#x003b3;1 mutants respectively, and 3&#x000d7; peroxisome proliferator response element (PPRE)-Tk-Luc reporter. Activation of the luciferase reporter, in the absence or presence of 1&#x000a0;&#x003bc;M rosiglitazone (left) or 15d-PGJ2 (right), is expressed as fold induction over that with empty vector (EV). Results are averages of at least three independent experiments assayed in duplicate&#x000a0;&#x000b1;&#x000a0;SEM. **P&#x000a0;&#x0003c;&#x000a0;0.01 cells transfected with mutant <italic>vs</italic>. WT. Expression levels of the different proteins were confirmed by western blot analysis using a PPAR&#x003b3; specific antibody. WT, wildtype. #, indicates PPAR&#x003b3;1 K319X.</p></caption><alt-text id="alttext0060">Figure&#x000a0;6</alt-text><graphic xlink:href="gr6"/></fig></p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0180">Here we show that the novel heterozygous PPAR&#x003b3; L451P mutation likely provides the molecular basis for the lipodystrophic phenotype in the index patient and her family. Although this is the first FPLD3-associated <italic>PPARG</italic> mutation located in helix 9, the adjacent lysine amino acid was found to be mutated (K450Q) in colorectal cancer cell lines <xref rid="bib17" ref-type="bibr">[17]</xref>. The L451P mutant displays reduced transcriptional activity due to multiple molecular defects, including 1) general defects in ligand-mediated cofactor interactions and 2) impaired DNA binding due to reduced RXR&#x003b1; heterodimerization. In contrast, the K450Q mutant behaved like the wild type protein under all our experimental settings, suggesting that only dramatic amino acid changes in helix 9 will result in impaired PPAR&#x003b3; function. Noteworthy, our side-by-side analysis of the FPLD3-associated PPAR&#x003b3; L451P and V318M with the previously reported colon cancer-associated PPAR&#x003b3; mutants Q286P <xref rid="bib17" ref-type="bibr">[17]</xref>, R288H <xref rid="bib17" ref-type="bibr">[17]</xref>, S289C <xref rid="bib43" ref-type="bibr">[43]</xref>, K319X <xref rid="bib17" ref-type="bibr">[17]</xref>, and K422Q <xref rid="bib16" ref-type="bibr">[16]</xref>, shows that the colon cancer-associated PPAR&#x003b3; mutants do not always cause profound intra- and/or intermolecular defects. Interestingly, while no clear molecular defects with the K450Q mutant in PPAR&#x003b3;2 (present study) or the analogous K422Q mutant in PPAR&#x003b3;1 <xref rid="bib17" ref-type="bibr">[17]</xref> could be identified, the PPAR&#x003b3;1 K422Q mutant failed to induce growth inhibition <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> and to induce intestinal epithelial cell differentiation when compared to the wild type protein <xref rid="bib17" ref-type="bibr">[17]</xref>. In addition, PPAR&#x003b3;1 mutant S289C seems to be at the nexus of colon tumorigenesis and metabolic diseases as only the mutation carriers displayed derangements in lipid profiles without clinical features of T2DM and FPLD3 and only the mutation carriers developed dysplastic colonic polyps during the fourth-fifth decade of life, which in one patient progressed to colon cancer <xref rid="bib43" ref-type="bibr">[43]</xref>. Together, these findings suggest that combined PPAR&#x003b3; transcriptome, cistrome, and interactome analyses within a specific cellular context may be required to identify specific phenotypic defects.</p><p id="p0185">Although members of the nuclear receptor superfamily share a common structural architecture between their LBDs, the leucine residue at position 451 in PPAR&#x003b3; is not conserved (<xref rid="appsec1" ref-type="sec">Supplemental Figure&#x000a0;1</xref>). As shown here, mutation of the corresponding position in PPAR&#x003b1; reduced transcriptional activity (S414P; <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A), while artificial mutants at this position in the vitamin D receptor (VDR; VDR C369G <xref rid="bib45" ref-type="bibr">[45]</xref>) and thyroid hormone receptor &#x003b2; (THR&#x003b2;; THR&#x003b2; Y409K and neighboring residues Y406K, and R410A <xref rid="bib46" ref-type="bibr">[46]</xref>) also show impaired LBD functions, including dimerization defects and impaired ligand- and cofactor binding. Together these findings support the view that L451 helps to maintain the integrity of helix 9, and that this helix is important for other nuclear receptors to function properly too. To the best of our knowledge, no naturally occurring mutations corresponding to the L451 position in PPAR&#x003b3; have been reported in other nuclear receptors so far.</p><p id="p0190">In light of studying genetic <italic>PPARG</italic> variants and their effect on function, the recently developed classifier Missense InTerpretation by Experimental Response (MITER, available at <ext-link ext-link-type="uri" xlink:href="http://miter.broadinstitute.org" id="interref0020">http://miter.broadinstitute.org</ext-link>) is of particular interest <xref rid="bib15" ref-type="bibr">[15]</xref>. MITER was generated by evaluating the effects all 9,595 possible single amino acid substitutions in PPAR&#x003b3; on CD36 expression using the human monocytic cell line THP-1. The MITER experimental function scores for the PPAR&#x003b3;2 mutants Q314P (&#x02212;2,907), R316H (0.831), S317C (&#x02212;0.309), V318M (&#x02212;4,191), K347X (not available as nonsense mutations were not evaluated in MITER), and K450Q (&#x02212;1.535) are in line with the findings of the current study. Interestingly, evaluation of the PPAR&#x003b3; L451P missense variant in MITER shows four-fold decreased transactivation function as compared to WT. When considered with the patient's family history and clinical presentation of lipodystrophy (corresponding to a prevalence of 20%), the MITER classifier emitted a probability of 12.7% for the L451P variant being causal for the patient's lipodystrophy. The MITER data are consistent with our own findings that the molecular effect of the L451P variant is more subtle than the canonical autosomal dominant FPLD3 variants previously reported <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>. The co-segregation of lipodystrophy with PPAR&#x003b3; L451P strongly suggests that this PPAR&#x003b3; variant even without causing complete loss of function has a pathogenic effect in adipose tissue. Applying the CRISPR/CAS9 technology to adipocytes to recapitulate the pathogenicity of the heterozygous <italic>PPARG</italic> L451P would support this observation. However, this approach is technically very challenging in relevant (pre-)adipocyte cell lines, as for example the pre-adipocyte cell line 3T3L1 is polyclonal and polypoid.</p><p id="p0195">The co-segregation of FPLD3 with the mutant receptor PPAR&#x003b3; L451P that displays reduced transcriptional activity due to multiple molecular defects, strongly indicates that this variant is causal for the condition. However, the molecular defects of the L451P mutant are subtler than previously reported FPLD3-associated PPAR&#x003b3; mutants, indicating that the index patient and affected family members may harbor additional co-segregating genetic variants that contribute to the lipodystrophic phenotype. Indeed, recent studies have shown that FPLD syndromes have a polygenic component. The importance of SNPs in regulatory regions in lipodystrophy has recently been depicted in a large population-level genetic study <xref rid="bib34" ref-type="bibr">[34]</xref>. Patients with FPLD1, a subtype of FPLD with hitherto unknown genetic cause, are enriched for 53 common variants associated with limited peripheral adipose tissue storage capacity <xref rid="bib34" ref-type="bibr">[34]</xref>. These observations not only suggest a polygenetic cause of FPLD1 <xref rid="bib34" ref-type="bibr">[34]</xref>, but also imply that genetic background affecting adipose tissue expandability can contribute to the penetrance of other types of lipodystrophy. The risk score analysis (z-score&#x000a0;=&#x000a0;&#x02212;1.28) of the 53 loci in the index patient indicated that the index patient is not fully predisposed to a lipodystrophic phenotype based on her genetic background at these 53 SNPs. However, our catalog of genetic modifiers for FPLD is far from complete. Whereas the previously identified 53 genomic loci have been identified in subjects who are predominantly from European Caucasian origin, it remains to be defined to what extent the identified risk alleles can be applied to subjects of other genetic ancestries. The index patient in the current study is from Turkish descent and we cannot exclude that other genetic factors modify the FPLD3 phenotype. Furthermore, recent work suggests that other non-coding SNPs can modulate human metabolic disease risk by altering PPAR&#x003b3; binding <xref rid="bib47" ref-type="bibr">[47]</xref>. Information from across the genome and from detailed mechanistic studies such as ours will continue to improve risk classification.</p><p id="p0200">In conclusion, extensive characterization of the PPAR&#x003b3; L451P mutant identified here in a family affected by FPLD3 at the clinical, cellular, molecular, and genetic level revealed valuable understanding of PPAR&#x003b3; structure and function. We show that the newly identified FPLD3-associated L451P mutant significantly impairs the transcriptional activity of PPAR&#x003b3; due to a range of molecular defects that disrupt intermolecular interactions, while leaving the intramolecular LBD-DBD interactions largely intact. In contrast, the colon cancer-associated PPAR&#x003b3; K450Q mutation does not robustly affect PPAR&#x003b3; function, indicating that amino acid changes at the C-terminus of helix 9 can have differential effects on LBD integrity. Previous analyses of natural PPAR&#x003b3; mutants together with the data presented here support the view that FPLD3-associated mutations consistently cause intra- and/or intermolecular defects, while the effect of colon cancer-associated PPAR&#x003b3; mutations varies considerably, suggesting subtler or context-dependent effects.</p></sec><sec id="sec5"><title>Author contribution statement</title><p id="p0205">MFB performed the experiments, data-analysis, and wrote the manuscript; MPGM and GWH performed the whole exome sequencing analysis; CD and AB performed experiments; JL performed the SNP score risk analysis; JS and AMJJB were involved in molecular modeling analysis; MGS, MNG, HM and MRS contributed to the clinical analysis. DM and RH were involved in NR-Coregulator interactions experiments and analysis. ARM advised on the SNP score risk analysis. EK designed and supervised the study. MFB and EK wrote the manuscript. All authors reviewed the manuscript.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Lehrke</surname><given-names>M.</given-names></name><name><surname>Lazar</surname><given-names>M.A.</given-names></name></person-group><article-title>The many faces of PPAR&#x003b3;</article-title><source>Cell</source><volume>123</volume><issue>6</issue><year>2005</year><fpage>993</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.11.026</pub-id><pub-id pub-id-type="pmid">16360030</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Fajas</surname><given-names>L.</given-names></name><name><surname>Auboeuf</surname><given-names>D.</given-names></name><name><surname>Rasp&#x000e9;</surname><given-names>E.</given-names></name><name><surname>Schoonjans</surname><given-names>K.</given-names></name><name><surname>Lefebvre</surname><given-names>A.-M.</given-names></name><name><surname>Saladin</surname><given-names>R.</given-names></name></person-group><article-title>The organization, promoter analysis, and expression of the human PPAR&#x003b3; Gene</article-title><source>Journal of Biological Chemistry</source><volume>272</volume><issue>30</issue><year>1997</year><fpage>18779</fpage><lpage>18789</lpage><pub-id pub-id-type="pmid">9228052</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Drori</surname><given-names>S.</given-names></name><name><surname>Aiyer</surname><given-names>A.</given-names></name><name><surname>Yie</surname><given-names>J.</given-names></name><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor &#x003b3; isoforms</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><issue>44</issue><year>2002</year><fpage>41925</fpage><lpage>41930</lpage><pub-id pub-id-type="pmid">12200443</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Graves</surname><given-names>R.A.</given-names></name><name><surname>Budavari</surname><given-names>A.I.</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H.</given-names></name><name><surname>Lui</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>E.</given-names></name></person-group><article-title>Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR&#x003b3; and RXRa</article-title><source>Nucleic Acids Research</source><volume>22</volume><issue>25</issue><year>1994</year><fpage>5628</fpage><lpage>5634</lpage><pub-id pub-id-type="pmid">7838715</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Lefterova</surname><given-names>M.I.</given-names></name><name><surname>Haakonsson</surname><given-names>A.K.</given-names></name><name><surname>Lazar</surname><given-names>M.A.</given-names></name><name><surname>Mandrup</surname><given-names>S.</given-names></name></person-group><article-title>PPAR&#x003b3; and the global map of adipogenesis and beyond</article-title><source>Trends in Endocrinology and Metabolism</source><volume>25</volume><issue>6</issue><year>2014</year><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">24793638</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Kliewer</surname><given-names>S.A.</given-names></name><name><surname>Lenhard</surname><given-names>J.M.</given-names></name><name><surname>Willson</surname><given-names>T.M.</given-names></name><name><surname>Patel</surname><given-names>I.</given-names></name><name><surname>Morris</surname><given-names>D.C.</given-names></name><name><surname>Lehmann</surname><given-names>J.M.</given-names></name></person-group><article-title>A&#x000a0;prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor &#x003b3; and promotes adipocyte differentiation</article-title><source>Cell</source><volume>83</volume><issue>5</issue><year>1995</year><fpage>813</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90194-9</pub-id><pub-id pub-id-type="pmid">8521498</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>B.M.</given-names></name><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Brun</surname><given-names>R.P.</given-names></name><name><surname>Spiegelman</surname><given-names>B.M.</given-names></name><name><surname>Evans</surname><given-names>R.M.</given-names></name></person-group><article-title>15-Deoxy-&#x00394;12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR&#x003b3;</article-title><source>Cell</source><volume>83</volume><issue>5</issue><year>1995</year><fpage>803</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90193-0</pub-id><pub-id pub-id-type="pmid">8521497</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Ahmadian</surname><given-names>M.</given-names></name><name><surname>Suh</surname><given-names>J.M.</given-names></name><name><surname>Hah</surname><given-names>N.</given-names></name><name><surname>Liddle</surname><given-names>C.</given-names></name><name><surname>Atkins</surname><given-names>A.R.</given-names></name><name><surname>Downes</surname><given-names>M.</given-names></name></person-group><article-title>PPARgamma signaling and metabolism: the good, the bad and the future</article-title><source>Nature Medicine</source><volume>19</volume><issue>5</issue><year>2013</year><fpage>557</fpage><lpage>566</lpage></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Soccio</surname><given-names>R.E.</given-names></name><name><surname>Chen</surname><given-names>E.R.</given-names></name><name><surname>Lazar</surname><given-names>M.A.</given-names></name></person-group><article-title>Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes</article-title><source>Cell Metabolism</source><volume>20</volume><issue>4</issue><year>2014</year><fpage>573</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">25242225</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Barroso</surname><given-names>I.</given-names></name><name><surname>Gurnell</surname><given-names>M.</given-names></name><name><surname>Crowley</surname><given-names>V.E.F.</given-names></name><name><surname>Agostini</surname><given-names>M.</given-names></name><name><surname>Schwabe</surname><given-names>J.W.</given-names></name><name><surname>Soos</surname><given-names>M.A.</given-names></name></person-group><article-title>Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension</article-title><source>Nature</source><volume>402</volume><issue>December</issue><year>1999</year><fpage>880</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">10622252</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>A.K.</given-names></name><name><surname>Garg</surname><given-names>A.</given-names></name></person-group><article-title>A&#x000a0;novel heterozygous mutation in peroxisome proliferator-activated receptor-&#x003b3; gene in a patient with familial partial lipodystrophy</article-title><source>The Journal of Clinical Endocrinology &#x00026; Metabolism</source><volume>87</volume><issue>1</issue><year>2002</year><fpage>408</fpage><pub-id pub-id-type="pmid">11788685</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Jeninga</surname><given-names>E.H.</given-names></name><name><surname>van Beekum</surname><given-names>O.</given-names></name><name><surname>van Dijk</surname><given-names>A.D.J.</given-names></name><name><surname>Hamers</surname><given-names>N.</given-names></name><name><surname>Hendriks-Stegeman</surname><given-names>B.I.</given-names></name><name><surname>Bonvin</surname><given-names>A.M.J.J.</given-names></name></person-group><article-title>Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy</article-title><source>Molecular Endocrinology (Baltimore, Md.)</source><volume>21</volume><issue>5</issue><year>2007</year><fpage>1049</fpage><lpage>1065</lpage></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Monajemi</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Jeninga</surname><given-names>E.H.</given-names></name><name><surname>Cao</surname><given-names>H.</given-names></name><name><surname>Maas</surname><given-names>M.</given-names></name></person-group><article-title>Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>92</volume><issue>5</issue><year>2007</year><fpage>1606</fpage><lpage>1612</lpage><pub-id pub-id-type="pmid">17299075</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M.E.</given-names></name><name><surname>Kropman</surname><given-names>E.</given-names></name><name><surname>Kranendonk</surname><given-names>M.E.</given-names></name><name><surname>Koppen</surname><given-names>a.</given-names></name><name><surname>Hamers</surname><given-names>N.</given-names></name><name><surname>Stroes</surname><given-names>E.S.</given-names></name></person-group><article-title>Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPAR&#x003b3; mutation (Y151C)</article-title><source>Diabetologia</source><volume>54</volume><issue>7</issue><year>2011</year><fpage>1639</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">21479595</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Majithia</surname><given-names>A.R.</given-names></name><name><surname>Tsuda</surname><given-names>B.</given-names></name><name><surname>Agostini</surname><given-names>M.</given-names></name><name><surname>Gnanapradeepan</surname><given-names>K.</given-names></name><name><surname>Rice</surname><given-names>R.</given-names></name><name><surname>Peloso</surname><given-names>G.</given-names></name></person-group><article-title>Prospective functional classification of all possible missense variants in PPARG</article-title><source>Nature Genetics</source><year>2016</year></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>W.M.</given-names></name><name><surname>Wright</surname><given-names>H.M.</given-names></name><name><surname>Kum</surname><given-names>J.B.</given-names></name><name><surname>Aaltonen</surname><given-names>L. a.</given-names></name></person-group><article-title>Loss-of-function mutations in PPAR gamma associated with human colon cancer</article-title><source>Molecular Cell</source><volume>3</volume><year>1999</year><fpage>799</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">10394368</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R.A.</given-names></name><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Brockman</surname><given-names>J.A.</given-names></name><name><surname>Prusakiewicz</surname><given-names>J.J.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor &#x003b3;-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><issue>25</issue><year>2003</year><fpage>22669</fpage><lpage>22677</lpage><pub-id pub-id-type="pmid">12591919</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Evans</surname><given-names>R.M.</given-names></name><name><surname>Martin</surname><given-names>K.J.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>Terminal differentiation of human breast cancer through PPAR&#x003b3;</article-title><source>Molecular Cell</source><volume>1</volume><issue>3</issue><year>1998</year><fpage>465</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80047-7</pub-id><pub-id pub-id-type="pmid">9660931</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>M.</given-names></name><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Kroll</surname><given-names>T.</given-names></name><name><surname>Aiyer</surname><given-names>A.</given-names></name><name><surname>Kaufman</surname><given-names>D.S.</given-names></name></person-group><article-title>Effects of ligand activation of peroxisome proliferator-activated receptor &#x003b3; in human prostate cancer</article-title><source>Proceedings of the National Academy of Sciences</source><volume>97</volume><issue>20</issue><year>2000</year><comment>10990 LP-10995</comment></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Girnun</surname><given-names>G.D.</given-names></name><name><surname>Naseri</surname><given-names>E.</given-names></name><name><surname>Vafai</surname><given-names>S.B.</given-names></name><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Szwaya</surname><given-names>J.D.</given-names></name><name><surname>Bronson</surname><given-names>R.</given-names></name></person-group><article-title>Synergy between PPAR&#x003b3; ligands and platinum-based drugs in cancer</article-title><source>Cancer Cell</source><volume>11</volume><issue>5</issue><year>2007</year><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.02.025</pub-id><pub-id pub-id-type="pmid">17482130</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Girnun</surname><given-names>G.D.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Silvaggi</surname><given-names>J.</given-names></name><name><surname>Drapkin</surname><given-names>R.</given-names></name><name><surname>Chirieac</surname><given-names>L.R.</given-names></name><name><surname>Padera</surname><given-names>R.F.</given-names></name></person-group><article-title>Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin</article-title><source>Clinical Cancer Research</source><volume>14</volume><issue>20</issue><year>2008</year><comment>6478 LP-6486</comment></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Khandekar</surname><given-names>M.J.</given-names></name><name><surname>Banks</surname><given-names>A.S.</given-names></name><name><surname>Laznik-Bogoslavski</surname><given-names>D.</given-names></name><name><surname>White</surname><given-names>J.P.</given-names></name><name><surname>Choi</surname><given-names>J.H.</given-names></name><name><surname>Kazak</surname><given-names>L.</given-names></name></person-group><article-title>Noncanonical agonist PPAR&#x003b3; ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy</article-title><source>Proceedings of the National Academy of Sciences</source><volume>115</volume><issue>3</issue><year>2018</year><comment>561 LP-566</comment></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Harakalova</surname><given-names>M.</given-names></name><name><surname>van Harssel</surname><given-names>J.J.T.</given-names></name><name><surname>Terhal</surname><given-names>P.A.</given-names></name><name><surname>van Lieshout</surname><given-names>S.</given-names></name><name><surname>Duran</surname><given-names>K.</given-names></name><name><surname>Renkens</surname><given-names>I.</given-names></name></person-group><article-title>Dominant missense mutations in ABCC9 cause Cantu syndrome</article-title><source>Nature Genetics</source><volume>44</volume><issue>7</issue><year>2012</year><fpage>793</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">22610116</pub-id></element-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="other" id="sref24">Exome Variant Server., n.d. No Title. NHLBI GO Exome Sequencing Project (ESP). <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/" id="intref0060">http://evs.gs.washington.edu/EVS/</ext-link>. [Accessed 1 April 2016].</mixed-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Consortium, T. 1000 G.P.</surname></name></person-group><article-title>A&#x000a0;global reference for human genetic variation</article-title><source>Nature</source><volume>526</volume><issue>7571</issue><year>2015</year><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">26432245</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Sherry</surname><given-names>S.T.</given-names></name><name><surname>Ward</surname><given-names>M.-H.</given-names></name><name><surname>Kholodov</surname><given-names>M.</given-names></name><name><surname>Baker</surname><given-names>J.</given-names></name><name><surname>Phan</surname><given-names>L.</given-names></name><name><surname>Smigielski</surname><given-names>E.M.</given-names></name></person-group><article-title>dbSNP: the NCBI database of genetic variation</article-title><source>Nucleic Acids Research</source><volume>29</volume><issue>1</issue><year>2001</year><fpage>308</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">11125122</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Lek</surname><given-names>M.</given-names></name><name><surname>Karczewski</surname><given-names>K.J.</given-names></name><name><surname>Minikel</surname><given-names>E.V.</given-names></name><name><surname>Samocha</surname><given-names>K.E.</given-names></name><name><surname>Banks</surname><given-names>E.</given-names></name><name><surname>Fennell</surname><given-names>T.</given-names></name></person-group><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title><source>Nature</source><volume>536</volume><issue>7616</issue><year>2016</year><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">27535533</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Kalkhoven</surname><given-names>E.</given-names></name><name><surname>Teunissen</surname><given-names>H.</given-names></name><name><surname>Houweling</surname><given-names>A.</given-names></name><name><surname>Verrijzer</surname><given-names>C.P.</given-names></name><name><surname>Zantema</surname><given-names>A.</given-names></name></person-group><article-title>The PHD type zinc finger is an integral part of the CBP acetyltransferase domain</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><issue>7</issue><year>2002</year><fpage>1961</fpage><lpage>1970</lpage><pub-id pub-id-type="pmid">11884585</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Gurnell</surname><given-names>M.</given-names></name><name><surname>Wentworth</surname><given-names>J.M.</given-names></name><name><surname>Agostini</surname><given-names>M.</given-names></name><name><surname>Adams</surname><given-names>M.</given-names></name><name><surname>Collingwood</surname><given-names>T.N.</given-names></name><name><surname>Provenzano</surname><given-names>C.</given-names></name></person-group><article-title>A&#x000a0;dominant-negative peroxisome proliferator-activated receptor g (PPARg) mutant is a constitutive repressor and inhibits PPARg-mediated adipogenesis</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><issue>8</issue><year>2000</year><fpage>5754</fpage><lpage>5759</lpage><pub-id pub-id-type="pmid">10681562</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.D.</given-names></name><name><surname>Evans</surname><given-names>R.M.</given-names></name></person-group><article-title>A&#x000a0;transcriptional co-repressor that interacts with nuclear hormone receptors</article-title><source>Nature</source><volume>377</volume><year>1995</year><fpage>454</fpage><pub-id pub-id-type="pmid">7566127</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Koppen</surname><given-names>A.</given-names></name><name><surname>Houtman</surname><given-names>R.</given-names></name><name><surname>Pijnenburg</surname><given-names>D.</given-names></name><name><surname>Jeninga</surname><given-names>E.H.</given-names></name><name><surname>Ruijtenbeek</surname><given-names>R.</given-names></name><name><surname>Kalkhoven</surname><given-names>E.</given-names></name></person-group><article-title>Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor &#x003b3; cofactor</article-title><source>Molecular &#x00026; Cellular Proteomics</source><volume>8</volume><issue>10</issue><year>2009</year><fpage>2212</fpage><lpage>2226</lpage><pub-id pub-id-type="pmid">19596656</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Vega</surname><given-names>R.B.</given-names></name><name><surname>Huss</surname><given-names>J.M.</given-names></name><name><surname>Kelly</surname><given-names>D.P.</given-names></name></person-group><article-title>The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor &#x003b1; in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><issue>5</issue><year>2000</year><comment>1868 LP-1876</comment></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Broekema</surname><given-names>M.F.</given-names></name><name><surname>Hollman</surname><given-names>D.A.A.</given-names></name><name><surname>Koppen</surname><given-names>A.</given-names></name><name><surname>van den Ham</surname><given-names>H.-J.</given-names></name><name><surname>Melchers</surname><given-names>D.</given-names></name><name><surname>Pijnenburg</surname><given-names>D.</given-names></name></person-group><article-title>Profiling of 3696 nuclear receptor-coregulator interactions: a resource for biological and clinical discovery</article-title><source>Endocrinology</source><year>2018</year></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Lotta</surname><given-names>L.A.</given-names></name><name><surname>Gulati</surname><given-names>P.</given-names></name><name><surname>Day</surname><given-names>F.R.</given-names></name><name><surname>Payne</surname><given-names>F.</given-names></name><name><surname>Ongen</surname><given-names>H.</given-names></name><name><surname>van de Bunt</surname><given-names>M.</given-names></name></person-group><article-title>Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance</article-title><source>Nature Genetics</source><volume>49</volume><issue>1</issue><year>2017</year><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">27841877</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="book" id="sref35"><person-group person-group-type="author"><name><surname>Leaver-Fay</surname><given-names>A.</given-names></name><name><surname>Tyka</surname><given-names>M.</given-names></name><name><surname>Lewis</surname><given-names>S.M.</given-names></name><name><surname>Lange</surname><given-names>O.F.</given-names></name><name><surname>Thompson</surname><given-names>J.</given-names></name><name><surname>Jacak</surname><given-names>R.</given-names></name></person-group><chapter-title>Chapter nineteen &#x02013; Rosetta3: an object-oriented software suite for the simulation and design of macromolecules</chapter-title><person-group person-group-type="editor"><name><surname>Johnson</surname><given-names>M.L.</given-names></name><name><surname>Brand</surname><given-names>L.B.T.-M.</given-names></name></person-group><series>Computer methods, part C</series><volume>vol. 487</volume><year>2011</year><publisher-name>Academic Press</publisher-name><fpage>545</fpage><lpage>574</lpage></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>V.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Hamuro</surname><given-names>Y.</given-names></name><name><surname>Raghuram</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Burris</surname><given-names>T.P.</given-names></name></person-group><article-title>Structure of the intact PPAR-gamma-RXR- alfa nuclear receptor complex on DNA</article-title><source>Nature</source><volume>456</volume><issue>7220</issue><year>2008</year><fpage>350</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">19043829</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>A.</given-names></name><name><surname>Kortemme</surname><given-names>T.</given-names></name></person-group><article-title>Improvements to robotics-inspired conformational sampling in Rosetta</article-title><source>PLoS One</source><volume>8</volume><issue>5</issue><year>2013</year><object-id pub-id-type="publisher-id">e63090</object-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.C.</given-names></name><name><surname>Ng</surname><given-names>Y.K.</given-names></name></person-group><article-title>Calibur: a tool for clustering large numbers of protein decoys</article-title><source>BMC Bioinformatics</source><volume>11</volume><issue>1</issue><year>2010</year><fpage>25</fpage><pub-id pub-id-type="pmid">20070892</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>A.</given-names></name><name><surname>Eisenbraun</surname><given-names>B.</given-names></name><name><surname>Key</surname><given-names>J.</given-names></name><name><surname>Sanschagrin</surname><given-names>P.C.</given-names></name><name><surname>Timony</surname><given-names>M.A.</given-names></name><name><surname>Ottaviano</surname><given-names>M.</given-names></name></person-group><article-title>Collaboration gets the most out of software</article-title><source>ELife</source><volume>2</volume><year>2013</year><object-id pub-id-type="publisher-id">e01456</object-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Tasdelen</surname><given-names>I.</given-names></name><name><surname>Berger</surname><given-names>R.</given-names></name><name><surname>Kalkhoven</surname><given-names>E.</given-names></name></person-group><article-title>PPAR&#x003b3; regulates expression of carbohydrate sulfotransferase 11 (CHST11/C4ST1), a regulator of LPL cell surface binding</article-title><source>PLoS One</source><volume>8</volume><issue>5</issue><year>2013</year><object-id pub-id-type="publisher-id">e64284</object-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>V.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Potluri</surname><given-names>N.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Rastinejad</surname><given-names>F.</given-names></name></person-group><article-title>The quaternary architecture of RAR&#x003b2;&#x02013;RXR&#x003b1; heterodimer facilitates domain&#x02013;domain signal transmission</article-title><source>Nature Communications</source><volume>8</volume><issue>1</issue><year>2017</year><fpage>868</fpage></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>C.G.</given-names></name><name><surname>Silveira</surname><given-names>R.L.</given-names></name><name><surname>Rivalta</surname><given-names>I.</given-names></name><name><surname>Batista</surname><given-names>V.S.</given-names></name><name><surname>Skaf</surname><given-names>M.S.</given-names></name></person-group><article-title>Allosteric pathways in the PPAR&#x003b3;-RXR&#x003b1; nuclear receptor complex</article-title><source>Scientific Reports</source><volume>6</volume><year>2016</year><fpage>19940</fpage><pub-id pub-id-type="pmid">26823026</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Capaccio</surname><given-names>D.</given-names></name><name><surname>Ciccodicola</surname><given-names>a.</given-names></name><name><surname>Sabatino</surname><given-names>L.</given-names></name><name><surname>Casamassimi</surname><given-names>a.</given-names></name><name><surname>Pancione</surname><given-names>M.</given-names></name><name><surname>Fucci</surname><given-names>a.</given-names></name></person-group><article-title>A&#x000a0;novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia</article-title><source>Biochimica et Biophysica Acta</source><volume>1802</volume><issue>6</issue><year>2010</year><fpage>572</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">20123124</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>D.B.</given-names></name><name><surname>Tan</surname><given-names>G.D.</given-names></name><name><surname>Acerini</surname><given-names>C.L.</given-names></name><name><surname>Jebb</surname><given-names>S.A.</given-names></name><name><surname>Agostini</surname><given-names>M.</given-names></name><name><surname>Gurnell</surname><given-names>M.</given-names></name></person-group><article-title>Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-&#x003b3;</article-title><source>Diabetes</source><volume>52</volume><issue>4</issue><year>2003</year><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">12663460</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>S.</given-names></name><name><surname>Hsieh</surname><given-names>J.-C.</given-names></name><name><surname>Jurutka</surname><given-names>P.W.</given-names></name><name><surname>Galligan</surname><given-names>M.A.</given-names></name><name><surname>Haussler</surname><given-names>C.A.</given-names></name><name><surname>Whitfield</surname><given-names>G.K.</given-names></name></person-group><article-title>Examination of the potential functional role of conserved cysteine residues in the hormone binding domain of the human 1,25-dihydroxyvitamin D receptor</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><issue>9</issue><year>1996</year><fpage>5143</fpage><lpage>5149</lpage><pub-id pub-id-type="pmid">8617794</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Tagami</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>H.</given-names></name><name><surname>Moriyama</surname><given-names>K.</given-names></name><name><surname>Sawai</surname><given-names>K.</given-names></name><name><surname>Usui</surname><given-names>T.</given-names></name><name><surname>Shimatsu</surname><given-names>A.</given-names></name></person-group><article-title>The retinoid X receptor binding to the thyroid hormone receptor: relationship with cofactor binding and transcriptional activity</article-title><source>Journal of Molecular Endocrinology</source><volume>42</volume><issue>5</issue><year>2009</year><fpage>415</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">19211732</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Soccio</surname><given-names>R.E.</given-names></name><name><surname>Chen</surname><given-names>E.R.</given-names></name><name><surname>Rajapurkar</surname><given-names>S.R.</given-names></name><name><surname>Safabakhsh</surname><given-names>P.</given-names></name><name><surname>Marinis</surname><given-names>J.M.</given-names></name><name><surname>Dispirito</surname><given-names>J.R.</given-names></name></person-group><article-title>Genetic variation determines PPAR&#x003b3; function and anti-diabetic drug response in&#x000a0;vivo</article-title><source>Cell</source><volume>162</volume><issue>1</issue><year>2015</year><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">26140591</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Conflict of interest</title><p id="p0220">The author reports no conflicts of interest in this work.</p></sec><sec id="appsec2" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0225">The following are the supplementary data to this article:<fig id="dfig1" position="anchor"><label>Supplemental Figure&#x000a0;1</label><caption><p><bold>Structural based sequence alignment of the amino acid residues surrounding PPAR&#x003b3; L451P between human PPARs and other members of the nuclear hormone superfamily.</bold> Human PPAR&#x003b3; (NP_056953.2), human PPAR&#x003b1; (CAG30433), human PPAR&#x003b4; (Q03181), chimpanzee PPAR&#x003b3; (XP_001153669.1), mouse PPAR&#x003b3; (NP_035276.2), rat PPAR&#x003b3; (NP_037256.1), cow PPAR&#x003b3; (NP_851367.1), dog PPAR&#x003b3; (NP_001019803.1), chicken PPAR&#x003b3; (NP_001001460.1), and zebrafish PPAR&#x003b3; (NP_571542.1). THRA, thyroid receptor alpha (NP_003241.2); THRB, thyroid receptor beta (AAI06931.1); GR, glucocorticoid receptor (NP_000167.1); MR, mineralocorticoid receptor (NP_000892.2); AR, androgen receptor (P10275.2); FXR, farnesoid X receptor (NP_001193908.1); VDR, vitamin D receptor (AAH60832.1); HNF&#x003b1;, Hepatocyte nuclear factor 4A (CAA61133.1). Residues analogous L451 and V318 are designated in yellow and bold. Residues analogous to 314, 316, S317, K347, and K422 are indicated in pink and bold. PPAR&#x003b3;2 nomenclature. Dashes (&#x02212;) represent the gaps included for appropriate alignment of the nuclear hormone receptors. The boundaries of the &#x003b1;-helices 9, and 10 are also shown.</p></caption><alt-text id="alttext0010">Supplemental Figure&#x000a0;1</alt-text><graphic xlink:href="figs1"/></fig><fig id="dfig2" position="anchor"><label>Supplemental Figure&#x000a0;2</label><caption><p><bold>Increasing L451P protein concentrations leads to a proportional increase in transcriptional activity, but the mutant never reaches WT levels.</bold> U2OS cells were transiently cotransfected with expression vectors encoding PPAR&#x003b3; WT or PPAR&#x003b3; L451P respectively, and a reporter construct harboring the promoter region of CIDEC. Activation of the luciferase reporter, in the absence or presence of 1&#x000a0;&#x003bc;M rosiglitazone, is expressed as fold induction over that with empty vector (EV). Results are averages of at least three independent experiments assayed in duplicate&#x000a0;&#x000b1;&#x000a0;SEM. *P&#x000a0;&#x0003c;&#x000a0;0.05 cells transfected with mutant <italic>vs</italic>. WT.</p></caption><alt-text id="alttext0015">Supplemental Figure&#x000a0;2</alt-text><graphic xlink:href="figs2"/></fig><fig id="dfig3" position="anchor"><label>Supplemental Figure&#x000a0;3</label><caption><p><bold>Proline substitutions in helix 9 impair transcriptional activity of PPAR&#x003b3;.</bold> U<sub>2</sub>OS cells were transiently cotransfected with expression vectors encoding PPAR&#x003b3; WT or PPAR&#x003b3; mutants respectively, and 3&#x000d7; peroxisome proliferator response element (PPRE)-Tk-Luc reporter. Activation of the luciferase reporter, in the absence or presence of 1&#x000a0;&#x003bc;M 15d-PGJ2, is expressed as fold induction over that with empty vector (EV). Results are averages of at least three independent experiments assayed in duplicate&#x000a0;&#x000b1;&#x000a0;SEM. *P&#x000a0;&#x0003c;&#x000a0;0.05 cells transfected with mutant <italic>vs</italic>. WT. Expression levels of the different proteins were confirmed by western blot analysis using a PPAR&#x003b3; specific antibody. The arrow indicates PPAR&#x003b3; and the asterisk indicates an unknown non-specific band. WT, wildtype.</p></caption><alt-text id="alttext0020">Supplemental Figure&#x000a0;3</alt-text><graphic xlink:href="figs3"/></fig><fig id="dfig4" position="anchor"><label>Supplemental Figure&#x000a0;4</label><caption><p><bold>Cofactor peptide binding profiles for GST-PPAR&#x003b3; LBD WT and L451P.</bold> GST-proteins were incubated with DMSO or 10&#x000a0;&#x003bc;M rosiglitazone. Images of all arrays were quantified and binding (AU; arbitrary units) was plotted. The experiments were performed in triple.</p></caption><alt-text id="alttext0025">Supplemental Figure&#x000a0;4</alt-text><graphic xlink:href="figs4"/></fig><fig id="dfig5" position="anchor"><label>Supplemental Table&#x000a0;1</label><caption><p><bold>SNP genotype of PPAR&#x003b3; L451P index patient.</bold> PCR was performed in the index patient to genotype the lead SNPs in 53 genomic regions that were previously identified to impair peripheral adipose tissue storage <xref rid="bib34" ref-type="bibr">[34]</xref>. The index patients harbors 53 risk alleles.</p></caption><alt-text id="alttext0030">Supplemental Table&#x000a0;1</alt-text><graphic xlink:href="figs5"/></fig><supplementary-material content-type="local-data" id="ec1"><media xlink:href="mmc1.docx"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p>We thank the index patient and her family for their participation in this study. We thank Dr. F. Payne (Wellcome Trust Sanger Institute, UK), Dr. I. Barroso (Wellcome Trust Sanger Institute, UK), and Prof. Dr. D. Savage (University of Cambridge, UK) for helpful discussions on the SNP analysis. Understanding Society: The UK Household Longitudinal Study is led by the Institute for Social and Economic Research at the University of Essex and funded by the <funding-source id="gs1">Economic and Social Research Council</funding-source>. The survey was conducted by NatCen and the genome-wide scan data were analyzed and deposited by the Wellcome Trust Sanger Institute. Information on how to access the data can be found on the Understanding Society website <ext-link ext-link-type="uri" xlink:href="https://www.understandingsociety.ac.uk/" id="intref0020">https://www.understandingsociety.ac.uk/</ext-link>. Bioinformatics support was provided by the UMCU Bioinformatics Expertise Core (UBEC; <ext-link ext-link-type="uri" xlink:href="http://www.ubec.nl" id="intref0025">www.ubec.nl</ext-link>). AMJJB and JS acknowledge financial support from the <funding-source id="gs2">Horizon 2020</funding-source> West-Life e-Infrastructure Virtual Research Environment project No. 675858. We also thank members of the Kalkhoven and Van Mil laboratories for helpful discussions.</p></ack><fn-group><fn id="appsec3" fn-type="supplementary-material"><label>Appendix A</label><p id="p0230">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molmet.2018.12.005" id="intref0030">https://doi.org/10.1016/j.molmet.2018.12.005</ext-link>.</p></fn></fn-group></back></article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.5.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art550.dtd?><?SourceDTD.Version 5.5.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_MOLMET742 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEfx1 jpg ?><?FILEmmc1 docx ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Mol Metab</journal-id><journal-title-group><journal-title>Molecular Metabolism</journal-title></journal-title-group><issn pub-type="epub">2212-8778</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6358589</article-id><article-id pub-id-type="publisher-id">S2212-8778(18)30906-2</article-id><article-id pub-id-type="doi">10.1016/j.molmet.2018.11.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nunez Lopez</surname><given-names>Yury O.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Retnakaran</surname><given-names>Ravi</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zinman</surname><given-names>Bernard</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Pratley</surname><given-names>Richard E.</given-names></name><email>Richard.Pratley@flhosp.org</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author"><name><surname>Seyhan</surname><given-names>Attila A.</given-names></name><email>Attila.Seyhan@fccc.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn1" ref-type="fn">4</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, FL 32804, USA</aff><aff id="aff2"><label>2</label>Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada</aff><aff id="aff3"><label>3</label>The Chemical Engineering Department, Massachusetts Institute of Technology, Cambridge, MA, USA</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Translational Research Institute for Metabolism and Diabetes, Florida Hospital Translational Research Institute, 301 East Princeton Street, Orlando, FL 32804, USA. Fax: +1 407 303 7199. <email>Richard.Pratley@flhosp.org</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author. Translational Research Institute for Metabolism and Diabetes, Florida Hospital Translational Research Institute, 301 East Princeton Street, Orlando, FL 32804, USA. Fax: +1 407 303 7199. <email>Attila.Seyhan@fccc.edu</email></corresp><fn id="fn1"><label>4</label><p id="ntpara0010">Current address: Fox Chase Cancer Center, Temple Health, Temple University, 333 Cottman Avenue, Philadelphia, PA, USA. Fax: +1 215 214 1590.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>16</day><month>11</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>2</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>16</day><month>11</month><year>2018</year></pub-date><volume>20</volume><fpage>63</fpage><lpage>78</lpage><history><date date-type="received"><day>10</day><month>9</month><year>2018</year></date><date date-type="rev-recd"><day>5</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Authors</copyright-statement><copyright-year>2018</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Objective</title><p>Short-term intensive insulin therapy (IIT) early in the course of type 2 diabetes acutely improves beta-cell function with long-lasting effects on glycemic control. However, conventional measures cannot determine which patients are better suited for IIT, and little is known about the molecular mechanisms determining response. Therefore, this study aimed to develop a model that could accurately predict the response to IIT and provide insight into molecular mechanisms driving such response in humans.</p></sec><sec><title>Methods</title><p>Twenty-four patients with early type 2 diabetes were assessed at baseline and four weeks after IIT, consisting of basal detemir and premeal insulin aspart. Twelve individuals had a beneficial beta-cell response to IIT (responders) and 12 did not (nonresponders). Beta-cell function was assessed by multiple methods, including Insulin Secretion-Sensitivity Index-2. MicroRNAs (miRNAs) were profiled in plasma samples before and after IIT. The response to IIT was modeled using a machine learning algorithm and potential miRNA-mediated regulatory mechanisms assessed by differential expression, correlation, and functional network analyses (FNA).</p></sec><sec><title>Results</title><p>Baseline levels of circulating miR-145-5p, miR-29c-3p, and HbA1c accurately (91.7%) predicted the response to IIT (OR&#x000a0;=&#x000a0;121 [95% CI: 6.7, 2188.3]). Mechanistically, a previously described regulatory loop between miR-145-5p and miR-483-3p/5p, which controls TP53-mediated apoptosis, appears to also occur in our study population of humans with early type 2 diabetes. In addition, significant (fold change&#x000a0;&#x0003e;&#x000a0;2, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) longitudinal changes due to IIT in the circulating levels of miR-138-5p, miR-192-5p, miR-195-5p, miR-320b, and let-7a-5p further characterized the responder group and significantly correlated (|r|&#x000a0;&#x0003e;&#x000a0;0.4, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) with the changes in measures of beta-cell function and insulin sensitivity. FNA identified a network of coordinately/cooperatively regulated miRNA-targeted genes that potentially drives the IIT response through negative regulation of apoptotic processes that underlie beta cell dysfunction and concomitant positive regulation of proliferation.</p></sec><sec><title>Conclusions</title><p>Responses to IIT in people with early type 2 diabetes are associated with characteristic miRNA signatures. This study represents a first step to identify potential responders to IIT (a current limitation in the field) and provides important insight into the pathophysiologic determinants of the reversibility of beta-cell dysfunction.</p><p>ClinicalTrial.gov identifier: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01270789" id="intref0010">NCT01270789</ext-link>.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="fx1"/></fig></p></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Baseline levels of miR-145 and miR-29c predict short-term IIT response.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">miR-138, -192, -195, -320b, and let-7a change in response to insulin therapy in patients with diabetes.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Changes in miRNAs correlate with changes in beta cell function and insulin sensitivity.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">A network of &#x0201c;miRNA-overtargeted&#x0201d; genes regulates cell death and proliferation.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Short-term intensive insulin therapy</kwd><kwd>Beta-cell dysfunction</kwd><kwd>Type 2 diabetes</kwd><kwd>MicroRNA</kwd><kwd>Response prediction</kwd><kwd>Cooperative overtargeting</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0030">Type 2 diabetes is characterized by multiple metabolic abnormalities including insulin resistance and beta-cell dysfunction which precede and predict the onset of the disease <xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib2" ref-type="bibr">[2]</xref>. Metabolic function continues to deteriorate after diagnosis, leading to worsening hyperglycemia and necessitating insulin therapy in many cases. The progression of type 2 diabetes is thought to be due to a decline in pancreatic islet beta-cell function which can be explained by considering two components: 1) a &#x0201c;reversible&#x0201d; component due to the metabolic milieu (<italic>e.g.</italic> glucotoxicity, lipotoxicity), and 2) an &#x0201c;irreversible/intrinsic&#x0201d; component (<italic>e.g.</italic> loss of beta-cell capacity/mass due to beta-cell death), each independently contributing to the pathological process of the disease <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>.</p><p id="p0035">Short-term (two to four week) intensive insulin therapy (IIT) administered early in the course of type 2 diabetes acutely improves beta-cell function by eliminating glucotoxicity and lipotoxicity <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>. Remarkably, this strategy can induce &#x0201c;glycemic remission&#x0201d; in some patients who can subsequently maintain normoglycemia without antidiabetic drugs for up to 1&#x02013;2 years <xref rid="bib10" ref-type="bibr">[10]</xref>. However, this beneficial effect is not seen in all patients <xref rid="bib11" ref-type="bibr">[11]</xref>. Similarly, short-term IIT is also effective in patients with established type 2 diabetes of longer duration, albeit with more variability in the response <xref rid="bib12" ref-type="bibr">[12]</xref>. This heterogeneity in the response to short-term IIT may reflect varying contributions of reversible and irreversible beta-cell dysfunction, components that cannot be determined using clinical parameters or conventional measures of beta-cell function. Thus, the identification of biomarkers that can predict the response to short-term IIT and other therapeutic interventions would be valuable for improving treatment decisions and outcomes. Such biomarkers might also provide insight into novel molecular mechanisms involved in disease pathogenesis.</p><p id="p0040">MicroRNAs (miRNAs) are endogenous, noncoding RNAs that are abundantly expressed in most cell types and tissues and play important roles in the regulation of a broad spectrum of physiological and pathological processes, including diabetes <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>. Altered miRNA levels in the circulation have been associated with a variety of disease states including obesity <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref> and diabetes <xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>. We hypothesized that circulating levels of miRNAs implicated in beta-cell dysfunction and insulin resistance (<italic>e.g.</italic>, involving adipose tissue, liver, skeletal muscle) might be useful to predict responses to therapies such as short-term IIT. To test this hypothesis, we assessed changes in a panel of miRNAs implicated in diabetes in response to short-term IIT in patients with early type 2 diabetes and explored potential mechanisms underlying the reversibility of beta-cell dysfunction. This study is the first assessing the miRNA response to short-term IIT and offers novel mechanistic insights into the pathophysiology of beta-cell dysfunction in early type 2 diabetes.</p></sec><sec id="sec2"><label>2</label><title>Methods</title><sec id="sec2.1"><label>2.1</label><title>Study population</title><p id="p0045">The study population consisted of 24 adult patients with early type 2 diabetes who underwent short-term IIT to determine eligibility for randomization in the <bold>LI</bold>raglutide and <bold>B</bold>eta-cell <bold>R</bold>ep<bold>A</bold>ir (LIBRA) Trial (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrial.gov" id="intref0015">clinicaltrial.gov</ext-link> identifier: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01270789" id="intref0020">NCT01270789</ext-link>) <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>. The LIBRA trial included participants with 1) duration of diabetes &#x02264;7 years, 2) treatment with none or up to two oral antidiabetic medications (which were stopped before starting IIT), and 3) hemoglobin HbA1c at screening between 5.5 and 9.0% inclusive if on oral antidiabetic medications or between 6.0 and 10.0% inclusive if not on antidiabetic medications. Exclusion criteria included insulin therapy, renal dysfunction, hepatic dysfunction, malignancy and chronic infection. The study protocol was approved by the Mount Sinai Hospital Research Ethics Board, and all participants provided written informed consent.</p></sec><sec id="sec2.2"><label>2.2</label><title>Study design</title><p id="p0050">In the LIBRA trial <xref rid="bib28" ref-type="bibr">[28]</xref>, 63 participants underwent 4-weeks of intensive insulin therapy (IIT). On the final day of IIT, the last insulin dose was the bolus insulin before dinner, with no bedtime basal insulin. To be eligible for randomization, participants needed to be able to maintain fasting venous glucose &#x0003c;7.0&#x000a0;mmol/l the next morning, reflecting the capacity of endogenous insulin secretion to maintain fasting glucose in the non-diabetic range. The achievement of this threshold was previously shown to identify reversibility of beta-cell dysfunction in response to IIT <xref rid="bib12" ref-type="bibr">[12]</xref>. Of the 63 LIBRA participants, there were 12 individuals who did not achieve this threshold and hence were not eligible for randomization. These 12 individuals comprised the nonresponder (NR) group for the current study (this study). Conversely, the responder (R) group was comprised of the 12 LIBRA participants who had the largest improvement in beta-cell function from baseline to the post-IIT assessment (as defined by the percentage increase in Insulin Secretion-Sensitivity Index-2 (ISSI-2)). While there was no prospective measure of efficacy of IIT in the current analysis, it should be recognized that the beneficial effect of IIT on beta-cell function in early type 2 diabetes has been well-established in previous studies, including a meta-analysis of the studies comprising this literature <xref rid="bib10" ref-type="bibr">[10]</xref>. In the current study, all participants thus underwent assessment of beta-cell function before and after IIT, which enabled systematic assessment of the impact of IIT on beta-cell function and stratification of participants into responders and nonresponders on this basis.</p><p id="p0055">The specific short-term IIT protocol, methods for laboratory measurements, and calculation of physiologic indices performed in this trial are described elsewhere <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>. Glucagon measurements were performed using a glucagon enzyme-linked immunosorbent assay 10-1271-01 from Mercodia (Uppsala, Sweden) as recently described <xref rid="bib29" ref-type="bibr">[29]</xref>. Beta-cell function was measured with the ISSI-2 index, which was the primary outcome measure in the LIBRA Trial <xref rid="bib28" ref-type="bibr">[28]</xref>. In addition, other indices of beta-cell function and insulin resistance were calculated from the OGTT, including the &#x00394;ISR<sub>0-120</sub>/&#x00394;Gluc<sub>0-120</sub>&#x000d7;Matsuda index and the homeostatic model assessment of insulin resistance (HOMA-IR) <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>. miRNA was isolated from the fasting baseline pre-IIT OGTT and post-IIT OGTT plasma samples. A custom panel of 94 miRNAs (<xref rid="appsec4" ref-type="sec">Supplementary Table&#x000a0;ST1</xref>) reported to play roles in metabolically-involved tissues such as adipose, brain, kidney, liver, muscle, and pancreas was measured by real-time PCR. All baseline clinical and biochemical data was used to generate a classifier with predictive value by implementing a machine learning approach based on the random forest algorithm <xref rid="bib30" ref-type="bibr">[30]</xref> (see Methods section: <xref rid="sec2.4" ref-type="sec">Predictive modeling</xref>). To gain additional biological insight of the mechanism of response to short-term IIT, we conducted differential miRNA expression analysis by implementing mixed-effect models for repeated measures (see Methods section: <xref rid="sec2.6" ref-type="sec">Statistical analysis</xref>) and miRNA&#x02013;mRNA interaction network analysis (as described in the Methods section: <xref rid="sec2.5" ref-type="sec">Functional network analysis</xref>).</p></sec><sec id="sec2.3"><label>2.3</label><title>Measurement of plasma miRNAs</title><p id="p0060">miRNAs from 200&#x000a0;&#x003bc;l plasma were extracted using the miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany), reverse transcribed, preamplified, and measured by quantitative real-time PCR using TaqMan<sup>&#x000ae;</sup> reagents and ViiA-7<sup>&#x000ae;</sup> instrument from ThermoFisher Scientific (Waltham, MA), following the manufacturer's instructions. Custom TaqMan<sup>&#x000ae;</sup> Array MicroRNA Cards from a single production batch were used. Data was analyzed using the <italic>HTqPCR</italic> package in the R 3.5.1 statistical computing environment <xref rid="bib31" ref-type="bibr">[31]</xref>. Data from each sample were first normalized to the levels of recovered spike-in cel-miR-39, then subjected to quantile normalization using the <italic>normalizeCtData</italic> function. The median of the quantile-normalized data for the NR group, pre-IIT time point, was then subtracted from each quantile-normalized value to generate&#x000a0;&#x02212;&#x00394;&#x00394;Ct data equivalent to log2 fold change data (denoted herein logFC). As hemolysis during plasma isolation could contaminate the specific pool of circulating miRNAs and contribute to degradation of sample quality <xref rid="bib32" ref-type="bibr">[32]</xref>, its impact was assessed by calculating the difference in logFC values between erythrocyte-enriched miR-451 and reference miR-23a-3p (hemolysis score&#x000a0;=&#x000a0;logFC<sub>miR-451</sub>&#x000a0;&#x02212;&#x000a0;logFC<sub>miR-23a-3p</sub>; equivalent to the log2 ratio between miR-451 and miR-23a-3p), which can detect very low levels of hemolysis <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>. A hemolysis score lower than 7 was required by study design for samples to be included in the final analysis. Only miRNAs with greater than 2-fold baseline-adjusted differences between R and NR groups were included in the reported differential abundance analysis.</p></sec><sec id="sec2.4"><label>2.4</label><title>Predictive modeling</title><p id="p0065">To the limitations of a small sample size, we selected a machine learning approach based on the random forests (RF) method, which implements an out-of-bag (&#x0201c;bagging&#x0201d;) technique to monitor error and ensure unbiased prediction with reduced risk of overfitting <xref rid="bib30" ref-type="bibr">[30]</xref>. As reported by <xref rid="bib30" ref-type="bibr">[30]</xref>, &#x0201c;by using bagging in tandem with random feature selection, the out-of-bag error estimate is as accurate as using a test set of the same size as the training set. Therefore, using the out-of-bag error estimate removes the need for a set aside test set.&#x0201d; <xref rid="bib30" ref-type="bibr">[30]</xref> In short: each new training set is drawn, with replacement, from the original training set (with each bootstrapped training set leaving about one-third of the instances out &#x02013; the out-of-bag (OOB) set); then a tree is grown on the new training set using random feature selection. Furthermore, because the RF variable selection process uses only a small random subset of predictor variables for each tree split in the classification tree, the technique can handle the &#x0201c;small <italic>n</italic> large <italic>p</italic>&#x0201d; problem, where the number of predictor variables (<italic>p</italic>) is greater than the number of subjects (<italic>n</italic>) <xref rid="bib35" ref-type="bibr">[35]</xref>. Regarding the diagnosis of human disorders, it has been demonstrated that, by means of the repeated random sampling from the learning data, RF automatically generates realistic estimates of the prediction accuracy on validation data <xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>.</p><p id="p0070">For our analysis, the RF algorithm was implemented using the <italic>randomForest</italic> package <xref rid="bib37" ref-type="bibr">[37]</xref> in the R environment. Only baseline values for all profiled miRNAs and clinical and metabolic measures were included as variables for tree splitting and classification. A twofold-iterative process of repeated, sequential backward elimination (SBE) <xref rid="bib38" ref-type="bibr">[38]</xref> was implemented. Each repetition of SBE (the &#x0201c;inner loop&#x0201d;) consisted of successive cycles of RF classification whereby the less informative variable (as calculated by the Gini variable importance index) was eliminated after every cycle, until a single variable remained in the classifier. The number of trees (<italic>ntree</italic>) in the forest was always set to 5000 and the number of variables to be randomly sampled at each tree split (<italic>mtry</italic>) set equal to the total number of variables included in the given SBE &#x0201c;inner cycle&#x0201d;. The OOB prediction error rate calculated for each instance of the RF classifier was recorded and the instance(s) generating the lower error rate selected as the optimal RF classifier(s) for the given SBE repetition. The SBE process was repeated 100 times (the &#x0201c;outer loop&#x0201d;), while choosing a distinct random number generator seed for each &#x0201c;outer cycle&#x0201d;. The collection of optimal RF classifiers with minimal OOB error rates for all 100 repetitions of the SBE process was then summarized and the most frequent instance of the RF classifier consistently producing the lowest OOB error rate was identified. Performance and sensitivity analysis of the best classifier was evaluated and visualized using the <italic>ROCR</italic> package in the R environment. ROC curves were generated by using the random forest responder/nonresponder vote fractions (based on the OOB data) as prediction scores to construct the ROC curves by stepping through different thresholds for calling responder versus nonresponder. By comparing these predictions based on the out-of-bag data to their known class, estimates of the performance of the classifier can be obtained.</p></sec><sec id="sec2.5"><label>2.5</label><title>Functional network analysis (FNA)</title><p id="p0075">Our previous experience and that from others studying disparate molecular mechanisms regulated by miRNAs indicate that global biologically significant miRNA-driven regulatory events commonly occur in a coordinated/cooperative fashion <xref rid="bib39" ref-type="bibr">[39]</xref>, <xref rid="bib40" ref-type="bibr">[40]</xref>, <xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>, <xref rid="bib45" ref-type="bibr">[45]</xref>, <xref rid="bib46" ref-type="bibr">[46]</xref>. This process can be readily described by a compact network of interactions between relevant miRNAs and corresponding &#x0201c;miRNA-overtargeted&#x0201d; genes <xref rid="bib40" ref-type="bibr">[40]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>, <xref rid="bib45" ref-type="bibr">[45]</xref>. The &#x0201c;overtargeted&#x0201d; genes in a particular network appear to interact with a significantly higher number of miRNAs than expected by chance (as determined by hypergeometric tests of network proportions compared to the respective proportions in the miRNA&#x02013;target interaction universe/background). In this study, we similarly conducted miRNA-overtargeting analyses following our published methodology <xref rid="bib40" ref-type="bibr">[40]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>, <xref rid="bib45" ref-type="bibr">[45]</xref>. Significance of the cooperative (more than 1 miRNA targeting a given gene) and overtargeting effect (significant higher number of miRNA-targeting events than expected by chance on a given gene) was assessed by comparing IIT-specific network proportions and relevant number of events against a collection of 10,000 simulated equivalent random networks. The list of validated targets supported by strong experimental evidence (<italic>i.e.</italic>, reporter assay or Western blot) used for this analysis was downloaded from miRTarBase (file: miRTarBase_SE_WR.xls) using the <italic>SpidermiR</italic> package <xref rid="bib47" ref-type="bibr">[47]</xref>. Interaction networks were constructed using Cytoscape 3.5.1 <xref rid="bib48" ref-type="bibr">[48]</xref>. Enrichment of gene ontology annotations among sets of overtargeted genes was assessed using the <italic>GOCluster_Report</italic> function of the <italic>systemPipeR</italic> package <xref rid="bib49" ref-type="bibr">[49]</xref> in the R environment.</p></sec><sec id="sec2.6"><label>2.6</label><title>Statistical analysis</title><p id="p0080">Data normality was tested with the Shapiro&#x02013;Wilk test. Data were log or square root transformed to approximate normality when necessary. Differences in baseline clinical characteristics were assessed using the Welch two sample t test (for continuous variables) or the Fisher exact test (for categorical variables). Standard Pearson's correlations between baseline levels of clinical/metabolic variables and the percent change in ISSI-2 were calculated to identify potential confounding covariates. For assessment of longitudinal differences in clinical, metabolic, and circulating miRNA variables, mixed-effect models for repeated measures were implemented using the <italic>lme4</italic> package. Age, duration of diabetes, baseline HbA1c, baseline AUC glucagon, and baseline HOMA-IR measures were included in the model as covariates to adjust for potential confounding effects, given their relevant correlations with the percent change in ISSI-2 (absolute |r|&#x000a0;&#x0003e;&#x000a0;0.4, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Post-hoc analysis was performed using the <italic>phia</italic> package. Partial correlations adjusting for the same covariates, were calculated using the <italic>ppcor</italic> package. Calculated effects and partial correlations were considered significant at <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05. False discovery rates (FDR) correcting for multiple testing were calculated using the Benjamini-Hochberg correction. Principal component analysis (PCA) using functions from the <italic>HTqPCR</italic> packages was used for high dimensional assessment and visualization of miRNA expression changes.</p></sec><sec id="sec2.7"><label>2.7</label><title>Power calculation</title><p id="p0085">Based on our data using equivalent miRNA profiling technology, we previously determined that a minimum sample size of N&#x000a0;=&#x000a0;11 subjects per group will detect a 1.5-fold change in the levels of circulating miRNAs with 80% power at a two-sided significance level &#x003b1;&#x000a0;=&#x000a0;0.05 <xref rid="bib50" ref-type="bibr">[50]</xref>, <xref rid="bib51" ref-type="bibr">[51]</xref>. This study, with a slightly larger sample size (N&#x000a0;=&#x000a0;12 per group) and a larger effect size required as per study design (miRNA fold change between groups greater than two), was designed to detect significant differences with greater than 80% statistical power.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Study participants</title><p id="p0090"><xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref> shows the baseline characteristics of the study cohort and highlights baseline group differences and correlations to the primary outcome variable, namely percent change in ISSI-2. These baseline imbalances (in duration of diabetes, HbA1c, HOMA-IR and AUC glucagon, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and most notably, the existence of significant correlations (absolute |r|&#x000a0;&#x0003e;&#x000a0;0.4, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) between the percent change in ISSI-2 and the baseline levels of HbA1c, AUC glucagon, and age, respectively, identified these variables as potential confounders that needed to be adjusted for during statistical modeling.<table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of the study cohort.</p></caption><alt-text id="alttext0045">Table&#x000a0;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>A. Baseline characteristics</th><th>Level</th><th>Nonresponder (n&#x000a0;=&#x000a0;12)</th><th>Responder (n&#x000a0;=&#x000a0;12)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td rowspan="2">Gender (%)</td><td>Female</td><td>4 (33.3)</td><td>3 (25.0)</td><td>1</td></tr><tr><td>Male</td><td>8 (66.7)</td><td>9 (75.0)</td><td/></tr><tr><td rowspan="2">Ethnicity (%)</td><td>Other</td><td>2 (16.7)</td><td>2 (16.7)</td><td>1</td></tr><tr><td>White</td><td>10 (83.3)</td><td>10 (83.3)</td><td/></tr><tr><td>Age (years)</td><td/><td>62.8 (8.3)</td><td>56.0 (10.2)</td><td>0.085</td></tr><tr><td>Duration of diabetes (years)<sup>&#x02020;</sup></td><td/><td>4.5 (2.3)</td><td>2.3 (2.4)</td><td>0.026</td></tr><tr><td rowspan="2">Pre-study metformin (%)</td><td>0</td><td>2 (16.7)</td><td>5 (41.7)</td><td>0.369</td></tr><tr><td>1</td><td>10 (83.3)</td><td>7 (58.3)</td><td/></tr><tr><td rowspan="2">Pre-study sulfonylurea (%)</td><td>0</td><td>10 (83.3)</td><td>11 (91.7)</td><td>1</td></tr><tr><td>1</td><td>2 (16.7)</td><td>1 (8.3)</td><td/></tr><tr><td rowspan="2">Pre-study oral agents (%)</td><td>0</td><td>2 (16.7)</td><td>5 (41.7)</td><td>0.369</td></tr><tr><td>1</td><td>10 (83.3)</td><td>7 (58.3)</td><td/></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td/><td>28.7 (4.6)</td><td>30.7 (4.1)</td><td>0.283</td></tr><tr><td>Waist circumference(cm)</td><td/><td>97.9 (10.2)</td><td>105.5 (11.8)</td><td>0.104</td></tr><tr><td>HbA1c (%)<sup>&#x000a7;</sup></td><td/><td>6.7 (0.4)</td><td>7.6 (1.2)</td><td>0.022</td></tr><tr><td>Fasting glucose (mmol/L)</td><td/><td>7.6 (1.1)</td><td>7.5 (1.6)</td><td>0.883</td></tr><tr><td>Fasting insulin (mmol/L)<sup>&#x000a7;</sup></td><td/><td>91.9 (59.6)</td><td>159.7 (149.5)</td><td>0.058</td></tr><tr><td>Fasting glucagon (Mercodia) (mmol/L)</td><td/><td>6.2 (2.3)</td><td>7.9 (3.5)</td><td>0.169</td></tr><tr><td>AUC glucagon (Mercodia)</td><td/><td>19.3 (4.6)</td><td>27.5 (9.5)</td><td>0.013</td></tr><tr><td>2-hour glucose on OGTT (mmol/L)</td><td/><td>17.3 (2.5)</td><td>16.1 (4.0)</td><td>0.391</td></tr><tr><td>HOMA IR<sup>&#x000a7;</sup></td><td/><td>4.5 (3.1)</td><td>7.5 (6.5)</td><td>0.086</td></tr><tr><td>ISSI-2</td><td/><td>113.0 (31.4)</td><td>135.0 (62.7)</td><td>0.289</td></tr><tr><td>ISR0-120/Gluc0-120&#x000d7;Matsuda index<hr/></td><td><hr/></td><td>0.10 (0.04)<hr/></td><td>0.09 (0.07)<hr/></td><td>0.698<hr/></td></tr><tr><td>B. Standard baseline correlations to % change in ISSI-2<hr/></td><td><hr/></td><td>n<hr/></td><td>cor<hr/></td><td><italic>P</italic> value<hr/></td></tr><tr><td>HbA1c<sup>&#x000a7;</sup></td><td/><td>24</td><td>0.69</td><td>2.1E-04</td></tr><tr><td>AUC glucagon (Mercodia)</td><td/><td>24</td><td>0.54</td><td>0.007</td></tr><tr><td>Age</td><td/><td>24</td><td>&#x02212;0.44</td><td>0.032</td></tr><tr><td>Duration of diabetes<sup>&#x02020;</sup></td><td/><td>24</td><td>&#x02212;0.44</td><td>0.033</td></tr><tr><td>HOMA IR<sup>&#x000a7;</sup></td><td/><td>24</td><td>0.42</td><td>0.044</td></tr><tr><td>Waist circumference</td><td/><td>24</td><td>0.36</td><td>0.081</td></tr><tr><td>Fasting insulin<sup>&#x000a7;</sup></td><td/><td>24</td><td>0.36</td><td>0.082</td></tr><tr><td>Fasting glucagon (Mercodia)</td><td/><td>24</td><td>0.35</td><td>0.093</td></tr><tr><td>Fasting glucose</td><td/><td>24</td><td>0.31</td><td>0.141</td></tr><tr><td>BMI</td><td/><td>24</td><td>0.29</td><td>0.171</td></tr><tr><td colspan="2">ISR0-120/Gluc0-120&#x000d7;Matsuda</td><td>24</td><td>&#x02212;0.29</td><td>0.173</td></tr><tr><td>2-hour glucose</td><td/><td>24</td><td>0.13</td><td>0.537</td></tr><tr><td>ISSI-2</td><td/><td>24</td><td>&#x02212;0.12</td><td>0.572</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Data sqrt<sup>(&#x02020;)</sup> or log<sup>(&#x000a7;)</sup> transformed to approximate normality for statistical inference tests.</p></fn><fn id="tspara0020"><p>Unadjusted differences in baseline measures were determined using the Welch two sample t test (for continuous variables) or the Fisher exact test (for categorical variables). Data is presented as mean with standard deviation or as percentage (%). Standard Pearson's correlation between baseline levels of clinical/metabolic variables and the percent change in ISSI-2 were calculated to identify potential confounding covariates.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.2"><label>3.2</label><title>Improvements in beta-cell function and insulin sensitivity in response to short-term IIT</title><p id="p0095">As reported in the parent trial <xref rid="bib28" ref-type="bibr">[28]</xref> and by selection in the current secondary analysis, people in the R group experienced a dramatic increase in ISSI-2 (greater than 2-fold increase), whereas people in the NR group displayed a nonsignificant reduction (Group-by-Time interaction effect FDR&#x000a0;&#x0003c;&#x000a0;0.001, <xref rid="appsec4" ref-type="sec">Supplementary Table&#x000a0;ST2</xref>), even after adjusting for confounding effects of age, duration of diabetes, and baseline levels of HbA1c, HOMA-IR, and AUC glucagon. Notably, insulin resistance (as measured by the HOMA-IR index) significantly improved in the R group only (Group-by-Time interaction effect FDR&#x000a0;&#x0003c;&#x000a0;0.01, <xref rid="appsec4" ref-type="sec">Supplementary Table&#x000a0;ST2</xref>). In addition, people that responded to short-term IIT significantly reduced their fasting glucose and insulin levels and were able to significantly reduce their levels of glycated hemoglobin HbA1c by close to a full percent unit on average, as compared to the respective baseline levels (all three comparisons displaying Group-by-Time interaction effects with <italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.0268 and FDR&#x000a0;&#x02264;&#x000a0;0.0603, <xref rid="appsec4" ref-type="sec">Supplementary Table&#x000a0;ST2</xref>). Although to a lesser extent, short-term IIT also reduced HbA1c levels in the NR group resulting in a significant Time effect for this measure (<italic>P</italic>&#x000a0;=&#x000a0;0.001, FDR&#x000a0;&#x0003c;&#x000a0;0.01).</p></sec><sec id="sec3.3"><label>3.3</label><title>MiRNA-based score of plasma quality</title><p id="p0100">The quality of the initial plasma samples was assessed by calculating a hemolysis score per sample, as described in <xref rid="sec2" ref-type="sec">Material and Methods</xref>. All samples produced hemolysis scores below five (<xref rid="appsec4" ref-type="sec">Supplementary Figure&#x000a0;SF1</xref>). Therefore, following reported guidance <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>, the risk of contamination by hemolysis was considered insignificant.</p></sec><sec id="sec3.4"><label>3.4</label><title>Baseline abundance of miR-145-5p, miR-29c-3p, together with baseline measures of glycated hemoglobin HbA1c accurately predict response to short-term IIT</title><p id="p0105">To assess the potential of circulating miRNAs and clinical/metabolic measures to predict, at baseline, responses to short-term IIT, we implemented a comprehensive classification approach based on an RF algorithm using the <italic>randomForest</italic> package in the R environment. By implementing 100 iterations of an SBE approach, 159 optimal classifiers with minimal cross-validated error rate (OOB error rate&#x000a0;=&#x000a0;8.3%) were generated. Baseline measurements of the trio miR-145-5p, miR-29c-3p, and HbA1c produced the best classifier 100 percent of the time, while the simpler classifier containing miR-145-5p and miR-29c-3p also attained the lowest error rate but only 56 percent of the time. A third more complex classifier including the above-mentioned trio and miR-326 also attained the lowest error rate but with a 2 percent frequency only. No combination of clinical parameters only (excluding miRNAs) generated an optimal classifier. Therefore, the RF classifier based on baseline measures of miR-145-5p, miR-29c-3p, and HbA1c was selected as the best RF classifier of response to short-term IIT. <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref> and <xref rid="appsec4" ref-type="sec">Supplementary Figure&#x000a0;SF2</xref> show the longitudinal data for the three features comprising the best classifier and a variety of performance measures demonstrating the high sensitivity (area under the receiver operator characteristic AUC&#x000a0;=&#x000a0;0.951) and accuracy (positive and negative predictive values both equal to 91.7%) of the classifier. Although the baseline-adjusted changes in miR-145-5p and miR-29c-3p in response to short-term IIT were not significantly different between the two groups as per our study criteria (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>), there was a trend (Group-by-Time interaction <italic>P</italic>&#x000a0;=&#x000a0;0.0547) for miR-145-5p to differentially increase with time in the responder group. However, the median post-therapy miR-145-5p level in this group was still lower than the nonresponder level (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). Importantly, the baseline levels of plasma miR-145-5p significantly correlated with the percent change in ISSI-2 (r&#x000a0;=&#x000a0;&#x02212;0.66, <italic>P</italic>&#x000a0;=&#x000a0;0.0005; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D upper panel), the change in HbA1c (r&#x000a0;=&#x000a0;0.48, <italic>P</italic>&#x000a0;=&#x000a0;0.0164; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E, upper panel), and with the change in fasting glucose levels (r&#x000a0;=&#x000a0;0.51, <italic>P</italic>&#x000a0;=&#x000a0;0.0101; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>F, upper panel). These correlations support the identification of miR-145-5p as a key variable in the RF classifier predictive of short-term IIT response and indicate that the lower the baseline levels of circulating miR-145-5p, the larger the subsequent short-term IIT-driven improvement in beta-cell function (as estimated by ISSI-2), reduction in HbA1c levels, and reduction in fasting glucose levels. Additionally, baseline levels of miR-145-5p significantly correlated with baseline levels of HbA1c (r&#x000a0;=&#x000a0;&#x02212;0.59, <italic>P</italic>&#x000a0;=&#x000a0;0.0024; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E, lower panel) and insulin resistance, as indicated by the HOMA-IR index (r&#x000a0;=&#x000a0;&#x02212;0.48, <italic>P</italic>&#x000a0;=&#x000a0;0.0183; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>G, lower panel).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Identification of an optimal miRNA classifier for response to short-term IIT and summary of performance measures following an iterative random forests (RF) approach. (<bold>A</bold><bold>&#x02013;</bold><bold>C</bold>) Dual plots for features comprising the best classifier of response. (<bold>D</bold><bold>&#x02013;</bold><bold>G</bold>) Correlations between baseline levels of miR-145-5p and changes in measures of beta cell function and glucose control. ISSI-2 was the main outcome measure of beta-cell function, in the parent LIBRA trial, in response to short-term IIT. (<bold>H</bold>) Sensitivity analysis using the receiver operator characteristic curve (ROC). (<bold>I</bold>) Odds ratio plot for the classification using the best RF classifier. (<bold>J</bold>) Confusion matrix for the best RF classifier. (<bold>K</bold>) Performance measures for the best RF classifier. Orange-filled circles represent individual values for Responder (R) group. Blue-filled circles represent individual values for Nonresponder (NR) group. AUC: area under the ROC curve; PPV: positive predictive value; NPV: negative predictive value; FPR: false positive rate; FNR: false negative rate.</p></caption><alt-text id="alttext0020">Figure&#x000a0;1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Several miRNAs are differential abundant in the circulation of participants in responders and nonresponders.</p></caption><alt-text id="alttext0050">Table&#x000a0;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Nonresponders (NR) (n&#x000a0;=&#x000a0;12)<hr/></th><th colspan="2">Responders (R) (n&#x000a0;=&#x000a0;12)<hr/></th><th colspan="3"><italic>P</italic> values<hr/></th><th colspan="3">FDR values<hr/></th></tr><tr><th>Pre</th><th>Post</th><th>Pre</th><th>Post</th><th>Group</th><th>Time</th><th>Group-by-Time</th><th>Group</th><th>Time</th><th>Group-by-Time</th></tr></thead><tbody><tr><td colspan="11"><bold>Pattern A</bold></td></tr><tr><td>miR.192</td><td>0.0 (&#x02212;3.2, 3.5)</td><td>0.9 (&#x02212;1.2, 3.2)</td><td>2.0 (&#x02212;1.5, 3.3)</td><td>&#x02212;1.6 (&#x02212;5.7, 1.9)</td><td>0.0759</td><td>0.5175</td><td><bold>0.0004</bold></td><td>0.4089</td><td>0.6116</td><td><bold>0.0104</bold></td></tr><tr><td>miR.320b</td><td>0.0 (&#x02212;0.8, 2.0)</td><td>0.2 (&#x02212;0.8, 2.7)</td><td>0.7 (&#x02212;0.4, 1.6)</td><td>&#x02212;0.1 (&#x02212;1.6, 1.0)</td><td>0.1489</td><td>0.4613</td><td><bold>0.0325</bold></td><td>0.4839</td><td>0.5825</td><td><bold>0.2028</bold></td></tr><tr><td>miR.195</td><td>0.0 (&#x02212;2.3, 1.4)</td><td>0.7 (&#x02212;0.1, 2.4)</td><td>0.3 (&#x02212;0.1, 1.7)</td><td>0.4 (&#x02212;0.5, 2.5)</td><td>0.1101</td><td>0.0018</td><td><bold>0.0364</bold></td><td>0.4089</td><td>0.0156</td><td><bold>0.2028</bold></td></tr><tr><td>let.7a</td><td>0.0 (&#x02212;1.7, 0.5)</td><td>&#x02212;0.4 (&#x02212;3.5, 0.5)</td><td>&#x02212;0.7 (&#x02212;1.5, 0.9)</td><td>&#x02212;0.2 (&#x02212;1.1, 0.9)</td><td>0.7438</td><td>0.0562</td><td><bold>0.0384</bold></td><td>0.9205</td><td>0.1624</td><td><bold>0.2028</bold></td></tr><tr><td>miR.138</td><td>0.0 (&#x02212;3.2, 7.8)</td><td>&#x02212;3.0 (&#x02212;3.6, 6.5)</td><td>&#x02212;0.9 (&#x02212;3.6, 6.5)</td><td>4.4 (&#x02212;3.5, 7.1)</td><td>0.7129</td><td>0.1627</td><td><bold>0.0390</bold></td><td>0.9205</td><td>0.3525</td><td><bold>0.2028</bold></td></tr><tr><td colspan="11"><bold>Pattern B</bold></td></tr><tr><td>miR.20a</td><td>0.0 (&#x02212;0.5, 1.7)</td><td>1.3 (0.9, 2.6)</td><td>0.3 (&#x02212;0.3, 2.6)</td><td>1.5 (&#x02212;0.1, 2.6)</td><td>0.2863</td><td><bold>0.0001</bold></td><td>0.3905</td><td>0.6203</td><td><bold>0.0026</bold></td><td>0.7529</td></tr><tr><td>let.7b</td><td>0.0 (&#x02212;1.1, 0.3)</td><td>0.6 (&#x02212;0.1, 1.9)</td><td>&#x02212;0.1 (&#x02212;0.8, 0.8)</td><td>0.9 (0.6, 2.2)</td><td>0.3767</td><td><bold>0.0002</bold></td><td>0.6532</td><td>0.7534</td><td><bold>0.0026</bold></td><td>0.7949</td></tr><tr><td>miR.802</td><td>0.0 (&#x02212;3.6, 4.2)</td><td>&#x02212;3.3 (&#x02212;5.1, 2.8)</td><td>&#x02212;1.0 (&#x02212;3.6, 2.2)</td><td>&#x02212;4.1 (&#x02212;5.0, 6.1)</td><td>0.4783</td><td><bold>0.0031</bold></td><td>0.3959</td><td>0.8291</td><td><bold>0.0201</bold></td><td>0.7529</td></tr><tr><td>miR.34a</td><td>0.0 (&#x02212;3.4, 2.2)</td><td>&#x02212;1.1 (&#x02212;4.3, 1.9)</td><td>&#x02212;0.5 (&#x02212;2.0, 1.7)</td><td>&#x02212;1.3 (&#x02212;3.6, 0.7)</td><td>0.8851</td><td><bold>0.005</bold></td><td>0.7357</td><td>0.9205</td><td><bold>0.026</bold></td><td>0.8317</td></tr><tr><td>miR.144</td><td>0.0 (&#x02212;6.1, 3.9)</td><td>3.1 (&#x02212;1.9, 4.7)</td><td>&#x02212;0.5 (&#x02212;6.8, 4.1)</td><td>2.4 (&#x02212;2.1, 3.9)</td><td>0.8685</td><td><bold>0.0117</bold></td><td>0.9194</td><td>0.9205</td><td><bold>0.0507</bold></td><td>0.9562</td></tr><tr><td>miR.183</td><td>0.0 (&#x02212;7.5, 1.6)</td><td>1.7 (&#x02212;6.7, 4.0)</td><td>0.9 (&#x02212;2.9, 3.0)</td><td>1.2 (&#x02212;2.9, 3.5)</td><td>0.0725</td><td><bold>0.0191</bold></td><td>0.1832</td><td>0.4089</td><td><bold>0.0709</bold></td><td>0.5954</td></tr><tr><td>miR.15b</td><td>0.0 (&#x02212;0.4, 2.0)</td><td>&#x02212;0.6 (&#x02212;2.9, 0.7)</td><td>&#x02212;0.2 (&#x02212;3.1, 0.7)</td><td>&#x02212;0.9 (&#x02212;4.2, 2.9)</td><td>0.7236</td><td><bold>0.0331</bold></td><td>0.4054</td><td>0.9205</td><td><bold>0.1076</bold></td><td>0.7529</td></tr><tr><td colspan="11"><bold>Predictive</bold></td></tr><tr><td>miR.145</td><td>0.0 (&#x02212;0.9, 0.5)</td><td>0.1 (&#x02212;1.5, 0.6)</td><td>&#x02212;0.8 (&#x02212;2.0, 0.7)</td><td>&#x02212;0.4 (&#x02212;1.4, 0.8)</td><td>0.2702</td><td>0.3457</td><td>0.0547</td><td>0.5404</td><td>0.3457</td><td>0.1094</td></tr><tr><td>miR.29c</td><td>0.0 (&#x02212;1.1, 0.4)</td><td>0.5 (&#x02212;0.6, 2.2)</td><td>0.5 (&#x02212;0.8, 1.1)</td><td>0.6 (&#x02212;0.2, 1.8)</td><td>0.5649</td><td>0.0057</td><td>0.4415</td><td>0.5649</td><td>0.0114</td><td>0.4415</td></tr><tr><td colspan="11"><bold>Correlative</bold></td></tr><tr><td>miR.483.5p</td><td>0.0 (&#x02212;1.1, 0.7)</td><td>&#x02212;0.6 (&#x02212;2.1, 0.2)</td><td>0.6 (&#x02212;1.2, 1.9)</td><td>&#x02212;0.6 (&#x02212;1.8, 0.4)</td><td>0.2423</td><td>0.0041</td><td>0.1376</td><td>0.8211</td><td>0.0178</td><td>0.4763</td></tr><tr><td>miR.483.3p</td><td>0.0 (&#x02212;1.5, 1.4)</td><td>&#x02212;1.0 (&#x02212;4.1, 0.7)</td><td>0.2 (&#x02212;1.0, 1.6)</td><td>&#x02212;0.5 (&#x02212;2.4, 0.2)</td><td>0.713</td><td>0.0018</td><td>0.6664</td><td>0.9209</td><td>0.0116</td><td>0.7726</td></tr></tbody></table><table-wrap-foot><fn><p>Pattern A miRNAs are characterized by significant Group-by-Time interaction effects (Fold Change&#x000a0;&#x0003e;&#x000a0;2, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and FDR&#x000a0;&#x02264;&#x000a0;0.2028), generally due to changes either in only one of the groups or in opposite directions in both R and NR groups. Pattern B miRNAs are characterized by significant Time effect (Fold Change&#x000a0;&#x0003e;&#x000a0;2, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and FDR&#x000a0;&#x0003c;&#x000a0;0.1), generally due to either a significant reduction or significant increase in plasma levels in both R and NR groups. Predictive miRNAs (as part of an RF classifier), although not considered differentially expressed by the study design criteria, are able to predict response to short-term IIT at baseline (pre-treatment stage). Both strands of miR-483 (-5p/-3p, potentially involved in regulatory loop with miR-145-5p) are stably detected and highly correlated among themselves and with miR-145-5p and miR-29c, respectively. Data is presented as median log2 fold change [relative to the median of the NR group baseline (Pre-IIT time point)], with 95% confidence interval in parenthesis. FDR calculated using the Benjamini-Hochberg correction.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.5"><label>3.5</label><title>Validation of a potential regulatory association between miR-145-5p and miR-483-5p/3p</title><p id="p0110">While revising the recent literature for the predictive miRNAs, we uncovered a potential mechanistically-relevant link between IIT response-predictive miR-145-5p and miR-483-5p/3p (the sense and corresponding antisense miRNAs originating from the same primary miR-483). The latter miRNAs were not originally included in our panel. Specifically, miR-145-5p and miR-483-3p are reported to be involved in a glucose level-dependent loop that regulates miR-145-induced TP53-dependent cell death in hepatocellular carcinoma <xref rid="bib52" ref-type="bibr">[52]</xref>. On the other hand, the complementary strand miR-483-5p has been reported to be differentially expressed in pancreatic &#x003b1; and &#x003b2; cells, and to protect against proinflammatory cytokine-induced apoptosis of &#x003b2; cells in culture and in mice, while increasing insulin transcription and secretion by the &#x003b2; cells and reducing glucagon transcription and secretion by the &#x003b1; cells <xref rid="bib53" ref-type="bibr">[53]</xref>. Therefore, we hypothesized that the miR-145/miR-483 regulatory loop may play a mechanistic role contributing to the response to short-term IIT in humans. To assess the potential association between miR-145-5p and miR-483 in humans with diabetes, we then profiled both miR-483-3p and miR-483-5p in this study's plasma samples using TaqMan<sup>&#x000ae;</sup> assays and quantitative real time PCR (these measurements were normalized against the expression of the internal/endogenous control miR-191, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A, D). Supporting our hypothesis, we found that circulating levels of miR-483-5p significantly negatively correlated with circulating levels of miR-145-5p (r&#x000a0;=&#x000a0;&#x02212;0.34, <italic>P</italic>&#x000a0;=&#x000a0;0.0203, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B) and positively with miR-192-5p (an IIT-responsive miRNA reported in the next section, r&#x000a0;=&#x000a0;0.38, <italic>P</italic>&#x000a0;=&#x000a0;0.009, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). Remarkably, the baseline circulating levels of miR-483-5p significantly correlated (absolute |r|&#x000a0;&#x0003e;&#x000a0;0.3 and <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) with the baseline levels and the change in levels of HbA1c, fasting insulin, HOMA IR, AUC of the response to glucagon (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>H&#x02013;G), as well as with the change in fasting glucose levels (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>L). On the other hand, levels of miR-483-5p expectedly and highly significantly correlated with the levels of miR-483-3p (r&#x000a0;=&#x000a0;0.53, <italic>P</italic>&#x000a0;=&#x000a0;1.30&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;04</sup>, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E), and the levels of miR-483-3p highly significantly negatively correlated with the levels of miR-29c-3p, the other IIT response-predictive miRNA (r&#x000a0;=&#x000a0;&#x02212;0.58, <italic>P</italic>&#x000a0;=&#x000a0;2.32&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;05</sup>, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>F) and with miR-195-5p (an IIT-responsive miRNA reported in the next section, r&#x000a0;=&#x000a0;&#x02212;0.47, <italic>P</italic>&#x000a0;=&#x000a0;0.001, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>G). Despite these strong correlations with clinical changes relevant to the response to short-term IIT, when baseline normalized miR-483 data was included among the set of baseline variables used to generate the RF classifiers and the BSE iterative RF process repeated, the optimal RF classifier continued to be comprised of the same three variables, namely miR-145-5p, miR-29c-3p, and HbA1c.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Expression profiling of miR-483-5p and miR-483-3p in circulation of humans with type 2 diabetes. Quantitation using real time PCR and TaqMan<sup>&#x000ae;</sup> assays. Measurements were normalized against the expression of the internal/endogenous control miR-191. Blue and orange circles represent nonresponder (NR) and responder (R) group data points, respectively, in panels H&#x02013;L. Black, red, green, and blue represent nonresponder-post, nonresponder-pre, responder-post, and responder-pre, respectively, in panels E<bold>&#x02013;</bold>G.</p></caption><alt-text id="alttext0025">Figure&#x000a0;2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec3.6"><label>3.6</label><title>Circulating levels of miR-138-5p, miR-192-5p, miR-195-5p, miR-320b, and let-7a-5p differentially change in response to short-term IIT</title><p id="p0115">To gain insight into potential miRNA-regulated mechanisms in response to short-term IIT, we evaluated the baseline and four-week follow-up changes in circulating miRNA levels and assessed the correlations between these changes and the changes in clinically relevant measures of beta-cell function (<italic>i.e.</italic>, ISSI-2 and &#x00394;ISR<sub>0-120</sub>/&#x00394;Gluc<sub>0-120</sub>&#x000d7;Matsuda index), insulin resistance (<italic>i.e.</italic>, HOMA-IR), glycemic control (<italic>e.g.</italic>, HbA1c), and glucagon response (<italic>e.g.</italic>, AUC glucagon). We anticipated that changes in short-term IIT-responsive miRNAs would track with improvements in beta-cell function and insulin sensitivity, among others.</p><p id="p0120">As shown in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, five circulating miRNAs (Pattern A: miR-138-5p, miR-192-5p, miR195-5p, miR-320b, and let-7a-5p) displayed significant differential expression changes (as denoted by the significant Group-by-Time interactions (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and FDR&#x000a0;&#x02264;&#x000a0;0.2)) in response to short-term-IIT. This effect was due to changes in the plasma miRNA levels either only in one of the groups or in opposite directions in both R and NR groups (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A&#x02013;E, <xref rid="appsec4" ref-type="sec">Supplementary Figure&#x000a0;SF4</xref>). In contrast to miR-145-5p and miR-29c-3p, which did not significantly change with treatment but were predictive of treatment response at baseline, Pattern A miRNAs did not significantly differ at baseline (as evidenced by their non-significant group effects) but changed in response to short-term IIT and their changes effectively separated responders from nonresponders as assessed by PCA (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A&#x02013;F). Interestingly, the changes in let-7a-5p, miR-195-5p, miR-320b, and miR-138-5p appear coregulated to some extent, as suggested by significant (|r|&#x000a0;&#x0003e;&#x000a0;0.4, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and marginally significant (|r|&#x000a0;&#x0003e;&#x000a0;0.4, <italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.062) correlations among them (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G&#x02013;I). Of note, the changes in the circulating levels of Pattern A miRNAs significantly correlated (see <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>) with changes in measures of &#x003b2;-cell function (r<sub>&#x00394;miR.192&#x0223c;&#x00394;ISSI2</sub>&#x000a0;=&#x000a0;&#x02212;0.51, <italic>P</italic>&#x000a0;=&#x000a0;0.024; r<sub>&#x00394;miR.138&#x0223c;&#x00394;(&#x00394;ISR0..120/&#x00394;gluc0..120&#x000d7;&#x000a0;=&#x000a0;0.48</sub>, <italic>P</italic>&#x000a0;=&#x000a0;0.039; and r<sub>&#x00394;miR.320b&#x0223c;&#x00394;ISSI2</sub>&#x000a0;=&#x000a0;&#x02212;0.48, <italic>P</italic>&#x000a0;=&#x000a0;0.037; all with FDR&#x000a0;&#x0003c;&#x000a0;0.10), insulin resistance (r<sub>&#x00394;miR.192&#x0223c;&#x00394;HOMA.IR</sub>&#x000a0;=&#x000a0;0.69, <italic>P</italic>&#x000a0;=&#x000a0;0.001, FDR&#x000a0;&#x0003c;&#x000a0;0.01), and fasting insulin (r<sub>&#x00394;miR.192&#x0223c;&#x00394;fasting.insulin</sub>&#x000a0;=&#x000a0;0.69, <italic>P</italic>&#x000a0;=&#x000a0;0.001, FDR&#x000a0;&#x0003c;&#x000a0;0.01). The change in levels of miR-192-5p and miR-195-5p additionally tracked with the change in measures of whole body composition (r<sub>&#x00394;miR.192&#x0223c;&#x00394;Waist.circumference</sub>&#x000a0;=&#x000a0;0.56, <italic>P</italic>&#x000a0;=&#x000a0;0.012; r<sub>&#x00394;miR.192&#x0223c;&#x00394;BMI</sub>&#x000a0;=&#x000a0;0.46, <italic>P</italic>&#x000a0;=&#x000a0;0.046; and r<sub>&#x00394;miR.195&#x0223c;&#x00394;BMI</sub>&#x000a0;=&#x000a0;&#x02212;0.49, <italic>P</italic>&#x000a0;=&#x000a0;0.034, all with FDR&#x000a0;&#x0003c;&#x000a0;0.10, <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>F,H). miR-195-5p displayed an additional trend with fasting glucose (r<sub>&#x00394;miR.195&#x0223c; &#x00394;fasting.glucose</sub>&#x000a0;=&#x000a0;&#x02212;0.44, <italic>P</italic>&#x000a0;=&#x000a0;0.062, FDR&#x000a0;&#x0003c;&#x000a0;0.1). MiRNAs with a second pattern of change displaying significant Time effect but nonsignificant Group-by-Time interaction (Pattern B, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, <xref rid="appsec4" ref-type="sec">Supplementary Figures&#x000a0;SF4 and SF5</xref>), were also identified.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Longitudinal changes and correlations in microRNAs (miRNAs) that significantly change in response to short-term intensive insulin therapy (IIT). (<bold>A</bold><bold>&#x02013;</bold><bold>E</bold>) Pattern A miRNAs with significant Group-by-Time interaction (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, FDR&#x000a0;&#x0003c;&#x000a0;0.2). Data presented as quantile-normalized log2 fold changes relative to the median of the nonresponders group at pre-IIT (NR.Pre) time point. The connected dots represent corresponding pre-therapy and post-therapy measurements for each individual participant (R: Responder group, orange filling; NR: Nonresponder group, blue filling; n&#x000a0;=&#x000a0;12 per group). In the boxplots, the box delineates the first and third quartiles (the interquartile range, IQR), whereas the whiskers delineate the smallest and largest values inside a 1.5 box-length from the end of the box. The boxplot summarizes the data presented in the corresponding side-by-side dot plot, while the dot plot reveals valuable information about the longitudinal changes taking place per subject. Note that some samples have similar normalized logFC values, therefore multiple lines may converge onto a single dot. The number of lines, not the number of dots, represents the number of samples contributing data for the specific plot. Red dots represent data points located at greater than 1.5 IQR from the end of the box. Blue filling used for NR group and orange filling for R group. (<bold>F</bold>) Principal component analysis plot based on changes in Pattern A miRNAs effectively separate the responders from the nonresponders subjects. (<bold>G</bold><bold>&#x02013;</bold><bold>I</bold>) Correlated changes in the circulating levels of Pattern A miRNAs in response to short-term IIT.</p></caption><alt-text id="alttext0030">Figure&#x000a0;3</alt-text><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Correlations between changes in Pattern A circulating miRNA levels and changes in relevant clinical variables and indices of interest. Partial correlations calculated using the <italic>ppcor</italic> R package and adjusting for age, duration of diabetes, baseline HbA1c, and baseline AUC glucagon. Blue-filled circles represent individual values for the Nonresponder (NR) group. Orange-filled circles represent individual values for the Responder (R) group.</p></caption><alt-text id="alttext0035">Figure&#x000a0;4</alt-text><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec3.7"><label>3.7</label><title>A network of cooperatively regulated validated miRNA targets is enriched in genes that regulate cell death and proliferation</title><p id="p0125">To gain additional general mechanistic insight, we assessed the functional relevance of the putative network of genes targeted (supported by strong experimental evidence, specifically reporter assay or western blot) by both the IIT predictive and responsive miRNAs (denoted herein as IIT miRNAs). The IIT miRNA-target gene network analysis identified a total of 1672 genes that are experimentally demonstrated to physically interact with at least one of the IIT miRNAs (note that there were no targets with strong validation support in the miRTarBase database for miR-483-5p/3p &#x02013;therefore, these miRNAs do not appear in our <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref> network). Remarkably, 109 of those (6.5%, <italic>P</italic>&#x000a0;=&#x000a0;0.0306 as empirically determined by comparison to 10000 simulated equivalent random networks) are targeted by more than one IIT miRNAs (&#x0201c;cooperatively targeted&#x0201d;) (<xref rid="appsec4" ref-type="sec">Supplementary Table&#x000a0;ST3</xref>). Furthermore, 91 of the cooperatively targeted genes were significantly overtargeted by the IIT miRNA set (hypergeometric <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and FDR&#x000a0;&#x0003c;&#x000a0;0.05, as compared to targeting proportions in the interaction universe/background, <xref rid="appsec4" ref-type="sec">Supplementary Table&#x000a0;ST3</xref>, interaction network shown in <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Consequently, this relatively large number of overtargeted genes was also highly significant (<italic>P</italic>&#x000a0;=&#x000a0;0.0039, as empirically determined by comparison to 10000 simulated equivalent random networks). As shown in <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>, <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B, the overtargeted gene network depicted a 9-gene central cluster including BCL2, CDK6, SPTBN1, DICER1 (these four genes targeted by four IIT miRNAs each), RPS6KB1 SERPINE1, SENP1, CDC25A, and SIRT1 (these five genes targeted by three IIT miRNAs each). Gene set enrichment analysis (for GO biological processes) highlighted the enrichment in overtargeted genes that regulate cell death, cell cycle, proliferation, and cell and tissue morphogenesis, among the most relevant processes (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C,D, <xref rid="appsec4" ref-type="sec">Supplementary Tables&#x000a0;ST4 and ST5</xref>).<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Functional network analysis. (<bold>A</bold>) Network of experimentally validated interactions between seven IIT miRNAs and corresponding 91 overtargeted genes. Overtargeted genes appear to interact with a significantly higher number of miRNAs than expected by chance (as determined by hypergeometric tests of network proportions compared to the respective proportions in the miRNA&#x02013;target interaction universe/background). (<bold>B</bold>) Enrichment of gene ontology annotations among the complete set of 91 overtargeted genes (method set to &#x02018;slim&#x02019; annotations and significance value cutoff Padj&#x000a0;&#x0003c;&#x000a0;0.05). (<bold>C</bold>) Re-drawn subnetwork for the central cluster of 9 highly overtargeted genes (3 or more targeting miRNAs per gene) and interacting set of six IIT miRNAs. (<bold>D</bold>) Enrichment of gene ontology annotations for the central cluster of 9 overtargeted genes (method set to &#x02018;all&#x02019; annotations and significance value cutoff Padj&#x000a0;&#x0003c;&#x000a0;0.001). Categories with the lowest <italic>P</italic> values at the bottom of the plot. Annotation enrichment analysis was assessed using the <italic>GOCluster_Report</italic> function of the <italic>systemPipeR</italic> package in the R environment.</p></caption><alt-text id="alttext0040">Figure&#x000a0;5</alt-text><graphic xlink:href="gr5"/></fig></p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0130">In this study, we provide evidence of a predictive multimodal signature in patients with early type 2 diabetes who were treated with short-term IIT. In addition, the longitudinal comparison of circulating miRNA levels between the group with considerable reversibility in beta-cell dysfunction in response to short-term IIT (the R group) and the group without such reversibility (the NR group), provides insights into potential underlying regulatory mechanisms determining the response to short-term IIT. A hallmark of reversibility of beta-cell dysfunction in early type 2 diabetes is the coupling of a high HbA1c with short duration of diabetes <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>. This situation arises because of the effect of glucotoxicity in amplifying the rise in glycemia that characterizes the natural history of type 2 diabetes. Specifically, early in the course of the disease, glycemia increases as beta-cell function worsens. When glucose levels reach the glucotoxic threshold at which they further compromise beta-cell function [<italic>i.e.</italic>, first-phase insulin secretion is abolished at blood glucose 6.4&#x000a0;mmol/l <xref rid="bib54" ref-type="bibr">[54]</xref>] there will be an amplification of beta-cell dysfunction and a more rapid rise in glycemia. While the resultant effect is one of higher glycemia in early type 2 diabetes, its emergence is indicative of reversible beta-cell dysfunction (<italic>e.g.</italic>, due to glucotoxicity). For this reason, it was expected that, compared to nonresponders, the responders may have shorter duration of diabetes coupled with higher HbA1c.</p><sec id="sec4.1"><label>4.1</label><title>Predictive value of baseline circulating levels of miR-145-5p, miR-29c-3p, and HbA1c</title><p id="p0135">Using an implementation of the RF algorithm described by Breiman <xref rid="bib30" ref-type="bibr">[30]</xref>, which reduces bias and is protected from overfitting, we demonstrated that baseline levels of miR-145-5p, miR-29c-3p, and HbA1c could accurately and sensitively predict the response to short-term IIT. This was further evidenced by the significant correlations between miR-145-5p baseline levels and the changes in measures of beta-cell function (ISSI-2) and glycemic control (fasting glucose and HbA1c). Although these associations do not demonstrate causality, they suggest that the lower the baseline levels of miR-145-5p, the larger the increase in ISSI-2 and the larger the reduction in fasting glucose and HbA1c levels. Consistent with our findings, the parent trial found that higher baseline HbA1c levels may predict response to short-term IIT <xref rid="bib11" ref-type="bibr">[11]</xref>. Importantly, no combination of clinical parameters demonstrated better performance than that of the multimodal RF classifier. This highlights the utility of profiling miRNA biomarkers alongside clinical parameters to predict response and aid selection of anti-diabetic therapies.</p><p id="p0140">Based on validated functions of miR-145-5p (discussed below) and the correlations observed in our study, we speculate that baseline levels of this miRNA may reflect the &#x0201c;irreversible component&#x0201d; (<italic>e.g.</italic>, dying beta-cell mass) that affects the response to short-term IIT. Notably, expression of miR-145-5p (originally considered a cardiovascular-specific miRNA) has been found to be upregulated in the liver, muscle, and pancreas of db/db obese mice <xref rid="bib55" ref-type="bibr">[55]</xref>, to be regulated by glucose concentration and to be involved in glucose homeostasis through regulation of ABCA1 and cholesterol efflux in liver and pancreas <xref rid="bib56" ref-type="bibr">[56]</xref>, and to be upregulated by resistin (an adipocyte-derived cytokine associated with insulin resistance) both <italic>in&#x000a0;vivo</italic> and <italic>in&#x000a0;vitro</italic>, consequently impairing insulin signaling <xref rid="bib57" ref-type="bibr">[57]</xref>. Other studies have found that miR-145-5p increases lipolysis in human adipocytes through increased production and processing of pro-inflammatory TNF-&#x003b1; <xref rid="bib58" ref-type="bibr">[58]</xref>. Remarkably, miR-145-5p was also recently reported to induce, depending on glucose availability, either inhibitory or stimulatory effects on the apoptotic rate of hepatocellular carcinoma <xref rid="bib52" ref-type="bibr">[52]</xref>. In that work, Lupini and colleagues demonstrated that miR-145-5p induced downregulation of [oncogenic] miR-483-3p under low-glucose and up-regulation under high-glucose conditions, which translated into induction or inhibition of miR-145-induced TP53-dependent apoptosis, respectively <xref rid="bib52" ref-type="bibr">[52]</xref>. The authors also reported the existence of a regulatory loop between miR-145-5p and miR-483-3p in normal cells, which is lost in tumor cells. On the other hand, Mohan and colleagues reported that miR-483-5p (the mature miRNA from the forward strand) respond to elevated glucose levels and is overexpressed in pancreatic beta cells (as compared to alpha cells, both <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic>), and that overexpression of miR-483-5p induces insulin secretion and inhibits glucagon secretion through activation of insulin signaling <xref rid="bib53" ref-type="bibr">[53]</xref>. These authors also reported that overexpression of miR-483-5p protects against cytokine-mediated apoptosis in beta cells and is consequently elevated in prediabetic mice islets in correspondence with the increase in beta cell mass. Extrapolating to our study scenario, we hypothesize that the lower glucose levels in subjects of the nonresponder group (which are in &#x0201c;more advanced&#x0201d; stages of early type 2 diabetes, with longer duration of diabetes and with lower glycemia), together with putative higher baseline miR-145-5p tissue levels, may &#x0201c;reinforce&#x0201d; the activity of the regulatory loop by which miR-145-5p represses miR-483 (both -5p and -3p) activities, therefore augmenting the rate of miR-145-induced apoptosis and presumably the demise of beta cells in the pancreas. On the other hand, the higher levels of blood glucose in subjects in the responder group (in &#x0201c;earlier&#x0201d; stages of early type 2 diabetes, with higher glycemia due to the stronger influence of reversible glucotoxicity and lower miR-145-5p baseline levels), may induce the upregulation of miR-483 activities, which consequently counteract the pro-apoptotic functions of miR-145 and presumably stimulates proliferation of beta cells in the pancreas. The consequent improvement in beta cell function in the responder group would then contribute to reversing glucotoxicity and lowering glycemic levels, consequently inducing the observed rising trend in miR-145-5p and correspondingly decreasing trend in miR-483-5p after short-term IIT. We hypothesize that the balanced interplay among these miRNAs and respective regulated genes, in a tissue-specific physiological/pathophysiological context are important determinants of disease progression and response to therapy in subjects with type 2 diabetes. These results represent an indirect validation of the occurrence of the regulatory loop between miR-145-5p and miR-483-3p/5p in tissues (likely the pancreas and/or liver) from humans with type 2 diabetes and indicate that baseline levels of miR-483-5p in circulation can also be predictive of the response to short-term IIT. Furthermore, Cui and colleagues recently demonstrated that downregulation of miR-145-5p in diabetes-bone marrow stromal-cells (diabetes-BMSCs) increased cell proliferation and decreased cell death in addition to improving vascular remodeling in the ischemic rat brain <xref rid="bib59" ref-type="bibr">[59]</xref>. We speculate that, in a somewhat similar fashion, people with type 2 diabetes that have lower levels of miR-145-5p (as in our R group) may experience reduced beta-cell death, improved proliferation, and an improved vasculogenic microenvironment in the pancreas that, therefore, may elicit a positive response to short-term IIT.</p><p id="p0145">On the other hand, miR-29, one of the most abundant miRNA family in human pancreatic &#x003b2;-cells and in the liver <xref rid="bib60" ref-type="bibr">[60]</xref>, has been reported to be downregulated under hyperinsulinemic conditions (<italic>e.g.</italic>, in the heart, possibly as an adaptive mechanism to protect the organ in the prediabetic stage <xref rid="bib61" ref-type="bibr">[61]</xref>), but increased in response to loss of hyperinsulinemia and elevated plasma glucose levels <xref rid="bib62" ref-type="bibr">[62]</xref>. However, an apparent inverse correlation between liver and circulating plasma miR-29 levels in type 2 diabetes has also been suggested and deemed intriguing <xref rid="bib63" ref-type="bibr">[63]</xref>. Although miR-29 did not show significant correlations with relevant clinical measurements in our subjects, we note that responders tend to have higher baseline levels of circulating miR-29. Therefore, considering the reported inverse correlation between circulating and tissue levels for miR-29 in type 2 diabetes, we speculate that responders may have lower levels of miR-29 in some insulin-sensitive tissues, which may provide for additional protection in these subjects and a positive response to the treatment.</p></sec><sec id="sec4.2"><label>4.2</label><title>Differential miRNA signature responsive to short-term IIT</title><p id="p0150">Five circulating miRNAs, miR-138-5p, miR-192-5p, miR-195-5p, miR-320b, and let-7a-5p, showed significant differential expression changes in response to four-week short-term IIT. Their changes in the subjects' circulation effectively separated the subjects that responded to the therapy from those that did not, as assessed by PCA. This suggests that short-term IIT induced major changes in the circulating levels of pattern A miRNAs that are defined by the subjects&#x02019; capacity to respond to the therapy. Those changes also associated with concomitant changes in beta-cell function (as evidenced by significant correlation with the change in ISSI-2), insulin resistance (as evidenced by significant correlation with the change in HOMA IR), and fasting insulin concentrations. This suggests that Pattern A miRNAs may regulate a reversible state, potentially due to glucotoxicity, that is responsive to short-term IIT in people with early type 2 diabetes.</p><p id="p0155">Notably, binding of miR-138-5p to the TATA-box region in the promoter of the insulin gene enhances the promoter activity and consequently the expression of the insulin gene <xref rid="bib64" ref-type="bibr">[64]</xref>. Therefore, the elevated plasma abundance detected for miR-138-5p in our R group suggests that short-term IIT may increase the expression of the insulin gene in pancreatic beta-cells. On the other hand, miR-192-5p is one of the most abundant miRNAs in pancreatic beta-cells, liver, and kidney <xref rid="bib65" ref-type="bibr">[65]</xref>, <xref rid="bib66" ref-type="bibr">[66]</xref>, and is significantly increased in the circulation in early disease stages, as in people with prediabetes <xref rid="bib67" ref-type="bibr">[67]</xref>. In addition, roles in insulin resistance, cardiometabolic phenotypes, diabetic nephropathy, and non-alcoholic fatty liver disease (NAFLD) have recently been suggested <xref rid="bib68" ref-type="bibr">[68]</xref>, <xref rid="bib69" ref-type="bibr">[69]</xref>, <xref rid="bib70" ref-type="bibr">[70]</xref>. Notably, we recently identified miR-192-5p as a key vitamin D-responsive miRNA in subjects with prediabetes <xref rid="bib50" ref-type="bibr">[50]</xref>. Supporting our findings in this study, miR-192-5p was also reduced by the vitamin D treatment and correlated with the change in fasting plasma glucose <xref rid="bib50" ref-type="bibr">[50]</xref>.</p><p id="p0160">Another subset of Pattern A miRNAs, namely let-7a-5p, miR-195-5p, and miR-320b appeared to be coregulated, as suggested by the significant correlations among them. Consistent with this notion, these three miRNAs have been similarly implicated in diabetes <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib71" ref-type="bibr">[71]</xref>, <xref rid="bib72" ref-type="bibr">[72]</xref>, <xref rid="bib73" ref-type="bibr">[73]</xref>, <xref rid="bib74" ref-type="bibr">[74]</xref>, <xref rid="bib75" ref-type="bibr">[75]</xref>, <xref rid="bib76" ref-type="bibr">[76]</xref>, <xref rid="bib77" ref-type="bibr">[77]</xref>, cardiovascular disease <xref rid="bib74" ref-type="bibr">[74]</xref>, <xref rid="bib77" ref-type="bibr">[77]</xref>, <xref rid="bib78" ref-type="bibr">[78]</xref>, <xref rid="bib79" ref-type="bibr">[79]</xref>, and cancer <xref rid="bib80" ref-type="bibr">[80]</xref>, <xref rid="bib81" ref-type="bibr">[81]</xref>, <xref rid="bib82" ref-type="bibr">[82]</xref>, <xref rid="bib83" ref-type="bibr">[83]</xref>, and their effects appear to be associated with the miRNA presence in exosomes <xref rid="bib73" ref-type="bibr">[73]</xref>, <xref rid="bib74" ref-type="bibr">[74]</xref>, <xref rid="bib75" ref-type="bibr">[75]</xref>, <xref rid="bib76" ref-type="bibr">[76]</xref>, <xref rid="bib80" ref-type="bibr">[80]</xref>. Consistent with our findings, let-7a-5p (a highly abundant miRNA in human &#x003b2;-cells <xref rid="bib84" ref-type="bibr">[84]</xref>) was found to be significantly downregulated in plasma exosomes from people with type 2 diabetes, significantly correlated with plasma glucose and HbA1c levels, and responsive to antidiabetic treatment <xref rid="bib75" ref-type="bibr">[75]</xref>. On the other hand, miR-195-5p was found upregulated in the liver of diabetic rats and its expression showed a linear relationship with the glycemic phenotype of three distinct strains, which suggested a role in the pathophysiology of type 2 diabetes <xref rid="bib72" ref-type="bibr">[72]</xref>. Remarkably, we have recently detected circulating exosomal miR-195-5p changing in diabetic people in response to treatment with pioglitazone <xref rid="bib85" ref-type="bibr">[85]</xref>. Regarding miR-320b, its upregulation in cultured adipocytes contributed to the development of insulin resistance <xref rid="bib71" ref-type="bibr">[71]</xref> while in diabetic mice contributed to the development of hyperglycemic/metabolic memory in the heart despite normoglycemia restoration <xref rid="bib77" ref-type="bibr">[77]</xref>. In addition, family member miR-320a was found to regulate skeletal muscle mitochondrial metabolism <xref rid="bib86" ref-type="bibr">[86]</xref>. These findings suggest potential clinical utility for the design of new strategies to interfere with the development of hyperglycemic memory in specific tissues. We hypothesize that the implementation of short-term IIT early in the development of type 2 diabetes could contribute to reducing the levels of miR-320b and consequently, interfere with the development of hyperglycemic memory later in the course of the disease, potentially contributing to reduced risk of disease progression and reduced risk of cardiovascular complications, as evidenced in the United Kingdom Prospective Diabetes Study <xref rid="bib87" ref-type="bibr">[87]</xref>.</p><p id="p0165">Collectively, the predictive and responsive miRNAs (IIT miRNAs) define a network of validated miRNA&#x02013;mRNA interactions that additionally suggests the coordinated regulation of genes that regulate cell proliferation, apoptosis, and cell/tissue morphogenesis. A central cluster of nine overtargeted genes including BCL2, CDK6, SPTBN1, DICER1, RPS6KB1 SERPINE1, SENP1, CDC25A, and SIRT1 (identified from among 91 genes targeted by more than one of the select IIT miRNAs) emerge as potentially key players driving a positive response to the insulin therapy in early diabetic patients. Reduced demise of challenged/dying beta-cells and concomitant enhanced beta-cell proliferation and pancreatic tissue remodeling (morphogenesis) in the diabetic pancreas is a plausible mechanism that could explain, at least in part, the beneficial and long-term effects of short-term IIT in humans with early type 2 diabetes. Interestingly, a recent trans-omic network analysis of selective responses to low (basal) and high (induced) insulin administration (<italic>in&#x000a0;vitro</italic> using rat hepatoma cells and <italic>in&#x000a0;vivo</italic> using insulin-clamped rat livers) found that basal and induced insulin effects are decoded by the cells via mostly mutually exclusive pathways <xref rid="bib88" ref-type="bibr">[88]</xref>. However, FoxO1, a key transcription factor inhibited by Akt phosphorylation and activated by Sirt1 deacetylation among other stimuli <xref rid="bib89" ref-type="bibr">[89]</xref>, was able to regulate both basal and induced insulin-responsive transcripts <xref rid="bib88" ref-type="bibr">[88]</xref>. As SIRT1, which has also been found to be a critical factor for Pdx1 transcription and &#x003b2; cell formation <xref rid="bib90" ref-type="bibr">[90]</xref>, is one of the most significantly overtargeted genes in our analysis and FOXA1 (also activated by Sirt1 and an interdependent binding partner and enhancer of FoxO1 binding to the promoter of insulin-sensitive genes <xref rid="bib91" ref-type="bibr">[91]</xref>) is also significantly overtargeted by IIT miRNAs (refer to <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref> networks and <xref rid="appsec4" ref-type="sec">Supplementary Table&#x000a0;ST3</xref>), these results suggest that IIT miRNAs may be functionally involved in the regulation of both the basal and induced cellular responses to insulin. Consequently, deregulation and/or individual variation in IIT miRNA levels may impact the natural history of type 2 diabetes and/or the heterogeneity in response to treatment.</p><p id="p0170">Also notably, DICER1, one of the top overtargeted genes in our network analysis (targeted by 4 of the 7 IIT miRNAs), was recently shown by the Kahn group to play a fundamental role in adipose tissue, which contributes a majority of exosomal miRNAs into the circulation <xref rid="bib92" ref-type="bibr">[92]</xref>. Additionally, DICER-dependent miRNA biogenesis was shown to be critical to sustain survival and activity of POMC neurons and to mediate hypothalamic regulation of energy balance by relaying peripheral nutrient excess and/or obesity <xref rid="bib93" ref-type="bibr">[93]</xref>, <xref rid="bib94" ref-type="bibr">[94]</xref>. Of note, the IIT miRNAs also significantly overtarget the PPARG transcript (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A), which is a master transcriptional regulator of metabolism and, in particular, critical for fat-cell formation/differentiation of adipose tissue <xref rid="bib95" ref-type="bibr">[95]</xref>, <xref rid="bib96" ref-type="bibr">[96]</xref>, <xref rid="bib97" ref-type="bibr">[97]</xref>. Importantly, a recent work by Taylor and collaborators demonstrated that substantial (15%) weight loss through a low-calorie diet in subjects with type 2 diabetes can lead to restoration of &#x003b2; cell function in about 2/3 of the intervened population <xref rid="bib98" ref-type="bibr">[98]</xref>. These authors found that the major difference between their responder and nonresponder groups was the respective ability to recover first-phase insulin response (response to the intervention was then dependent upon the capacity of &#x003b2; cell recovery) and, as in our cohort, that response was predicted by shorter duration of diabetes. Those results, in the context of our work and the work of others discussed here, support the hypothesis that short-term IIT and significant weight loss interventions may similarly improve &#x003b2; cell function, possibly via alterations in adipocyte miRNA release, and contribute to remission of type 2 diabetes.</p><p id="p0175">Pattern B miRNAs, which show a significant Time effect generally due to similar directional changes in both R and NR groups, appear to represent miRNAs modulated by the insulin therapy or glycemia but not causally related to the improvements in insulin secretion and sensitivity evidenced by the change in the ISSI-2 index. These miRNAs may be responsible, at least in part, for the significant reduction of HbA1c levels in both groups. Supporting this reasoning, we and others have previously found several of the Pattern B miRNAs changing in the circulation of people with obesity and/or diabetes (<italic>e.g.</italic>, miR-34a, miR-144, let-7b <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib51" ref-type="bibr">[51]</xref>, <xref rid="bib99" ref-type="bibr">[99]</xref>), and playing mechanistic roles in obesity and glucose metabolism (<italic>e.g.</italic>, miR-15b, miR-802 <xref rid="bib100" ref-type="bibr">[100]</xref>, <xref rid="bib101" ref-type="bibr">[101]</xref>).</p><p id="p0180">Although we consider these results exciting and promising, there are several limitations in our study. First, the limited cohort size makes validation in independent cohorts important. Second, our study involved people with type 2 diabetes in an early stage in the natural history of the disease, therefore limiting the generalizability to other disease stages. In addition, direct experimental validation of target gene changes and mRNA knockdown/overexpression in human diabetic tissue samples is lacking, which could strengthen our findings by clarifying potential mechanisms. It is not clear, for example, whether the between group differences in the change in miRNA abundance are causally related to changes in blood glucose, insulin secretion, insulin resistance, or changes in some other unmeasured factors. Lastly, beta-cell function and insulin resistance were assessed with OGTT-based surrogate indices instead of with &#x0201c;gold standard&#x0201d; clamp measurements. However, ISSI-2 and HOMA-IR indexes are well-validated measurements used in previous studies <xref rid="bib11" ref-type="bibr">[11]</xref>.</p></sec></sec><sec id="sec5"><label>5</label><title>Conclusions</title><p id="p0185">In this study, we have generated an accurate multimodal RF classifier with potential clinical utility for predicting responses to short-term IIT among patients with recently diagnosed type 2 diabetes. An important current limitation of short-term IIT is the inability to identify potential responders at baseline. Therefore, we emphasize the potential clinical relevance of our study, as it represents a first step in that context and provides key insight into the pathophysiologic determinants of reversibility of beta-cell dysfunction. Such reversibility cannot be identified by any other conventional measure in use today. This insight may inform targeted therapeutic interventions aimed at ameliorating reversible beta-cell dysfunction and thereby changing the natural history of type 2 diabetes. Whether the specific miRNAs and RF classifier will also be useful to predict responses to antidiabetic therapies is an intriguing question warranting further study.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>S.E.</given-names></name><name><surname>Zraika</surname><given-names>S.</given-names></name><name><surname>Utzschneider</surname><given-names>K.M.</given-names></name><name><surname>Hull</surname><given-names>R.L.</given-names></name></person-group><article-title>The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality</article-title><source>Diabetologia</source><volume>52</volume><year>2009</year><fpage>1003</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">19326096</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Wajchenberg</surname><given-names>B.L.</given-names></name></person-group><article-title>beta-cell failure in diabetes and preservation by clinical treatment</article-title><source>Endocrine Reviews</source><volume>28</volume><year>2007</year><fpage>187</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">17353295</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Retnakaran</surname><given-names>R.</given-names></name><name><surname>Zinman</surname><given-names>B.</given-names></name></person-group><article-title>Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function</article-title><source>Diabetes, Obesity &#x00026; Metabolism</source><volume>14</volume><issue>Suppl 3</issue><year>2012</year><fpage>161</fpage><lpage>166</lpage></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>C.K.</given-names></name><name><surname>Choi</surname><given-names>H.</given-names></name><name><surname>Zinman</surname><given-names>B.</given-names></name><name><surname>Retnakaran</surname><given-names>R.</given-names></name></person-group><article-title>Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function</article-title><source>Diabetes Care</source><volume>37</volume><year>2014</year><fpage>1116</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">24550219</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>J.</given-names></name><name><surname>Retnakaran</surname><given-names>R.</given-names></name><name><surname>Ariachery</surname><given-names>C.A.</given-names></name><name><surname>Ji</surname><given-names>L.</given-names></name><name><surname>Meneghini</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps</article-title><source>Diabetes/Metabolism Research and Reviews</source><volume>31</volume><year>2015</year><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">25196375</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>E.A.</given-names></name><name><surname>Imes</surname><given-names>S.</given-names></name><name><surname>Wallace</surname><given-names>C.</given-names></name></person-group><article-title>Short-term intensive insulin therapy in newly diagnosed type 2 diabetes</article-title><source>Diabetes Care</source><volume>27</volume><year>2004</year><fpage>1028</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">15111515</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Liao</surname><given-names>Z.</given-names></name><name><surname>Yao</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name></person-group><article-title>Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function</article-title><source>Diabetes Care</source><volume>27</volume><year>2004</year><fpage>2597</fpage><lpage>2602</lpage><pub-id pub-id-type="pmid">15504992</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name></person-group><article-title>Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial</article-title><source>Lancet (London, England)</source><volume>371</volume><year>2008</year><fpage>1753</fpage><lpage>1760</lpage></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Wallia</surname><given-names>A.</given-names></name><name><surname>Molitch</surname><given-names>M.E.</given-names></name></person-group><article-title>Insulin therapy for type 2 diabetes mellitus</article-title><source>Journal of the American Medical Association</source><volume>311</volume><year>2014</year><fpage>2315</fpage><lpage>2325</lpage><pub-id pub-id-type="pmid">24915263</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>C.K.</given-names></name><name><surname>Zinman</surname><given-names>B.</given-names></name><name><surname>Retnakaran</surname><given-names>R.</given-names></name></person-group><article-title>Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis</article-title><source>The Lancet Diabetes &#x00026; Endocrinology</source><volume>1</volume><year>2013</year><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">24622264</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>C.K.</given-names></name><name><surname>Choi</surname><given-names>H.</given-names></name><name><surname>Zinman</surname><given-names>B.</given-names></name><name><surname>Retnakaran</surname><given-names>R.</given-names></name></person-group><article-title>Determinants of reversibility of beta-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes</article-title><source>American Journal of Physiology Endocrinology and Metabolism</source><volume>305</volume><year>2013</year><fpage>E1398</fpage><lpage>E1407</lpage><pub-id pub-id-type="pmid">24129396</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Retnakaran</surname><given-names>R.</given-names></name><name><surname>Yakubovich</surname><given-names>N.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name><name><surname>Opsteen</surname><given-names>C.</given-names></name><name><surname>Zinman</surname><given-names>B.</given-names></name></person-group><article-title>The response to short-term intensive insulin therapy in type 2 diabetes</article-title><source>Diabetes, Obesity &#x00026; Metabolism</source><volume>12</volume><year>2010</year><fpage>65</fpage><lpage>71</lpage></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Sayed</surname><given-names>D.</given-names></name><name><surname>Abdellatif</surname><given-names>M.</given-names></name></person-group><article-title>MicroRNAs in development and disease</article-title><source>Physiological Reviews</source><volume>91</volume><year>2011</year><fpage>827</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">21742789</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Victoria</surname><given-names>B.</given-names></name><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Masternak</surname><given-names>M.M.</given-names></name></person-group><article-title>MicroRNAs and the metabolic hallmarks of aging</article-title><source>Molecular and Cellular Endocrinology</source><volume>455</volume><year>2017</year><fpage>131</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">28062199</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Shantikumar</surname><given-names>S.</given-names></name><name><surname>Caporali</surname><given-names>A.</given-names></name><name><surname>Emanueli</surname><given-names>C.</given-names></name></person-group><article-title>Role of microRNAs in diabetes and its cardiovascular complications</article-title><source>Cardiovascular Research</source><volume>93</volume><year>2012</year><fpage>583</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">22065734</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Guay</surname><given-names>C.</given-names></name><name><surname>Regazzi</surname><given-names>R.</given-names></name></person-group><article-title>Role of islet microRNAs in diabetes: which model for which question?</article-title><source>Diabetologia</source><volume>58</volume><year>2015</year><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">25512004</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Prats-Puig</surname><given-names>A.</given-names></name><name><surname>Ortega</surname><given-names>F.J.</given-names></name><name><surname>Mercader</surname><given-names>J.M.</given-names></name><name><surname>Moreno-Navarrete</surname><given-names>J.M.</given-names></name><name><surname>Moreno</surname><given-names>M.</given-names></name><name><surname>Bonet</surname><given-names>N.</given-names></name></person-group><article-title>Changes in circulating microRNAs are associated with childhood obesity</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>98</volume><year>2013</year><fpage>E1655</fpage><lpage>E1660</lpage><pub-id pub-id-type="pmid">23928666</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Garufi</surname><given-names>G.</given-names></name><name><surname>Seyhan</surname><given-names>A.A.</given-names></name></person-group><article-title>Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes</article-title><source>Molecular BioSystems</source><volume>13</volume><year>2016</year><fpage>106</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">27869909</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>A.</given-names></name><name><surname>Danielson</surname><given-names>K.M.</given-names></name><name><surname>Benton</surname><given-names>M.C.</given-names></name><name><surname>Ziegler</surname><given-names>O.</given-names></name><name><surname>Shah</surname><given-names>R.</given-names></name><name><surname>Stubbs</surname><given-names>R.S.</given-names></name></person-group><article-title>miRNA signatures of insulin resistance in obesity</article-title><source>Obesity (Silver Spring, Md)</source><volume>25</volume><year>2017</year><fpage>1734</fpage><lpage>1744</lpage></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Garufi</surname><given-names>G.</given-names></name><name><surname>Pasarica</surname><given-names>M.</given-names></name><name><surname>Seyhan</surname><given-names>A.A.</given-names></name></person-group><article-title>Elevated and correlated expressions of miR-24, miR-30d, miR-146a, and SFRP-4 in human abdominal adipose tissue play a role in adiposity and insulin resistance</article-title><source>International Journal of Endocrinology</source><volume>2018</volume><year>2018</year><fpage>7</fpage></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>F.J.</given-names></name><name><surname>Mercader</surname><given-names>J.M.</given-names></name><name><surname>Catalan</surname><given-names>V.</given-names></name><name><surname>Moreno-Navarrete</surname><given-names>J.M.</given-names></name><name><surname>Pueyo</surname><given-names>N.</given-names></name><name><surname>Sabater</surname><given-names>M.</given-names></name></person-group><article-title>Targeting the circulating microRNA signature of obesity</article-title><source>Clinical Chemistry</source><volume>59</volume><year>2013</year><fpage>781</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">23396142</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Zampetaki</surname><given-names>A.</given-names></name><name><surname>Kiechl</surname><given-names>S.</given-names></name><name><surname>Drozdov</surname><given-names>I.</given-names></name><name><surname>Willeit</surname><given-names>P.</given-names></name><name><surname>Mayr</surname><given-names>U.</given-names></name><name><surname>Prokopi</surname><given-names>M.</given-names></name></person-group><article-title>Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes</article-title><source>Circulation Research</source><volume>107</volume><year>2010</year><fpage>810</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">20651284</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>F.J.</given-names></name><name><surname>Mercader</surname><given-names>J.M.</given-names></name><name><surname>Moreno-Navarrete</surname><given-names>J.M.</given-names></name><name><surname>Rovira</surname><given-names>O.</given-names></name><name><surname>Guerra</surname><given-names>E.</given-names></name><name><surname>Esteve</surname><given-names>E.</given-names></name></person-group><article-title>Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization</article-title><source>Diabetes Care</source><volume>37</volume><year>2014</year><fpage>1375</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">24478399</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Seyhan</surname><given-names>A.A.</given-names></name><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Yi</surname><given-names>F.</given-names></name><name><surname>Mathews</surname><given-names>C.</given-names></name><name><surname>Pasarica</surname><given-names>M.</given-names></name></person-group><article-title>Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study</article-title><source>Scientific Reports</source><volume>6</volume><year>2016</year><fpage>31479</fpage><pub-id pub-id-type="pmid">27558530</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>T.K.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>A&#x000a0;systematic study of dysregulated microRNA in type 2 diabetes mellitus</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><year>2017</year></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Copier</surname><given-names>C.U.</given-names></name><name><surname>Le&#x000f3;n</surname><given-names>L.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>M.</given-names></name><name><surname>Contador</surname><given-names>D.</given-names></name><name><surname>Calligaris</surname><given-names>S.D.</given-names></name></person-group><article-title>Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy</article-title><source>Scientific Reports</source><volume>7</volume><year>2017</year></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Catanzaro</surname><given-names>G.</given-names></name><name><surname>Besharat</surname><given-names>Z.M.</given-names></name><name><surname>Chiacchiarini</surname><given-names>M.</given-names></name><name><surname>Abballe</surname><given-names>L.</given-names></name><name><surname>Sabato</surname><given-names>C.</given-names></name><name><surname>Vacca</surname><given-names>A.</given-names></name></person-group><article-title>Circulating microRNAs in elderly type 2 diabetic patients</article-title><source>International Journal of Endocrinology</source><volume>2018</volume><year>2018</year><fpage>11</fpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Retnakaran</surname><given-names>R.</given-names></name><name><surname>Kramer</surname><given-names>C.K.</given-names></name><name><surname>Choi</surname><given-names>H.</given-names></name><name><surname>Swaminathan</surname><given-names>B.</given-names></name><name><surname>Zinman</surname><given-names>B.</given-names></name></person-group><article-title>Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial</article-title><source>Diabetes Care</source><volume>37</volume><year>2014</year><fpage>3270</fpage><lpage>3278</lpage><pub-id pub-id-type="pmid">25249651</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>C.K.</given-names></name><name><surname>Zinman</surname><given-names>B.</given-names></name><name><surname>Choi</surname><given-names>H.</given-names></name><name><surname>Connelly</surname><given-names>P.W.</given-names></name><name><surname>Retnakaran</surname><given-names>R.</given-names></name></person-group><article-title>Impact of the glucagon assay when assessing the effect of chronic liraglutide therapy on glucagon secretion</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><year>2017</year></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Breiman</surname><given-names>L.</given-names></name></person-group><article-title>Random forests</article-title><source>Machine Learning</source><volume>45</volume><year>2001</year><fpage>5</fpage><lpage>32</lpage></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="book" id="sref31"><person-group person-group-type="author"><collab>R Core Team</collab></person-group><chapter-title>R: a language and environment for statistical computing</chapter-title><year>2018</year><publisher-name>R Foundation for Statistical Computing</publisher-name><publisher-loc>Vienna, Austria</publisher-loc></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Kirschner</surname><given-names>M.B.</given-names></name><name><surname>Edelman</surname><given-names>J.B.</given-names></name><name><surname>Kao</surname><given-names>S.C.H.</given-names></name><name><surname>Vallely</surname><given-names>M.P.</given-names></name><name><surname>van Zandwijk</surname><given-names>N.</given-names></name><name><surname>Reid</surname><given-names>G.</given-names></name></person-group><article-title>The impact of hemolysis on cell-free microRNA biomarkers</article-title><source>Frontiers in Genetics</source><volume>4</volume><year>2013</year><fpage>94</fpage><pub-id pub-id-type="pmid">23745127</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>J.S.</given-names></name><name><surname>Soon</surname><given-names>P.S.</given-names></name><name><surname>Marsh</surname><given-names>D.J.</given-names></name></person-group><article-title>Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><fpage>e0153200</fpage><pub-id pub-id-type="pmid">27054342</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Blondal</surname><given-names>T.</given-names></name><name><surname>Jensby Nielsen</surname><given-names>S.</given-names></name><name><surname>Baker</surname><given-names>A.</given-names></name><name><surname>Andreasen</surname><given-names>D.</given-names></name><name><surname>Mouritzen</surname><given-names>P.</given-names></name><name><surname>Wrang Teilum</surname><given-names>M.</given-names></name></person-group><article-title>Assessing sample and miRNA profile quality in serum and plasma or other biofluids</article-title><source>Methods (San Diego, Calif)</source><volume>59</volume><year>2013</year><fpage>S1</fpage><lpage>S6</lpage></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Strobl</surname><given-names>C.</given-names></name><name><surname>Malley</surname><given-names>J.</given-names></name><name><surname>Tutz</surname><given-names>G.</given-names></name></person-group><article-title>An introduction to recursive partitioning: rationale, application and characteristics of classification and regression trees, bagging and random forests</article-title><source>Psychological Methods</source><volume>14</volume><year>2009</year><fpage>323</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">19968396</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Marinic</surname><given-names>I.</given-names></name><name><surname>Supek</surname><given-names>F.</given-names></name><name><surname>Kovacic</surname><given-names>Z.</given-names></name><name><surname>Rukavina</surname><given-names>L.</given-names></name><name><surname>Jendricko</surname><given-names>T.</given-names></name><name><surname>Kozaric-Kovacic</surname><given-names>D.</given-names></name></person-group><article-title>Posttraumatic stress disorder: diagnostic data analysis by data mining methodology</article-title><source>Croatian Medical Journal</source><volume>48</volume><year>2007</year><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">17436383</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Liaw</surname><given-names>A.</given-names></name><name><surname>Wiener</surname><given-names>M.</given-names></name></person-group><article-title>Classification and regression by randomForest</article-title><source>R&#x000a0;News</source><volume>2</volume><year>2002</year></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>D&#x000ed;az-Uriarte</surname><given-names>R.</given-names></name><name><surname>Alvarez de Andr&#x000e9;s</surname><given-names>S.</given-names></name></person-group><article-title>Gene selection and classification of microarray data using random forest</article-title><source>BMC Bioinformatics</source><volume>7</volume><year>2006</year><fpage>3</fpage><pub-id pub-id-type="pmid">16398926</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Laurent</surname><given-names>L.C.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Ulitsky</surname><given-names>I.</given-names></name><name><surname>Mueller</surname><given-names>F.J.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Shamir</surname><given-names>R.</given-names></name></person-group><article-title>Comprehensive microRNA profiling reveals a unique human embryonic stem cell signature dominated by a single seed sequence</article-title><source>Stem cells (Dayton, Ohio)</source><volume>26</volume><year>2008</year><fpage>1506</fpage><lpage>1516</lpage></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Lewohl</surname><given-names>J.M.</given-names></name><name><surname>Nunez</surname><given-names>Y.O.</given-names></name><name><surname>Dodd</surname><given-names>P.R.</given-names></name><name><surname>Tiwari</surname><given-names>G.R.</given-names></name><name><surname>Harris</surname><given-names>R.A.</given-names></name><name><surname>Mayfield</surname><given-names>R.D.</given-names></name></person-group><article-title>Up-regulation of microRNAs in brain of human alcoholics</article-title><source>Alcoholism: Clinical and Experimental Research</source><volume>35</volume><year>2011</year><fpage>1928</fpage><lpage>1937</lpage></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Guan</surname><given-names>J.</given-names></name><name><surname>Ping</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Discovering dysfunction of multiple microRNAs cooperation in disease by a conserved microRNA co-expression network</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e32201</fpage><pub-id pub-id-type="pmid">22384175</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Nunez</surname><given-names>Y.O.</given-names></name><name><surname>Truitt</surname><given-names>J.M.</given-names></name><name><surname>Gorini</surname><given-names>G.</given-names></name><name><surname>Ponomareva</surname><given-names>O.N.</given-names></name><name><surname>Blednov</surname><given-names>Y.A.</given-names></name><name><surname>Harris</surname><given-names>R.A.</given-names></name></person-group><article-title>Positively correlated miRNA-mRNA regulatory networks in mouse frontal cortex during early stages of alcohol dependence</article-title><source>BMC Genomics</source><volume>14</volume><year>2013</year><fpage>725</fpage><pub-id pub-id-type="pmid">24148570</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Gorini</surname><given-names>G.</given-names></name><name><surname>Nunez</surname><given-names>Y.O.</given-names></name><name><surname>Mayfield</surname><given-names>R.D.</given-names></name></person-group><article-title>Integration of miRNA and protein profiling reveals coordinated neuroadaptations in the alcohol-dependent mouse brain</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e82565</fpage><pub-id pub-id-type="pmid">24358208</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Victoria Martinez</surname><given-names>B.</given-names></name><name><surname>Dhahbi</surname><given-names>J.M.</given-names></name><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Lamperska</surname><given-names>K.</given-names></name><name><surname>Golusinski</surname><given-names>P.</given-names></name><name><surname>Luczewski</surname><given-names>L.</given-names></name></person-group><article-title>Circulating small non-coding RNA signature in head and neck squamous cell carcinoma</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>19246</fpage><lpage>19263</lpage><pub-id pub-id-type="pmid">26057471</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Victoria</surname><given-names>B.</given-names></name><name><surname>Dhahbi</surname><given-names>J.M.</given-names></name><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Spinel</surname><given-names>L.</given-names></name><name><surname>Atamna</surname><given-names>H.</given-names></name><name><surname>Spindler</surname><given-names>S.R.</given-names></name></person-group><article-title>Circulating microRNA signature of genotype-by-age interactions in the long-lived Ames dwarf mouse</article-title><source>Aging Cell</source><volume>14</volume><year>2015</year><fpage>1055</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">26176567</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>J.</given-names></name></person-group><article-title>Survey of miRNA-miRNA cooperative regulation principles across cancer types</article-title><source>Briefings in Bioinformatics</source><year>2018</year></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Cava</surname><given-names>C.</given-names></name><name><surname>Colaprico</surname><given-names>A.</given-names></name><name><surname>Bertoli</surname><given-names>G.</given-names></name><name><surname>Graudenzi</surname><given-names>A.</given-names></name><name><surname>Silva</surname><given-names>T.C.</given-names></name><name><surname>Olsen</surname><given-names>C.</given-names></name></person-group><article-title>SpidermiR: an R/bioconductor package for integrative analysis with miRNA data</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><year>2017</year><fpage>274</fpage></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Demchak</surname><given-names>B.</given-names></name><name><surname>Hull</surname><given-names>T.</given-names></name><name><surname>Reich</surname><given-names>M.</given-names></name><name><surname>Liefeld</surname><given-names>T.</given-names></name><name><surname>Smoot</surname><given-names>M.</given-names></name><name><surname>Ideker</surname><given-names>T.</given-names></name></person-group><article-title>Cytoscape: the network visualization tool for GenomeSpace workflows</article-title><source>F1000Research</source><volume>3</volume><year>2014</year><fpage>151</fpage><pub-id pub-id-type="pmid">25165537</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Backman</surname><given-names>T.W.H.</given-names></name><name><surname>Girke</surname><given-names>T.</given-names></name></person-group><article-title>systemPipeR: NGS workflow and report generation environment</article-title><source>BMC Bioinformatics</source><volume>17</volume><year>2016</year><fpage>388</fpage><pub-id pub-id-type="pmid">27650223</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Pittas</surname><given-names>A.G.</given-names></name><name><surname>Pratley</surname><given-names>R.E.</given-names></name><name><surname>Seyhan</surname><given-names>A.A.</given-names></name></person-group><article-title>Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control</article-title><source>The Journal of Nutritional Biochemistry</source><volume>49</volume><year>2017</year><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">28945992</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Coen</surname><given-names>P.M.</given-names></name><name><surname>Goodpaster</surname><given-names>B.H.</given-names></name><name><surname>Seyhan</surname><given-names>A.A.</given-names></name></person-group><article-title>Gastric bypass surgery with exercise alters plasma microRNAs that predict improvements in cardiometabolic risk</article-title><source>International Journal of Obesity</source><volume>41</volume><year>2017</year><fpage>1121</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">28344345</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Lupini</surname><given-names>L.</given-names></name><name><surname>Pepe</surname><given-names>F.</given-names></name><name><surname>Ferracin</surname><given-names>M.</given-names></name><name><surname>Braconi</surname><given-names>C.</given-names></name><name><surname>Callegari</surname><given-names>E.</given-names></name><name><surname>Pagotto</surname><given-names>S.</given-names></name></person-group><article-title>Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma</article-title><source>Oncotarget</source><volume>7</volume><year>2016</year><fpage>31361</fpage><lpage>31371</lpage><pub-id pub-id-type="pmid">27120784</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>R.</given-names></name><name><surname>Mao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.W.</given-names></name><name><surname>Xu</surname><given-names>C.R.</given-names></name><name><surname>Gradwohl</surname><given-names>G.</given-names></name></person-group><article-title>Differentially expressed microRNA-483 confers distinct functions in pancreatic beta- and alpha-cells</article-title><source>Journal of Biological Chemistry</source><volume>290</volume><year>2015</year><fpage>19955</fpage><lpage>19966</lpage><pub-id pub-id-type="pmid">26109062</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Brunzell</surname><given-names>J.D.</given-names></name><name><surname>Robertson</surname><given-names>R.P.</given-names></name><name><surname>Lerner</surname><given-names>R.L.</given-names></name><name><surname>Hazzard</surname><given-names>W.R.</given-names></name><name><surname>Ensinck</surname><given-names>J.W.</given-names></name><name><surname>Bierman</surname><given-names>E.L.</given-names></name></person-group><article-title>Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>42</volume><year>1976</year><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">1262429</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>S.D.</given-names></name><name><surname>Kruger</surname><given-names>M.</given-names></name><name><surname>Willmes</surname><given-names>D.M.</given-names></name><name><surname>Redemann</surname><given-names>N.</given-names></name><name><surname>Wunderlich</surname><given-names>F.T.</given-names></name><name><surname>Bronneke</surname><given-names>H.S.</given-names></name></person-group><article-title>Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism</article-title><source>Nature Cell Biology</source><volume>13</volume><year>2011</year><fpage>434</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">21441927</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>M.H.</given-names></name><name><surname>Zhang</surname><given-names>L.H.</given-names></name><name><surname>Wijesekara</surname><given-names>N.</given-names></name><name><surname>de Haan</surname><given-names>W.</given-names></name><name><surname>Butland</surname><given-names>S.</given-names></name><name><surname>Bhattacharjee</surname><given-names>A.</given-names></name></person-group><article-title>Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>33</volume><year>2013</year><fpage>2724</fpage><lpage>2732</lpage></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name></person-group><article-title>MiRNA-145 is involved in the development of resistin-induced insulin resistance in HepG2 cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>445</volume><year>2014</year><fpage>517</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">24548410</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Lorente-Cebrian</surname><given-names>S.</given-names></name><name><surname>Mejhert</surname><given-names>N.</given-names></name><name><surname>Kulyte</surname><given-names>A.</given-names></name><name><surname>Laurencikiene</surname><given-names>J.</given-names></name><name><surname>Astrom</surname><given-names>G.</given-names></name><name><surname>Heden</surname><given-names>P.</given-names></name></person-group><article-title>MicroRNAs regulate human adipocyte lipolysis: effects of miR-145 are linked to TNF-alpha</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><fpage>e86800</fpage><pub-id pub-id-type="pmid">24475180</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>C.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Chopp</surname><given-names>M.</given-names></name><name><surname>Venkat</surname><given-names>P.</given-names></name><name><surname>Zacharek</surname><given-names>A.</given-names></name><name><surname>Yan</surname><given-names>T.</given-names></name></person-group><article-title>miR-145 regulates diabetes-bone marrow stromal cell-induced neurorestorative effects in diabetes stroke rats</article-title><source>Stem Cells Translational Medicine</source><volume>5</volume><year>2016</year><fpage>1656</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">27460851</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>J.</given-names></name><name><surname>Garcia-Perez</surname><given-names>J.E.</given-names></name><name><surname>Sreenivasan</surname><given-names>J.</given-names></name><name><surname>Schlenner</surname><given-names>S.M.</given-names></name><name><surname>Vangoitsenhoven</surname><given-names>R.</given-names></name><name><surname>Papadopoulou</surname><given-names>A.S.</given-names></name></person-group><article-title>The microRNA-29 family dictates the balance between homeostatic and pathological glucose handling in diabetes and obesity</article-title><source>Diabetes</source><volume>65</volume><year>2016</year><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">26696639</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>N.</given-names></name><name><surname>Koppula</surname><given-names>P.R.</given-names></name><name><surname>Gul</surname><given-names>R.</given-names></name><name><surname>Luck</surname><given-names>C.</given-names></name><name><surname>Pulakat</surname><given-names>L.</given-names></name></person-group><article-title>Regulation of cardiac expression of the diabetic marker microRNA miR-29</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><fpage>e103284</fpage><pub-id pub-id-type="pmid">25062042</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Slusarz</surname><given-names>A.</given-names></name><name><surname>Pulakat</surname><given-names>L.</given-names></name></person-group><article-title>The two faces of miR-29</article-title><source>Journal of Cardiovascular Medicine (Hagerstown, Md)</source><volume>16</volume><year>2015</year><fpage>480</fpage><lpage>490</lpage></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>C.L.</given-names></name><name><surname>Peck</surname><given-names>B.C.</given-names></name><name><surname>Fannin</surname><given-names>E.E.</given-names></name><name><surname>Beysen</surname><given-names>C.</given-names></name><name><surname>Miao</surname><given-names>J.</given-names></name><name><surname>Landstreet</surname><given-names>S.R.</given-names></name></person-group><article-title>MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes</article-title><source>Diabetes</source><volume>63</volume><year>2014</year><fpage>3141</fpage><lpage>3148</lpage><pub-id pub-id-type="pmid">24722248</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs</article-title><source>RNA (New York, NY)</source><volume>20</volume><year>2014</year><fpage>1878</fpage><lpage>1889</lpage></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>van de Bunt</surname><given-names>M.</given-names></name><name><surname>Gaulton</surname><given-names>K.J.</given-names></name><name><surname>Parts</surname><given-names>L.</given-names></name><name><surname>Moran</surname><given-names>I.</given-names></name><name><surname>Johnson</surname><given-names>P.R.</given-names></name><name><surname>Lindgren</surname><given-names>C.M.</given-names></name></person-group><article-title>The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e55272</fpage><pub-id pub-id-type="pmid">23372846</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Koo</surname><given-names>S.</given-names></name><name><surname>White</surname><given-names>N.</given-names></name><name><surname>Peralta</surname><given-names>E.</given-names></name><name><surname>Esau</surname><given-names>C.</given-names></name><name><surname>Dean</surname><given-names>N.M.</given-names></name></person-group><article-title>Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs</article-title><source>Nucleic Acids Research</source><volume>32</volume><year>2004</year><fpage>e188</fpage><pub-id pub-id-type="pmid">15616155</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Parrizas</surname><given-names>M.</given-names></name><name><surname>Brugnara</surname><given-names>L.</given-names></name><name><surname>Esteban</surname><given-names>Y.</given-names></name><name><surname>Gonzalez-Franquesa</surname><given-names>A.</given-names></name><name><surname>Canivell</surname><given-names>S.</given-names></name><name><surname>Murillo</surname><given-names>S.</given-names></name></person-group><article-title>Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><year>2014</year><comment>jc20142574</comment></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>R.</given-names></name><name><surname>Murthy</surname><given-names>V.</given-names></name><name><surname>Pacold</surname><given-names>M.</given-names></name><name><surname>Danielson</surname><given-names>K.</given-names></name><name><surname>Tanriverdi</surname><given-names>K.</given-names></name><name><surname>Larson</surname><given-names>M.G.</given-names></name></person-group><article-title>Extracellular RNAs are associated with insulin resistance and metabolic phenotypes</article-title><source>Diabetes Care</source><volume>40</volume><year>2017</year><fpage>546</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">28183786</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Lanting</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Rossi</surname><given-names>J.J.</given-names></name></person-group><article-title>MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>104</volume><year>2007</year><fpage>3432</fpage><lpage>3437</lpage><pub-id pub-id-type="pmid">17360662</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Pirola</surname><given-names>C.J.</given-names></name><name><surname>Fernandez Gianotti</surname><given-names>T.</given-names></name><name><surname>Castano</surname><given-names>G.O.</given-names></name><name><surname>Mallardi</surname><given-names>P.</given-names></name><name><surname>San Martino</surname><given-names>J.</given-names></name><name><surname>Mora Gonzalez Lopez Ledesma</surname><given-names>M.</given-names></name></person-group><article-title>Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis</article-title><source>Gut</source><volume>64</volume><year>2015</year><fpage>800</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">24973316</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>H.Y.</given-names></name><name><surname>Ou</surname><given-names>H.S.</given-names></name><name><surname>Feng</surname><given-names>S.D.</given-names></name><name><surname>Zhang</surname><given-names>X.Y.</given-names></name><name><surname>Tuo</surname><given-names>Q.H.</given-names></name><name><surname>Chen</surname><given-names>L.X.</given-names></name></person-group><article-title>Changes in microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes</article-title><source>Clinical and Experimental Pharmacology &#x00026; Physiology</source><volume>36</volume><year>2009</year><fpage>e32</fpage><lpage>e39</lpage><pub-id pub-id-type="pmid">19473196</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>B.M.</given-names></name><name><surname>Lockstone</surname><given-names>H.E.</given-names></name><name><surname>Taylor</surname><given-names>J.M.</given-names></name><name><surname>Ria</surname><given-names>M.</given-names></name><name><surname>Barrett</surname><given-names>A.</given-names></name><name><surname>Collins</surname><given-names>S.</given-names></name></person-group><article-title>Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes</article-title><source>Diabetologia</source><volume>53</volume><year>2010</year><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">20198361</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Karolina</surname><given-names>D.S.</given-names></name><name><surname>Tavintharan</surname><given-names>S.</given-names></name><name><surname>Armugam</surname><given-names>A.</given-names></name><name><surname>Sepramaniam</surname><given-names>S.</given-names></name><name><surname>Pek</surname><given-names>S.L.</given-names></name><name><surname>Wong</surname><given-names>M.T.</given-names></name></person-group><article-title>Circulating miRNA profiles in patients with metabolic syndrome</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>97</volume><year>2012</year><fpage>E2271</fpage><lpage>E2276</lpage><pub-id pub-id-type="pmid">23032062</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Cai</surname><given-names>W.</given-names></name><name><surname>Millard</surname><given-names>R.W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>74</volume><year>2014</year><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">24825548</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Santovito</surname><given-names>D.</given-names></name><name><surname>De Nardis</surname><given-names>V.</given-names></name><name><surname>Marcantonio</surname><given-names>P.</given-names></name><name><surname>Mandolini</surname><given-names>C.</given-names></name><name><surname>Paganelli</surname><given-names>C.</given-names></name><name><surname>Vitale</surname><given-names>E.</given-names></name></person-group><article-title>Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>99</volume><year>2014</year><fpage>E1681</fpage><lpage>E1685</lpage><pub-id pub-id-type="pmid">24937531</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Guay</surname><given-names>C.</given-names></name><name><surname>Menoud</surname><given-names>V.</given-names></name><name><surname>Rome</surname><given-names>S.</given-names></name><name><surname>Regazzi</surname><given-names>R.</given-names></name></person-group><article-title>Horizontal transfer of exosomal microRNAs transduce apoptotic signals between pancreatic beta-cells</article-title><source>Cell Communication and Signaling</source><volume>13</volume><year>2015</year><fpage>17</fpage><pub-id pub-id-type="pmid">25880779</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Costantino</surname><given-names>S.</given-names></name><name><surname>Paneni</surname><given-names>F.</given-names></name><name><surname>Luscher</surname><given-names>T.F.</given-names></name><name><surname>Cosentino</surname><given-names>F.</given-names></name></person-group><article-title>MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart</article-title><source>European Heart Journal</source><volume>37</volume><year>2016</year><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">26553540</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>F.Z.</given-names></name><name><surname>Vizi</surname><given-names>D.</given-names></name><name><surname>Khammy</surname><given-names>O.</given-names></name><name><surname>Mariani</surname><given-names>J.A.</given-names></name><name><surname>Kaye</surname><given-names>D.M.</given-names></name></person-group><article-title>The transcardiac gradient of cardio-microRNAs in the failing heart</article-title><source>European Journal of Heart Failure</source><volume>18</volume><year>2016</year><fpage>1000</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">27072074</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>F.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name></person-group><article-title>Let-7a is an antihypertrophic regulator in the heart via targeting calmodulin</article-title><source>International Journal of Biological Sciences</source><volume>13</volume><year>2017</year><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">28123343</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Hannafon</surname><given-names>B.N.</given-names></name><name><surname>Carpenter</surname><given-names>K.J.</given-names></name><name><surname>Berry</surname><given-names>W.L.</given-names></name><name><surname>Janknecht</surname><given-names>R.</given-names></name><name><surname>Dooley</surname><given-names>W.C.</given-names></name><name><surname>Ding</surname><given-names>W.Q.</given-names></name></person-group><article-title>Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA)</article-title><source>Molecular Cancer</source><volume>14</volume><year>2015</year><fpage>133</fpage><pub-id pub-id-type="pmid">26178901</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name></person-group><article-title>Overexpression of mitochondria mediator gene TRIAP1 by miR-320b loss is associated with progression in nasopharyngeal carcinoma</article-title><source>PLoS Genetics</source><volume>12</volume><year>2016</year><fpage>e1006183</fpage><pub-id pub-id-type="pmid">27428374</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Serguienko</surname><given-names>A.</given-names></name><name><surname>Grad</surname><given-names>I.</given-names></name><name><surname>Wennerstrom</surname><given-names>A.B.</given-names></name><name><surname>Meza-Zepeda</surname><given-names>L.A.</given-names></name><name><surname>Thiede</surname><given-names>B.</given-names></name><name><surname>Stratford</surname><given-names>E.W.</given-names></name></person-group><article-title>Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>2451</fpage><lpage>2465</lpage><pub-id pub-id-type="pmid">25669981</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Victoria</surname><given-names>B.</given-names></name><name><surname>Golusinski</surname><given-names>P.</given-names></name><name><surname>Golusinski</surname><given-names>W.</given-names></name><name><surname>Masternak</surname><given-names>M.M.</given-names></name></person-group><article-title>Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes. Reports of practical oncology and radiotherapy</article-title><source>Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology</source><volume>23</volume><year>2018</year><fpage>6</fpage><lpage>20</lpage></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>R.J.A.</given-names></name><name><surname>Olson</surname><given-names>E.N.</given-names></name></person-group><article-title>Control of glucose homeostasis and insulin sensitivity by the &#x0003c;em&#x0003e;Let-7&#x0003c;/em&#x0003e; family of microRNAs</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>108</volume><year>2011</year><fpage>21075</fpage><lpage>21080</lpage><pub-id pub-id-type="pmid">22160727</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="book" id="sref85"><person-group person-group-type="author"><name><surname>Nunez Lopez</surname><given-names>Y.O.</given-names></name><name><surname>Pratley</surname><given-names>R.E.</given-names></name></person-group><chapter-title>Pioglitazone alters the cargo composition of circulating exosomes in subjects with type 2 diabetes</chapter-title><series>American Diabetes Association's 78th Scientific Sessions</series><year>2018</year><publisher-name>American Diabetes Association</publisher-name><publisher-loc>Orlando, FL</publisher-loc></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Dahlmans</surname><given-names>D.</given-names></name><name><surname>Houzelle</surname><given-names>A.</given-names></name><name><surname>Andreux</surname><given-names>P.</given-names></name><name><surname>Jorgensen</surname><given-names>J.A.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>de Windt</surname><given-names>L.J.</given-names></name></person-group><article-title>An unbiased silencing screen in muscle cells identifies miR-320a, miR-150, miR-196b, and miR-34c as regulators of skeletal muscle mitochondrial metabolism</article-title><source>Molecular Metabolism</source><volume>6</volume><year>2017</year><fpage>1429</fpage><lpage>1442</lpage><pub-id pub-id-type="pmid">29107290</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>R.R.</given-names></name><name><surname>Paul</surname><given-names>S.K.</given-names></name><name><surname>Bethel</surname><given-names>M.A.</given-names></name><name><surname>Matthews</surname><given-names>D.R.</given-names></name><name><surname>Neil</surname><given-names>H.A.</given-names></name></person-group><article-title>10-year follow-up of intensive glucose control in type 2 diabetes</article-title><source>New England Journal of Medicine</source><volume>359</volume><year>2008</year><fpage>1577</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">18784090</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Kawata</surname><given-names>K.</given-names></name><name><surname>Hatano</surname><given-names>A.</given-names></name><name><surname>Yugi</surname><given-names>K.</given-names></name><name><surname>Kubota</surname><given-names>H.</given-names></name><name><surname>Sano</surname><given-names>T.</given-names></name><name><surname>Fujii</surname><given-names>M.</given-names></name></person-group><article-title>Trans-omic analysis reveals selective responses to induced and basal insulin across signaling, transcriptional, and metabolic networks</article-title><source>iScience</source><volume>7</volume><year>2018</year><fpage>212</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">30267682</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Daitoku</surname><given-names>H.</given-names></name><name><surname>Sakamaki</surname><given-names>J.</given-names></name><name><surname>Fukamizu</surname><given-names>A.</given-names></name></person-group><article-title>Regulation of FoxO transcription factors by acetylation and protein-protein interactions</article-title><source>Biochimica et Biophysica Acta</source><volume>1813</volume><year>2011</year><fpage>1954</fpage><lpage>1960</lpage><pub-id pub-id-type="pmid">21396404</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.H.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Xiao</surname><given-names>Z.</given-names></name><name><surname>Deng</surname><given-names>C.X.</given-names></name></person-group><article-title>SIRT1 deacetylates FOXA2 and is critical for Pdx1 transcription and beta-cell formation</article-title><source>International Journal of Biological Sciences</source><volume>9</volume><year>2013</year><fpage>934</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">24163589</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Yalley</surname><given-names>A.</given-names></name><name><surname>Schill</surname><given-names>D.</given-names></name><name><surname>Hatta</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>N.</given-names></name><name><surname>Cirillo</surname><given-names>L.A.</given-names></name></person-group><article-title>Loss of interdependent binding by the FoxO1 and FoxA1/A2 forkhead transcription factors culminates in perturbation of active chromatin marks and binding of transcriptional regulators at insulin-sensitive genes</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><year>2016</year><fpage>8848</fpage><lpage>8861</lpage><pub-id pub-id-type="pmid">26929406</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Thomou</surname><given-names>T.</given-names></name><name><surname>Mori</surname><given-names>M.A.</given-names></name><name><surname>Dreyfuss</surname><given-names>J.M.</given-names></name><name><surname>Konishi</surname><given-names>M.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Wolfrum</surname><given-names>C.</given-names></name></person-group><article-title>Adipose-derived circulating miRNAs regulate gene expression in other tissues</article-title><source>Nature</source><year>2017</year></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Cansell</surname><given-names>C.</given-names></name><name><surname>Luquet</surname><given-names>S.</given-names></name></person-group><article-title>Hypothalamic regulation of energy balance: a key role for DICER miRNA processing in arcuate POMC neurons</article-title><source>Molecular Metabolism</source><volume>2</volume><year>2012</year><fpage>55</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">24199145</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Schneeberger</surname><given-names>M.</given-names></name><name><surname>Altirriba</surname><given-names>J.</given-names></name><name><surname>Garcia</surname><given-names>A.</given-names></name><name><surname>Esteban</surname><given-names>Y.</given-names></name><name><surname>Castano</surname><given-names>C.</given-names></name><name><surname>Garcia-Lavandeira</surname><given-names>M.</given-names></name></person-group><article-title>Deletion of miRNA processing enzyme Dicer in POMC-expressing cells leads to pituitary dysfunction, neurodegeneration and development of obesity</article-title><source>Molecular Metabolism</source><volume>2</volume><year>2012</year><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">24199146</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Lehrke</surname><given-names>M.</given-names></name><name><surname>Lazar</surname><given-names>M.A.</given-names></name></person-group><article-title>The many faces of PPAR&#x003b3;</article-title><source>Cell</source><volume>123</volume><year>2005</year><fpage>993</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">16360030</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>E.D.</given-names></name><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Troy</surname><given-names>A.E.</given-names></name><name><surname>Bradwin</surname><given-names>G.</given-names></name><name><surname>Moore</surname><given-names>K.</given-names></name><name><surname>Milstone</surname><given-names>D.S.</given-names></name></person-group><article-title>PPAR&#x003b3; is required for the differentiation of adipose tissue in&#x000a0;vivo and in&#x000a0;vitro</article-title><source>Molecular Cell</source><volume>4</volume><year>1999</year><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">10549292</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A.M.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name></person-group><article-title>Review: Peroxisome proliferator-activated receptor gamma and adipose tissue &#x02013; understanding obesity-related changes in regulation of lipid and glucose metabolism</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>92</volume><year>2007</year><fpage>386</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">17148564</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>R.</given-names></name><name><surname>Al-Mrabeh</surname><given-names>A.</given-names></name><name><surname>Zhyzhneuskaya</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>C.</given-names></name><name><surname>Barnes</surname><given-names>A.C.</given-names></name><name><surname>Aribisala</surname><given-names>B.S.</given-names></name></person-group><article-title>Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery</article-title><source>Cell Metabolism</source><volume>28</volume><year>2018</year><fpage>547</fpage><lpage>556 e543</lpage><pub-id pub-id-type="pmid">30078554</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Guay</surname><given-names>C.</given-names></name><name><surname>Regazzi</surname><given-names>R.</given-names></name></person-group><article-title>Circulating microRNAs as novel biomarkers for diabetes mellitus</article-title><source>Nature Reviews Endocrinology</source><volume>9</volume><year>2013</year><fpage>513</fpage><lpage>521</lpage></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.M.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Park</surname><given-names>S.W.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name></person-group><article-title>Obesity-induced miR-15b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytes</article-title><source>Molecular Nutrition &#x00026; Food Research</source><volume>59</volume><year>2015</year><fpage>2303</fpage><lpage>2314</lpage><pub-id pub-id-type="pmid">26179126</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>Kornfeld</surname><given-names>J.W.</given-names></name><name><surname>Baitzel</surname><given-names>C.</given-names></name><name><surname>Konner</surname><given-names>A.C.</given-names></name><name><surname>Nicholls</surname><given-names>H.T.</given-names></name><name><surname>Vogt</surname><given-names>M.C.</given-names></name><name><surname>Herrmanns</surname><given-names>K.</given-names></name></person-group><article-title>Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b</article-title><source>Nature</source><volume>494</volume><year>2013</year><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">23389544</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Author contributions</title><p id="p0195">A.A.S, R.R., and REP contributed to the conception and design of the research design, analysis plan, supervision of the analysis, study implementation, data acquisition, and interpretation, writing of the manuscript, and critical revision and final approval of the manuscript. Y.O.N.L performed experiments, conducted data analysis, and contributed to data interpretation and writing of the manuscript. R.E.P and B.Z. contributed to the study design, study implementation, data interpretation, and critical revision and final approval of the manuscript. A.A.S is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p></sec><sec id="appsec2"><title>Prior presentation</title><p id="p0200">None.</p></sec><sec id="appsec3"><title>Conflict of interests/Disclosure summary</title><p id="p0205">This study was funded by startup funds granted to A.S. and R.E.P by Florida Hospital. The LIBRA trial was funded by Novo Nordisk as an investigator-initiated trial to R.R. and B.Z.. R.R. and B.Z. have received consulting honoraria and research support from Novo Nordisk. REP has received research grants (to his institution) from Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Sanofi-Aventis US, LLC, and Takeda and has previously received speaker and/or consultancy fees (to his institution) from AstraZeneca, Boehringer Ingelheim, Eisai, Inc., GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd., Janssen Scientific Affairs, LLC, Ligand Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Pfizer, Sanofi and Takeda. No other potential conflicts of interest relevant to this article were reported.</p></sec><sec id="appsec4" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0210">The following is the supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.docx"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>We would like to thank Florida Hospital for granting funds to A.S. and R.E.P. to conduct this study. The LIBRA trial (parent study) was funded by <funding-source id="gs1">Novo Nordisk</funding-source> as an investigator-initiated trial to R.R. and B.Z. R.R holds the Boehringer Ingelheim Chair in Beta-cell Preservation, Function and Regeneration at Mount Sinai Hospital.</p></ack><fn-group><fn id="appsec5" fn-type="supplementary-material"><label>Appendix A</label><p id="p0215">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molmet.2018.11.003" id="intref0025">https://doi.org/10.1016/j.molmet.2018.11.003</ext-link>.</p></fn></fn-group></back></article>
</articles>
